{
  "0": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies estrogen receptor antagonism as the mechanism, and provides additional accurate, relevant mechanistic detail without any inaccuracies or omissions."
  },
  "1": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately details the glucocorticoid receptor pathway, and provides relevant, correct mechanistic elaboration without any inaccuracies or omissions."
  },
  "2": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies TNF-α as the inhibited cytokine, provides accurate clinical reasoning, and includes only relevant, factually correct information without omissions or inaccuracies."
  },
  "3": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies the glucocorticoid receptor as the direct mediator, explains the mechanism, and provides relevant, accurate context without any errors or omissions."
  },
  "4": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies thioredoxin reductase as the inhibited enzyme and provides relevant clinical context, but omits the specific mitochondrial isoform \"thioredoxin reductase 2,\" which is a minor omission."
  },
  "5": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the GnRH receptor as the direct target, thoroughly explains the mechanism, and provides only accurate, clinically relevant details with no omissions or inaccuracies."
  },
  "6": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the molecular target, thoroughly explains its intracellular/nuclear location and mechanism, and provides relevant clinical context without any inaccuracies or omissions."
  },
  "7": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the VEGF pathway as the direct target, matches all key clinical facts, and provides accurate, relevant additional context without any inaccuracies or omissions."
  },
  "8": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the glucocorticoid receptor mechanism, and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "9": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies IGF-1R as the direct molecular target, provides accurate and clinically relevant context, and contains no inaccuracies or omissions."
  },
  "10": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the direct mediator, thoroughly explains the mechanism, and includes only relevant, accurate, and clinically appropriate details with no omissions or inaccuracies."
  },
  "11": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies DNMT2 (TRDMT1) as the tRNA (Cytosine(38)-C(5))-Methyltransferase, explains azacitidine’s mechanism, and clearly links enzyme inhibition to improved erythropoiesis in sideroblastic anemia, with no inaccuracies or omissions."
  },
  "12": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor, explains the mechanism of action, and provides relevant, accurate additional detail without any errors or omissions."
  },
  "13": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies TNF-α as the key molecular target, accurately explains thalidomide’s mechanism, and provides relevant, factually correct additional context without any inaccuracies or omissions."
  },
  "14": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies VEGF-A as the most direct target, thoroughly explains its role in neovascularization, and accurately contrasts it with Ang-2, matching all key clinical facts without errors or omissions."
  },
  "15": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies the thrombopoietin receptor (c-MPL)–JAK2 complex as the primary molecular target, whereas the reference specifies the interferon alpha receptor complex; this is a moderate factual error, though the rest of the explanation is relevant and not unsafe."
  },
  "16": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies VEGF-A as the most critical target, and provides accurate, relevant explanations without any inaccuracies or omissions."
  },
  "17": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies CXCR4 as the inhibited receptor and clearly explains how its inhibition mobilizes neutrophils from the bone marrow, improving immune surveillance and reducing infections, fully covering all key clinical facts with relevant, accurate elaboration."
  },
  "18": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the clinical syndrome, the use of somatostatin analogs, and their mechanism via SSTR2, but it misses the reference answer's key fact that the intended molecular target is the interferon alpha receptor complex, not the somatostatin receptor; thus, it covers about 70-89% of key facts but with a moderate omission."
  },
  "19": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies transthyretin as the target, explains the disease mechanism, describes how antisense oligonucleotides reduce TTR production, and links this to clinical benefit, with no inaccuracies or omissions."
  },
  "20": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies 5-alpha-reductase as the target enzyme and provides relevant clinical context, but it does not specify the Type II isoform (3-Oxo-5-Alpha-Steroid 4-Dehydrogenase 2) as in the reference answer, representing a minor omission."
  },
  "21": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies SSTR2 as the primary molecular target, whereas the reference specifies SSTR5; while the explanation is otherwise accurate and relevant, this represents a moderate factual error."
  },
  "22": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies PDE4 (cAMP-specific) instead of the reference's cGMP-specific phosphodiesterase (PDE5), which is the key fact; while the explanation is detailed, the main molecular target is wrong, constituting a moderate factual error."
  },
  "23": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies thymidylate synthase as the inhibited enzyme, explains the mechanism, and provides relevant, accurate additional details without any errors or omissions."
  },
  "24": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the Vitamin D Receptor (VDR), explains its nuclear transcription factor role, and covers all key clinical facts from the reference, with additional accurate and relevant details."
  },
  "25": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies cyclooxygenase (COX) as the molecular target, missing the key fact that the question specifically describes an NSAID that inhibits a phosphodiesterase (cGMP-specific PDE), not COX. While the explanation is detailed, it does not address the actual mechanism described in the question stem, constituting a moderate factual error."
  },
  "26": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the angiotensin II type 1 (AT1) receptor as the direct target, provides accurate and clinically relevant explanation, and contains no inaccuracies or omissions."
  },
  "27": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies ornithine decarboxylase as the inhibited enzyme and provides accurate, clinically relevant details about the drug (eflornithine), its mechanism, and the biochemical pathway, with no omissions or inaccuracies."
  },
  "28": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the clinical context and mechanism (epigenetic modification to increase HbF), but incorrectly names LSD1/KDM1A as the primary target instead of histone deacetylase, which is specified in the reference. While LSD1 is a relevant target in some recent therapies, the question and reference focus on histone deacetylase, making this a moderate factual error."
  },
  "29": {
    "score": 3.0,
    "explanation": "3: The model answer correctly explains the downstream signaling (ISGF3 complex) but does not directly name the interferon alpha receptor complex as the primary mediator, which is the focus of the reference answer; it covers most key facts but omits the specific identification of the receptor complex as the primary mediator."
  },
  "30": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the JAK-STAT pathway and discusses cytokine receptors, but incorrectly names the interleukin-6 receptor complex as the direct target instead of the interferon alpha receptor complex, missing the key reference fact. The rest of the content is relevant and accurate, but the main molecular target is not correctly matched."
  },
  "31": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies IL-6 as the target, and provides a detailed, accurate, and clinically relevant explanation of the mechanism and therapeutic effects, with no inaccuracies or omissions."
  },
  "32": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies thymidylate synthase as the inhibited enzyme, provides accurate and clinically relevant explanations, and includes a helpful summary table without any inaccuracies or omissions."
  },
  "33": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies the glucocorticoid receptor as the primary target, and all additional explanation is accurate and clinically relevant with no errors or omissions."
  },
  "34": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies the growth hormone receptor as the target, explains the mechanism, and provides relevant clinical context without inaccuracies or omissions."
  },
  "35": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the clinical context, drug, and lists all relevant receptors, but incorrectly selects PDGFR instead of VEGFR as the direct answer, missing the key fact required by the question."
  },
  "36": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies dihydrofolate reductase as the primary target, explains methotrexate’s mechanism, and all additional content is accurate and clinically relevant."
  },
  "37": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies VDR as the principal nuclear receptor, and provides accurate, relevant mechanistic detail without any inaccuracies or omissions."
  },
  "38": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor, thoroughly explains the clinical reasoning, and accurately describes the mechanism of action with no omissions or inaccuracies."
  },
  "39": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies the glucocorticoid receptor and provides accurate, relevant mechanistic details without any errors or omissions."
  },
  "40": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies somatostatin receptor subtype 2 (SSTR2) as the primary molecular target, explains the mechanism, and provides relevant clinical context without any inaccuracies or omissions."
  },
  "41": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies DNA methyltransferase as the inhibited enzyme and provides relevant clinical context, but it omits the specific isoform (tRNA (Cytosine(38)-C(5))-Methyltransferase) named in the reference, which is a key detail."
  },
  "42": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the direct molecular target as the interleukin-6 receptor (IL-6R), specifies both soluble and membrane-bound forms, and provides accurate, relevant mechanistic detail with no omissions or inaccuracies."
  },
  "43": {
    "score": 5.0,
    "explanation": "5: Fully identifies the spike protein as the target and accurately explains its role in viral entry and antibody neutralization, with no inaccuracies or omissions."
  },
  "44": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies complement component C5 as the target, provides a clear and accurate explanation of its role in MAC formation, and relates this to clinical therapy in myasthenia gravis, with no omissions or inaccuracies."
  },
  "45": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies DNA methyltransferase as the directly inhibited enzyme, provides accurate and clinically relevant details about the medication, its mechanism, and its therapeutic context, with no inaccuracies or omissions."
  },
  "46": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the vitamin D receptor (VDR) as the molecular target, thoroughly explains its role, and provides relevant clinical context and supporting details without any inaccuracies or omissions."
  },
  "47": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies CXCR4 as the molecular target, thoroughly explains its role in leukocyte retention and mobilization, and provides accurate, clinically relevant context without any inaccuracies or omissions."
  },
  "48": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies thymidylate synthase as the directly inhibited enzyme, provides accurate and clinically relevant additional details about 5-FU’s mechanism, and contains no inaccuracies or omissions."
  },
  "49": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies HIF-2α as the inhibited protein, thoroughly explains the VHL-HIF-2α pathophysiology, and details how direct HIF-2α inhibition addresses the disease mechanism, with all content accurate and clinically relevant."
  },
  "50": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies microtubules as the targeted structure and provides relevant, accurate explanation, but does not explicitly name \"tubulin\" as the primary molecular target, which is a minor omission compared to the reference answer."
  },
  "51": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies TNF-α as the key cytokine, specifies thalidomide as the drug, and accurately describes its mechanism (enhancing TNF-α mRNA degradation), fully covering all key clinical facts with relevant, accurate elaboration and no errors."
  },
  "52": {
    "score": 5.0,
    "explanation": "5: Fully identifies HMG-CoA reductase as the enzyme, explains the mechanism, and provides correct, relevant extra information without inaccuracies or omissions."
  },
  "53": {
    "score": 2.0,
    "explanation": "2: The model answer correctly describes a cytokine receptor complex activating JAK-STAT signaling but incorrectly identifies the direct target as the Interleukin-7 receptor complex rather than the Interferon Alpha Receptor Complex, which is the key fact; this is a moderate factual error."
  },
  "54": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies the glucocorticoid receptor as the direct molecular target, provides accurate and clinically relevant explanation, and notes the distinction from mineralocorticoid therapy without introducing inaccuracies or irrelevant content."
  },
  "55": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies CD20 as the target, provides a thorough and clinically relevant explanation, and covers all key facts from the reference answer without inaccuracies or omissions."
  },
  "56": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies CMV DNA polymerase as the primary molecular target, explains its role in viral DNA chain elongation, and provides relevant, accurate context about ganciclovir without any inaccuracies or omissions."
  },
  "57": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies RANKL as the direct molecular target, provides accurate and clinically relevant explanation, and contains no inaccuracies or omissions."
  },
  "58": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies complement C5 as the molecular target, provides accurate and clinically relevant explanation, and contains no inaccuracies or omissions."
  },
  "59": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies the glucocorticoid receptor as the direct molecular target and provides a clinically relevant, accurate explanation with no omissions or inaccuracies."
  },
  "60": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the glucocorticoid receptor as the molecular target, and provides accurate, relevant mechanistic and clinical context without any inaccuracies or omissions."
  },
  "61": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the histamine H2 receptor as the direct molecular target, thoroughly explains the mechanism, and provides relevant supporting details without any inaccuracies or omissions."
  },
  "62": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies cyclooxygenase (COX) as the target and explains the mechanism, but does not specify COX-2 (prostaglandin G/H synthase 2) as the primary molecular target, missing a key detail from the reference answer."
  },
  "63": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies nintedanib as the drug and PDGFR as a relevant target, but it misses the specific reference answer (CSF1R), which is the receptor on macrophages mediating fibrotic remodeling; thus, it covers some but not all key facts and omits the most specific detail."
  },
  "64": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the molecular target, thoroughly explains the mechanism, and provides only relevant, accurate, and clinically appropriate additional information without any omissions or errors."
  },
  "65": {
    "score": 5.0,
    "explanation": "5: All key clinical facts are covered, including the enzyme name, mechanism, and clinical context; extra explanation is accurate and clinically relevant with no errors or omissions."
  },
  "66": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies CD20 as the target, provides accurate and clinically relevant explanation, and contains no inaccuracies or omissions."
  },
  "67": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the primary molecular target mediating the therapeutic effect on hyperglycemia, fully explaining the clinical context and mechanism, and covers all key facts in the reference answer without inaccuracies."
  },
  "68": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies VEGF/VEGF-A as the primary molecular target and provides relevant clinical reasoning, but it introduces some ambiguity by mentioning VEGFR as an alternative and references infliximab (which is not primarily anti-VEGF), constituting a minor inaccuracy in specificity."
  },
  "69": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies HMG-CoA reductase as the direct molecular target and provides both the full and abbreviated names, matching all key facts in the reference answer with no errors or omissions."
  },
  "70": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies thyroid peroxidase as the target enzyme, explains the clinical scenario, names the drug class, and accurately describes the enzyme's functions, with no inaccuracies or omissions."
  },
  "71": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor and accurately explains its mechanism of action and clinical relevance in acute MS exacerbations, with no omissions or inaccuracies."
  },
  "72": {
    "score": 3.0,
    "explanation": "3: The model answer incorrectly identifies COX-2 as the primary target, whereas the reference specifies COX-1; however, the explanation is otherwise accurate and relevant, covering most key facts except for the precise enzyme required."
  },
  "73": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies IL-1β as the targeted cytokine, explains the disease mechanism, and describes how inhibition of IL-1β addresses the underlying pathology, with no inaccuracies or omissions."
  },
  "74": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the vasopressin V2 receptor as the molecular target, provides accurate and clinically relevant explanation, and contains no inaccuracies or omissions."
  },
  "75": {
    "score": 3.0,
    "explanation": "3: The model answer correctly explains the downstream signaling (ISGF3 complex) but omits the essential mediator specified in the reference (the interferon alpha receptor complex), which is the direct target of the drug; thus, it covers about 70-89% of key facts but misses the primary focus of the question."
  },
  "76": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies the vitamin D receptor (VDR) as the molecular target, explains the drug mechanism, and covers all key clinical facts without errors or omissions."
  },
  "77": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies the glucocorticoid receptor as the molecular target, accurately explains the mechanism, and provides relevant clinical context with no errors or omissions."
  },
  "78": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies bacterial RNA polymerase as the molecular target, provides accurate and clinically relevant additional information about fidaxomicin and vancomycin, and contains no inaccuracies or omissions."
  },
  "79": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies complement C5 as the direct molecular target, explains the mechanism of action, and clearly links C5 inhibition to prevention of MAC formation and symptom mitigation in PNH. All key clinical facts are covered with relevant, accurate elaboration and no errors."
  },
  "80": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies the thrombopoietin (TPO) receptor (c-Mpl) as the target, names the drug, and provides relevant, accurate context without any errors or omissions."
  },
  "81": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the estrogen receptor as the molecular target, explains the clinical scenario, mechanism, and relevant drug class, with no inaccuracies or omissions."
  },
  "82": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the progesterone receptor as the molecular target, provides accurate and clinically relevant explanation, and contains no inaccuracies or omissions."
  },
  "83": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies α4β7 integrin as the molecular target and provides accurate, clinically relevant explanation and context without any inaccuracies or omissions."
  },
  "84": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the relevant intracellular receptor, provides accurate and clinically relevant details about budesonide, its mechanism, and its effects, with no omissions or inaccuracies."
  },
  "85": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the molecular target, thoroughly explains the mechanism, and provides relevant clinical context without any inaccuracies or omissions."
  },
  "86": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the primary target, thoroughly explains the clinical context, mechanism of action, and relevance, with no inaccuracies or omissions."
  },
  "87": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies VEGF-A as the molecular target, provides accurate and clinically relevant explanation, and includes a correct summary table without any inaccuracies or omissions."
  },
  "88": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies SSTR2 as the primary molecular target, provides accurate and relevant clinical context, and includes only factually correct and clinically pertinent extra information without any errors or omissions."
  },
  "89": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the estrogen receptor as the relevant nuclear receptor, explains the mechanism of action, and provides accurate, clinically relevant context without any inaccuracies or omissions."
  },
  "90": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies \"tryptophan hydroxylase\" as the inhibited enzyme and provides accurate, relevant explanation, but omits the specific isoform \"tryptophan 5-hydroxylase 1\" named in the reference, which is a minor omission."
  },
  "91": {
    "score": 1.0,
    "explanation": "1: The model answer incorrectly identifies cholesterol as the direct target, rather than asparagine or conjugated bile acids, and provides a confusing rationale that misinterprets the role of amino acids in the context; this constitutes a major inaccuracy and covers less than 40% of key facts."
  },
  "92": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the molecular target as the interleukin-1 receptor (IL-1RI), matches the reference answer, and provides accurate, clinically relevant explanations without any inaccuracies or omissions."
  },
  "93": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately identifies the histamine H2 receptor as the target, and provides a detailed, clinically relevant explanation of the mechanism without inaccuracies or omissions."
  },
  "94": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the histamine H2 receptor as the direct molecular target, thoroughly explains the mechanism, and provides relevant, accurate pharmacological context without any errors or omissions."
  },
  "95": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies the glucocorticoid receptor, explains its mechanism, and provides relevant, accurate clinical context without errors or omissions."
  },
  "96": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX) inhibition and explains the mechanism, but does not specifically name COX-2 (prostaglandin G/H synthase 2) as required by the reference; this is a minor omission."
  },
  "97": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies the progesterone receptor as the molecular target, provides accurate and relevant explanation, and contains no errors or omissions."
  },
  "98": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies VEGF-A as the target, explains the VEGF–VEGFR signaling pathway, and provides relevant clinical context without inaccuracies or omissions."
  },
  "99": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies HMG-CoA reductase as the inhibited enzyme and provides a clinically relevant, accurate explanation consistent with the reference answer, with no omissions or inaccuracies."
  },
  "100": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies TNF-alpha as the key inflammatory mediator, provides accurate and clinically relevant context about Behçet disease and anti-TNF therapy, and contains no inaccuracies or omissions."
  },
  "101": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies VEGF-A as the direct molecular target, accurately explains the mechanism of aflibercept, and provides clinically relevant detail without any inaccuracies or omissions."
  },
  "102": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the beta-1 adrenergic receptor as the molecular target, provides accurate and clinically relevant mechanistic detail, and contains no inaccuracies or omissions."
  },
  "103": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies CD20 as the essential molecular target, provides accurate and clinically relevant explanation, and contains no inaccuracies or omissions."
  },
  "104": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies PTH as the hormone suppressed, explains the mechanism of action, and provides relevant clinical context without inaccuracies or omissions."
  },
  "105": {
    "score": 2.0,
    "explanation": "2: The model answer correctly identifies the clinical scenario and the use of eculizumab, but incorrectly states that C5 is the target, whereas the reference answer specifies C3. This is a moderate factual error regarding the specific complement protein targeted."
  },
  "106": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies α4β7 integrin as the key molecular target, accurately describes the mechanism, and specifies the inhibited interaction (α4β7 integrin – MAdCAM-1 binding) without any inaccuracies or omissions."
  },
  "107": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the vitamin D receptor (VDR) as the defective molecular target, thoroughly explains the clinical context, and provides accurate, relevant additional information without any errors or omissions."
  },
  "108": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies ornithine decarboxylase as the inhibited enzyme, explains the mechanism, and provides relevant clinical context without any inaccuracies or omissions."
  },
  "109": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies PDGFR as the primary target, provides accurate context about nintedanib, and includes only relevant, factually correct additional information without any omissions or inaccuracies."
  },
  "110": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies ribonucleotide reductase as the enzyme, provides a clear and accurate explanation of the mechanism, and includes only clinically relevant, factually correct information with no omissions or inaccuracies."
  },
  "111": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies the vitamin D receptor (VDR) as the answer, explains its intracellular nuclear location, mechanism, and clinical context, with no inaccuracies or omissions."
  },
  "112": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the histamine H2 receptor as the target and explains that its blockade inhibits gastric acid secretion by parietal cells, fully covering all key clinical facts in the reference answer with relevant, accurate elaboration."
  },
  "113": {
    "score": 5.0,
    "explanation": "5: All key clinical facts from the reference are covered, with accurate and clinically relevant additional explanation about maraviroc, its mechanism, and the need for CCR5-tropism testing; no inaccuracies or omissions."
  },
  "114": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies FGF23 as the direct molecular target, provides accurate and clinically relevant context about XLH, burosumab, and the pathophysiology, with no inaccuracies or omissions."
  },
  "115": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX) as the target enzyme and explains the mechanism, but does not specify the COX-2 isoform, which is most directly responsible for the anti-inflammatory effect; otherwise, all key facts are covered."
  },
  "116": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies acetylcholinesterase as the direct molecular target, provides accurate and relevant clinical context, and contains no inaccuracies or omissions."
  },
  "117": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies phosphodiesterase type 5 (PDE5) as the molecular target, matches all key facts from the reference, and provides accurate, relevant additional explanation without any errors or omissions."
  },
  "118": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the interferon alpha receptor (IFNAR) complex, specifies its subunits (IFNAR1/IFNAR2), and accurately describes the relevant signaling pathway and clinical mechanism, with no omissions or inaccuracies."
  },
  "119": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies the progesterone receptor as the principal molecular target, provides accurate and clinically relevant context, and contains no inaccuracies or omissions."
  },
  "120": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies C5 as the direct target and provides accurate, clinically relevant explanation of its role in MAC formation and complement-mediated injury, with no errors or omissions."
  },
  "121": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies the GnRH receptor as the direct molecular target, explains the clinical context, mechanism, and effect, with no inaccuracies or omissions."
  },
  "122": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies TNF-α as the cytokine, provides accurate and clinically relevant explanation, and contains no inaccuracies or omissions compared to the reference."
  },
  "123": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the immediate target as the type I interferon receptor complex (IFNAR1/IFNAR2), fully aligns with the reference answer, and provides accurate, relevant additional detail without any errors or omissions."
  },
  "124": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the molecular target, fully explains the mechanism, and provides only relevant, accurate information with no omissions or inaccuracies."
  },
  "125": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the molecular target and provides accurate, clinically relevant explanation without any inaccuracies or omissions."
  },
  "126": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies IL-1 as the target and provides relevant clinical context, but does not specify the beta isoform (IL-1β) as in the reference; this is a minor omission since monoclonal antibodies like canakinumab specifically target IL-1β."
  },
  "127": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies phosphodiesterase-4 (PDE4) as the molecular target, provides accurate and clinically relevant additional explanation, and contains no inaccuracies or omissions."
  },
  "128": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies the estrogen receptor as the direct molecular target and provides accurate, clinically relevant explanation with no errors or omissions."
  },
  "129": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies VEGF-A as the molecular target, provides accurate clinical context, and includes only relevant, factually correct information with no omissions or inaccuracies."
  },
  "130": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the clinical scenario, drug (thalidomide), and its immunomodulatory action, but incorrectly names TNF-α as the most direct molecular target, rather than VEGF-A as specified in the reference. This constitutes a moderate factual error, though the rest of the content is accurate and relevant."
  },
  "131": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies glucosylceramide synthase (synonymous with ceramide glucosyltransferase) as the inhibited enzyme, provides accurate and clinically relevant explanation, and contains no inaccuracies or omissions."
  },
  "132": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies S1P1 as the primary molecular target, thoroughly explains the mechanism, and provides relevant additional context without inaccuracies or omissions."
  },
  "133": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies DNA methyltransferase as the target, and provides relevant, accurate explanations without any errors or omissions."
  },
  "134": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies CD20 as the molecular target, provides accurate and clinically relevant additional information about rituximab, its mechanism, and disease context, with no inaccuracies or omissions."
  },
  "135": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies EGFR as a receptor tyrosine kinase involved in cell proliferation and discusses its relevance to actinic keratosis, but the reference specifically requires HER2/neu (erbB-2) as the most direct target; thus, the model omits the key fact and focuses on a related but distinct receptor."
  },
  "136": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies COX (specifically COX-2) as the principal target, explains the clinical context, mechanism, and relevance, and contains no inaccuracies or omissions."
  },
  "137": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies HMG-CoA reductase as the inhibited enzyme, provides accurate and clinically relevant explanation, and contains no inaccuracies or omissions."
  },
  "138": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the glucocorticoid receptor mechanism, and provides relevant, correct additional detail without inaccuracies or omissions."
  },
  "139": {
    "score": 5.0,
    "explanation": "5: All key clinical facts from the reference are covered, with additional correct and relevant explanation about statins, the enzyme's function, and the downstream effects; there are no inaccuracies or omissions."
  },
  "140": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the interferon alpha (type I interferon) receptor complex as the principal target, provides accurate mechanistic detail, and includes only relevant, factually correct information with no omissions or inaccuracies."
  },
  "141": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the androgen receptor as the molecular target, provides accurate and clinically relevant explanation, and contains no inaccuracies or omissions compared to the reference answer."
  },
  "142": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the primary molecular receptor, thoroughly explains the mechanism of action, and provides only relevant, accurate, and clinically appropriate additional information with no omissions or inaccuracies."
  },
  "143": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies JAK1 as the primary molecular target, whereas the reference specifies JAK3, which is most directly linked to common γ-chain cytokine signaling. While the answer provides relevant background and is not unsafe, it contains a moderate factual error regarding the specific JAK inhibited for therapeutic benefit."
  },
  "144": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the angiotensin II type 1 receptor (AT₁ receptor) as the target, provides accurate and clinically relevant explanation, and contains no inaccuracies or omissions."
  },
  "145": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies the progesterone receptor as the molecular target, explains the mechanism, and provides relevant, accurate extra detail without any errors or omissions."
  },
  "146": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies type II 5α-reductase as the direct molecular target, matches all key clinical facts, and provides accurate, relevant additional explanation without any inaccuracies or omissions."
  },
  "147": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies IL-1β as the direct molecular target, provides accurate clinical context, and includes only relevant, factually correct information with no omissions or inaccuracies."
  },
  "148": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the clinical scenario, the use of tocilizumab, and that the direct molecular target is the interleukin-6 receptor (IL-6R), but it does not specify the \"soluble interleukin-6 receptor subunit alpha (IL-6Rα)\" as in the reference; this is a minor omission in specificity."
  },
  "149": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the β1-adrenergic receptor as the specific molecular target, accurately describes its mechanism and clinical relevance in acute MI, and contains no inaccuracies or omissions."
  },
  "150": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the androgen receptor as the molecular target, accurately describes its intracellular/nuclear location, mechanism of action, and clinical relevance, with no omissions or inaccuracies."
  },
  "151": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the principal molecular target, accurately explains the mechanism, and provides relevant, factually correct additional information without any omissions or inaccuracies."
  },
  "152": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately details the glucocorticoid mechanism, and provides relevant, correct elaboration without any inaccuracies or omissions."
  },
  "153": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies histone deacetylase as the target, explains the epigenetic mechanism, and relates it to increased HbF in sickle cell disease; all content is accurate and clinically relevant."
  },
  "154": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the molecular target, thoroughly explains the mechanism, and provides relevant clinical context without any inaccuracies or omissions."
  },
  "155": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor, explains the clinical context (sarcoidosis), and accurately describes the mechanism of action, matching all key facts in the reference without errors or omissions."
  },
  "156": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the erythropoietin receptor, provides accurate and clinically relevant explanation, and includes additional correct details without any omissions or inaccuracies."
  },
  "157": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies C5 as the direct molecular target and provides accurate, clinically relevant additional explanation without any inaccuracies or omissions."
  },
  "158": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the primary molecular target, provides accurate and clinically relevant explanation, and includes no inaccuracies or omissions."
  },
  "159": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX) as the target enzyme and explains the mechanism, but does not specify COX-2 (prostaglandin G/H synthase 2) as the primary isoform relevant to the therapeutic effect, which is a minor omission."
  },
  "160": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the key intracellular receptor, accurately explains the mechanism of action, and provides relevant clinical context without any inaccuracies or omissions."
  },
  "161": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies S1P₁ as the direct target, matches all key reference facts, and provides accurate, relevant explanation without errors or omissions."
  },
  "162": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the molecular target, provides accurate and clinically relevant explanation of the mechanism, and includes no inaccuracies or omissions. All key facts from the reference are covered."
  },
  "163": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies ranibizumab and its mechanism (direct inhibition of VEGF-A), and provides relevant, accurate clinical context without any inaccuracies or omissions."
  },
  "164": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the molecular mechanism of estrogen receptor antagonism by tamoxifen, and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "165": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the interferon-α/β receptor (IFNAR) complex as the pharmacologic target, details its subunits, mechanism (JAK-STAT pathway), and clinical context, covering all key facts with relevant, accurate elaboration and no errors."
  },
  "166": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies the D2 dopamine receptor as the primary target, explains its role in Tourette syndrome treatment, and provides relevant, accurate extra details without any errors or omissions."
  },
  "167": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the enzyme, its role, and the clinical rationale; additional details are accurate and relevant with no omissions or inaccuracies."
  },
  "168": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies S1P1 as the direct molecular target, accurately describes the mechanism, and provides relevant clinical context without any inaccuracies or omissions."
  },
  "169": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the GnRH receptor as the direct molecular target, provides accurate and clinically relevant explanation, and contains no inaccuracies or omissions."
  },
  "170": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the IL-6 receptor as the molecular target and provides accurate, relevant clinical context, but it omits specifying the \"alpha subunit\" of the receptor, which is a minor omission compared to the reference answer."
  },
  "171": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the D₂ dopamine receptor as the primary target, provides accurate clinical reasoning, and includes only relevant, factually correct information with no omissions or inaccuracies."
  },
  "172": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies cyclooxygenase (COX), specifies both COX-1 and COX-2, and accurately explains their role in prostaglandin synthesis and inflammation; all key facts from the reference are covered with relevant, correct elaboration."
  },
  "173": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies HMG-CoA reductase as the inhibited enzyme, provides accurate and clinically relevant explanation, and includes only factually correct, relevant extra content without any omissions or inaccuracies."
  },
  "174": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies ornithine decarboxylase as the target, explains its role in polyamine synthesis, and clearly describes how its inhibition impairs parasite survival, with all content factually accurate and clinically relevant."
  },
  "175": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies ribonucleotide reductase as the primary molecular target, explains the mechanism of hydroxyurea, and provides relevant clinical context without any inaccuracies or omissions."
  },
  "176": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies ACE as the molecular target, accurately explains the mechanism, and provides clinically relevant details without any inaccuracies or omissions."
  },
  "177": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the GnRH receptor as the primary molecular target, provides accurate and clinically relevant explanation, and contains no inaccuracies or omissions."
  },
  "178": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies angiopoietin-2 as the additional target, provides accurate and clinically relevant explanation, and contains no inaccuracies or omissions compared to the reference answer."
  },
  "179": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the GnRH receptor as the direct molecular target, accurately describes the mechanism (initial stimulation then downregulation), and provides relevant clinical context without any inaccuracies or omissions."
  },
  "180": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the primary molecular target, thoroughly explains the mechanism, and provides clinically relevant details without inaccuracies or omissions."
  },
  "181": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies BMPR2 and ALK1 (ACVRL1) as the primary molecular targets, rather than ACVR2A, and provides a confusing discussion conflating ligand traps and receptor targets; while some mechanistic context is relevant, the key fact (ACVR2A) is omitted and there are moderate factual inaccuracies regarding the direct molecular target."
  },
  "182": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately identifies the VEGF signaling pathway and its inhibition, and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "183": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the molecular target, thoroughly explains the mechanism, and provides relevant clinical context without any inaccuracies or omissions."
  },
  "184": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies acetylcholinesterase as the inhibited target and provides relevant, accurate explanation without errors or omissions."
  },
  "185": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the molecular target, fully explains the clinical context, and provides accurate, relevant mechanistic detail with no omissions or inaccuracies."
  },
  "186": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies acetylcholinesterase as the molecular target, thoroughly explains the clinical context, mechanism of action, and relevance to myasthenia gravis, with no inaccuracies or omissions."
  },
  "187": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies Angiopoietin-2 as the molecular target, provides accurate and clinically relevant explanation, and contains no inaccuracies or omissions compared to the reference."
  },
  "188": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor, provides accurate and clinically relevant mechanistic detail, and contains no inaccuracies or omissions."
  },
  "189": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies inhibition of PDE5 as the direct mechanism, thoroughly explains the molecular pathway, and contains no inaccuracies or omissions; all content is clinically relevant and accurate."
  },
  "190": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor, thoroughly explains the mechanism, and provides only relevant, accurate, and clinically appropriate information with no omissions or inaccuracies."
  },
  "191": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX) as the target and explains the mechanism, but does not specify COX-2 (prostaglandin G/H synthase 2) as in the reference; this is a minor omission since aspirin inhibits both COX-1 and COX-2, but COX-2 is more relevant for inflammation."
  },
  "192": {
    "score": 5.0,
    "explanation": "5: All key facts from the reference are included, with additional correct and clinically relevant details about the mechanism and signaling pathway; no inaccuracies or omissions."
  },
  "193": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies thymidylate synthase as the principal molecular target, provides accurate and relevant mechanistic details, and contains no inaccuracies or omissions compared to the reference answer."
  },
  "194": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies cyclooxygenase (COX) as the directly targeted enzyme, explains the clinical context, and accurately describes the mechanism, matching all key facts in the reference without errors or omissions."
  },
  "195": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies the glucocorticoid receptor, accurately explains the mechanism, and provides relevant clinical context without inaccuracies or omissions."
  },
  "196": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the somatostatin receptor (specifically SSTR5) as the molecular target, and provides accurate, relevant mechanistic detail without any inaccuracies or omissions."
  },
  "197": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies ornithine decarboxylase as the inhibited enzyme, and provides additional accurate, clinically relevant details about the drug, mechanism, and selective toxicity, with no inaccuracies or omissions."
  },
  "198": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX) as the molecular target and explains its role, but does not specify COX-2 as the primary anti-inflammatory target, which is a minor omission."
  },
  "199": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the primary molecular target, covers all key clinical and mechanistic facts from the reference, and provides additional accurate, relevant explanation without any errors or omissions."
  },
  "200": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies histone deacetylase as the target and provides a clear, accurate, and clinically relevant explanation with no omissions or errors."
  },
  "201": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies COMT as the inhibited enzyme, explains the clinical context, and accurately distinguishes between tolcapone and entacapone, with no omissions or inaccuracies."
  },
  "202": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the clinical context, the drug (niclosamide), and the mechanism involving AR splice variants, but it names AR-V7 instead of AR-V3 as the specific target, which is a moderate factual inaccuracy since the question asks for AR-V3. Otherwise, the explanation is thorough and relevant."
  },
  "203": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the key intracellular protein, thoroughly explains the mechanism, and contains no inaccuracies or omissions."
  },
  "204": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies COX-2 as the molecular target, provides accurate and clinically relevant explanation, and contains no inaccuracies or omissions compared to the reference answer."
  },
  "205": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies the glucocorticoid receptor as the primary target, accurately describes the mechanism, and provides relevant, factually correct explanation with no omissions or inaccuracies."
  },
  "206": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies ACE as the target enzyme and provides a clinically relevant, accurate explanation matching all key facts in the reference answer."
  },
  "207": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the retinoic acid receptor as the molecular target, provides accurate and clinically relevant explanation, and contains no inaccuracies or omissions."
  },
  "208": {
    "score": 3.0,
    "explanation": "3: The model answer covers most clinical features and relevant background, but incorrectly identifies CD20 as the molecular target, whereas the reference specifies CD19. This is a moderate factual error, as the question's description matches anti-CD19 therapy (e.g., inebilizumab), not anti-CD20."
  },
  "209": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies IMP dehydrogenase as the direct target, provides accurate and clinically relevant explanation, and contains no inaccuracies or omissions."
  },
  "210": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the disease, the use of tocilizumab, and that it targets the interleukin-6 receptor, specifically mentioning the IL-6Rα subunit. However, the direct answer is less precise than the reference, as it does not specify \"soluble\" IL-6 receptor subunit alpha, which is the most accurate molecular target."
  },
  "211": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the receptor (thrombopoietin receptor/c-MPL), and provides relevant, accurate clinical context and mechanism without any inaccuracies or omissions."
  },
  "212": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies the adenosine A1 receptor as the direct target, whereas the reference specifies the beta-1 adrenergic receptor; it also misinterprets the mechanism (antagonism vs. agonism) and provides some relevant but ultimately incorrect rationale, covering less than 70% of key facts."
  },
  "213": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies ribonucleotide reductase as the molecular target, provides accurate and clinically relevant context about essential thrombocythemia and hydroxyurea, and contains no inaccuracies or omissions."
  },
  "214": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies the calcium-sensing receptor (CaSR) as the molecular target, provides accurate mechanism, and includes only relevant, factually correct details. No omissions or inaccuracies."
  },
  "215": {
    "score": 5.0,
    "explanation": "5: Fully correct identification of the glucocorticoid receptor as the principal target, with a clear, relevant, and accurate explanation matching all key clinical facts from the reference answer."
  },
  "216": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies the glucocorticoid receptor as the relevant intracellular receptor, accurately describes the mechanism, and provides clinically relevant context without any errors or omissions."
  },
  "217": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies VEGF-A as the molecular target and provides a clinically relevant, accurate explanation without any omissions or inaccuracies."
  },
  "218": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies CD20 as the molecular target, and provides accurate, relevant explanations without any inaccuracies or omissions."
  },
  "219": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies HMG-CoA reductase as the inhibited enzyme, provides a clinically relevant explanation, and contains no inaccuracies or omissions compared to the reference answer."
  },
  "220": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies the AT1 receptor as the target, explains its role in mediating angiotensin II effects, and correctly links the mechanism to ARBs; no omissions or inaccuracies."
  },
  "221": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the histamine H₂ receptor as the primary target, thoroughly explains the clinical context, mechanism, and differential receptors, and contains no inaccuracies or omissions."
  },
  "222": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the key intracellular receptor, accurately explains the mechanism of action, and contains no inaccuracies or omissions."
  },
  "223": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the primary intracellular target, thoroughly explains the clinical context, mechanism of action, and relevance to pemphigus vulgaris, with no inaccuracies or omissions."
  },
  "224": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the GnRH receptor as the specific molecular target, provides accurate and clinically relevant explanation, and contains no inaccuracies or omissions compared to the reference answer."
  },
  "225": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies CCR7 instead of CXCR4 as the molecular target, which is a moderate factual error. While the explanation is logical and relevant, it misses the key fact from the reference answer and thus covers less than 70% of the required content."
  },
  "226": {
    "score": 5.0,
    "explanation": "5: Fully identifies the glucocorticoid receptor as the molecular target, accurately explains its intracellular/nuclear nature and mechanism, and provides only correct, relevant details with no omissions or inaccuracies."
  },
  "227": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the primary intracellular target, thoroughly explains the mechanism, and provides relevant clinical context without any inaccuracies or omissions."
  },
  "228": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies the spike (S) protein as the direct target, matches the reference answer, and provides accurate, clinically relevant explanation with no errors or omissions."
  },
  "229": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the beta-1 adrenergic receptor as the primary target, provides accurate and clinically relevant explanation, and contains no inaccuracies or omissions."
  },
  "230": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies phosphodiesterase type 5 (PDE5) as the enzyme, explains its role in cGMP degradation, and accurately describes the mechanism and clinical relevance without any errors or omissions."
  },
  "231": {
    "score": 3.0,
    "explanation": "3: The answer correctly identifies nintedanib and lists the relevant receptor families it inhibits, including FGFR, but incorrectly states that PDGFR is the principal molecular target mediating antifibrotic effects, rather than the fibroblast growth factor receptor family as in the reference. This is a moderate factual error, though most key facts are present."
  },
  "232": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the primary molecular target, thoroughly explains the mechanism, and provides only relevant, accurate, and clinically appropriate additional details with no omissions or inaccuracies."
  },
  "233": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies DNA methyltransferase as the molecular target, explains the novel epigenetic mechanism, and provides relevant, accurate context without any errors or omissions."
  },
  "234": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX), specifically COX-2, as the molecular target and provides relevant clinical context, but omits mention of COX-1 (also a target of most NSAIDs) and the full enzyme name (prostaglandin G/H synthase), which is a minor omission."
  },
  "235": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies phosphodiesterase as the enzyme class but does not specify cGMP-specific PDE as in the reference, omitting the key detail of enzyme specificity; otherwise, the explanation is accurate and relevant."
  },
  "236": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies acetylcholinesterase as the targeted enzyme and provides accurate, clinically relevant explanations without any inaccuracies or omissions."
  },
  "237": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies PDGFR as the key receptor, provides accurate and clinically relevant explanation, and includes only factually correct, relevant extra content without any omissions or inaccuracies."
  },
  "238": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies the glucocorticoid receptor as the target, provides accurate and relevant additional detail about the mechanism, and contains no errors or omissions."
  },
  "239": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies cyclooxygenase (COX) as the molecular target and explains the mechanism, but does not specifically name COX-1 (prostaglandin G/H synthase 1) as required by the reference answer, and instead refers to both COX-1 and COX-2, which is less precise for this context."
  },
  "240": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies COX-2 as the principal target, provides accurate and clinically relevant explanation, and contains no inaccuracies or omissions compared to the reference."
  },
  "241": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the clinical scenario as FIP1L1-PDGFRA–driven HES and explains the rationale, but it does not match the reference answer, which specifies BCR-ABL as the targeted abnormality. The model answer provides a plausible alternative but misses the key fact required by the reference, resulting in a moderate factual error."
  },
  "242": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies CTLA-4 as the immune checkpoint molecule, accurately explains the mechanism of abatacept, and provides clinically relevant details without any inaccuracies or omissions."
  },
  "243": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor, thoroughly explains its mechanism, and provides relevant clinical context without any inaccuracies or omissions."
  },
  "244": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies COX-2 as the primary target, explains the clinical context, and provides relevant, accurate mechanistic detail with no omissions or inaccuracies."
  },
  "245": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX) as the molecular target and explains the mechanism, but does not specifically name COX-1 as in the reference; it mentions both COX-1 and COX-2, which is accurate for many NSAIDs, but slightly less specific than the reference answer."
  },
  "246": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the molecular target, provides accurate and clinically relevant explanation, and contains no inaccuracies or omissions."
  },
  "247": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the primary target, accurately describes the mechanism of action, and provides relevant clinical context without any inaccuracies or omissions."
  },
  "248": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the estrogen receptor as the molecular target, thoroughly explains the mechanism, and provides relevant, accurate additional details without any errors or omissions."
  },
  "249": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies dihydrofolate reductase as the inhibited enzyme and provides accurate, clinically relevant additional explanation without any errors or omissions."
  },
  "250": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies 5-lipoxygenase as the primary molecular target, explains the rationale, and addresses the catechol-derived agent (masoprocol/NDGA) with accurate, clinically relevant detail and no inaccuracies or omissions."
  },
  "251": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies SGLT2 as the target and provides a clinically relevant, accurate explanation matching all key facts in the reference answer, with no errors or omissions."
  },
  "252": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies mitochondrial complex I (NADH:ubiquinone oxidoreductase) as the inhibited enzyme, fully explains the mechanism, and provides only accurate, clinically relevant information with no omissions or inaccuracies."
  },
  "253": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies HMG-CoA reductase as the directly inhibited enzyme, explains the mechanism, and provides relevant additional context without any inaccuracies or omissions."
  },
  "254": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the clinical scenario, drug (nintedanib), and its inhibition of PDGFR, VEGFR, and FGFR, but it omits CSF1R, the specific molecular target highlighted in the reference answer, which is a key fact. The rest of the content is accurate and relevant."
  },
  "255": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies VEGF as the direct molecular target, provides accurate context about thalidomide’s mechanism, and includes only relevant, factually correct information without any omissions or inaccuracies."
  },
  "256": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the interferon-α receptor (IFNAR) as the molecular target, thoroughly explains its role, and covers all key clinical facts from the reference without inaccuracies or omissions."
  },
  "257": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the molecular target, thoroughly explains the mechanism, and includes only relevant, accurate information with no omissions or inaccuracies."
  },
  "258": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies TNF-α as the primary cytokine target, provides accurate and clinically relevant additional information about thalidomide and its mechanism, and contains no inaccuracies or omissions."
  },
  "259": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies the muscarinic M2 receptor instead of the beta-1 adrenergic receptor, which is the key fact; while the explanation is detailed, the main answer is a moderate factual error, and the correct receptor is not named."
  },
  "260": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the histamine H₂ receptor as the principal molecular target, provides accurate and clinically relevant explanation, and contains no inaccuracies or omissions."
  },
  "261": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the IL-6 receptor as the molecular target and provides accurate, relevant clinical context, but omits the specific mention of the alpha subunit (IL-6Rα) as in the reference answer."
  },
  "262": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies the glucocorticoid receptor and provides a clinically relevant, accurate explanation matching all key facts in the reference answer."
  },
  "263": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies blockade of the IL-6 receptor as the primary mechanism, specifies both soluble and membrane-bound forms, and provides accurate, relevant clinical and molecular details without any inaccuracies or omissions."
  },
  "264": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the activation and mechanism of vitamin D via the nuclear receptor, and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "265": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies HMG-CoA reductase as the primary molecular target and provides accurate, clinically relevant additional explanation without any errors or omissions."
  },
  "266": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies IMP dehydrogenase as the target, provides the drug name, and explains the mechanism, all of which are clinically relevant and accurate with no omissions or errors."
  },
  "267": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies interferon-gamma as the molecular target, and provides additional accurate and clinically relevant context without any inaccuracies or omissions."
  },
  "268": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies C5 as the molecular target, and provides accurate, relevant clinical context and mechanism without any inaccuracies or omissions."
  },
  "269": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the clinical scenario and explains the mechanism of ruxolitinib, but it does not match the reference answer's key fact—tumor necrosis factor—as the direct molecular target; instead, it focuses on JAK inhibition, which is a different, though relevant, therapeutic approach."
  },
  "270": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the AT₁ receptor as the molecular target, covers all key clinical facts from the reference, and provides accurate, clinically relevant explanations without any inaccuracies or omissions."
  },
  "271": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies HMG-CoA reductase as the direct target and provides a concise, accurate explanation matching all key clinical facts in the reference answer."
  },
  "272": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies topoisomerase II as the direct molecular target, provides accurate clinical context, and explains the mechanism of action without any inaccuracies or omissions."
  },
  "273": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies VEGF as the primary molecular mediator targeted, provides accurate clinical reasoning, and includes only relevant, factually correct additional information without omissions or inaccuracies."
  },
  "274": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the primary molecular target, provides accurate and clinically relevant mechanistic details, and contains no inaccuracies or omissions."
  },
  "275": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies the glucocorticoid receptor as the molecular target, with accurate and relevant explanation of mechanism; no errors or omissions."
  },
  "276": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the vitamin D receptor (VDR) as the target, accurately explains the drug's activation and mechanism, and provides only relevant, factually correct information with no omissions or inaccuracies."
  },
  "277": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies IL-4Rα as the molecular target, explains its role as the shared receptor for IL-4 and IL-13, and provides relevant, accurate additional context without any inaccuracies or omissions."
  },
  "278": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the molecular target and provides accurate, clinically relevant mechanistic details without any errors or omissions."
  },
  "279": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies the glucocorticoid receptor, explains the mechanism, and all extra content is accurate and clinically relevant with no omissions or inaccuracies."
  },
  "280": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies the glucocorticoid receptor, explains the mechanism, and provides relevant clinical context without inaccuracies or omissions."
  },
  "281": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the intracellular target and provides accurate, clinically relevant details about the mechanism of action, with no inaccuracies or omissions."
  },
  "282": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies HMG-CoA reductase as the inhibited enzyme, explains the mechanism, and provides the enzyme's full name with no inaccuracies or omissions."
  },
  "283": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies aldosterone synthase (CYP11B2) as the mitochondrial enzyme, explains its role in aldosterone synthesis, and clearly outlines the clinical significance of its inhibition, covering all key facts from the reference with relevant, accurate elaboration."
  },
  "284": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies ACE as the direct molecular target, explains the clinical context, mechanism, and alternatives, and contains no inaccuracies or omissions. All key facts from the reference are covered with relevant, accurate elaboration."
  },
  "285": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the primary molecular receptor, accurately describes its intracellular/nuclear nature, and explains its mechanism of action, fully covering all key clinical facts without errors or omissions."
  },
  "286": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the insulin receptor as the directly activated molecule, provides accurate and clinically relevant explanation, and contains no inaccuracies or omissions."
  },
  "287": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the Fibroblast Growth Factor Receptor family and provides additional accurate, relevant information about other targeted receptors, but the reference specifically asks for the FGFR family, so listing others is a minor wording inaccuracy that does not alter the clinical meaning."
  },
  "288": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the interferon alpha (type I interferon) receptor complex (IFNAR1/IFNAR2) as the primary molecular target, accurately explains its mechanism, and contains no inaccuracies or omissions."
  },
  "289": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies DPP-4 as the inhibited enzyme and provides a clinically relevant, accurate explanation of the mechanism without any errors or omissions."
  },
  "290": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies cyclooxygenase-2 (COX-2) as the principal molecular target, provides accurate and clinically relevant explanation, and includes no inaccuracies or omissions compared to the reference answer."
  },
  "291": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the Vitamin D Receptor (VDR) as the mediator, explains its nuclear receptor function, the active form of vitamin D, and its role in immune modulation, fully matching all key clinical facts in the reference without errors or omissions."
  },
  "292": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies HMG-CoA reductase as the inhibited enzyme, explains the mechanism, and provides clinically relevant context without any inaccuracies or omissions."
  },
  "293": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the molecular mechanism, negative feedback, and clinical effects, and provides additional correct and relevant details without any inaccuracies or omissions."
  },
  "294": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the intracellular target, thoroughly explains the clinical context, mechanism, and provides relevant supporting details without inaccuracies or omissions."
  },
  "295": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies dihydrofolate reductase as the enzyme inhibited, explains methotrexate’s mechanism, and provides clinically relevant details without inaccuracies or omissions."
  },
  "296": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the mu-opioid receptor as the molecular target and provides additional, accurate, and clinically relevant detail about its location and mechanism, with no inaccuracies or omissions."
  },
  "297": {
    "score": 5.0,
    "explanation": "5: Fully covers all key clinical facts, correctly identifies the GnRH receptor as the primary target, and provides accurate, relevant mechanistic detail without any inaccuracies or omissions."
  },
  "298": {
    "score": 5.0,
    "explanation": "5: Fully identifies the glucocorticoid receptor as the molecular target, accurately explains its intracellular mechanism, and provides clinically relevant details without any inaccuracies or omissions."
  },
  "299": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies TNF-α as the molecular target, thoroughly explains the clinical context, and provides accurate, relevant details without any inaccuracies or omissions."
  },
  "300": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies inosine monophosphate dehydrogenase as the primary enzyme target, provides accurate clinical context, and includes only relevant, factually correct information without any omissions or inaccuracies."
  },
  "301": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies spleen tyrosine kinase (Syk) as the direct molecular target, covers all key clinical facts, and provides relevant, accurate explanation without any errors or omissions."
  },
  "302": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the molecular target, provides accurate and clinically relevant explanation, and contains no inaccuracies or omissions."
  },
  "303": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies somatostatin receptor subtype 2 (SSTR2) as the primary target, provides accurate and relevant clinical context, and contains no inaccuracies or omissions."
  },
  "304": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies angiotensin-converting enzyme as the direct molecular target and provides a clinically relevant, accurate explanation with no omissions or inaccuracies."
  },
  "305": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies HMG-CoA reductase as the targeted enzyme, covers all key clinical facts, and provides accurate, relevant explanation without any errors or omissions."
  },
  "306": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the thrombopoietin receptor (c-Mpl) as the target, provides accurate and relevant additional context about the drug (eltrombopag), and contains no inaccuracies or omissions."
  },
  "307": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the primary molecular target, provides accurate and clinically relevant explanation of the mechanism, and includes all key facts from the reference answer without any inaccuracies or omissions."
  },
  "308": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies TNF-α as the molecular target instead of interleukin-1 beta, which is a moderate factual error, though the rest of the explanation is relevant and not unsafe."
  },
  "309": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the primary molecular mediator, thoroughly explains the diagnosis, pathophysiology, and treatment, and provides accurate, clinically relevant details without any inaccuracies or omissions."
  },
  "310": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies TNF-α as the key cytokine, explains the clinical scenario, the drug (thalidomide), its mechanism, and its relevance to the condition, with no inaccuracies or omissions."
  },
  "311": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies HMG-CoA reductase as the target enzyme and provides a clinically relevant, accurate explanation matching all key facts in the reference answer."
  },
  "312": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies COX-2 as the primary target, explains the mechanism, and provides relevant additional detail without inaccuracies or omissions."
  },
  "313": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the insulin receptor as the primary molecular target and provides a clear, clinically relevant explanation that covers all key facts from the reference answer without any inaccuracies or omissions."
  },
  "314": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the intracellular mediator, provides accurate and clinically relevant additional details, and contains no inaccuracies or omissions."
  },
  "315": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the molecular target, accurately describes the mechanism of action, and provides relevant, factually correct additional details without any omissions or inaccuracies."
  },
  "316": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the histamine H2 receptor as the specific molecular target, provides accurate and relevant additional context about other receptors, and contains no inaccuracies or omissions."
  },
  "317": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the direct molecular target, provides accurate and clinically relevant explanation, and contains no inaccuracies or omissions."
  },
  "318": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX), including both COX-1 and COX-2, and accurately describes their role and the mechanism of NSAIDs. However, it does not specify COX-1 as the primary target as in the reference, representing a minor omission."
  },
  "319": {
    "score": 5.0,
    "explanation": "5: Fully identifies the IL-1 receptor as the molecular target, correctly names anakinra, and explains its mechanism; all key facts are present with no inaccuracies or omissions."
  },
  "320": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies nintedanib and lists all relevant inhibited receptors, but incorrectly states that PDGFR is the central receptor for reducing fibrosis, whereas the reference specifies VEGFR; this is a moderate factual error, though most key facts are otherwise covered."
  },
  "321": {
    "score": 3.0,
    "explanation": "3: The model answer incorrectly identifies SSTR2 instead of SSTR5 as the primary receptor, which is a moderate factual error, but otherwise provides accurate and relevant information about somatostatin analogs and their mechanism."
  },
  "322": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the molecular target, thoroughly explains its mechanism, and provides clinically relevant context without any inaccuracies or omissions."
  },
  "323": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX), specifically COX-1 and/or COX-2, as the molecular target and explains the mechanism, but does not specify COX-2 as the primary isoform relevant to dysmenorrhea, which is a minor omission."
  },
  "324": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies interleukin-5 as the molecular target, provides accurate and clinically relevant explanations, and includes additional correct information about related biologics and their targets without any inaccuracies or omissions."
  },
  "325": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the molecular target, thoroughly explains its intracellular location and mechanism, and provides only relevant, accurate information with no omissions or inaccuracies."
  },
  "326": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies COX-2 as the molecular target and provides accurate, relevant explanation and context, but does not explicitly use the full enzyme name \"Prostaglandin G/H Synthase 2\" as in the reference, which is a minor wording inaccuracy."
  },
  "327": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies spleen tyrosine kinase (SYK) as the direct molecular target, provides accurate and clinically relevant explanation, and contains no inaccuracies or omissions."
  },
  "328": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX) as the inhibited enzyme and provides a relevant explanation, but it does not specify COX-1 (prostaglandin G/H synthase 1) as in the reference, representing a minor omission."
  },
  "329": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies PDGFRA tyrosine kinase as the specific molecular target, provides relevant clinical context, and contains no inaccuracies or omissions."
  },
  "330": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the insulin receptor as the primary molecular target, accurately describes its nature as a transmembrane tyrosine kinase receptor, and provides clinically relevant mechanistic details without any inaccuracies or omissions."
  },
  "331": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies the estrogen receptor as the molecular target, explains the clinical context, and clarifies the distinction from standard therapy; all content is accurate and clinically relevant with no omissions."
  },
  "332": {
    "score": 5.0,
    "explanation": "5: The model answer includes all key clinical facts from the reference, correctly identifies HMG-CoA reductase as the target, and provides accurate, relevant additional explanation without any errors or omissions."
  },
  "333": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor, thoroughly explains the clinical context, mechanism of action, and distinguishes from other agents; all content is accurate and clinically relevant with no omissions or errors."
  },
  "334": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the glucocorticoid receptor as the target, and provides accurate, relevant mechanistic detail without inaccuracies or omissions."
  },
  "335": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies FIP1L1-PDGFRA as the causative fusion protein, provides accurate clinical reasoning, and includes relevant, factually correct extra content without any inaccuracies or omissions."
  },
  "336": {
    "score": 5.0,
    "explanation": "5: Fully correct identification of the enzyme, with accurate and clinically relevant explanation matching all key facts from the reference answer and no inaccuracies."
  },
  "337": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the proteasome and provides a thorough, accurate explanation, but it omits the specific \"26S\" designation, which is a key detail in the reference answer. All other content is correct and relevant."
  },
  "338": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies ROCK2 as the specific molecular target, provides the drug name (belumosudil), and accurately explains its mechanism and clinical context, with no omissions or inaccuracies."
  },
  "339": {
    "score": 5.0,
    "explanation": "5: Fully identifies the GnRH receptor as the direct target, explains its location and mechanism, and provides only clinically relevant, accurate details with no omissions or inaccuracies."
  },
  "340": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies thyroid peroxidase as the direct molecular target, thoroughly explains the mechanism, and provides relevant additional details without inaccuracies or omissions."
  },
  "341": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX) as the primary target and notes inhibition of both COX-1 and COX-2, but does not specifically name \"Prostaglandin G/H Synthase 2 (COX-2)\" as in the reference; this is a minor omission in specificity. All other content is accurate and relevant."
  },
  "342": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies the GnRH receptor as the molecular target, provides accurate and clinically relevant explanation of the mechanism, and contains no inaccuracies or omissions."
  },
  "343": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies VDR activation as the pathway, and provides accurate, relevant mechanistic detail without inaccuracies or omissions."
  },
  "344": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies β-tubulin as the primary molecular target and explains the mechanism of microtubule disruption, fully covering all key facts in the reference answer with accurate, relevant clinical context and no inaccuracies or omissions."
  },
  "345": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the molecular target, explains its intracellular location and mechanism, and provides relevant clinical context without any inaccuracies or omissions."
  },
  "346": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the clinical scenario, mechanism of action, and drug class, but incorrectly names SSTR2 instead of SSTR5 as the primary receptor subtype, which is a moderate factual error."
  },
  "347": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies tumor necrosis factor alpha (TNF-α) as the direct molecular target, provides accurate and relevant clinical context, and includes a helpful summary table without any inaccuracies or omissions."
  },
  "348": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies TNF-α as the direct molecular target, and provides relevant, accurate clinical context without any inaccuracies or omissions."
  },
  "349": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies angiotensin-converting enzyme as the primary molecular target, explains the clinical context, mechanism, and effect on angiotensin II, and provides only relevant, accurate information with no omissions or inaccuracies."
  },
  "350": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies HMG-CoA reductase as the inhibited enzyme and provides accurate, clinically relevant explanation matching all key facts in the reference answer without any errors or omissions."
  },
  "351": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the insulin receptor as the direct molecular target, provides accurate and clinically relevant explanation of its mechanism, and contains no inaccuracies or omissions."
  },
  "352": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the glucocorticoid receptor as the target, and provides accurate, relevant explanations without any inaccuracies or omissions."
  },
  "353": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies calcineurin as the direct molecular target, explains its role in T-cell activation and IL-2 transcription, and accurately describes the mechanism of action of cyclosporine and tacrolimus, with no omissions or inaccuracies."
  },
  "354": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies L-type calcium channels as the primary target, omitting the key fact that beta-1 adrenergic receptors are the main molecular target for the described medication (a beta-blocker). While the explanation is detailed and relevant for calcium channel blockers, it does not address the reference answer's focus, constituting a moderate factual error."
  },
  "355": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies topoisomerase II as the inhibited enzyme, names mitoxantrone, and provides accurate, clinically relevant context without any inaccuracies or omissions."
  },
  "356": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the primary molecular target, provides accurate and clinically relevant explanation, and contains no inaccuracies or omissions."
  },
  "357": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies CD20 as the molecular target, explains its presence on pre-B and mature B lymphocytes, and accurately describes the mechanism of B cell depletion in MS, fully covering all key clinical facts without errors or omissions."
  },
  "358": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies the histamine H₂ receptor as the molecular target, provides accurate and relevant explanation, and contains no errors or omissions."
  },
  "359": {
    "score": 3.0,
    "explanation": "3: The model answer correctly describes the clinical scenario, mechanism of glucocorticoids, and the role of NF-κB, but it omits the glucocorticoid receptor as the primary molecular target, which is the key fact in the reference answer."
  },
  "360": {
    "score": 5.0,
    "explanation": "5: All key facts are covered, including the precise molecular target (HMG-CoA reductase), and the additional explanation about statins and their mechanism is accurate and clinically relevant. No inaccuracies or omissions."
  },
  "361": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the molecular target, thoroughly explains its intracellular location, mechanism of action, and clinical relevance, with no inaccuracies or omissions."
  },
  "362": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the molecular target, thoroughly explains the mechanism, and provides relevant clinical context without any inaccuracies or omissions."
  },
  "363": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies xanthine oxidase as the target, explains its role in purine metabolism, names relevant drugs, and clearly links enzyme inhibition to reduced uric acid and gout prevention, with no inaccuracies or omissions."
  },
  "364": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key facts from the reference (activation of the glucocorticoid receptor), accurately describes the molecular mechanism, and provides clinically relevant, correct additional detail without inaccuracies or omissions."
  },
  "365": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies the glucocorticoid receptor, accurately describes its intracellular/nuclear location, mechanism of action, and clinical relevance; no errors or omissions."
  },
  "366": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the beta-1 adrenergic receptor, and provides relevant, accurate explanations without any inaccuracies or omissions."
  },
  "367": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the principal target as viral DNA polymerase and provides accurate, relevant mechanistic details, but omits the more precise term \"DNA-directed DNA polymerase\" as in the reference answer; this is a minor wording inaccuracy that does not alter the clinical meaning."
  },
  "368": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the principal mediator and provides accurate, clinically relevant explanation without any errors or omissions."
  },
  "369": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies PDGFRA as the molecular target, provides accurate clinical reasoning, and includes only relevant, factually correct additional information without any omissions or inaccuracies."
  },
  "370": {
    "score": 5.0,
    "explanation": "5: All key facts are present, including the direct molecular target (HMG-CoA reductase), its role, and the mechanism; extra content is accurate and clinically relevant."
  },
  "371": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies DNA methyltransferase as the molecular target, explains its role in methyl group transfer to DNA, and links this to the drug's long-term effects; all key facts are covered with no inaccuracies or omissions."
  },
  "372": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor, thoroughly explains the mechanism, and provides relevant comparisons to other drug classes without any inaccuracies or omissions."
  },
  "373": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the primary molecular target, thoroughly explains the mechanism, and provides relevant clinical context without any inaccuracies or omissions."
  },
  "374": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies the glucocorticoid receptor as the molecular target, provides accurate and clinically relevant explanation, and contains no inaccuracies or omissions."
  },
  "375": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the dopamine D2 receptor as the molecular target, thoroughly explains the clinical context, mechanism, and relevant pharmacology, and contains no inaccuracies or omissions."
  },
  "376": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the beta-1 adrenergic receptor as the molecular target, provides accurate reasoning, and includes relevant, factually correct comparisons to other GPCRs without any inaccuracies or omissions."
  },
  "377": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies the glucocorticoid receptor and provides a clinically relevant, accurate explanation with no errors or omissions."
  },
  "378": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the primary mediator, covers all key clinical facts from the reference, and provides accurate, relevant clinical context without any inaccuracies or omissions."
  },
  "379": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the primary molecular target, thoroughly explains the mechanism, and provides relevant clinical context without any inaccuracies or omissions."
  },
  "380": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies ACE as the specific molecular target and provides a relevant, accurate explanation with no omissions or inaccuracies."
  },
  "381": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the AT₁ receptor as the target, clearly explains its role in diabetic nephropathy, and provides accurate, clinically relevant details without any omissions or inaccuracies."
  },
  "382": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the molecular target and provides accurate, clinically relevant explanation without any errors or omissions."
  },
  "383": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and relevant additional explanation, and correctly identifies complement C5 as the direct molecular target without any inaccuracies or omissions."
  },
  "384": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies TNF-α as the inhibited cytokine, and provides relevant, accurate clinical reasoning without any inaccuracies or omissions."
  },
  "385": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the clinical scenario, the likely drug (foscarnet), and accurately states that the molecular target is viral DNA polymerase (DNA-directed DNA polymerase), matching the reference answer. All key facts are covered with relevant, correct elaboration and no inaccuracies."
  },
  "386": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies the glucocorticoid receptor as the primary target and provides accurate, clinically relevant explanation without errors or omissions."
  },
  "387": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the molecular target, provides accurate and clinically relevant explanation, and contains no inaccuracies or omissions compared to the reference answer."
  },
  "388": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the glucocorticoid receptor pathway, and provides relevant, correct additional details without any inaccuracies or omissions."
  },
  "389": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies the glucocorticoid receptor as the primary intracellular receptor, accurately describes its mechanism, and provides relevant, factually correct additional detail without any errors or omissions."
  },
  "390": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX-1/COX-2) as the molecular target and provides relevant, accurate clinical context, but it emphasizes COX-2 as the \"precise target,\" which is a minor inaccuracy since most oral NSAIDs inhibit both COX-1 and COX-2; otherwise, all key facts are covered."
  },
  "391": {
    "score": 5.0,
    "explanation": "5: All key facts are covered, including the direct inhibition of calcineurin, and the additional mechanistic details are accurate and clinically relevant with no inaccuracies or omissions."
  },
  "392": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX) as the inhibited enzyme and provides a thorough, accurate explanation of its role in prostaglandin synthesis and urate handling. However, it does not specify COX-2 (prostaglandin G/H synthase 2) as in the reference, representing a minor omission in precision."
  },
  "393": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the β₁-adrenergic receptor as the molecular target, thoroughly explains its role, and provides only clinically relevant, accurate information with no omissions or inaccuracies."
  },
  "394": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies ACE as the direct molecular target, explains its role, and provides relevant, accurate clinical context without any errors or omissions."
  },
  "395": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies cyclooxygenase-2 (COX-2) as the molecular target, explains its role in both therapeutic effects and GI side effects, and provides accurate, relevant additional information without any inaccuracies or omissions."
  },
  "396": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the primary molecular target, thoroughly explains the mechanism, and provides relevant clinical context without any inaccuracies or omissions."
  },
  "397": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies Janus kinase (JAK) as the primary molecular target, whereas the reference specifies the glucocorticoid receptor; while the explanation is relevant and not unsafe, this represents a moderate factual error."
  },
  "398": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the molecular target, thoroughly explains the mechanism, and provides relevant differential considerations without any inaccuracies or omissions."
  },
  "399": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the molecular target, fully explains the mechanism, and provides only relevant, accurate, and clinically appropriate additional detail with no omissions or inaccuracies."
  },
  "400": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the p40 subunit as the target, explains its relevance to both IL-12 and IL-23, and provides accurate, clinically relevant context without any omissions or inaccuracies."
  },
  "401": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies cyclooxygenase-2 (COX-2) as the primary target, provides accurate and clinically relevant explanation, and covers all key facts from the reference answer without any errors or omissions."
  },
  "402": {
    "score": 2.0,
    "explanation": "2: The model answer provides a detailed discussion of possible agents but ultimately identifies mTOR as the primary target, which is incorrect; the reference answer is VEGF-A. While the answer covers some relevant background, it misses the key fact and includes moderate factual inaccuracies regarding the main molecular target."
  },
  "403": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX) as the inhibited enzyme and provides a thorough, accurate explanation, but does not specify COX-1 (prostaglandin G/H synthase 1) as in the reference; this is a minor omission since NSAIDs inhibit both COX-1 and COX-2, but the reference asks for the most direct enzyme (COX-1)."
  },
  "404": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the direct molecular target, provides accurate and clinically relevant explanation, and contains no inaccuracies or omissions."
  },
  "405": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies the estrogen receptor as the molecular target, explains the agonist/antagonist actions in relevant tissues, and provides accurate, clinically relevant detail with no errors or omissions."
  },
  "406": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies inosine monophosphate dehydrogenase as the molecular target and provides accurate, clinically relevant explanation without any errors or omissions."
  },
  "407": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the p40 subunit as the direct molecular target, explains its relevance to both IL-12 and IL-23, and provides accurate, clinically relevant extra information without any inaccuracies or omissions."
  },
  "408": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX) as the molecular target and explains the mechanism, but does not specify COX-2 (prostaglandin G/H synthase 2) as in the reference; this is a minor omission since NSAIDs often inhibit both COX-1 and COX-2, but COX-2 is more relevant to the question."
  },
  "409": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the glucocorticoid receptor as the primary intracellular target, and provides accurate, relevant mechanistic detail without any inaccuracies or omissions."
  },
  "410": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies the glucocorticoid receptor as the direct molecular target, provides accurate and clinically relevant explanation, and contains no inaccuracies or omissions."
  },
  "411": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the histamine H2 receptor as the molecular target, provides accurate clinical context, and contains no inaccuracies or omissions."
  },
  "412": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional explanation, and contains no inaccuracies or omissions."
  },
  "413": {
    "score": 5.0,
    "explanation": "5: Fully identifies the estrogen receptor as the molecular target, explains the mechanism, names raloxifene as the likely drug, and provides relevant, accurate clinical context without any errors or omissions."
  },
  "414": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies ornithine decarboxylase as the target enzyme and provides accurate, clinically relevant explanations and context, with no omissions or inaccuracies."
  },
  "415": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies HMG-CoA reductase as the primary molecular target and provides accurate, clinically relevant explanation without any errors or omissions."
  },
  "416": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies HMG-CoA reductase as the inhibited enzyme and provides accurate, clinically relevant explanation matching all key facts in the reference without any errors or omissions."
  },
  "417": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies CD25 as the target, explains its role as the IL-2 receptor alpha chain, and provides relevant clinical context without inaccuracies or omissions."
  },
  "418": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the primary target and provides a clinically relevant, accurate explanation with no omissions or inaccuracies."
  },
  "419": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies cyclooxygenase-2 (COX-2) as the direct pharmacologic target, covers all key clinical facts, and provides relevant, accurate explanation without any errors or omissions."
  },
  "420": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the molecular mechanism (glucocorticoid receptor activation), and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "421": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the IL-6 receptor α subunit (CD126) as the target, covers all key clinical facts, and provides relevant, accurate explanations without any inaccuracies or omissions."
  },
  "422": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describing androgen receptor activation and providing additional correct, clinically relevant mechanistic detail without any inaccuracies or omissions."
  },
  "423": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the histamine H2 receptor as the molecular target, explains the mechanism, and provides relevant clinical context without any inaccuracies or omissions."
  },
  "424": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies the glucocorticoid receptor and provides a clinically relevant, accurate explanation of the drug’s mechanism, with no errors or omissions."
  },
  "425": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies cyclooxygenase (COX) as the enzyme, explains its role in prostaglandin synthesis, and accurately describes the clinical relevance without any inaccuracies or omissions."
  },
  "426": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the β₁-adrenergic receptor as the molecular target, provides accurate and relevant explanation, and includes only factually correct, clinically pertinent extra content without omissions or inaccuracies."
  },
  "427": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies SGLT2 as the primary target, accurately describes its location and mechanism, and provides relevant examples without any inaccuracies or omissions."
  },
  "428": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies inosine monophosphate dehydrogenase (IMPDH) as the enzyme inhibited, provides accurate clinical context, and contains no inaccuracies or omissions."
  },
  "429": {
    "score": 5.0,
    "explanation": "5: Fully correct—names the enzyme acetylcholinesterase, provides accurate and relevant explanation, and includes correct examples of drugs without any errors or omissions."
  },
  "430": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies SGLT2 as the molecular target and provides accurate, clinically relevant explanation without any errors or omissions."
  },
  "431": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies the thrombopoietin receptor (c-Mpl) as the direct target, provides relevant drug context, and contains no inaccuracies or omissions."
  },
  "432": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key facts from the reference, accurately describing activation of the glucocorticoid receptor and its downstream effects, with additional correct and relevant mechanistic detail."
  },
  "433": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the molecular target, explains the mechanism of action, and provides clinically relevant details without any inaccuracies or omissions."
  },
  "434": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the retinoic acid receptor as the primary molecular target, provides accurate and clinically relevant explanation, and contains no inaccuracies or omissions."
  },
  "435": {
    "score": 3.0,
    "explanation": "3: The model answer provides a thorough discussion of actinic keratosis and topical therapies, but incorrectly identifies EGFR as the most directly targeted receptor, rather than IGF-1R as in the reference. While the mechanistic discussion is detailed and relevant, the key fact (the specific receptor) is incorrect, constituting a moderate factual error."
  },
  "436": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the primary target and accurately describes the mechanism of action, matching all key clinical facts in the reference without any errors or omissions."
  },
  "437": {
    "score": 5.0,
    "explanation": "5: Fully covers all key clinical facts from the reference answer, accurately identifies acetylcholinesterase as the target, explains the mechanism, and provides clinically relevant elaboration without inaccuracies or irrelevant content."
  },
  "438": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies the glucocorticoid receptor and provides accurate, relevant mechanistic details without any errors or omissions."
  },
  "439": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies HMG-CoA reductase as the target enzyme and provides accurate, clinically relevant explanation without errors or omissions."
  },
  "440": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the primary mediator, explains the clinical context, mechanism of action, and provides no inaccuracies or omissions."
  },
  "441": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies HMG-CoA reductase as the direct molecular target and provides a clinically relevant, accurate explanation with no omissions or inaccuracies."
  },
  "442": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies the glucocorticoid receptor as the principal molecular receptor, explains its cytosolic location, nuclear translocation, and gene transcription effects, with all content factually accurate and clinically relevant."
  },
  "443": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX) as the molecular target and explains its role, but does not specify COX-2 (prostaglandin G/H synthase 2) as the primary isoform relevant to anti-inflammatory effects, which is a minor omission."
  },
  "444": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies isotretinoin and provides a detailed, accurate mechanism involving RARs and RXRs, but it incorrectly names RAR as the primary direct target, whereas the reference specifies RXR; this constitutes a moderate factual inaccuracy."
  },
  "445": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the molecular target, thoroughly explains the mechanism, and provides only relevant, accurate, and clinically appropriate additional information without any omissions or inaccuracies."
  },
  "446": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the primary molecular target, accurately describes the mechanism of action, and provides relevant clinical context without any inaccuracies or omissions."
  },
  "447": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies RANKL as the direct molecular target, provides accurate mechanism, and all extra content is factually correct and clinically relevant. No omissions or inaccuracies."
  },
  "448": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX) as the principal molecular target and explains its role, but does not specifically name \"Prostaglandin G/H Synthase 1 (Cyclooxygenase-1)\" as in the reference; it also mentions COX-2, which is not the principal target per the reference, representing a minor inaccuracy in specificity."
  },
  "449": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies HMG-CoA reductase as the direct molecular target and accurately explains the mechanism, matching all key clinical facts in the reference without any errors or omissions."
  },
  "450": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the G-CSF receptor as the molecular target, provides its alternative name (CD114), and accurately explains the clinical context and mechanism, with all content factually correct and clinically relevant."
  },
  "451": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies the H2 histamine receptor as the molecular target, explains its mechanism, and provides relevant, accurate detail without any errors or omissions."
  },
  "452": {
    "score": 5.0,
    "explanation": "5: Fully identifies the β₁-adrenergic receptor as the primary target, matches all key clinical facts, and provides correct, relevant extra explanation without inaccuracies or omissions."
  },
  "453": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the intracellular target, thoroughly explains the mechanism of action, and provides relevant clinical context without any inaccuracies or omissions."
  },
  "454": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor, fully explains the mechanism, and contains no inaccuracies or omissions."
  },
  "455": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies the glucocorticoid receptor, explains the mechanism, and provides relevant clinical context without inaccuracies or omissions."
  },
  "456": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies dihydrofolate reductase as the target enzyme, explains the mechanism, and relates it to methotrexate, matching all key clinical facts in the reference without errors or omissions."
  },
  "457": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies cyclooxygenase (COX) inhibition as the mechanism and mentions both COX-1 and COX-2, but does not specify COX-2 (prostaglandin G/H synthase 2) as the primary enzyme responsible for the anti-inflammatory effect, missing the key fact emphasized in the reference answer."
  },
  "458": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor, provides accurate and relevant mechanistic detail, and contains no inaccuracies or omissions."
  },
  "459": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies angiotensin-converting enzyme (ACE) as the inhibited enzyme and accurately explains the mechanism and clinical benefits, with all key facts from the reference included and no inaccuracies."
  },
  "460": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies HMG-CoA reductase as the direct target and provides a clinically relevant, accurate explanation matching all key facts in the reference answer."
  },
  "461": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the glucocorticoid receptor pathway, and provides additional correct and relevant mechanistic detail without any inaccuracies or omissions."
  },
  "462": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor, thoroughly explains the mechanism, and provides clinically relevant context without any inaccuracies or omissions."
  },
  "463": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the JAK-STAT pathway and the thrombopoietin receptor (c-MPL)–JAK2 complex as the molecular mediator, but it incorrectly assumes the therapy is a thrombopoietin receptor agonist rather than interferon alpha, missing the key fact that the interferon alpha receptor complex is the direct mediator in this context."
  },
  "464": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the primary target, accurately describes the mechanism of action, and provides relevant, factually correct additional details without any omissions or inaccuracies."
  },
  "465": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and relevant additional explanation, and contains no inaccuracies or omissions."
  },
  "466": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies the glucocorticoid receptor as the target, explains the drug class and mechanism, and contains no inaccuracies or omissions."
  },
  "467": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies integrin alpha-4 (specifically α4β7 integrin) as the direct molecular target, covers all key clinical facts, and provides relevant, accurate additional explanation without any errors or omissions."
  },
  "468": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies the vitamin D receptor (VDR) as the target, explains its nuclear receptor mechanism, and relates it to the clinical scenario without any inaccuracies or omissions."
  },
  "469": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the molecular target and provides a clear, accurate, and clinically relevant explanation without any errors or omissions."
  },
  "470": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies thioredoxin reductase as the inhibited enzyme and provides accurate, relevant explanation, but it omits the specific mitochondrial isoform (thioredoxin reductase 2) named in the reference answer, which is a minor omission."
  },
  "471": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the glucocorticoid receptor, and provides accurate, relevant mechanistic and clinical context without any inaccuracies or omissions."
  },
  "472": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the mediator, accurately describes the mechanism of action, and provides relevant clinical context without any inaccuracies or omissions."
  },
  "473": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies COX-2 as the primary molecular target, explains its role in prostaglandin synthesis, and accurately describes the mechanism and clinical relevance without any inaccuracies or omissions."
  },
  "474": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies PDGFRA as the direct molecular target, provides accurate and clinically relevant explanation, and includes only factually correct, relevant extra content without any omissions or inaccuracies."
  },
  "475": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies COX-2 as the primary target, whereas the reference specifies COX-1; while the explanation is accurate regarding COX-2's role in inflammation, it omits that most NSAIDs used in acute gout are nonselective and that COX-1 is the key enzyme per the reference, constituting a moderate factual error."
  },
  "476": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the beta-1 adrenergic receptor as the specific molecular target, provides accurate and relevant clinical context, and contains no inaccuracies or omissions."
  },
  "477": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the molecular target, provides accurate clinical reasoning, and includes only relevant, factually correct additional information without any omissions or inaccuracies."
  },
  "478": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies the insulin receptor, provides accurate and relevant explanation, and contains no errors or omissions."
  },
  "479": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies the glucocorticoid receptor as the target, explains the mechanism, and provides relevant clinical context with no inaccuracies or omissions."
  },
  "480": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies interleukin-5 receptor alpha (IL-5Rα) as the molecular target, provides accurate and clinically relevant explanation, and contains no inaccuracies or omissions."
  },
  "481": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the medication as aspirin and explains its mechanism, including irreversible inhibition of COX-1 and COX-2, but does not specifically name \"Prostaglandin G/H Synthase 2 (COX-2)\" as the most directly relevant molecular target, which is a minor omission."
  },
  "482": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX), including both COX-1 and COX-2, as the molecular targets of NSAIDs and provides accurate, relevant clinical context. However, it does not specifically name \"Prostaglandin G/H Synthase 1 (COX-1)\" as in the reference, representing a minor omission in precision."
  },
  "483": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX), notes irreversible inhibition, and specifies both COX-1 and COX-2, but does not explicitly name COX-2 (prostaglandin G/H synthase 2) as the most directly relevant target for the anti-inflammatory effect, which is a minor omission."
  },
  "484": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor, explains the mechanism, and provides relevant clinical context without any inaccuracies or omissions."
  },
  "485": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the interferon alpha receptor complex (IFNAR1/IFNAR2), and provides accurate, relevant mechanistic detail with no inaccuracies or omissions."
  },
  "486": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the primary intracellular target, thoroughly explains the mechanism, and provides relevant clinical context without any inaccuracies or omissions."
  },
  "487": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies HMG-CoA reductase as the target enzyme, accurately describes its mechanism and effect, and includes only relevant, factually correct information with no omissions or inaccuracies."
  },
  "488": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX) as the direct molecular target and provides accurate, relevant reasoning, but does not specify COX-2 (prostaglandin G/H synthase 2) as in the reference answer, representing a minor omission in precision."
  },
  "489": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies ribonucleotide reductase as the inhibited enzyme, provides accurate and relevant explanation, and includes no inaccuracies or omissions."
  },
  "490": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the principal target, provides accurate and clinically relevant explanation, and covers all key facts from the reference answer without any errors or omissions."
  },
  "491": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor, provides accurate and clinically relevant explanation of its mechanism, and contains no inaccuracies or omissions."
  },
  "492": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the AT1 receptor as the molecular target, covers all key clinical facts, and provides accurate, relevant explanations without any errors or omissions."
  },
  "493": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the thrombopoietin (TPO) receptor (c-Mpl) as the target, provides accurate and clinically relevant explanation, and contains no inaccuracies or omissions."
  },
  "494": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies dihydrofolate reductase as the inhibited enzyme, provides accurate and clinically relevant explanation, and contains no inaccuracies or omissions."
  },
  "495": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the IL-2 receptor (CD25) as the direct molecular target, explains its role in T-cell proliferation, and provides relevant, accurate detail without any omissions or inaccuracies."
  },
  "496": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor and provides a clinically relevant, accurate explanation of its mechanism, fully covering all key facts in the reference answer."
  },
  "497": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the IL-23 p19 subunit as the direct molecular target, explains its relevance to Th17 cells, and provides accurate, clinically relevant details without any inaccuracies or omissions."
  },
  "498": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies dihydrofolate reductase as the principal molecular target, provides accurate and clinically relevant additional details about methotrexate and its mechanism, and contains no inaccuracies or omissions."
  },
  "499": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the AT1 receptor as the molecular target, thoroughly explains the clinical scenario, mechanism, and rationale, and contains no inaccuracies or omissions."
  },
  "500": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies PDGFRA as the molecular target and explains the pathophysiology and treatment, but it does not mention KIT (the reference answer), thus missing a key fact. The rest of the content is accurate and relevant."
  },
  "501": {
    "score": 3.0,
    "explanation": "3: The model answer provides a thorough explanation of the mechanism of abatacept and correctly describes the drug’s action, but it ultimately names CD80/CD86 as the primary molecular target, rather than CTLA-4 as specified in the reference answer. This represents a minor but important factual inaccuracy, as the question asks for the inhibitory receptor (CTLA-4) rather than its ligand."
  },
  "502": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the primary molecular target, thoroughly explains its mechanism of action, and provides additional clinically relevant details without any inaccuracies or omissions."
  },
  "503": {
    "score": 5.0,
    "explanation": "5: All key clinical facts are covered, including the direct molecular target (BAFF/BLyS), its role, and the mechanism of action; additional content is accurate and clinically relevant with no omissions or inaccuracies."
  },
  "504": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies inosine monophosphate dehydrogenase as the inhibited enzyme, provides accurate clinical context, and includes only relevant, factually correct information without omissions or inaccuracies."
  },
  "505": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor, provides accurate and clinically relevant explanation, and contains no inaccuracies or omissions."
  },
  "506": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies TNF (TNF-α) as the cytokine, provides accurate and clinically relevant explanation, and includes a helpful summary table without any inaccuracies or omissions."
  },
  "507": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the molecular target, thoroughly explains the clinical scenario, mechanism of action, and links all key facts without any inaccuracies or omissions."
  },
  "508": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies TNF-α as the molecular target, provides accurate and clinically relevant explanation, and includes additional correct details without any inaccuracies or omissions."
  },
  "509": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies phosphodiesterase 5 (PDE5) as the molecular target, explains its role in cGMP breakdown, and links its inhibition to increased cGMP and anti-inflammatory effects, fully covering all key clinical facts in the reference answer."
  },
  "510": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the primary molecular target, thoroughly explains the mechanism, and provides clinically relevant context without any inaccuracies or omissions."
  },
  "511": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the β1-adrenergic receptor as the molecular target, covers all key clinical facts, and provides accurate, relevant explanations without any inaccuracies or omissions."
  },
  "512": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies CD25 (IL-2 receptor α chain) as the direct molecular target, provides accurate clinical context, and includes only relevant, factually correct information with no omissions or inaccuracies."
  },
  "513": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies inosine monophosphate dehydrogenase as the inhibited enzyme, covers all key clinical facts, and provides relevant, accurate additional context without any errors or omissions."
  },
  "514": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies cyclooxygenase (COX), specifies both COX-1 and COX-2, and accurately describes their role in prostaglandin synthesis and inflammation; all key facts from the reference are included with relevant, accurate elaboration."
  },
  "515": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor, explains the clinical scenario, and accurately describes the mechanism of action, with no inaccuracies or omissions."
  },
  "516": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describing glucocorticoid receptor activation and altered gene transcription, with additional correct and relevant mechanistic details and no inaccuracies or omissions."
  },
  "517": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX-1 and COX-2) as the directly inhibited enzymes and provides relevant, accurate context, but does not explicitly use the full name \"Prostaglandin G/H Synthase 1\" as in the reference, which is a minor wording inaccuracy."
  },
  "518": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the diagnosis, mechanism, and receptor, and provides relevant, accurate explanations without any inaccuracies or omissions."
  },
  "519": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies TNF-α as the cytokine inhibited, explains the mechanism, and accurately names thalidomide as the agent, with all content factually correct and clinically relevant."
  },
  "520": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies IL-6Rα as the direct molecular target, provides accurate clinical reasoning, and includes only relevant, factually correct information with no omissions or inaccuracies."
  },
  "521": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the glucocorticoid receptor mechanism, and provides additional correct and clinically relevant molecular details without any inaccuracies or omissions."
  },
  "522": {
    "score": 5.0,
    "explanation": "5: All key clinical facts are covered, including the enzyme name, drug, mechanism, and clinical context; extra details are accurate and clinically relevant with no errors or omissions."
  },
  "523": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies α4-integrin (CD49d) as the primary target, explains the mechanism, and provides relevant clinical context without any inaccuracies or omissions."
  },
  "524": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies TNF-α as the molecular target, covers all key clinical facts, and provides relevant, accurate additional context without any inaccuracies or omissions."
  },
  "525": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the intracellular mediator, provides accurate and clinically relevant additional explanation, and contains no inaccuracies or omissions."
  },
  "526": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies Janus kinase (JAK) as the molecular target and provides accurate, relevant explanation, but does not specify JAK1 as the direct target as in the reference answer, representing a minor omission."
  },
  "527": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies dihydrofolate reductase as the direct molecular target, provides accurate and relevant clinical context, and contains no inaccuracies or omissions."
  },
  "528": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor, thoroughly explains the mechanism of action, and provides relevant clinical context without any inaccuracies or omissions."
  },
  "529": {
    "score": 3.0,
    "explanation": "3: The model answer provides a thorough explanation of insulin signaling and correctly identifies the insulin receptor as the binding target, but it ultimately names GLUT4 as the \"directly activated molecular target,\" which is inaccurate for this question; the reference answer is \"insulin receptor.\" This constitutes a moderate factual error, though most key facts are otherwise covered."
  },
  "530": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies HMG-CoA reductase as the target enzyme and provides a clinically relevant, accurate explanation of statin mechanism with no errors or omissions."
  },
  "531": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor and provides accurate, clinically relevant explanation without any errors or omissions."
  },
  "532": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies COX-2 as the molecular target, covers all key clinical facts, and provides relevant, accurate explanations without any errors or omissions."
  },
  "533": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the molecular target, thoroughly explains the mechanism, and provides clinically relevant details without inaccuracies or omissions."
  },
  "534": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX), particularly COX-2, as the molecular target and provides accurate, relevant clinical reasoning. However, it does not explicitly name \"Prostaglandin G/H Synthase 2 (COX-2)\" as in the reference, representing a minor omission in specificity."
  },
  "535": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies HMG-CoA reductase as the enzyme, explains the mechanism, and provides relevant, accurate extra information without any errors or omissions."
  },
  "536": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies PPAR-γ as the direct molecular target and provides accurate, clinically relevant explanation without any inaccuracies or omissions."
  },
  "537": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the specific intracellular receptor, thoroughly explains the mechanism, and provides only relevant, accurate information with no omissions or inaccuracies."
  },
  "538": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies inosine monophosphate dehydrogenase as the direct molecular target and provides accurate, clinically relevant additional explanation without any inaccuracies or omissions."
  },
  "539": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies ROCK2 as the direct molecular target, provides accurate and clinically relevant context, and contains no inaccuracies or omissions."
  },
  "540": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies the glucocorticoid receptor as the molecular target and provides a clinically relevant, accurate explanation with no omissions or inaccuracies."
  },
  "541": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies protein kinase C (PKC) as the primary enzyme inhibited by gold-based therapy and provides accurate, relevant explanation, but it omits the specific isoform \"iota type\" mentioned in the reference answer, which is a minor omission."
  },
  "542": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies cyclooxygenase (COX) as the enzyme, provides both names (COX and prostaglandin-endoperoxide synthase), and accurately explains the clinical context and mechanism, with no omissions or inaccuracies."
  },
  "543": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies cyclooxygenase-2 (COX-2) as the molecular target and provides a clinically relevant, accurate explanation with no omissions or inaccuracies."
  },
  "544": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the primary molecular target as phosphodiesterase 5 (PDE5), which is a cGMP-specific phosphodiesterase, and accurately explains the mechanism and therapeutic effect. There is a minor inaccuracy in suggesting that NSAIDs like celecoxib have clinically significant PDE5 inhibition, which is not a primary or well-established mechanism in osteoarthritis therapy, but this does not substantially alter the core meaning."
  },
  "545": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies HMG-CoA reductase as the molecular target and provides accurate, clinically relevant explanation without any errors or omissions."
  },
  "546": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the clinical scenario and mechanism of action for abatacept, but incorrectly names CD28 as the direct molecular target, rather than CD2 as in the reference. The answer is otherwise thorough and accurate, but this constitutes a moderate factual error."
  },
  "547": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX) as the molecular target and explains its role, but it does not specify COX-1 as the reference answer does; instead, it mentions both COX-1 and COX-2, which is accurate for NSAIDs in general but slightly less specific than required."
  },
  "548": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the retinoic acid receptor as the molecular target, explains the mechanism, and provides relevant, accurate additional information without any errors or omissions."
  },
  "549": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies phosphodiesterase type 5 (PDE5) as the cGMP-specific enzyme, which is a clinically relevant and accurate synonym for \"cGMP-specific 3',5'-cyclic phosphodiesterase.\" There is a minor wording inaccuracy with mention of PDE3, but this does not alter the core meaning or clinical accuracy."
  },
  "550": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies cyclooxygenase (COX) as the enzyme, provides accurate clinical context, and explains the mechanism without any inaccuracies or omissions."
  },
  "551": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describing ACE inhibition, the blocked conversion of angiotensin I to II, and the resulting decrease in angiotensin II-mediated vasoconstriction; all additional details are correct and clinically relevant."
  },
  "552": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies bacterial RNA polymerase as the target and provides relevant context, but specifying the \"sigma subunit\" is a minor inaccuracy—fidaxomicin inhibits the initiation of transcription by binding to the RNA polymerase complex, not exclusively the sigma subunit. Otherwise, all key facts are present."
  },
  "553": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor, fully explains the clinical context and mechanism, and contains no inaccuracies or omissions."
  },
  "554": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies cyclooxygenase (COX) as the primary molecular target, provides the alternative name (prostaglandin-endoperoxide synthase), and accurately explains the mechanism, matching all key facts in the reference without errors or omissions."
  },
  "555": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies COX-2 (PTGS2) as the primary target, explains its inducible nature, role in prostaglandin synthesis, and clinical relevance in RA, with no inaccuracies or omissions."
  },
  "556": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the primary target, provides relevant context about hydrocortisone, and includes only accurate, clinically relevant additional information without any omissions or inaccuracies."
  },
  "557": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies topoisomerase II as the primary molecular target, provides accurate and clinically relevant context about mitoxantrone, and contains no inaccuracies or omissions."
  },
  "558": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX), including both COX-1 and COX-2, as the molecular targets, which is accurate and clinically relevant. However, it does not specify COX-1 (Prostaglandin G/H Synthase 1) as the primary target as in the reference, representing a minor omission."
  },
  "559": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies dihydroorotate dehydrogenase as the targeted enzyme, provides accurate and relevant clinical context, and includes only factually correct, clinically relevant extra information without any omissions or inaccuracies."
  },
  "560": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies the glucocorticoid receptor as the molecular target and provides a clinically relevant, accurate explanation with no omissions or inaccuracies."
  },
  "561": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the molecular mechanism as inhibition of cyclooxygenase (COX), which blocks the conversion of arachidonic acid to prostaglandins, and provides relevant clinical context. However, it does not specifically name \"Prostaglandin G/H Synthase 2 (COX-2)\" as in the reference, representing a minor omission in precision."
  },
  "562": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies AMPK as the molecular target, covers all key clinical facts, and provides relevant, accurate explanations without any omissions or inaccuracies."
  },
  "563": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies DPP-4 as the direct molecular target and provides accurate, relevant explanation without any errors or omissions."
  },
  "564": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the primary molecular target and provides accurate, clinically relevant details about its intracellular location and mechanism of action, with no omissions or inaccuracies."
  },
  "565": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies ornithine decarboxylase as the direct target, explains the clinical context, mechanism, and drug (eflornithine) with no inaccuracies or omissions."
  },
  "566": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX), including both COX-1 and COX-2, as the inhibited enzyme and accurately describes the mechanism, but does not specify \"Prostaglandin G/H Synthase 1 (COX-1)\" as in the reference; this is a minor wording inaccuracy."
  },
  "567": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies TNF-α as the molecular target, provides relevant clinical context, and includes accurate, clinically relevant details about the therapy and its mechanism, with no inaccuracies or omissions."
  },
  "568": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the mechanism as protein synthesis inhibition via the 30S ribosomal subunit, and provides relevant, accurate additional context without any errors or omissions."
  },
  "569": {
    "score": 3.0,
    "explanation": "3: The model answer accurately describes pyrantel pamoate’s mechanism (persistent activation of nicotinic acetylcholine receptors causing spastic paralysis), but it does not mention cholinesterase inhibition, which is the specific molecular mechanism referenced in the key. Thus, it covers most but not all key facts."
  },
  "570": {
    "score": 3.0,
    "explanation": "3: The model answer correctly states that the precise mechanism of action against trematodes is not well established, but it incorrectly identifies the drug as nitazoxanide instead of emetine hydrochloride, which is a moderate factual error; otherwise, it covers the uncertainty about the mechanism."
  },
  "571": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies transpeptidases (penicillin-binding proteins) as the target, provides accurate clinical context, and offers relevant, factually correct explanations with no omissions or inaccuracies."
  },
  "572": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies NSAIDs as the drug class and COX as the molecular target, with additional accurate and clinically relevant explanation; no omissions or inaccuracies."
  },
  "573": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies CD20 as the target, explains the monoclonal antibody mechanism, and directly states that binding to CD20 on B cells is the key molecular interaction, fully covering all key clinical facts without inaccuracies or omissions."
  },
  "574": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the agent as an interferon, describes its mechanism, and provides relevant clinical context, but does not explicitly use the term \"biological response modifiers,\" which is the most accurate pharmacological class per the reference answer; otherwise, coverage is thorough and accurate."
  },
  "575": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key facts from the reference, accurately identifies colchicine, explains its known actions, and clearly states that the precise molecular mechanism of its anti-inflammatory effect in gout remains incompletely understood, with no inaccuracies or omissions."
  },
  "576": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the Na⁺-K⁺-2Cl⁻ cotransporter (NKCC2) in the thick ascending limb, matches all key facts, and provides additional clinically relevant and accurate information without any errors or omissions."
  },
  "577": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the mechanism, and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "578": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the mechanism, names relevant drugs, and provides clinically relevant context without any inaccuracies or omissions."
  },
  "579": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the drug class as interleukin-1 receptor antagonists, explains the mechanism, and provides relevant context without inaccuracies or omissions."
  },
  "580": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies proton pump inhibitors as the drug class sharing the molecular target and provides relevant context, but it introduces a minor inaccuracy by suggesting that azole antifungals clinically inhibit the H⁺/K⁺-ATPase, which is not their primary or clinically relevant mechanism; otherwise, the key facts are covered."
  },
  "581": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the key pharmacological property as increased tubular osmolarity (osmotic activity), thoroughly explains the mechanism, and provides clinically relevant, accurate details with no omissions or inaccuracies."
  },
  "582": {
    "score": 3.0,
    "explanation": "3: The answer correctly identifies benzimidazoles and explains their mechanism, but it does not directly state \"enzyme inhibitors\" as the general class, instead focusing on microtubule inhibition; this misses the key fact from the reference answer, though most relevant details are present."
  },
  "583": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the enzymatic mechanism, and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "584": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key facts from the reference, correctly identifies interferon beta, and clearly states that its precise molecular mechanism and direct target are incompletely defined, with all additional content being accurate and clinically relevant."
  },
  "585": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies transpeptidase (penicillin-binding protein) as the enzyme inhibited, provides accurate and clinically relevant explanation, and includes only correct, relevant extra information without any inaccuracies or omissions."
  },
  "586": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies thalidomide and its teratogenicity, and accurately explains the inhibition of TNF-α as the main molecular mechanism, with no inaccuracies or omissions."
  },
  "587": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, including the clinical context, drug class, and general mechanism, but it incorrectly emphasizes norepinephrine reuptake inhibition as primary, whereas the reference specifies dopamine reuptake inhibition as the main mechanism; this is a minor but clinically relevant inaccuracy."
  },
  "588": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key facts from the reference, explicitly stating that the precise molecular mechanism is not fully established, while providing additional accurate and clinically relevant context about horse chestnut seed extract and its proposed actions."
  },
  "589": {
    "score": 5.0,
    "explanation": "5: The model answer accurately states that the agent digests necrotic tissue and denatured proteins, facilitating debridement, and explicitly notes that the precise molecular mechanisms underlying enhanced healing remain incompletely understood, fully aligning with the reference answer."
  },
  "590": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies DNA gyrase (topoisomerase II) as the target, explains the mechanism, and all extra content is accurate and clinically relevant with no omissions or inaccuracies."
  },
  "591": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains thiamine’s coenzyme role, details relevant enzymes, and provides clinically relevant context without inaccuracies or omissions."
  },
  "592": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key facts except it incorrectly describes the antagonism as \"competitive\" rather than \"noncompetitive,\" which is a minor wording inaccuracy; otherwise, it is thorough, accurate, and clinically relevant."
  },
  "593": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies glucocorticoids as the pharmacological class, accurately describes their mechanism of action, and provides relevant clinical context without any inaccuracies or omissions."
  },
  "594": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately identifies sodium channel blockade as the primary mechanism, and provides additional correct and clinically relevant details without any inaccuracies or omissions."
  },
  "595": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately identifies the drug class, and provides correct, clinically relevant additional detail without any inaccuracies or omissions."
  },
  "596": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies CYP3A4 instead of CYP2D6 as the primary enzyme implicated, which is a moderate factual error, though the explanation is otherwise relevant and not unsafe."
  },
  "597": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describing tetracyclines' inhibition of protein synthesis via binding to the 30S ribosomal subunit, and provides additional correct and relevant mechanistic detail."
  },
  "598": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies chylomicrons as the bypassed component and thoroughly explains the mechanism, but it does not explicitly mention chylomicron \"structural macromolecules\" (e.g., apolipoproteins, phospholipids) as in the reference; this is a minor omission."
  },
  "599": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the mechanism (inhibition of transpeptidases/cell wall synthesis), and provides relevant, correct elaboration without any inaccuracies or omissions."
  },
  "600": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the pharmacological class and mechanism, and provides additional accurate, clinically relevant details without any inaccuracies or omissions."
  },
  "601": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the mechanism (inhibition of DNA gyrase), and provides relevant, correct additional details without any inaccuracies or omissions."
  },
  "602": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies GnRH agonists as the drug class, thoroughly explains their mechanism (including both pulsatile and continuous administration), clinical uses, and distinguishes them from other classes; all key facts from the reference are covered with no inaccuracies or omissions."
  },
  "603": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies PABA competition, dihydropteroate synthase inhibition, and the folic acid synthesis pathway, with additional accurate and relevant mechanistic detail and no inaccuracies or omissions."
  },
  "604": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies DNA gyrase as the primary target, includes the alternative name (topoisomerase II), and provides accurate, relevant explanation without any errors or omissions."
  },
  "605": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key facts, correctly stating that the precise molecular target in atrial fibrillation is not fully defined and that amiodarone acts via multiple mechanisms; however, it provides more detail than required and slightly emphasizes classification over the core point of \"unknown cellular or molecular interaction,\" which is a minor wording inaccuracy."
  },
  "606": {
    "score": 3.0,
    "explanation": "3: The model answer correctly states that the antiparasitic mechanism of povidone-iodine is not well established and emphasizes its main role in preventing secondary infection, but it provides mechanistic details (oxidation/iodination) that are not supported for parasites and may imply a known mechanism where none is established, thus not fully aligning with the reference answer's emphasis on the unknown nature of the interaction."
  },
  "607": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the pharmacological class as beta-lactam antibiotics and accurately explains the mechanism, covering over 90% of key facts; however, it does not explicitly use the broader term \"enzyme inhibitors\" as in the reference, which is a minor wording inaccuracy."
  },
  "608": {
    "score": 4.0,
    "explanation": "4: The model answer thoroughly explains the molecular mechanism of glucocorticoid action, covering binding, nuclear translocation, and gene transcription effects, but omits explicit mention of mineralocorticoid receptor agonism, which is a key fact in the reference answer."
  },
  "609": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the class (glucocorticoids), their intracellular receptor binding, gene transcription modulation, and suppression of pro-inflammatory cytokines, with additional correct and relevant mechanistic detail."
  },
  "610": {
    "score": 5.0,
    "explanation": "5: Fully covers all key clinical facts from the reference answer, accurately describing the blockade of voltage-gated sodium channels as the mechanism, with additional correct and relevant explanation; no inaccuracies or omissions."
  },
  "611": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the mechanism (inhibition of protein synthesis via 30S binding), and provides additional correct and relevant details without any inaccuracies or omissions."
  },
  "612": {
    "score": 5.0,
    "explanation": "5: Fully covers all key facts—identifies penicillin-binding proteins (PBPs) as the target, equates them with transpeptidase enzymes, and explains their role in peptidoglycan cross-linking; all extra content is accurate and clinically relevant."
  },
  "613": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the pharmacological class as corticosteroids/glucocorticoids, accurately describes the mechanism of action, and contains no inaccuracies or omissions compared to the reference answer."
  },
  "614": {
    "score": 4.0,
    "explanation": "4: The model answer correctly states that the precise mechanism is unknown and provides plausible, factually accurate hypotheses about primaquine’s action, with no inaccuracies; however, it elaborates beyond the reference, and the core fact (\"unknown mechanism\") is somewhat diluted by the additional mechanistic speculation, constituting a minor wording inaccuracy."
  },
  "615": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the mechanism (raising threshold potential via calcium-mediated membrane stabilization), and provides relevant mechanistic detail without inaccuracies or omissions."
  },
  "616": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies beta-adrenergic receptors as the primary target, thoroughly explains the mechanism in both blood pressure and intraocular pressure control, and provides relevant examples, with no omissions or inaccuracies."
  },
  "617": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key facts from the reference, accurately states that the precise mechanism is unknown, and provides clinically relevant context without introducing inaccuracies or irrelevant information."
  },
  "618": {
    "score": 3.0,
    "explanation": "3: The model answer correctly describes the mechanism and class (centrally acting sympathomimetic amines) but does not specifically identify serotonin uptake inhibitors as in the reference; it focuses on noradrenergic agents and phentermine, omitting the key reference to serotonin reuptake inhibition."
  },
  "619": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies beta2-adrenergic antagonism as the mechanism, and provides relevant, accurate clinical context without any inaccuracies or omissions."
  },
  "620": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies the precise molecular target (14-α-sterol demethylase/CYP51A1), provides accurate clinical context, and all additional explanations are factually correct and clinically relevant. No omissions or inaccuracies."
  },
  "621": {
    "score": 5.0,
    "explanation": "5: Fully covers all key facts, correctly identifies carbonic anhydrase as the enzyme class inhibited, and provides relevant, accurate clinical context without any errors or omissions."
  },
  "622": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies potassium channel activation as the direct mechanism, and provides additional accurate, clinically relevant detail without inaccuracies or omissions."
  },
  "623": {
    "score": 5.0,
    "explanation": "5: Fully covers all key clinical facts from the reference answer, with additional correct and relevant detail about ACE2 interaction and viral replication; no inaccuracies or omissions."
  },
  "624": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies demeclocycline and its clinical use, but incorrectly lists \"vasopressin antagonist\" as the primary pharmacological class, rather than \"protein synthesis inhibitor\" as required by the question; it covers some key facts but misses the main classification asked for."
  },
  "625": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies interferon-gamma as the target, explains the mechanism, and provides the correct drug class with no inaccuracies or omissions."
  },
  "626": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies ergosterol biosynthesis as the inhibited process, and provides accurate, relevant additional detail without any inaccuracies or omissions."
  },
  "627": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies ergosterol as the molecular target and provides accurate, relevant explanation without any errors or omissions."
  },
  "628": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the general class as \"inhibition of bacterial protein synthesis,\" matching the reference answer, and provides accurate, relevant elaboration without any inaccuracies or omissions."
  },
  "629": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the drug class, mechanism, and clinical context, and provides relevant additional explanation without inaccuracies or omissions."
  },
  "630": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the mechanism (protein synthesis inhibition via 50S ribosomal binding), and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "631": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the mechanism as inhibition of bacterial protein synthesis via the 50S ribosomal subunit, and provides relevant, accurate elaboration without any inaccuracies or omissions."
  },
  "632": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describing muscarinic (M3) receptor antagonism in the bladder, and provides additional correct and clinically relevant detail without any inaccuracies or omissions."
  },
  "633": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the selective antagonism of the CGRP receptor, and provides relevant, correct clinical context and mechanistic detail without any inaccuracies or omissions."
  },
  "634": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the mechanism as inhibition of cell wall synthesis via transpeptidase (penicillin-binding protein) inhibition, and provides clinically relevant elaboration without inaccuracies or omissions."
  },
  "635": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the siRNA mechanism, provides relevant examples, and includes a clear summary table without any inaccuracies or omissions."
  },
  "636": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the mechanism, provides relevant examples, and contains no inaccuracies or omissions."
  },
  "637": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies GABA_A receptor modulators as the relevant class, accurately explains the mechanism (allosteric binding, increased frequency of channel opening), and relates it to the clinical scenario without any inaccuracies or omissions."
  },
  "638": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies NSAIDs and explains their mechanism as COX inhibitors, covering over 90% of key facts, but the primary pharmacological class asked for is \"cyclooxygenase inhibitors\" rather than the therapeutic class \"NSAID,\" which is a minor wording inaccuracy."
  },
  "639": {
    "score": 4.0,
    "explanation": "4: The model answer covers over 90% of the key facts, correctly identifies mupirocin, its general mechanism, and acknowledges that the precise molecular details remain unclear; however, it provides more mechanistic detail than the reference, which could be seen as slightly exceeding the scope of \"unknown cellular or molecular interaction,\" but does not introduce inaccuracies."
  },
  "640": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the antibody-receptor (Fc region–Fc receptor) interaction, and provides accurate, clinically relevant elaboration without inaccuracies or omissions."
  },
  "641": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the mechanism as inhibition of bacterial protein synthesis, and provides accurate, clinically relevant elaboration without any inaccuracies or omissions."
  },
  "642": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the clinical syndrome, the drug (defibrotide), and its mechanism, and states that the relevant class is \"fibrinolytic (antithrombotic) agents,\" but does not explicitly name \"tissue plasminogen activators\" as the primary class, which is a minor omission. All other content is accurate and relevant."
  },
  "643": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies the glucocorticoid receptor as the primary target, explains its nuclear receptor mechanism, and provides relevant, accurate extra detail without any errors or omissions."
  },
  "644": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key facts from the reference, explicitly states the lack of a well-defined molecular target, and accurately describes the nonspecific mechanism without introducing inaccuracies or irrelevant content."
  },
  "645": {
    "score": 5.0,
    "explanation": "5: Fully covers all key facts from the reference answer, correctly identifies muscarinic antagonists/anticholinergics as the class, and provides accurate, relevant mechanistic detail without any errors or omissions."
  },
  "646": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the sodium-chloride symporter (NCC) as the target, accurately explains its location and mechanism, and clearly links inhibition to natriuresis, diuresis, and reduction of edema, with no omissions or inaccuracies."
  },
  "647": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes estrogen receptor agonism, and provides a detailed, clinically relevant explanation of the molecular mechanism without any inaccuracies or omissions."
  },
  "648": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies muscarinic acetylcholine receptors as the target, thoroughly explains the mechanism, and provides clinically relevant examples without any inaccuracies or omissions."
  },
  "649": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the drug class and receptor, explains the molecular mechanism, and links it to clinical effects; all additional details are accurate and relevant."
  },
  "650": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional details, and contains no inaccuracies or omissions."
  },
  "651": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies free radical scavenging (antioxidant) activity as the key mechanism, thoroughly explains the process, and provides relevant examples without inaccuracies or omissions."
  },
  "652": {
    "score": 5.0,
    "explanation": "5: The model answer accurately identifies artemisinin, describes its proposed mechanism (free radical generation via heme activation), and clearly states that its precise molecular target is unknown, fully aligning with the reference answer and key points."
  },
  "653": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the mechanism as alkylating agents and explains the covalent DNA modification and cross-linking, but it does not explicitly state \"nucleic acid synthesis inhibitors\" as the class, missing the key terminology required by the reference answer."
  },
  "654": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the agent and its alkalinizing property, and provides relevant, accurate clinical context without any inaccuracies or omissions."
  },
  "655": {
    "score": 4.0,
    "explanation": "4: The model answer covers over 90% of the key facts, correctly identifying complement inhibition (specifically C5) as the mechanism and explaining its effect on intestinal protein loss; however, it introduces some ambiguity by mentioning C1q as a possible target, which is less relevant here, constituting a minor inaccuracy."
  },
  "656": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies alpha-1 adrenergic receptor blockade as the main mechanism, explains the competitive inhibition, and links it to vasodilation and improved circulation, fully covering all key clinical facts in the reference answer with no inaccuracies or omissions."
  },
  "657": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies ergosterol as the molecular target, provides accurate clinical reasoning, and includes only relevant, factually correct additional information without any omissions or inaccuracies."
  },
  "658": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key facts from the reference, clearly stating that the precise molecular mechanism of exogenous lactase’s effect in vivo is not fully understood, while also providing accurate and clinically relevant background without inaccuracies or omissions."
  },
  "659": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies calcium channel interactions and the mechanism of increased calcium influx, but introduces some ambiguity by referencing both ligand-gated and voltage-gated channels, whereas praziquantel acts primarily on voltage-gated calcium channels; this constitutes a minor wording inaccuracy but does not alter the core meaning."
  },
  "660": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the class as ATP citrate lyase inhibitors and explains the mechanism, covering all key facts and providing relevant extra detail; however, it does not use the broader term \"enzyme inhibitors\" as in the reference, which is a minor wording inaccuracy."
  },
  "661": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies transpeptidase enzymes (penicillin-binding proteins) as the direct molecular target, fully explains their role, and provides relevant, accurate additional context without any errors or omissions."
  },
  "662": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describing the demulcent/lubricating film mechanism, and provides additional correct and relevant details without any inaccuracies or omissions."
  },
  "663": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies beta1-selective beta blockers as the relevant class, names examples, and accurately classifies them as Class II antiarrhythmics, with all information factually correct and clinically relevant."
  },
  "664": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies AMPK pathway activation, and provides accurate, relevant additional details without any inaccuracies or omissions."
  },
  "665": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the GABA_A receptor as the primary target, accurately explains the mechanism, and provides relevant clinical context without any inaccuracies or omissions."
  },
  "666": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies amantadine, its use, and its primary mechanisms—enhancing dopamine release and NMDA antagonism—covering over 90% of key facts. It slightly underemphasizes NMDA antagonism as a primary mechanism (listing it as secondary), but this is a minor wording issue and does not alter the clinical meaning."
  },
  "667": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key facts from the reference (enzyme inhibition of viral replication), correctly identifies the pharmacologic class, and provides accurate, clinically relevant details about cidofovir’s mechanism and use, with no inaccuracies or omissions."
  },
  "668": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the molecular mechanism (modulation of enzymatic activity involved in skin cell differentiation and repair), and provides additional correct and clinically relevant detail without any inaccuracies or omissions."
  },
  "669": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the glucocorticoid receptor as the relevant class, and provides accurate, clinically relevant elaboration without any inaccuracies or omissions."
  },
  "670": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the mechanism as binding/adsorption, and provides relevant, accurate elaboration without any inaccuracies or omissions."
  },
  "671": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describing the mechanism (increasing stool mass and water content to facilitate transit and decrease pressure) and provides relevant, correct additional details without inaccuracies or omissions."
  },
  "672": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies H1 histamine receptor antagonism as the pharmacologic action, explains the mechanism, and provides relevant clinical context without inaccuracies or omissions."
  },
  "673": {
    "score": 5.0,
    "explanation": "5: Fully identifies the pharmacologic class as \"ribonucleotide reductase inhibitor,\" includes correct mechanism, and any extra detail is accurate and clinically relevant; no errors or omissions."
  },
  "674": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies interferons and their mechanism, but does not explicitly state the pharmacologic class as \"biological response modifiers,\" which is the key fact in the reference answer; it instead uses \"immunomodulator,\" which is related but less precise, and omits the exact class terminology."
  },
  "675": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies osmotic activity as the key pharmacological property, explains its mechanism in the GI tract, and provides relevant context without inaccuracies or omissions."
  },
  "676": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies ergosterol as the molecular target, provides accurate clinical context, and explains the mechanism of action without any errors or omissions."
  },
  "677": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the drug class and mechanism, and provides relevant, accurate additional detail without any errors or omissions."
  },
  "678": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the disease, drug (miltefosine), and its general mechanism (disruption of membrane and signaling), but incorrectly specifies the primary molecular pathway as PI3K/Akt rather than lysophospholipid receptor interactions, omitting the key fact from the reference answer."
  },
  "679": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately details the molecular mechanism (agonism of pituitary/adrenal melanocortin receptors to increase corticosteroid production), and provides additional correct, clinically relevant context without inaccuracies or omissions."
  },
  "680": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies atovaquone and thoroughly explains its mechanism, but it does not directly state \"nucleic acid synthesis inhibitors\" as the class, which is the key fact required by the reference answer; instead, it focuses on \"mitochondrial electron transport chain inhibition,\" which is mechanistically accurate but not the requested pharmacologic class."
  },
  "681": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly describing integrin antagonism, lymphocyte trafficking blockade, and the specific mechanism; extra details are accurate and clinically relevant."
  },
  "682": {
    "score": 3.0,
    "explanation": "3: The model answer covers the clinical context and identifies salicylic acid as the likely agent, but it does not directly state \"unknown cellular or molecular interaction\" as the mechanism-of-action category, instead focusing on keratolysis; this misses the key fact that the mechanism is officially classified as unknown, per the reference."
  },
  "683": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the GABA_A receptor as the direct molecular target, accurately describes the mechanism, and provides relevant, factually correct additional information without any inaccuracies or omissions."
  },
  "684": {
    "score": 5.0,
    "explanation": "5: Thoroughly covers all key clinical facts from the reference, accurately explains the drug class, mechanism, and its effect on the underlying pathophysiology, with no errors or omissions."
  },
  "685": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies both the drug class and target enzyme, and the additional explanation is accurate and clinically relevant without any errors or omissions."
  },
  "686": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies valproic acid as the agent, whereas the reference answer clearly refers to levetiracetam; this is a moderate factual error. While the mechanistic discussion is accurate for valproic acid, it is not relevant to the agent described in the question."
  },
  "687": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies glucocorticoid receptors as the relevant intracellular receptor class, explains their mechanism, and links them to the clinical scenario without any inaccuracies or omissions."
  },
  "688": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies norepinephrine as the key neurotransmitter, explains the mechanism of action, and relates it to the clinical scenario without any inaccuracies or omissions."
  },
  "689": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies chondroitin sulfate, its source, and its mechanism involving inhibition of cartilage-degrading enzymes, which is a specific example of biological macromolecular activity. However, it does not explicitly use the broader term \"biological macromolecular activity\" as in the reference, representing a minor wording inaccuracy."
  },
  "690": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies prostaglandin receptor agonism and provides accurate, relevant mechanistic detail, but emphasizes the downstream signaling (Gq-mediated calcium increase) rather than directly stating \"agonism of prostaglandin (EP) receptors\" as the most direct mechanism, which is a minor wording inaccuracy."
  },
  "691": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies nucleoside analogs (specifically guanosine analogs like acyclovir/ganciclovir) and explains their mechanism, but does not explicitly use the term \"DNA polymerase inhibitors\" as in the reference; otherwise, it covers all key facts with accurate and relevant detail."
  },
  "692": {
    "score": 5.0,
    "explanation": "5: Fully correct—covers all key facts from the reference, accurately describes the mechanism, clinical use, and provides relevant examples without any errors or omissions."
  },
  "693": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the class (nucleoside analog anti-herpesvirus drugs), mechanism (phosphorylation by viral thymidine kinase, inhibition of viral DNA polymerase), and provides relevant examples, but does not explicitly use the term \"DNA polymerase inhibitors\" as in the reference; this is a minor wording inaccuracy."
  },
  "694": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately details the molecular mechanism, and provides relevant, correct additional explanation without any inaccuracies or omissions."
  },
  "695": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies antagonism of muscarinic acetylcholine receptors as the main mechanism, specifies the M3 subtype, and provides relevant clinical context without inaccuracies or omissions."
  },
  "696": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the mechanism (inhibition of PBPs/transpeptidases), and provides relevant, correct elaboration without any inaccuracies or omissions."
  },
  "697": {
    "score": 5.0,
    "explanation": "5: Fully covers all key facts from the reference, correctly identifies the CGRP receptor as the target, accurately describes the mechanism, and provides relevant, factually correct additional details without any inaccuracies or omissions."
  },
  "698": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies protein synthesis inhibition as the mechanism, elaborates accurately on the differential mechanisms of antifungals, and specifies inhibition at the ribosomal level via aminoacyl-tRNA synthetase. However, the answer is somewhat verbose and the final concise answer could be more directly aligned with the reference wording; there are no clinically significant errors or omissions."
  },
  "699": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key facts and provides accurate, relevant detail about the enzymatic action of lactase, while also noting the limitations in mechanistic understanding; however, it goes beyond the reference's \"unknown\" by describing the general enzymatic mechanism, which is biochemically established, making the answer slightly more detailed than required but not incorrect."
  },
  "700": {
    "score": 3.0,
    "explanation": "3: The model answer provides a thorough explanation and correctly identifies muscarinic (M1) receptor antagonism as the main mechanism for antiemetic effects of first-generation antihistamines, but it misses the key fact from the reference answer—dopamine receptor antagonism—which is specifically asked in the context of the medication's interaction with central receptors involved in antipsychotic drug action."
  },
  "701": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately identifies inhibition of DNA gyrase as the mechanism, and provides correct, relevant elaboration without any inaccuracies or omissions."
  },
  "702": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies SNRIs as the pharmacological class and matches all key clinical facts in the reference answer without any inaccuracies or omissions."
  },
  "703": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the pharmacological mechanism, and provides relevant clinical context without any inaccuracies or omissions."
  },
  "704": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the disease, the role of IL-1β, and the use of IL-1 inhibitors, and explains that the therapy blocks IL-1 receptor–mediated NF-κB signaling. However, it does not explicitly state \"antagonism of the interleukin-1 receptor\" as the direct mechanism, instead focusing on downstream NF-κB signaling, which is slightly less precise than the reference."
  },
  "705": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies androgen receptor agonism as the class of drug action, accurately describes the mechanism, and provides relevant clinical context without any inaccuracies or omissions."
  },
  "706": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes dopamine receptor stimulation as the primary mechanism, and provides correct, relevant additional detail without any inaccuracies or omissions."
  },
  "707": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the glucocorticoid receptor as the molecular target, and provides accurate, relevant additional explanation without any inaccuracies or omissions."
  },
  "708": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describing denosumab’s mechanism as RANKL blockade and its effect on osteoclasts, with additional correct and relevant details."
  },
  "709": {
    "score": 5.0,
    "explanation": "5: The model answer fully and accurately explains that inhibition of the norepinephrine reuptake transporter (NET) increases synaptic norepinephrine, directly addressing the mechanism in the reference answer with correct and clinically relevant elaboration."
  },
  "710": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately identifies potassium channel blockade as the mechanism, and provides relevant, correct, and clinically pertinent additional explanation without any inaccuracies or omissions."
  },
  "711": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and accurate discussion of pentoxifylline’s known pharmacologic actions but does not clearly state that the precise molecular mechanism in cerebral malaria is unknown, as required by the reference; instead, it implies a partial understanding, which is a minor but meaningful omission."
  },
  "712": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key clinical facts and provides a thorough, accurate explanation, but it places slightly more emphasis on dopamine reuptake inhibition than norepinephrine, whereas the reference specifically highlights norepinephrine. This is a minor wording inaccuracy but does not alter the clinical meaning."
  },
  "713": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the direct molecular target as the bacterial transpeptidase enzyme, explains its role in peptidoglycan cross-linking, and provides relevant, accurate context about beta-lactam antibiotics and PBPs without any inaccuracies or omissions."
  },
  "714": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies viral DNA polymerase as the primary molecular target, provides accurate and clinically relevant details about the drug's mechanism, and contains no inaccuracies or omissions."
  },
  "715": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the drug, its selective activation, and its primary mechanism—direct inhibition of viral DNA polymerase—without inaccuracies or omissions."
  },
  "716": {
    "score": 3.0,
    "explanation": "3: The model answer accurately describes the mechanism of polyene antifungals (binding to ergosterol and forming pores), but the reference specifically asks for disruption of ergosterol synthesis, which is the mechanism of azoles, not polyenes. Thus, the model answer covers the clinical context and mechanism for the likely drug used, but misses the precise molecular mechanism requested in the reference."
  },
  "717": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies transpeptidases/penicillin-binding proteins as the target, and provides accurate, relevant clinical context without inaccuracies or omissions."
  },
  "718": {
    "score": 3.0,
    "explanation": "3: The model answer focuses on Fc receptor blockade rather than the reference answer's key mechanism of autoantibody neutralization; while the explanation is accurate and relevant, it omits the primary mechanism requested and instead describes a secondary one."
  },
  "719": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies topoisomerase IV as the primary target, explains its role in chromosome segregation, and provides accurate, relevant context without any inaccuracies or omissions."
  },
  "720": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies microtubule polymerization (mitotic spindle formation) as the directly inhibited process, fully matching the reference answer with accurate, relevant clinical context and no inaccuracies or omissions."
  },
  "721": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the mechanism as hormone (specifically pituitary hormone) receptor agonism, accurately describes the clinical context, and provides additional relevant mechanistic detail without any inaccuracies or omissions."
  },
  "722": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes vitamin K’s role, acknowledges the incomplete understanding of its molecular action in preterm infants, and provides relevant, correct additional detail without inaccuracies or omissions."
  },
  "723": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the pharmacologic class, and provides accurate, relevant explanations without any inaccuracies or omissions."
  },
  "724": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the sodium-chloride symporter (NCC) as the inhibited transporter, provides accurate and relevant additional explanation, and contains no inaccuracies or omissions."
  },
  "725": {
    "score": 2.0,
    "explanation": "2: The model answer focuses on the hormone's receptor (GPCRs) rather than the structural macromolecules (collagen in bone matrix) that are directly responsible for bone strength, as specified in the reference. While the mechanistic pathway is described, the key clinical fact—structural macromolecules as the direct therapeutic target—is omitted, constituting a moderate omission."
  },
  "726": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies glucocorticoids/corticosteroids, accurately describes their mechanism via intracellular nuclear receptor binding and gene transcription modulation, and relates this to the therapeutic effect in uveitis, with no omissions or inaccuracies."
  },
  "727": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies DNA polymerase inhibition as the primary mechanism, explains the activation steps, and provides relevant, accurate extra detail without any errors or omissions."
  },
  "728": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes biotin’s role as a coenzyme for carboxylase enzymes, details relevant metabolic pathways, and links these mechanisms to keratin synthesis and hair regrowth without any inaccuracies or omissions."
  },
  "729": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, correctly identifies dapsone and its mechanisms, and explains the distinction between its antibacterial and immunomodulatory actions. However, it is overly verbose, introduces some ambiguity about which mechanism is being asked, and does not clearly and concisely state the reference answer (PABA inhibition/folate synthesis interference) as the best explanation per the question stem."
  },
  "730": {
    "score": 2.0,
    "explanation": "2: The model answer does not identify \"RNA replicase inhibitors\" as the class most similar in mechanism to interferon's antiviral effect, instead focusing on TLR agonists, which act upstream by inducing interferon production rather than directly inhibiting viral genome replication. This represents a moderate omission of the key fact required by the reference answer."
  },
  "731": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies albumin as the agent, explains its mechanism (increasing oncotic pressure), and classifies it as a \"colloid plasma volume expander,\" which is accurate. However, it omits the explicit term \"structural macromolecule\" from the reference, which is a minor omission."
  },
  "732": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the molecular mechanism of iron chelation, and provides relevant additional details without any inaccuracies or omissions."
  },
  "733": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies PPAR-α activation as the key mechanism, thoroughly explains the molecular pathway, and provides relevant, accurate additional details without any errors or omissions."
  },
  "734": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies inhibition of bacterial protein synthesis via binding to the 30S ribosomal subunit, matches all key facts, and provides additional accurate, relevant explanation without any errors or omissions."
  },
  "735": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the mechanism of tetracyclines, and provides relevant clinical context without any inaccuracies or omissions."
  },
  "736": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key facts from the reference, explicitly states that the precise mechanism is unknown, and provides additional correct and clinically relevant context about talc pleurodesis without inaccuracies or omissions."
  },
  "737": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the mechanism (water absorption, gel formation, stool bulking), and provides relevant, correct additional explanation without any inaccuracies or omissions."
  },
  "738": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies inhibition of DNA and RNA synthesis as the key mechanism and provides accurate, relevant additional detail about heme detoxification and chloroquine, but the primary mechanism per the reference is inhibition of nucleic acid synthesis; the extra mechanistic detail is correct but slightly shifts focus, constituting a minor wording inaccuracy."
  },
  "739": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key facts from the reference, accurately identifies the unknown mechanism of benznidazole as the limitation, and provides relevant, correct elaboration without inaccuracies or omissions."
  },
  "740": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the class (statins/HMG-CoA reductase inhibitors), the enzyme inhibited, and the molecular mechanism, with additional correct and relevant detail about LDL receptor upregulation and lipoprotein clearance. No inaccuracies or omissions are present."
  },
  "741": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes enzyme replacement as the mechanism, and provides additional correct and clinically relevant details about the therapy, its delivery, and cellular uptake, with no inaccuracies or omissions."
  },
  "742": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies thiamine as the cofactor, details its enzymatic roles (especially pyruvate dehydrogenase), and clearly explains the molecular basis for rapid neurological improvement, with no inaccuracies or omissions."
  },
  "743": {
    "score": 5.0,
    "explanation": "5: Fully covers all key clinical facts from the reference answer, accurately describing the blockade of voltage-gated sodium channels as the primary mechanism, with relevant and correct additional context."
  },
  "744": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers the key fact—cefotaxime inhibits bacterial transpeptidase enzymes—while providing accurate, clinically relevant elaboration without any errors or omissions."
  },
  "745": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the clinical diagnosis and the actual first-line treatment (topical corticosteroids), but it does not match the reference answer's focus on estrogen receptor agonists as the class described in the question stem. It covers the mechanism of corticosteroids well but misses the key fact that the question is testing knowledge of estrogen receptor agonists, not corticosteroids."
  },
  "746": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies IL-6 signaling as the directly inhibited pathway, and provides accurate, relevant mechanistic detail without inaccuracies or omissions."
  },
  "747": {
    "score": 3.0,
    "explanation": "3: The model answer provides a thorough explanation of corticosteroid action, correctly identifying phospholipase A2 as the enzyme most directly inhibited, but it does not match the reference answer, which specifies lipoxygenase inhibitors. While the mechanistic reasoning is accurate, it omits the key fact required by the question and reference, resulting in a moderate omission."
  },
  "748": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the mechanism, and provides relevant additional context without any inaccuracies or omissions."
  },
  "749": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including the identification of the H1 receptor, mechanism of action, symptom relief, and the reason for sedation, with no inaccuracies or omissions."
  },
  "750": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the mechanism as C5 inhibition preventing complement-mediated hemolysis, and provides accurate, relevant additional detail without inaccuracies or omissions."
  },
  "751": {
    "score": 2.0,
    "explanation": "2: The model answer focuses on retinoid receptor-mediated gene transcription and epithelial differentiation, omitting the key reference mechanism of antioxidant (free radical scavenging) activity; while mechanistically accurate, it misses the principal molecular mechanism asked, constituting a moderate omission."
  },
  "752": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies DNA gyrase (topoisomerase II) as the target, matches all key clinical and mechanistic details, and provides relevant, accurate explanation without errors or omissions."
  },
  "753": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the class as thyroid hormone receptor agonists, and provides additional accurate, relevant mechanistic detail without any inaccuracies or omissions."
  },
  "754": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the drug class and mechanism, and provides additional clinically relevant detail without inaccuracies or omissions."
  },
  "755": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the molecular mechanism of caplacizumab, and provides relevant clinical context without any inaccuracies or omissions."
  },
  "756": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies fluoroquinolones as DNA gyrase inhibitors, explains the mechanism, and provides relevant clinical context without inaccuracies or omissions."
  },
  "757": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies IL-1 as the molecular target, and provides accurate, relevant explanations without any inaccuracies or omissions."
  },
  "758": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the mechanism (inhibition of protein synthesis via 50S ribosomal subunit binding), and provides correct, relevant elaboration without inaccuracies or omissions."
  },
  "759": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately identifies the drug and its mechanism, and provides correct, clinically relevant additional detail without any inaccuracies or omissions."
  },
  "760": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies alpha-adrenergic antagonists as the drug class that inhibits adrenergic receptors responsible for vascular smooth muscle constriction, matching the reference answer. It also provides accurate, relevant context about PPHN management without any inaccuracies or omissions."
  },
  "761": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the mechanism (bicarbonate supplementation buffers excess hydrogen ions to correct acidosis), and provides relevant, correct additional context without any inaccuracies or omissions."
  },
  "762": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies inhibition of ergosterol biosynthesis and the specific enzyme targeted by azoles (lanosterol 14α-demethylase), but it does not match the reference answer, which specifies squalene epoxidase inhibition (the target of allylamines, not azoles). This is a moderate factual error regarding the drug class and mechanism."
  },
  "763": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the pharmacological class (peripheral dopa decarboxylase inhibitors), the specific molecular target (dopa decarboxylase), and provides accurate, relevant additional explanation without any inaccuracies or omissions."
  },
  "764": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the pharmacological class as anticholinergics/antimuscarinics, explains the mechanism (competitive inhibition of acetylcholine at muscarinic receptors), and details both bronchodilation and decreased mucus production, fully covering all key clinical facts with relevant, accurate elaboration."
  },
  "765": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the mechanism (binding to PBPs, inhibition of cell wall synthesis), and provides additional correct and relevant detail without any inaccuracies or omissions."
  },
  "766": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly explains beta-adrenergic stimulation, increased heart rate, and QT shortening, and adds accurate, relevant mechanistic detail without any inaccuracies or omissions."
  },
  "767": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the molecular mechanism (replacement of ADA enzymatic activity and degradation of toxic metabolites), and provides additional correct and clinically relevant detail without any inaccuracies or omissions."
  },
  "768": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately identifies the drug class and mechanism, and provides relevant, correct elaboration without any inaccuracies or omissions."
  },
  "769": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately and precisely describes the molecular mechanism, and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "770": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the mechanism and the specific molecular target (glutamate-gated chloride channels), but this does not match the reference answer (GABA A receptors), which is the expected target for the described mechanism; thus, there is a moderate factual error."
  },
  "771": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the drug class as a kinase inhibitor (specifically PI3Kδ inhibitor), accurately explains the mechanism, and provides clinically relevant additional details without inaccuracies or omissions."
  },
  "772": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and accurate general mechanism of corticosteroids but does not directly state that the mechanism in cutaneous tuberculosis is \"unknown,\" as required by the reference. It covers most key facts but adds mechanistic details that, while correct, do not fully align with the reference's emphasis on the mechanism being unknown."
  },
  "773": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies ROCK inhibitors as the drug class, explains their mechanism, cites a relevant agent (belumosudil), and provides accurate, clinically relevant comparisons without inaccuracies or omissions."
  },
  "774": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key facts and provides additional correct, relevant details (identifying clindamycin, its class, and mechanism). However, it omits the broader pharmacologic class \"protein synthesis inhibitors\" as in the reference, focusing instead on the specific subclass (lincosamide), which is a minor omission."
  },
  "775": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the drug class and mechanism, and provides relevant, accurate elaboration without any inaccuracies or omissions."
  },
  "776": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the thrombopoietin receptor (c-Mpl) as the molecular target, and provides additional accurate and relevant details without any inaccuracies or omissions."
  },
  "777": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies fluoroquinolones and their mechanism but incorrectly states DNA gyrase as the most direct target, whereas the reference specifies topoisomerase IV; it covers most key facts but misses the precise molecular target required."
  },
  "778": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies CYP450 induction as the mechanism, explains the effect on contraceptive metabolism, and links this to reduced efficacy and spotting. However, it does not specifically mention CYP3A4, the key isoenzyme in the reference, representing a minor omission."
  },
  "779": {
    "score": 5.0,
    "explanation": "5: Fully covers all key facts, correctly identifies penicillin-binding proteins (transpeptidases) as the molecular target, and provides accurate, relevant clinical context without any inaccuracies or omissions."
  },
  "780": {
    "score": 4.0,
    "explanation": "4: The model answer correctly states that the precise molecular mechanism is not fully understood and describes the general antifibrotic actions, but it goes beyond the reference by listing proposed pathways, which, while accurate and relevant, are not strictly required. No clinically significant errors or omissions are present."
  },
  "781": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the sodium-chloride symporter (NCC) in the distal convoluted tubule, covers all key clinical facts, and provides accurate, relevant additional explanation without any inaccuracies or omissions."
  },
  "782": {
    "score": 0.0,
    "explanation": "0: The model answer does not match the reference answer, which specifies serotonin antagonists; instead, it discusses neuromuscular blocking agents and botulinum toxin, which is factually incorrect for this question and constitutes a major inaccuracy."
  },
  "783": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the class-based mechanism (competitive inhibition of dihydropteroate synthase, blocking folate synthesis), and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "784": {
    "score": 3.0,
    "explanation": "3: The model answer covers the general mechanism of retinoic acid via nuclear receptor-mediated gene transcription and its effects on epithelial health and mucin production, but it omits the specific principal mechanism of direct free radical scavenging (antioxidant activity) emphasized in the reference answer."
  },
  "785": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the general mechanism as inhibition of bacterial protein synthesis, matching the reference, and provides accurate, relevant additional detail without any errors or omissions."
  },
  "786": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies activation of the glucocorticoid receptor as the primary mechanism, thoroughly explains the molecular pathway, and provides clinically relevant context without inaccuracies or omissions."
  },
  "787": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies transpeptidase enzymes (penicillin-binding proteins) as the molecular target, provides accurate and relevant additional context about β-lactam antibiotics, and contains no inaccuracies or omissions."
  },
  "788": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies ergosterol as the direct molecular target, provides accurate clinical context, and contains no inaccuracies or omissions; all key facts from the reference are covered."
  },
  "789": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies corticosteroid/glucocorticoid receptor agonism as the mechanism, and provides accurate, relevant elaboration without any inaccuracies or omissions."
  },
  "790": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies beta-3 adrenergic agonists as the drug class that increases cAMP in detrusor muscle, matching the described mechanism, and provides accurate, clinically relevant explanation with no inaccuracies or omissions."
  },
  "791": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies IGF-1R as the targeted receptor, names the drug, and provides accurate, clinically relevant explanation without any errors or omissions."
  },
  "792": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies antimuscarinic agents as the pharmacologic class, explains the mechanism via muscarinic (cholinergic) receptor antagonism, and relates this to the clinical scenario; all key facts are covered with no inaccuracies or omissions."
  },
  "793": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies CYP2C9 as the inhibited enzyme, provides accurate and clinically relevant explanations, and includes a helpful summary table without any inaccuracies or omissions."
  },
  "794": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately identifies the drug class and molecular mechanism, and provides additional correct and clinically relevant details without any inaccuracies or omissions."
  },
  "795": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key facts from the reference, accurately stating that the precise molecular mechanism is unknown, while providing correct and clinically relevant additional detail about the general mechanism of action of Povidone K12. There are no inaccuracies or omissions."
  },
  "796": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies phospholipase A2 as the primary enzyme class inhibited to reduce leukotriene synthesis, rather than lipoxygenase; while it provides relevant background, this constitutes a moderate factual error and covers only part of the key fact."
  },
  "797": {
    "score": 2.0,
    "explanation": "2: The model answer provides a detailed, textbook mechanism of metronidazole but omits the key fact from the reference that the precise molecular mechanism in bacterial vaginosis is unclear, thus overstating current knowledge and missing the main point."
  },
  "798": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the mechanism (binding to 50S ribosomal subunit and inhibiting protein synthesis by blocking translocation), and provides relevant, correct additional context without any inaccuracies or omissions."
  },
  "799": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies ACE inhibitors (and appropriately includes ARBs), and provides a detailed, accurate, and clinically relevant explanation of the mechanism without any inaccuracies or omissions."
  },
  "800": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the CD20 target, B-cell depletion, and the mechanisms (ADCC, complement-mediated cytotoxicity), and adds correct, relevant context without any inaccuracies or omissions."
  },
  "801": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the mechanism of action, and correctly identifies glucocorticoid receptor agonism as fundamental; all additional details are correct and clinically relevant."
  },
  "802": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the drug class and mechanism, and provides relevant, accurate additional details without any inaccuracies or omissions."
  },
  "803": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies the sodium-chloride symporter (NCC) as the target, uses correct synonyms, and provides relevant, accurate clinical context with no errors or omissions."
  },
  "804": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts and the molecular mechanism (alkylating activity, DNA crosslinking, immune suppression), with additional correct and relevant detail; there are no inaccuracies or omissions."
  },
  "805": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the pharmacological class, mechanism, and site of action, and provides relevant, accurate additional detail without any inaccuracies or omissions."
  },
  "806": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies inhibition of nucleic acid synthesis as the primary mechanism and provides relevant details about atovaquone and quinine, but includes some extraneous mechanistic detail (free radical generation) that is not central to the reference answer and could be misleading; otherwise, it covers all key facts."
  },
  "807": {
    "score": 5.0,
    "explanation": "5: Fully covers all key facts from the reference, correctly identifies the drug class as cholinesterase inhibitors, explains the mechanism, and provides relevant clinical context without inaccuracies or omissions."
  },
  "808": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key facts from the reference, accurately stating that the mechanism is unknown and not well characterized, while providing correct and clinically relevant additional detail about the symptomatic, non-antiviral actions of the emulsion."
  },
  "809": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately identifies the mechanism as inhibition of norepinephrine reuptake, and provides relevant, correct clinical context without any inaccuracies or omissions."
  },
  "810": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies inhibition of transpeptidase enzymes (PBPs) as the molecular mechanism, fully explaining the process and matching all key clinical facts in the reference answer without inaccuracies or omissions."
  },
  "811": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies monoamine oxidase inhibition as the mechanism, and provides accurate, clinically relevant explanations without any inaccuracies or omissions."
  },
  "812": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies phospholipase A2 as the most directly inhibited enzyme class, rather than lipoxygenase, which is specifically responsible for leukotriene synthesis; while the mechanistic explanation is accurate, this constitutes a moderate factual error regarding the direct target relevant to the question."
  },
  "813": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately identifies the drug class and mechanism, and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "814": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the drug class, mechanism, and provides relevant examples without inaccuracies or omissions."
  },
  "815": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the drug class as a pituitary hormone receptor agonist, and provides accurate, relevant mechanistic detail without any inaccuracies or omissions."
  },
  "816": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies \"orexin receptor antagonist\" as the pharmacological class, thoroughly explains the mechanism, provides relevant examples, and includes only accurate, clinically relevant information with no omissions or inaccuracies."
  },
  "817": {
    "score": 3.0,
    "explanation": "3: The answer correctly identifies inhibition of folate synthesis via PABA antagonism and adds relevant details about dihydropteroate synthase, but introduces mechanisms (immunomodulation, T-cell effects) that are not directly attributable to sulfonamides in autoimmune disease and may conflate with other agents, leading to minor inaccuracies and some irrelevant content."
  },
  "818": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the enzymatic redox mechanism, and provides additional correct and clinically relevant details without any inaccuracies or omissions."
  },
  "819": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the histamine H1 receptor as the primary molecular target, covers all key clinical facts, and provides relevant, accurate additional explanation without any errors or omissions."
  },
  "820": {
    "score": 4.0,
    "explanation": "4: The model answer correctly states that the precise molecular mechanism is unclear and describes the best current understanding, but it goes beyond the reference by detailing proposed mechanisms (calcium influx, paralysis, tegumental damage) that, while accurate, are not strictly required; there are no inaccuracies or unsafe statements, but the extra detail is not essential per the reference."
  },
  "821": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the interleukin-1 (IL-1β) signaling pathway as the target, provides accurate clinical context, and includes only relevant, factually correct additional details without any omissions or inaccuracies."
  },
  "822": {
    "score": 3.0,
    "explanation": "3: The model answer provides a thorough clinical explanation and correctly identifies the therapy as coagulation factor replacement, but it does not explicitly use the reference term \"enzyme activators,\" missing the precise pharmacologic class required by the question."
  },
  "823": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies GABA-A instead of GABA-B as the receptor mediating the therapeutic effect in this context (baclofen is the typical agent used, acting on GABA-B), which is a moderate factual error; while the explanation is otherwise accurate, the key fact is wrong."
  },
  "824": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies glucocorticoid/nuclear hormone receptors as the target, and provides accurate, clinically relevant mechanistic detail without any inaccuracies or omissions."
  },
  "825": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the drug class and mechanism, and provides additional correct and clinically relevant details without any inaccuracies or omissions."
  },
  "826": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the prostacyclin (IP) receptor as the primary target and provides accurate, relevant mechanistic detail, but the reference specifically asks for \"receptor class,\" and the model's emphasis on \"Gs-protein-coupled\" is a minor wording inaccuracy compared to the reference's focus on \"prostacyclin (IP) receptor agonists.\""
  },
  "827": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies glucocorticoids as the drug class, accurately describes their mechanism of action, and provides relevant clinical context without any inaccuracies or omissions."
  },
  "828": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describing the mechanism (enhanced echogenicity via scattering/reflection of ultrasound by albumin microspheres), and provides additional correct and relevant detail without inaccuracies or omissions."
  },
  "829": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies chelation as the principal property and links it to iron removal, covering nearly all key facts. However, it introduces specific subtypes (PKAN/NBIA) and iron chelation, which, while plausible, are not explicitly stated in the reference and may slightly over-specify the scenario; otherwise, the answer is accurate and clinically relevant."
  },
  "830": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the drug (adenosine), its mechanism, and specifies GPCRs as the target, which is accurate and clinically relevant. However, it omits the broader category \"structural macromolecules (purinergic receptors)\" as in the reference, making \"GPCRs\" a slightly narrower answer—this is a minor omission."
  },
  "831": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies adsorption as the primary mechanism, accurately describes the physical binding process, and provides relevant mechanistic detail without inaccuracies or omissions."
  },
  "832": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the clinical scenario, mechanism, and specific drug class (DNA methyltransferase inhibitors/hypomethylating agents), which are nucleoside analogs and thus nucleoside synthesis inhibitors. However, it does not explicitly use the term \"nucleoside synthesis inhibitors\" as in the reference, representing a minor wording inaccuracy."
  },
  "833": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the drug class and receptor, and provides accurate, relevant explanations without any errors or omissions."
  },
  "834": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes caplacizumab’s mechanism (binding vWF A1 domain, blocking interaction with platelet GPIb, preventing aggregation), and provides correct, relevant clinical context without inaccuracies or omissions."
  },
  "835": {
    "score": 5.0,
    "explanation": "5: Fully covers all key clinical facts—oxygen release, local cleansing, mechanical debridement, and effervescence—with accurate, relevant elaboration and no inaccuracies or omissions."
  },
  "836": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the mechanism (restoring viscoelastic properties of synovial fluid), and provides correct, relevant additional detail without any inaccuracies or omissions."
  },
  "837": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key facts from the reference, clearly stating that the precise molecular mechanism is unknown, and provides additional correct and relevant context without inaccuracies or omissions."
  },
  "838": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the pharmacological class as acetylcholinesterase inhibitor, explains the mechanism, and provides a clinically relevant example (pyrantel pamoate) with no inaccuracies or omissions."
  },
  "839": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "840": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies μ-opioid receptors as the primary mediators, explains their CNS location and mechanism, and provides relevant context without inaccuracies or omissions."
  },
  "841": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the drug class as potassium channel antagonists (blockers), and provides accurate, relevant clinical context without any inaccuracies or omissions."
  },
  "842": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies alkylating agents as structurally related to nitrogen mustard, explains their DNA cross-linking mechanism, and directly links this to inhibition of megakaryocyte proliferation and platelet reduction, fully matching the reference answer with no inaccuracies or omissions."
  },
  "843": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies dopamine D2 receptors as the principal target, accurately explains the mechanism, and provides relevant clinical context without any inaccuracies or omissions."
  },
  "844": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the mechanism (binding to 30S ribosomal subunit and inhibition of protein synthesis), and provides relevant, correct additional details without any inaccuracies or omissions."
  },
  "845": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the mechanism as enzyme activation (specifically allosteric activation), and provides relevant, accurate elaboration without any inaccuracies or omissions."
  },
  "846": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly explains both the therapeutic and drug interaction mechanisms via cytochrome P450 inhibition, and provides relevant, accurate additional detail without any inaccuracies or omissions."
  },
  "847": {
    "score": 5.0,
    "explanation": "5: Fully covers all key clinical facts from the reference, accurately describing praziquantel’s mechanism (increased calcium permeability, spastic paralysis, and expulsion), with additional correct and relevant details."
  },
  "848": {
    "score": 5.0,
    "explanation": "5: Fully covers the key fact (inhibition of bacterial protein synthesis), adds correct and relevant mechanistic detail, and contains no inaccuracies or omissions."
  },
  "849": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies beta-lactamase inhibitors, explains their mechanism, provides relevant examples, and includes a concise summary table without inaccuracies or omissions."
  },
  "850": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the class as beta-lactam antibiotics and accurately describes their mechanism, but it does not explicitly state the general pharmacological class \"enzyme inhibitors\" as required by the reference answer, omitting a key fact."
  },
  "851": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies glucocorticoid receptor agonism as the primary pathway, thoroughly explains the mechanism, and provides relevant, accurate extra details without any inaccuracies or omissions."
  },
  "852": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the alkylating and DNA cross-linking action of cyclophosphamide, its immunosuppressive effect, and the restoration of erythropoiesis, with no inaccuracies or omissions."
  },
  "853": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the molecular mechanism (binding to CD20 and B cell depletion via antibody-dependent mechanisms), and provides additional correct and relevant clinical context without any inaccuracies or omissions."
  },
  "854": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the mechanism as competitive muscarinic antagonism, explains the role of acetylcholine and vagal tone, and links this to restoration of SA node function; all key facts are covered with relevant, accurate elaboration."
  },
  "855": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies free radical scavenging as the relevant mechanism, and provides accurate, clinically relevant explanations without any inaccuracies or omissions."
  },
  "856": {
    "score": 5.0,
    "explanation": "5: The model answer accurately and thoroughly explains that dantrolene inhibits the ryanodine receptor (RyR1) calcium channel in skeletal muscle, matching all key clinical and mechanistic details from the reference answer with no omissions or inaccuracies."
  },
  "857": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies viral DNA polymerase as the primary target, explains the mechanism of action, and provides relevant pharmacological context without inaccuracies or omissions."
  },
  "858": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies covalent bond formation as the key interaction, explains the mechanism with reference to PBPs and the β-lactam ring, and provides accurate, clinically relevant detail without any inaccuracies or omissions."
  },
  "859": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the drug and its mechanism (squalene epoxidase inhibition in ergosterol synthesis), and provides relevant, accurate additional context without any inaccuracies or omissions."
  },
  "860": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the pharmacological mechanism, and provides relevant clinical context without any inaccuracies or omissions."
  },
  "861": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies glucocorticoids and their inhibition of phospholipase A2, which reduces eicosanoid synthesis, but it does not specifically mention lipoxygenase inhibition as central to leukotriene formation, missing the key enzyme class highlighted in the reference."
  },
  "862": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant explanations, and contains no inaccuracies or omissions."
  },
  "863": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies glucocorticoids (corticosteroids) as the class, accurately describes their mechanism via intracellular receptor binding and gene expression alteration, and covers all key clinical facts without inaccuracies or omissions."
  },
  "864": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including the diagnosis, mechanism of iron chelation, prevention of iron-mediated oxidative damage, and the link to skeletal complications, with no inaccuracies or omissions."
  },
  "865": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the general pharmacological class as β-lactam antibiotics and accurately explains the mechanism, but it does not use the broader term \"enzyme inhibitors\" as in the reference answer, which is a minor wording inaccuracy. Otherwise, all key facts are covered."
  },
  "866": {
    "score": 3.0,
    "explanation": "3: The model answer covers the mechanism of psoralen activation by UVA and its downstream effects, but it overemphasizes increased gene transcription and melanogenic enzyme upregulation rather than directly identifying photoabsorption/activation of psoralen as the most immediate molecular process, as specified in the reference."
  },
  "867": {
    "score": 5.0,
    "explanation": "5: The model answer correctly and thoroughly explains 5-alpha reductase inhibition, specifies type II, details the testosterone-to-DHT conversion, and links this to the pathophysiology and treatment of androgenetic alopecia, with no inaccuracies or omissions."
  },
  "868": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies nucleoside analogs as DNA polymerase inhibitors, explains the mechanism, provides relevant examples, and includes no inaccuracies or omissions."
  },
  "869": {
    "score": 3.0,
    "explanation": "3: The model answer correctly explains the clinical scenario, the role of vitamin A in vision, and the concept of replacement therapy, but it does not explicitly identify \"enzyme interactions\" as the pharmacological mechanism, which is the key fact in the reference answer."
  },
  "870": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the mechanism and pharmacologic class, and provides additional accurate, relevant clinical context without any inaccuracies or omissions."
  },
  "871": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies melatonin receptor agonists, names ramelteon, and accurately distinguishes mechanism from other hypnotics; all extra details are relevant and factually correct."
  },
  "872": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key facts from the reference, correctly identifies thalidomide, discusses its known immunomodulatory actions, and clearly states that the precise mechanism in Behçet disease is unknown, with no inaccuracies or omissions."
  },
  "873": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the sodium-chloride symporter (NCC) as the inhibited transporter, matches all key clinical facts, and provides relevant, accurate additional explanation without any errors or omissions."
  },
  "874": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies bedaquiline and its mechanism (inhibition of mycobacterial ATP synthase/F-type ATPase), but does not mention \"Organic Anion Transporter 3 Inhibitors\" as specified in the reference, thus missing the key fact required by the question."
  },
  "875": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the drug class as \"receptor tyrosine kinase inhibitor,\" which is a more specific subset of \"protein kinase inhibitors\" (the reference answer). It covers all key facts and provides accurate, relevant extra detail, but the slightly narrower terminology could be considered a minor wording inaccuracy."
  },
  "876": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies the drug class as acetylcholinesterase inhibitors and provides a clinically relevant, accurate explanation with no omissions or inaccuracies."
  },
  "877": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the drug, its specific enzyme target (PDE3), and the resulting increase in cAMP, which aligns with the reference's \"enzyme interactions\" mechanism. However, it does not explicitly generalize the mechanism as \"enzyme interactions,\" which is the core of the reference answer, representing a minor wording inaccuracy."
  },
  "878": {
    "score": 2.0,
    "explanation": "2: The model answer provides plausible mechanisms but does not acknowledge that the precise molecular mechanism is not fully understood, which is the key fact in the reference. It includes some relevant information but omits the central uncertainty, constituting a moderate omission."
  },
  "879": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the drug class and mechanism, and provides accurate, relevant additional explanation without any inaccuracies or omissions."
  },
  "880": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key facts from the reference, accurately stating that the precise mechanism is unknown while providing correct, clinically relevant context about AHAs' effects; there are no inaccuracies or omissions."
  },
  "881": {
    "score": 5.0,
    "explanation": "5: Fully covers all key facts from the reference, accurately describing biotin’s role as a cofactor for carboxylase enzymes and its effect on metabolic pathways; extra details are correct and clinically relevant."
  },
  "882": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains both acetylcholine and phospholipid synthesis, and provides clinically relevant mechanistic detail without inaccuracies or omissions."
  },
  "883": {
    "score": 5.0,
    "explanation": "5: Fully covers the key fact of protein synthesis inhibition, correctly specifies the 30S ribosomal subunit, and accurately describes the mechanism; all extra details are factually correct and clinically relevant."
  },
  "884": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the CXCR4/CXCL12 axis, explains the pathogenesis and therapeutic mechanism, and provides relevant, accurate, and clinically pertinent additional details without any inaccuracies or omissions."
  },
  "885": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies L-type voltage-gated calcium channels as the specific molecular target, provides accurate and clinically relevant explanation, and contains no inaccuracies or omissions."
  },
  "886": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides a detailed and accurate molecular mechanism, and includes only relevant, correct additional information without any inaccuracies or omissions."
  },
  "887": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the vitamin D receptor’s nuclear, transcriptional mechanism, and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "888": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately identifies the pharmacological class and mechanism, and provides relevant, correct additional details without any inaccuracies or omissions."
  },
  "889": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the mechanism as inhibition of cell wall synthesis via transpeptidase (PBP) inhibition, and provides relevant, accurate context without any errors or omissions."
  },
  "890": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies enzymes as the principal molecular targets and explains their role in glucose metabolism, but omits explicit mention of transporters, which are also highlighted in the reference answer; otherwise, the content is accurate and clinically relevant."
  },
  "891": {
    "score": 5.0,
    "explanation": "5: Fully correct—clearly identifies H1 receptor antagonism as the main mechanism, with all extra content accurate and clinically relevant; no omissions or inaccuracies."
  },
  "892": {
    "score": 3.0,
    "explanation": "3: The model answer provides a plausible and detailed mechanism for omega-3 fatty acids' anti-inflammatory effects, but this is not supported by current evidence in Sjögren’s syndrome, where the precise mechanism remains unclear; thus, it overstates the certainty of the pathway and omits the key fact that the mechanism is not definitively known."
  },
  "893": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies deferoxamine, details its iron-chelating mechanism, and explains how this reduces tissue toxicity, with all additional content being accurate and clinically relevant."
  },
  "894": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies phosphodiesterase as the enzyme class, provides accurate and clinically relevant explanation about anagrelide’s mechanism, and contains no inaccuracies or omissions."
  },
  "895": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the EP (specifically EP4) receptor as the direct molecular target, and provides accurate, relevant mechanistic detail without inaccuracies or omissions."
  },
  "896": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the drug class (nitrate vasodilator/organic nitrate), mechanism (NO-mediated cGMP increase), and clinical context, but does not explicitly use the term \"nitric oxide donors\" as in the reference; this is a minor wording inaccuracy that does not alter the clinical meaning."
  },
  "897": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies growth hormone analogs as the class, specifies growth hormone receptor agonism as the mechanism, and provides additional accurate, relevant details without inaccuracies or omissions."
  },
  "898": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the pharmacological class as antifolate antimalarial drugs and explains their mechanism, which aligns with nucleic acid synthesis inhibition, but does not explicitly use the term \"Nucleic Acid Synthesis Inhibitors\" as in the reference; this is a minor wording inaccuracy."
  },
  "899": {
    "score": 3.0,
    "explanation": "3: The model answer correctly describes bismuth's barrier-forming action but omits the key reference point of acid-base activity and modulation of gastric pH, which is central to the reference answer; it covers most, but not all, key facts."
  },
  "900": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the dopamine agonist mechanism, and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "901": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, accurately describes the sodium channel mechanism, and provides relevant, correct additional context without any inaccuracies or omissions."
  },
  "902": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the drug class as antimetabolite immunosuppressant and explains the mechanism as inhibition of DNA and RNA synthesis, matching the reference's \"nucleic acid synthesis inhibitors.\" However, it focuses specifically on purine synthesis and mycophenolate, which, while accurate and relevant, slightly narrows the general class described in the reference. No major omissions or inaccuracies are present."
  },
  "903": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies transpeptidase (penicillin-binding protein) as the target, and provides relevant, accurate clinical context and explanation without any inaccuracies or omissions."
  },
  "904": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies GnRH agonists as the drug class, explains their mechanism (initial stimulation then suppression of LH/FSH via continuous GnRH receptor activation), and provides accurate, relevant extra details without any errors or omissions."
  },
  "905": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the cytochrome P450 system and the clinical importance of drug interactions, but incorrectly specifies CYP3A4 instead of CYP1A as in the reference answer, which is a moderate factual inaccuracy. Most other key facts are covered, but the specific isoenzyme mismatch lowers the score."
  },
  "906": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies muscarinic acetylcholine receptors as the target, provides accurate and clinically relevant explanation, and covers all key facts from the reference without any errors or omissions."
  },
  "907": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies calcium channel blockers as the drug class and explains their mechanism, but does not specify \"L-type\" calcium channels as in the reference answer, which is a minor omission."
  },
  "908": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies direct thrombin inhibitor as the mechanism, explains thrombin’s role, distinguishes from other anticoagulant classes, and provides relevant examples without inaccuracies or omissions."
  },
  "909": {
    "score": 5.0,
    "explanation": "5: Fully covers all key facts, correctly identifies penicillin-binding proteins as transpeptidases, explains their role, and links the mechanism to β-lactam antibiotics; no inaccuracies or omissions."
  },
  "910": {
    "score": 5.0,
    "explanation": "5: The model answer accurately states that the mechanism is not well established at the cellular or molecular level, matches all key facts from the reference, and any additional content is correct and clinically relevant."
  },
  "911": {
    "score": 3.0,
    "explanation": "3: The answer covers most key facts, including the role of IVIG in modulating immune responses and mentions neutralization of autoantibodies, but it incorrectly emphasizes Fc receptor blockade as the principal mechanism rather than direct neutralization of pathogenic autoantibodies, which is the reference answer's focus. No unsafe statements are present, but the main mechanism is misidentified."
  },
  "912": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies sulfonamides as PABA inhibitors, accurately describes the mechanism, and provides relevant, factually correct additional detail without any inaccuracies or omissions."
  },
  "913": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies P-glycoprotein as the primary transporter inhibited, explains its role, and provides relevant additional context without inaccuracies or omissions."
  },
  "914": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the mechanism (inhibition of PBPs involved in cell wall synthesis), and provides relevant, correct elaboration without any inaccuracies or omissions."
  },
  "915": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the clinical scenario, treatment, and mechanism of glucocorticoids but incorrectly names phospholipase A2 as the directly targeted enzyme for anti-inflammatory effects, rather than lipoxygenase; this is a moderate factual error regarding the specific enzyme class asked in the question."
  },
  "916": {
    "score": 4.0,
    "explanation": "4: The model answer accurately describes the mechanism (physical and chemical blocking/absorption of UV radiation) and details both types of sunscreen agents, but it does not explicitly use the term \"physiochemical activity\" as in the reference answer, representing a minor wording inaccuracy."
  },
  "917": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the molecular mechanism, and provides relevant additional details without any inaccuracies or omissions."
  },
  "918": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies β2-adrenergic agonists as the drug class, covers all key clinical facts, and provides accurate, relevant explanations without any errors or omissions."
  },
  "919": {
    "score": 4.0,
    "explanation": "4: The model answer correctly describes the mechanism and class (antifibrinolytic agents/lysine analogues) and provides accurate, relevant detail, but does not explicitly use the term \"plasmin inhibitors\" as in the reference answer, which is a minor wording inaccuracy."
  },
  "920": {
    "score": 4.0,
    "explanation": "4: The answer correctly identifies botulinum toxin, accurately describes its mechanism as inhibiting presynaptic acetylcholine release, and links this to internal sphincter relaxation. However, it does not explicitly use the reference term \"acetylcholine release inhibitors\" as the pharmacological class, which is a minor wording inaccuracy."
  },
  "921": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies acetylcholine as the neurotransmitter, explains botulinum toxin's mechanism, and all extra content is accurate and clinically relevant."
  },
  "922": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key facts about zinc's role as a metalloenzyme cofactor in tissue repair and regeneration, with accurate and relevant elaboration. However, it does not explicitly mention \"electrolyte activity\" as in the reference, representing a minor omission in terminology."
  },
  "923": {
    "score": 3.0,
    "explanation": "3: The model answer covers the antimicrobial effect and the role of acidity but emphasizes protein precipitation and metallic ion action rather than directly stating acid-base activity as the primary mechanism, missing the key fact required by the reference."
  },
  "924": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies gentian violet, states that its precise mechanism is incompletely understood, and summarizes current hypotheses without inaccuracies; however, it includes speculative mechanisms (DNA binding, cell wall synthesis inhibition) that are not definitively established, making the answer slightly less precise than the reference."
  },
  "925": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including the specific enzyme (CYP2C19), the mechanism of interaction, and the clinical significance (reduced clopidogrel activation and increased thrombotic risk), with no inaccuracies or omissions."
  },
  "926": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the supplement's role as a coenzyme/cosubstrate in enzymatic reactions, and provides accurate, relevant additional detail without any inaccuracies or omissions."
  },
  "927": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the diagnosis, explains the rationale for corticosteroid use, and accurately names the glucocorticoid receptor as the direct molecular target, with no inaccuracies or omissions."
  },
  "928": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes estrogen receptor agonism as the mechanism, and provides correct, relevant molecular details without any inaccuracies or omissions."
  },
  "929": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies adalimumab and its mechanism, and provides additional relevant and accurate clinical context without any inaccuracies or omissions."
  },
  "930": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the mechanism (enzymatic degradation of collagen by collagenase), and provides relevant, correct additional details without any inaccuracies or omissions."
  },
  "931": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the inhibition of cyclooxygenase enzymes and reduction of prostaglandin synthesis, and provides relevant, correct additional context without any inaccuracies or omissions."
  },
  "932": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies cytochrome P450 enzymes, specifically CYP3A4, as the inhibited class, explains the clinical relevance, and provides accurate, relevant extra information without any inaccuracies or omissions."
  },
  "933": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies phospholipase A2 as the enzyme directly inhibited by glucocorticoids, but the reference answer specifies lipoxygenase enzymes as the primary system responsible for the relevant lipid mediators (leukotrienes). The model answer covers most key facts but misses the specific enzyme system asked for, resulting in a moderate omission."
  },
  "934": {
    "score": 2.0,
    "explanation": "2: The model answer focuses on mucin gene upregulation via nuclear receptors, which is a secondary effect of vitamin A but omits the primary mechanism of free radical scavenging (antioxidant effect) as specified in the reference. The explanation is relevant but misses the key fact, constituting a moderate omission."
  },
  "935": {
    "score": 3.0,
    "explanation": "3: The answer provides a detailed explanation of benzimidazoles and their mechanism, which is factually correct and relevant, but it does not directly state \"enzyme inhibitors\" as the general pharmacological class, missing the key fact from the reference answer."
  },
  "936": {
    "score": 5.0,
    "explanation": "5: The model answer accurately and completely describes the irreversible antagonism of α₁-adrenergic receptors, the resulting smooth muscle relaxation, and the clinical effect on urinary symptoms, with no omissions or inaccuracies."
  },
  "937": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the agent as a retinoid and accurately describes its mechanism as modulation of gene transcription via nuclear receptors, but it does not mention enzyme interactions or modulation of skin enzyme activity as specified in the reference answer, missing a key fact."
  },
  "938": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the mechanism of recombinant factor VIIa, and provides additional correct and clinically relevant detail without any inaccuracies or omissions."
  },
  "939": {
    "score": 2.0,
    "explanation": "2: The model answer focuses on mast cell stabilization and inhibition of calcium influx, which is accurate for mast cell stabilizers, but the reference answer specifies histamine H1 receptor antagonism as the directly targeted pathway. The model omits this key fact and instead describes a related but distinct mechanism, covering less than 70% of the required key facts."
  },
  "940": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the drug and its mechanism (agonism of thyroid hormone receptors), and provides accurate, relevant elaboration without inaccuracies or omissions."
  },
  "941": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the drug and its mechanism (bradykinin B2 receptor blockade), and provides relevant, accurate clinical context without any inaccuracies or omissions."
  },
  "942": {
    "score": 4.0,
    "explanation": "4: The model answer correctly explains that vitamin A acts via modulation of gene expression through nuclear receptors, which is a more detailed and precise mechanism underlying the reference answer's \"modulation of enzyme-mediated biological processes.\" It covers all key facts and adds relevant mechanistic detail, but the wording does not exactly match the general mechanism requested (i.e., it focuses on gene transcription rather than the broader enzyme modulation), which is a minor inaccuracy."
  },
  "943": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies lipoxygenase as the enzyme class most directly inhibited, thoroughly explains the clinical context, and accurately describes the mechanism of action without any inaccuracies or omissions."
  },
  "944": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describing COX inhibition and reduced prostaglandin synthesis, with additional correct and relevant clinical context; there are no inaccuracies or omissions."
  },
  "945": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the mechanism (enzyme inhibition via PBPs), and provides relevant, correct additional context without any inaccuracies or omissions."
  },
  "946": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the clinical scenario, the drug (dantrolene), its direct action on skeletal muscle, and its mechanism (inhibition of ryanodine receptor-mediated calcium release). However, it omits the specific term \"calcium channel antagonist\" as used in the reference, which is a minor wording inaccuracy."
  },
  "947": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies both DNA gyrase and topoisomerase IV as fluoroquinolone targets and explains their roles, but the reference specifically asks for the primary mechanism in this context—topoisomerase IV inhibition—whereas the model answer gives both enzymes equal emphasis, representing a minor inaccuracy in focus."
  },
  "948": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies GABA-A as the primary receptor, explains the mechanism, and provides relevant examples without inaccuracies or omissions."
  },
  "949": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies competitive inhibition as the mechanism and provides relevant clinical and pharmacological context, but it does not specifically name \"Cytochrome P450 17A1 inhibitors\" as required by the reference answer, and instead focuses on azoles and CYP51/CYP3A4, which is less precise for this question."
  },
  "950": {
    "score": 3.0,
    "explanation": "3: The model answer covers the anti-inflammatory effect of hyperbaric oxygen via reduced leukocyte-endothelial adhesion, which is a relevant mechanism, but it omits the reference answer's key point about free radical scavenging and direct neutralization of reactive oxygen species; thus, it addresses 70-89% of the key facts."
  },
  "951": {
    "score": 3.0,
    "explanation": "3: The model answer covers the uncertainty of the mechanism and correctly identifies iodoquinol, but it goes beyond the reference by specifying metal chelation as a likely mechanism, which is speculative and not definitively established; this introduces a minor inaccuracy relative to the reference's more cautious stance."
  },
  "952": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly explaining that sodium acetate provides sodium to correct hyponatremia and is metabolized to bicarbonate to address metabolic acidosis, with no inaccuracies or omissions."
  },
  "953": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the drug class and molecular target, and provides relevant, accurate clinical context without any inaccuracies or omissions."
  },
  "954": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the molecular target, provides a clear explanation matching all key clinical facts, and includes only relevant, accurate additional information."
  },
  "955": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the drug class as GnRH antagonists, thoroughly explains the mechanism, distinguishes from agonists, and provides clinically relevant details with no inaccuracies or omissions."
  },
  "956": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies beta blockers as the drug class, explains the mechanism (β1-adrenergic antagonism slowing AV nodal conduction), and relates it to the clinical scenario without inaccuracies or omissions."
  },
  "957": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the β₂-adrenergic receptor as the mediator, provides accurate and clinically relevant explanation, and contains no inaccuracies or omissions."
  },
  "958": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains thiamine’s cofactor role in relevant enzymes, and provides correct, clinically relevant additional details without inaccuracies or omissions."
  },
  "959": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies chondroitin sulfate, explains its role in cartilage and extracellular matrix, and describes its mechanism as modulation of extracellular matrix metabolism, which closely aligns with \"biological macromolecular activity.\" There is a minor wording difference in the category label, but the meaning is preserved and all key facts are covered."
  },
  "960": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the drug and its mechanism, and explicitly notes that the precise mechanism is not fully understood, matching the reference answer with no inaccuracies or omissions."
  },
  "961": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key facts from the reference, explicitly noting that the precise mechanism is not fully defined, while providing accurate, relevant clinical and pharmacological context without inaccuracies or omissions."
  },
  "962": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately identifies PDE4 inhibitors as the class, and provides correct, relevant mechanistic and clinical details without any inaccuracies or omissions."
  },
  "963": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies CYP2C9 inhibitors as the relevant class and provides accurate, clinically relevant explanation, but adds \"competitive inhibitors\" which, while not incorrect, is not specifically required and could be seen as a minor wording inaccuracy. All key facts are present with only this minor deviation."
  },
  "964": {
    "score": 2.0,
    "explanation": "2: The model answer focuses on antimuscarinic agents rather than serotonin antagonists, missing the key fact that serotonin antagonists (e.g., ondansetron) are the class referenced in the question. While the pharmacology of antimuscarinics is described accurately, this is a moderate omission of the main point."
  },
  "965": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and accurate description of the general mechanism of vitamin K in coagulation, but it does not address the reference answer's key point that the precise cellular or molecular mechanism in premature infants is currently unknown; thus, it omits the most critical fact."
  },
  "966": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies FXR agonists, details their mechanism (decreased bile acid synthesis, increased transport/excretion, reduced inflammation), and provides accurate, clinically relevant elaboration without errors or omissions."
  },
  "967": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies mineralocorticoid receptor agonism as the mechanism, and provides accurate, relevant mechanistic detail without inaccuracies or omissions."
  },
  "968": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers all key clinical facts from the reference, accurately describing the GI phosphate binding mechanism, and provides additional correct and relevant clinical context without any inaccuracies or omissions."
  },
  "969": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies NMDA receptor antagonism as the key mechanism, explains the clinical context, names amantadine, and provides accurate, relevant details without any inaccuracies or omissions."
  },
  "970": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies vitamin K epoxide reductase as the enzyme inhibited, provides accurate and relevant additional details about warfarin’s mechanism, and contains no inaccuracies or omissions."
  },
  "971": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the molecular mechanism, and provides relevant additional context without any inaccuracies or omissions."
  },
  "972": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies NSAIDs as the pharmacological class, explains the mechanism (COX inhibition), and addresses relevant differentials; all key facts from the reference are covered with no inaccuracies or omissions."
  },
  "973": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies NSAIDs as cyclooxygenase inhibitors, specifies their molecular target, and provides accurate, relevant additional detail without any inaccuracies or omissions."
  },
  "974": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies coenzyme Q10, explains its mitochondrial role, addresses its potential to alter CYP450-mediated drug metabolism, and highlights relevant clinical monitoring points, fully covering all key facts in the reference answer without inaccuracies or omissions."
  },
  "975": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the mechanism (protein synthesis inhibition via 30S ribosomal subunit binding and prevention of aminoacyl-tRNA attachment), and provides relevant, correct elaboration without inaccuracies or omissions."
  },
  "976": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies plasminogen activators (tPA and uPA), and provides relevant, accurate additional explanation without any inaccuracies or omissions."
  },
  "977": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies cyclooxygenase (COX) as the inhibited enzyme, provides accurate and clinically relevant explanation, and contains no inaccuracies or omissions."
  },
  "978": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the class as nucleoside reverse transcriptase inhibitors, explains the mechanism, and clarifies the cytidine analog (lamivudine) as the most likely agent, matching all key clinical facts in the reference without inaccuracies."
  },
  "979": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the molecular mechanism (inhibition of transpeptidase/PBP, disruption of cell wall synthesis), and provides relevant, correct elaboration without inaccuracies or omissions."
  },
  "980": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies hormone receptor agonism at melanocortin receptors, and provides additional accurate, clinically relevant details without any inaccuracies or omissions."
  },
  "981": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies bacterial DNA gyrase (topoisomerase II) as the main molecular target, provides accurate and clinically relevant additional details, and contains no inaccuracies or omissions."
  },
  "982": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies DNA gyrase (bacterial topoisomerase II) as the primary molecular target, provides accurate and relevant clinical context, and contains no inaccuracies or omissions."
  },
  "983": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies beta-2 adrenergic agonists as the drug class, accurately explains the mechanism, and provides relevant clinical context without any inaccuracies or omissions."
  },
  "984": {
    "score": 5.0,
    "explanation": "5: The model answer accurately describes the principal mechanism—non-selective GI adsorption of uremic toxins to prevent reabsorption and promote elimination—matching all key clinical facts in the reference without inaccuracies or omissions."
  },
  "985": {
    "score": 3.0,
    "explanation": "3: The model answer discusses apremilast and its mechanism in detail, but the reference answer is about modified cyclosporine, not apremilast. Thus, the model answer covers some general principles (unclear mechanism), but misses the key fact that the agent in question is cyclosporine, not apremilast."
  },
  "986": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the pharmacological class as antimuscarinic (anticholinergic) agents, and provides accurate, relevant explanations without any inaccuracies or omissions."
  },
  "987": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies amphotericin B and its mechanism, but it does not directly state \"ergosterol synthesis inhibitors\" as the class most closely related, instead focusing on polyenes and nystatin. This misses the key reference answer point and may confuse the intended comparison, though most clinical facts are present."
  },
  "988": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describing benzodiazepines as positive allosteric modulators of the GABA-A receptor and specifying the increase in chloride channel opening frequency; all additional details are correct and clinically relevant."
  },
  "989": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the pharmacological class as cell wall synthesis inhibitors and accurately explains the mechanism involving PBPs, fully covering all key clinical facts with no errors or omissions."
  },
  "990": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describing endothelial injury and sclerosis as the primary mechanism, with additional correct and relevant mechanistic detail; there are no inaccuracies or omissions."
  },
  "991": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the pharmacologic mechanism (inhibition of viral DNA synthesis via chain termination), and provides relevant, correct clinical context without inaccuracies or omissions."
  },
  "992": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describing glucocorticoid receptor agonism and providing additional, correct, and clinically relevant mechanistic detail without any inaccuracies or omissions."
  },
  "993": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, including the physiochemical alteration of the scalp environment and the antifungal action of selenium sulfide, with correct and relevant extra detail. However, it emphasizes antifungal activity as the primary mechanism rather than the physiochemical alteration, which is the focus of the reference answer, representing a minor wording inaccuracy."
  },
  "994": {
    "score": 3.0,
    "explanation": "3: The model answer correctly discusses modulation of bile acid synthesis via FXR activation, which is relevant, but it omits the key fact that the therapeutic effect is most directly due to increased hepatic fatty acid β-oxidation. The focus on FXR and bile acid regulation covers much of the mechanism but misses the primary metabolic process specified in the reference."
  },
  "995": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the pharmacological mechanism, and provides relevant, correct elaboration without any inaccuracies or omissions."
  },
  "996": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the mechanism (inhibition of PBPs/transpeptidases and cell wall synthesis), and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "997": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the pharmacologic class and principal mechanism, covering all key facts from the reference. Additional details are accurate, clinically relevant, and enhance understanding without introducing errors or irrelevant content."
  },
  "998": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies ergosterol as the molecular target, explains the mechanism of action, and provides relevant additional information without any inaccuracies or omissions."
  },
  "999": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies dantrolene, its mechanism, and its pharmacological class, but does not mention \"calcium channel antagonists,\" which is the key fact in the reference answer; instead, it focuses on \"direct-acting skeletal muscle relaxants,\" which is related but not the specific class asked for."
  },
  "1000": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies cyclophosphamide, details its alkylating (covalent DNA modification) mechanism, and explains the clinical relevance without inaccuracies or omissions."
  },
  "1001": {
    "score": 3.0,
    "explanation": "3: The model answer accurately describes the mechanism and effects of the topical agent but does not use the mechanistic class term \"physiochemical activity\" as in the reference; instead, it focuses on \"keratolytic agent,\" which is a therapeutic class, not a mechanistic one, resulting in a moderate omission."
  },
  "1002": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describing insulin's action via activation of the insulin receptor's tyrosine kinase activity, autophosphorylation, and downstream effects; all additional details are correct and clinically relevant."
  },
  "1003": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the mechanism as inhibition of viral DNA polymerase, covers all key clinical facts, and provides additional accurate and relevant details without any inaccuracies or omissions."
  },
  "1004": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the agent as recombinant human growth hormone, details its action as a growth hormone receptor agonist, and accurately describes the downstream JAK-STAT signaling and IGF-1 induction, fully covering all key clinical facts in the reference answer."
  },
  "1005": {
    "score": 5.0,
    "explanation": "5: Thoroughly covers all key facts from the reference, correctly identifies NS5A inhibitors as the most accurate class, and provides relevant, accurate additional context without any errors or omissions."
  },
  "1006": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the molecular mechanism, and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "1007": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies glucocorticoid receptors (a subclass of corticosteroid hormone receptors) as the primary target, accurately explains the mechanism, and contains no inaccuracies or omissions."
  },
  "1008": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies modulation of gene expression and growth factor upregulation as the primary mechanism, closely aligning with the reference's \"modulation of transcription factor activity,\" but introduces EGFR pathway activation, which is plausible but not the central, referenced mechanism; minor wording inaccuracy but no clinically significant errors."
  },
  "1009": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies ACTH analogs/melanocortin receptor agonists, explains the mechanism, and provides relevant examples, fully covering all key clinical facts in the reference answer with no inaccuracies or omissions."
  },
  "1010": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies the histamine H1 receptor as the principal target, explains the clinical context, mechanism, and symptom relief, and provides only relevant, accurate extra information."
  },
  "1011": {
    "score": 5.0,
    "explanation": "5: Fully covers all key facts from the reference, correctly identifies the protective antigen as the target, and accurately explains the mechanistic basis; all additional details are correct and clinically relevant."
  },
  "1012": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the pharmacological class (H1 antihistamines), explains the mechanistic rationale, and provides relevant examples without inaccuracies or omissions."
  },
  "1013": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the blockade of voltage-gated sodium channels, and provides relevant, correct additional explanation without any inaccuracies or omissions."
  },
  "1014": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies direct neutralization of gastric acid via acid-base reaction as the key pharmacodynamic mechanism, fully aligns with the reference, and provides only relevant, accurate elaboration without any errors or omissions."
  },
  "1015": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies VMAT2 inhibition as the molecular mechanism, fully explains the process, and provides relevant clinical context without any inaccuracies or omissions."
  },
  "1016": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the growth hormone receptor as the principal molecular target, thoroughly explains the mechanism, and provides clinically relevant details without inaccuracies or omissions."
  },
  "1017": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the general class as nucleic acid synthesis inhibitors, provides accurate supporting details, and contains no inaccuracies or omissions relevant to the reference answer."
  },
  "1018": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the mechanism (PABA antimetabolite blockade of folate synthesis), and provides correct, relevant additional detail without any inaccuracies or omissions."
  },
  "1019": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately identifies the mechanism (protein synthesis inhibition via 50S ribosomal subunit binding), and provides relevant, correct elaboration without any inaccuracies or omissions."
  },
  "1020": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the drug class and molecular target, and provides accurate, relevant mechanistic detail without any inaccuracies or omissions."
  },
  "1021": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies pentamidine, states that its precise mechanism is incompletely understood, and notes possible interference with nucleic acid and protein synthesis, fully aligning with the reference answer and adding only clinically relevant, accurate context."
  },
  "1022": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes mesna's mechanism as chemical neutralization of toxic metabolites, and provides correct, clinically relevant additional detail without inaccuracies or omissions."
  },
  "1023": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies inhibition of transpeptidase (penicillin-binding protein) as the mechanism, fully explains the context, and provides accurate, clinically relevant details without any inaccuracies or omissions."
  },
  "1024": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and accurate explanation of adenosine's mechanism and correctly identifies muscarinic receptor agonists as sharing a similar effect via Gi-coupled receptors, but it does not explicitly state \"adenosine receptor agonists\" as the class sharing the *primary molecular target* (i.e., the adenosine receptor itself), which is the key fact in the reference answer."
  },
  "1025": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the molecular mechanism, and adds correct, clinically relevant details about heme synthesis and neurotransmitter production without any inaccuracies or omissions."
  },
  "1026": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies ergosterol as the direct target, explains the drug mechanism, and all extra content is accurate and clinically relevant. No omissions or inaccuracies."
  },
  "1027": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the binding to aggregated β-amyloid plaques, and provides relevant, accurate additional explanation without any inaccuracies or omissions."
  },
  "1028": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the drug class, explains the mechanism, names the enzyme, and provides relevant examples without any inaccuracies or omissions."
  },
  "1029": {
    "score": 3.0,
    "explanation": "3: The model answer explains the mechanism in detail (mucoadhesion, lubrication, tear film stabilization), but does not explicitly mention \"demulcent activity,\" the principal pharmacological property asked for. While the mechanistic explanation is accurate and relevant, the omission of the key term constitutes a minor but meaningful omission."
  },
  "1030": {
    "score": 4.0,
    "explanation": "4: The model answer covers over 90% of the key facts, accurately describing the reduction of metronidazole, formation of reactive intermediates, and DNA damage, while noting the mechanism is not fully understood; however, it provides more mechanistic detail than the reference, which simply states the mechanism is unknown, making the answer slightly more specific than required but not incorrect."
  },
  "1031": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies glucocorticoid receptor agonism as the targeted pathway, and provides accurate, relevant mechanistic detail without any inaccuracies or omissions."
  },
  "1032": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies dopamine reuptake inhibitors as the primary mechanism and provides accurate, relevant detail about modafinil and its action, but includes extra terminology (\"CNS stimulants,\" \"wakefulness-promoting agents\") that, while not incorrect, could introduce minor ambiguity compared to the reference's concise \"dopamine uptake inhibitors.\""
  },
  "1033": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies beta-1 adrenergic antagonism, and provides additional accurate, relevant mechanistic detail without any inaccuracies or omissions."
  },
  "1034": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies 5-HT1B/1D serotonin receptor partial agonism as the main mechanism for vasoconstriction and neurotransmitter modulation in migraine therapy, but it omits the reference answer's focus on dopamine receptor interactions, which was specifically asked; thus, it covers about 70-89% of key facts."
  },
  "1035": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly describing antibody-mediated neutralization of cytokine-receptor binding, and provides accurate, clinically relevant elaboration without any inaccuracies or omissions."
  },
  "1036": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the androgen receptor as the nuclear receptor agonist, and provides accurate, relevant explanations without inaccuracies or omissions."
  },
  "1037": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies RNA interference (RNAi) as the mechanism and provides relevant clinical context, but it does not explicitly state \"nucleic acid synthesis inhibition\" as in the reference answer, missing the key fact required by the rubric."
  },
  "1038": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies serotonin reuptake inhibition as the primary pharmacological class, matches all key clinical facts, and provides accurate, relevant additional detail without any inaccuracies or omissions."
  },
  "1039": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the mechanistic class as immunomodulation via cytokine signaling and references interferon-alpha, which is accurate and relevant. However, it does not explicitly use the term \"biological response modifiers,\" which is the key phrase in the reference answer, representing a minor wording inaccuracy."
  },
  "1040": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies bacterial transpeptidase as the specific molecular target, provides accurate and relevant mechanistic details, and contains no inaccuracies or omissions compared to the reference answer."
  },
  "1041": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the molecular process (fibrinolysis via plasminogen activation), and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "1042": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies transpeptidase (penicillin-binding protein) as the molecular target, provides accurate mechanistic detail, and includes only clinically relevant, factually correct extra information without any omissions or inaccuracies."
  },
  "1043": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies muscarinic (M1) antagonism as the relevant mechanism, and provides accurate, clinically relevant reasoning without inaccuracies or omissions."
  },
  "1044": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies calcineurin inhibition as the primary mechanism, and provides accurate, relevant additional explanation without any inaccuracies or omissions."
  },
  "1045": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies somatostatin analogs as the mechanism, rather than dopamine agonism as specified in the reference answer, which is a moderate factual error; while the pathophysiology is described well, the key pharmacologic mechanism is missed."
  },
  "1046": {
    "score": 5.0,
    "explanation": "5: Fully correct; identifies the glucocorticoid receptor and provides a clinically relevant, accurate explanation matching all key facts in the reference answer."
  },
  "1047": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies penicillin-binding proteins (PBPs)/transpeptidases as the critical molecular target, fully explains their role in peptidoglycan cross-linking, and provides relevant clinical context without any inaccuracies or omissions."
  },
  "1048": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies DNA gyrase (topoisomerase II) as the direct molecular target, covers all key clinical facts, and provides accurate, relevant explanations without any errors or omissions."
  },
  "1049": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the mechanism as inhibition of transpeptidase (penicillin-binding protein) activity by beta-lactam antibiotics, and provides relevant, accurate additional context without any inaccuracies or omissions."
  },
  "1050": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies N-acetylcysteine, its antioxidant/free radical scavenging mechanism, and its relevance to amyloid-associated tissue injury, with no inaccuracies or omissions."
  },
  "1051": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies ACE inhibitors as the drug class, explains their mechanism of action, and clearly links this to the pathophysiology of Bartter syndrome, covering all key clinical facts in the reference answer with relevant, accurate, and clinically appropriate elaboration."
  },
  "1052": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies transpeptidase (penicillin-binding protein, PBP) as the primary molecular target, covers all key facts, and provides relevant, accurate additional context without any inaccuracies or omissions."
  },
  "1053": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the histamine H₁ receptor as the molecular target and accurately explains the mechanism of symptom relief, covering all key clinical facts in the reference answer with relevant, accurate elaboration and no omissions or inaccuracies."
  },
  "1054": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the pharmacological class, mechanism, and clinical effects, and adds correct, relevant details without any inaccuracies or omissions."
  },
  "1055": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies thalidomide as the drug, explains its teratogenicity, and accurately describes its mechanism as decreasing TNF-α production via posttranscriptional regulation and NF-κB inhibition, fully covering all key clinical facts in the reference answer with relevant, accurate elaboration."
  },
  "1056": {
    "score": 5.0,
    "explanation": "5: Fully covers all key facts, correctly identifies NMDA receptor as the principal target, and provides accurate, clinically relevant context without any inaccuracies or omissions."
  },
  "1057": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describing passive transfer of preformed antibodies that bind and neutralize VZV, with additional correct and relevant explanation; there are no inaccuracies or omissions."
  },
  "1058": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies \"proton pump inhibitor\" as the pharmacological class and provides accurate, clinically relevant details matching all key facts in the reference answer, with no errors or omissions."
  },
  "1059": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies sulfonamides as the pharmacological class and thoroughly explains the mechanism, but it does not explicitly state \"PABA inhibitors\" as the class, which is the precise term in the reference; this is a minor wording inaccuracy."
  },
  "1060": {
    "score": 2.0,
    "explanation": "2: The model answer focuses on FXR and PPARs, omitting the thyroid hormone receptor agonists specified in the reference answer, which is a moderate factual omission; while the discussion is relevant, it does not identify the correct receptor class."
  },
  "1061": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately identifies ion channel modulation as the relevant property, and provides correct, clinically relevant additional detail without inaccuracies or omissions."
  },
  "1062": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies bismuth subsalicylate and details its prostaglandin-inhibiting and mucosal-coating actions, but it omits the key reference fact that bismuth alters local GI pH, which is central to the question; thus, it covers about 70–89% of key facts."
  },
  "1063": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the drug and its mechanism (cardiac myosin inhibition), and provides accurate, relevant clinical context without inaccuracies or omissions."
  },
  "1064": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the glucocorticoid mechanism, and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "1065": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies prostaglandin receptor agonists (specifically PGE1 analogs), explains the mechanism, and provides relevant, accurate additional details without any inaccuracies or omissions."
  },
  "1066": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the physiochemical mechanism (disruption of hydrogen bonds and increased hydration in the stratum corneum), and provides additional clinically relevant detail without inaccuracies or omissions."
  },
  "1067": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the mechanism as protein synthesis inhibition, and provides additional accurate, relevant details without any inaccuracies or omissions."
  },
  "1068": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies histamine H1 receptors as the primary target, explains the clinical context, and provides accurate, relevant additional information without any inaccuracies or omissions."
  },
  "1069": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies free radical scavenging (antioxidant activity) as the molecular mechanism, thoroughly explains the process, and provides clinically relevant details without inaccuracies or omissions."
  },
  "1070": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key facts from the reference, explicitly stating that the precise molecular target is incompletely defined, and provides additional correct and clinically relevant context about pentavalent antimonials' proposed mechanisms without inaccuracies or omissions."
  },
  "1071": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the molecular process (isomerization to 11-cis-retinal), explains the enzymatic pathway, and provides relevant clinical context without inaccuracies or omissions."
  },
  "1072": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the agent and its mechanism (enzymatic degradation of uric acid via exogenous uricase), and provides relevant, accurate additional detail without any inaccuracies or omissions."
  },
  "1073": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the drug class and receptor pathway, and provides additional accurate, clinically relevant details without any inaccuracies or omissions."
  },
  "1074": {
    "score": 4.0,
    "explanation": "4: The answer covers nearly all key facts, correctly identifying magnesium sulfate, its electrolyte-replenishing role, and its weak base/acid-base activity. However, it overstates the direct acid-buffering effect of sulfate, which is not a primary mechanism in clinical acid-base management, making this a minor inaccuracy. Otherwise, the explanation is thorough and clinically relevant."
  },
  "1075": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies dihydropteroate synthase as the target, explains the mechanism, and provides relevant, accurate additional information without any inaccuracies or omissions."
  },
  "1076": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the clinical syndrome, drug, and mechanism of action, but does not explicitly state \"enzyme inhibitors\" as the drug class, instead focusing on \"antimalarial drugs,\" which is less precise per the reference. Most key facts are present, but the main classification is not directly addressed."
  },
  "1077": {
    "score": 5.0,
    "explanation": "5: Fully covers all key facts—identifies NSAIDs, explains COX inhibition and prostaglandin synthesis reduction, and provides relevant extra detail without inaccuracies or omissions."
  },
  "1078": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies dopamine agonists as the drug class, explains the mechanism, provides relevant examples, and includes only accurate, clinically relevant extra information without any errors or omissions."
  },
  "1079": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the mediator, fully explains the mechanism, and provides relevant clinical context without inaccuracies or omissions."
  },
  "1080": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the drug class and mechanism, and provides additional correct and clinically relevant details without any inaccuracies or omissions."
  },
  "1081": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key facts, correctly identifying erythropoietin receptor activation and the downstream JAK2-STAT pathway, but the final answer emphasizes the JAK2–STAT pathway rather than directly stating \"erythropoietin receptor activation,\" which is the most direct answer per the reference; this is a minor wording inaccuracy."
  },
  "1082": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately identifies COX inhibition as the pathway, and provides correct, clinically relevant elaboration without any inaccuracies or omissions."
  },
  "1083": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key facts from the reference (bismuth's mucosal protection and alteration of the gastric environment), and adds correct, relevant details about direct antimicrobial effects; however, it emphasizes direct bacterial action more than acid-base modulation, which is the focus of the reference, representing a minor wording inaccuracy."
  },
  "1084": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the inhibited process (melanin synthesis in melanocytes via tyrosinase inhibition), and provides additional accurate, relevant detail without any inaccuracies or omissions."
  },
  "1085": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the sodium-chloride symporter in the distal convoluted tubule as the target, and provides accurate, relevant additional detail without any inaccuracies or omissions."
  },
  "1086": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies estrogen receptor agonists as the pharmacological class, accurately describes the mechanism of action, and provides clinically relevant detail without any inaccuracies or omissions."
  },
  "1087": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cytochrome P450 (specifically CYP3A4) as the inhibited enzyme and provides relevant clinical context, but omits mention of CYP2C19, which is also important for some triazoles (e.g., voriconazole); otherwise, the explanation is accurate and clinically relevant."
  },
  "1088": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explaining the antioxidant (free radical scavenging) mechanism and its relevance to limiting organ damage in amyloidosis, with no inaccuracies or omissions."
  },
  "1089": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the pharmacologic class (beta-2 agonists), accurately describes the mechanism (selective beta-2 stimulation causing bronchodilation), and clearly explains the clinical benefit, fully covering all key facts in the reference answer with relevant, accurate elaboration."
  },
  "1090": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the clinical scenario, the drug (rasburicase), and its mechanism (enzymatic conversion of uric acid to allantoin), but uses \"enzyme catalysis\" and \"enzymatic oxidation\" rather than the more precise \"enzyme activation\" as in the reference; this is a minor wording inaccuracy that does not alter the essential meaning."
  },
  "1091": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies HIF inhibitors (specifically HIF-2α), explains the VHL disease mechanism, and provides a relevant example (belzutifan) with no inaccuracies or omissions."
  },
  "1092": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the drug, its mechanism (allosteric activation of CPS1), and its clinical relevance, with no inaccuracies or omissions."
  },
  "1093": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key facts from the reference, clearly stating that the precise molecular or cellular mechanism is unknown, while providing additional, accurate, and clinically relevant context without any inaccuracies or omissions."
  },
  "1094": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies insulin and its mechanism, and provides detailed, accurate, and clinically relevant explanation without any inaccuracies or omissions."
  },
  "1095": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the general pharmacological mechanism as inhibition of bacterial protein synthesis, matching the reference answer, and provides additional accurate and clinically relevant details without any inaccuracies or omissions."
  },
  "1096": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the drug’s mechanism (binding 30S subunit, blocking tRNA attachment, inhibiting protein synthesis), and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "1097": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the general mechanism as inhibition of the mitochondrial electron transport chain, which leads to impaired nucleic acid synthesis, but does not directly state \"inhibition of nucleic acid synthesis\" as the general pharmacologic mechanism, resulting in a minor wording inaccuracy."
  },
  "1098": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers all key clinical facts, accurately describing the demulcent (soothing, protective) action as a physical barrier, with no omissions or inaccuracies."
  },
  "1099": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies SNRIs as the class matching the described mechanism and clinical scenario, and provides accurate, relevant explanation and comparison. However, the reference answer specifically asks for \"serotonin uptake inhibitors,\" so the model's answer, while more precise and clinically accurate, does not exactly match the reference wording, representing a minor wording inaccuracy."
  },
  "1100": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the mechanism (inhibition of bacterial protein synthesis), and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "1101": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and accurate description of the proposed mechanisms of ursodeoxycholic acid, but it does not explicitly state that the precise molecular mechanism is unknown, as required by the reference answer. It covers the clinical facts but omits the key point that the exact cellular or molecular interaction is not fully established."
  },
  "1102": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains iron’s role as a cofactor in hemoglobin synthesis and redox reactions, and provides additional correct, clinically relevant detail without inaccuracies or omissions."
  },
  "1103": {
    "score": 3.0,
    "explanation": "3: The model answer correctly describes the disruption of cell membranes and mentions interference with enzyme activity, but ultimately selects \"disruption of cell membrane function\" rather than \"enzyme interactions\" as the general class, missing the key fact required by the reference."
  },
  "1104": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the mechanism (restoration of enzymatic activity and facilitation of bone mineralization), and provides additional correct, clinically relevant detail without any inaccuracies or omissions."
  },
  "1105": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and accurate description of the drug's mechanism, including incorporation into DNA/RNA and inhibition of DNA methyltransferase, but it does not directly state \"inhibition of nucleic acid synthesis\" as the best pharmacological mechanism, which is the key fact in the reference answer."
  },
  "1106": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies viral DNA polymerase as the primary enzyme inhibited, and provides accurate, relevant mechanistic details without any inaccuracies or omissions."
  },
  "1107": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the drug, its mechanism, and explicitly states the broad class as \"inhibitors of nucleic acid synthesis,\" matching all key facts in the reference without inaccuracies or omissions."
  },
  "1108": {
    "score": 3.0,
    "explanation": "3: The answer correctly describes the chelation mechanism and its role in binding and removing metal ions, but it introduces confusion about copper versus iron, does not specifically identify deferoxamine or iron as in the reference, and includes some irrelevant speculation about copper, which detracts from clarity."
  },
  "1109": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the histamine H1 receptor as the molecular target, provides accurate and clinically relevant explanation, and contains no inaccuracies or omissions."
  },
  "1110": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the clinical context and mechanism but incorrectly names PPAR-α agonists instead of thyroid hormone receptor agonists, which is a moderate factual error; otherwise, the explanation is detailed and relevant."
  },
  "1111": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately identifies the molecular mechanism (inhibition of transpeptidases/penicillin-binding proteins), and provides correct, relevant elaboration without any inaccuracies or omissions."
  },
  "1112": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies magnesium sulfate and explains its role as a calcium antagonist, but it does not explicitly mention calcium chelation or reduction of free extracellular calcium, which is the key mechanism in the reference answer; instead, it focuses on channel antagonism, which is related but not identical."
  },
  "1113": {
    "score": 4.0,
    "explanation": "4: The model answer correctly explains the mechanism (inhibition of transpeptidation/cross-linking via PBPs) and identifies beta-lactams, but does not explicitly use the term \"transpeptidase inhibitors\" as in the reference; otherwise, all key facts are present."
  },
  "1114": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key facts in the reference (that the precise mechanism is unknown) and provides additional, accurate, and clinically relevant mechanistic details without any inaccuracies or omissions."
  },
  "1115": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the F (fusion) protein as the target, explains the mechanism of blocking viral entry, and provides clinically relevant additional detail without inaccuracies or omissions."
  },
  "1116": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies ergosterol as the molecular target and provides a clinically relevant, accurate explanation without any errors or omissions."
  },
  "1117": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies magnesium as the supplement, explains its role in restoring electrolyte balance, and details its physiological importance, fully covering and expanding on the reference answer with accurate and clinically relevant information."
  },
  "1118": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies histamine H1 receptors as the target, explains the antimuscarinic and antihistaminic actions, and provides clinically relevant context without inaccuracies or omissions."
  },
  "1119": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies transpeptidase as the principal target, explains its role as a penicillin-binding protein, and accurately describes the mechanism of beta-lactam antibiotics with no omissions or inaccuracies."
  },
  "1120": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies ergosterol as the target, explains amphotericin B’s mechanism and selective toxicity, and provides relevant additional detail without inaccuracies or omissions."
  },
  "1121": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describing Fc gamma receptor saturation on splenic macrophages and inhibition of phagocytosis, with no inaccuracies or omissions."
  },
  "1122": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describing both H1 receptor antagonism and mast cell stabilization as the drug class mechanism, with correct and clinically relevant additional explanation and no inaccuracies."
  },
  "1123": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies muscarinic acetylcholine receptors (specifically M3), explains the mechanism, and provides relevant, accurate additional detail without any inaccuracies or omissions."
  },
  "1124": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and accurate clinical context and mechanism, but it does not explicitly identify \"enzyme activators\" as the pharmacological class, instead using \"anticoagulant\" and related terms, which is less precise than the reference answer. All key facts are present except for the specific class required by the question."
  },
  "1125": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the pharmacological class, mechanism, and clinical effect, and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "1126": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the mechanism, primary effect, and clinical relevance of statins, and provides correct examples without any inaccuracies or omissions."
  },
  "1127": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies inhibition of bacterial transpeptidases (penicillin-binding proteins) as the mechanism, provides accurate and relevant elaboration, and contains no inaccuracies or omissions."
  },
  "1128": {
    "score": 3.0,
    "explanation": "3: The model answer covers that gentian violet’s mechanism is not fully understood and lists several proposed mechanisms, but it does not clearly state that the precise mechanism is unknown, as required by the reference. The extra mechanistic details are not established as definitive and may mislead, representing minor inaccuracies."
  },
  "1129": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately identifies H2 receptor antagonism as the mechanism, and provides correct, relevant molecular details without any inaccuracies or omissions."
  },
  "1130": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the mechanism (inhibition of sarcoplasmic reticulum calcium release), specifies dantrolene, and provides accurate, relevant additional detail without any inaccuracies or omissions."
  },
  "1131": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describing the reduction of alveolar surface tension as the primary mechanism, and provides additional correct and relevant details without any inaccuracies or omissions."
  },
  "1132": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the mechanism and specifies beta-lactam antibiotics and cell wall synthesis inhibitors, but it omits the broader class \"enzyme inhibitors\" as in the reference answer, missing a key fact."
  },
  "1133": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies beta-lactam antibiotics and explains their mechanism, covering over 90% of key facts, but does not explicitly use the broader term \"enzyme inhibitors\" as in the reference answer, which is a minor omission."
  },
  "1134": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies cytochrome P450 (specifically CYP3A4) as the relevant enzyme class, explains the mechanism, and provides clinically relevant context without inaccuracies or omissions."
  },
  "1135": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the alpha-1 adrenergic receptor as the molecular target, explains the clinical scenario, discusses first-line and alternative therapies, and provides accurate, relevant mechanistic detail with no inaccuracies or omissions."
  },
  "1136": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies passive antibody-mediated pathogen neutralization as the primary mechanism, explicitly describes neutralization and opsonization, and provides accurate, clinically relevant detail without any inaccuracies or omissions."
  },
  "1137": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides additional correct and relevant mechanistic detail, and contains no inaccuracies or omissions."
  },
  "1138": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies the glucocorticoid receptor as the primary target, accurately explains the mechanism, and provides relevant, factually correct extra detail without any omissions or inaccuracies."
  },
  "1139": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the primary molecular target, explains its cytosolic/nuclear nature, and accurately describes the mechanism of gene transcription modulation, fully covering all key clinical facts without errors or omissions."
  },
  "1140": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes iron’s role in hemoglobin synthesis, and provides additional correct and relevant mechanistic detail without any inaccuracies or omissions."
  },
  "1141": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies muscarinic (M3) receptors as the primary target, whereas the reference specifies adrenergic beta2-agonists; while the explanation is detailed and relevant, this represents a moderate factual error regarding the receptor class."
  },
  "1142": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies ranibizumab as a monoclonal antibody fragment that binds VEGF (specifically VEGF-A), preventing its interaction with endothelial receptors, and explains the clinical effect; all key facts from the reference are included with relevant, accurate elaboration."
  },
  "1143": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the mechanism as protein synthesis inhibition via 30S ribosomal subunit binding, and provides accurate, relevant reasoning without any inaccuracies or omissions."
  },
  "1144": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the pharmacological class as \"indirect factor Xa inhibitor (antithrombin-dependent factor Xa inhibitor)\" and explains the mechanism, but it omits the specific reference to \"serine proteinase inhibitors (serpins) potentiators\" as in the reference answer, which is a minor omission."
  },
  "1145": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the disease, mechanism of calcitonin, and osteoclast inhibition, but incorrectly specifies hydroxyapatite (the inorganic component) rather than structural macromolecules like collagen as the key matrix target, missing the reference answer's focus."
  },
  "1146": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the likely diagnosis and drug, and accurately describes ivermectin’s mechanism (chloride channel modulation), but does not address the reference answer’s focus on \"enzyme inhibition\" as the general mechanism, thus missing the key fact required by the question."
  },
  "1147": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the class as GABA_A modulators, and provides accurate, relevant clinical and mechanistic details without any inaccuracies or omissions."
  },
  "1148": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor (a nuclear hormone receptor) as the primary mediator, thoroughly explains the mechanism, and provides relevant clinical context without inaccuracies or omissions."
  },
  "1149": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the 5-HT1B/1D receptors as the drug targets and accurately explains their roles, but does not single out the 5-HT1B receptor as the direct molecular target for cranial vasoconstriction, which is the specific answer required by the reference."
  },
  "1150": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies CYP2C19 as the key enzyme, provides accurate and clinically relevant reasoning, and contains no inaccuracies or omissions."
  },
  "1151": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describing the barrier and astringent effects as the mechanistic action, with correct and relevant elaboration and no inaccuracies or omissions."
  },
  "1152": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies glucocorticoid receptor activation as the key pathway and provides accurate, relevant mechanistic detail, but it overemphasizes NF-κB inhibition as the \"primary\" pathway rather than the broader glucocorticoid receptor agonism, which is the reference answer's focus; this is a minor wording inaccuracy."
  },
  "1153": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies PDE4 as the molecular target, explains the mechanism, and links it to the clinical scenario without inaccuracies or omissions."
  },
  "1154": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies PAR-1 as the target and provides accurate, relevant explanation without errors or omissions."
  },
  "1155": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies B cell-mediated immunity, CD20 targeting, and the inhibition of antigen presentation and autoantibody production, but does not explicitly mention \"antibody-dependent cytotoxicity\" as the direct mechanism, which is a minor omission. Otherwise, the content is accurate and clinically relevant."
  },
  "1156": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies ergosterol as the primary target, provides accurate clinical reasoning, and includes only relevant, factually correct additional information without any omissions or inaccuracies."
  },
  "1157": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the pharmacological class as protein synthesis inhibitors (specifically tetracyclines), and provides accurate, relevant mechanistic and clinical details without any inaccuracies or omissions."
  },
  "1158": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the neonatal Fc receptor (FcRn) as the target, provides an accurate and clinically relevant explanation of its role in IgG recycling and myasthenia gravis therapy, and includes no inaccuracies or omissions."
  },
  "1159": {
    "score": 3.0,
    "explanation": "3: The model answer identifies P-glycoprotein (ABCB1) instead of the correct BCRP (ABCG2), which is specifically implicated in resistance to azole antifungals in leishmaniasis; while the explanation is detailed and mostly accurate regarding general drug resistance, it misses the key fact required by the question."
  },
  "1160": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the clinical scenario, the likely diagnosis (HPV warts), the drug (imiquimod), and its mechanism (TLR7 agonist), but it does not mention RNA replicase as the most directly inhibited molecular target, which is the key fact in the reference answer."
  },
  "1161": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the mechanism, and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "1162": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies covalent/irreversible binding to PBPs (specifically PBP-3) as the mechanism, covering over 90% of key facts. However, it does not explicitly state \"covalent\" binding in the final answer, which is a minor omission compared to the reference."
  },
  "1163": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies that the anticoagulant targets serine proteases (which includes thrombin), and provides accurate mechanistic detail, but it omits that the primary therapeutic effect in this context is specifically due to thrombin inhibition, as required by the reference answer."
  },
  "1164": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the drug class, thoroughly explains the mechanism, and provides relevant examples, with no omissions or inaccuracies."
  },
  "1165": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the mechanism as inhibition of protein synthesis, and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "1166": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the androgen receptor as the direct molecular target, explains the mechanism, and provides relevant clinical context without inaccuracies or omissions."
  },
  "1167": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies dihydropteroate synthase as the molecular target, explains the mechanism of PABA mimicry, and provides relevant, accurate additional details without any errors or omissions."
  },
  "1168": {
    "score": 2.0,
    "explanation": "2: The model answer correctly identifies the clinical scenario, the drug (valproic acid), and its mechanism of increasing GABA by inhibiting GABA transaminase, but it fails to identify the actual molecular target mediating the therapeutic effect (GABA B receptor) as specified in the reference answer. This is a moderate omission."
  },
  "1169": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the drug class and mechanism, and provides additional clinically relevant details without inaccuracies or omissions."
  },
  "1170": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts and the precise molecular mechanism (restoration of NAD/NADP-dependent redox reactions), with correct and relevant additional explanations; there are no inaccuracies or omissions."
  },
  "1171": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies heparins as the class that potentiates antithrombin III and inhibits thrombin, covering nearly all key facts, but does not directly name \"thrombin inhibitors\" as in the reference; however, its explanation is accurate and clinically relevant."
  },
  "1172": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the drug as a biologic DMARD and TNF inhibitor, accurately describes its mechanism, and provides relevant examples. However, it omits the specific term \"Biological Response Modifiers\" used in the reference, which is a minor wording inaccuracy."
  },
  "1173": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the mechanism (enzymatic hydrolysis of sucrose by exogenous sucrase), and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "1174": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the mechanism of iron chelation, and provides relevant, correct additional details without any inaccuracies or omissions."
  },
  "1175": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies PAR-1 antagonism as the mechanism, names vorapaxar, and accurately explains its action without any inaccuracies or omissions."
  },
  "1176": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the pharmacologic class as VEGF inhibitors, and provides accurate, relevant additional details without any inaccuracies or omissions."
  },
  "1177": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucagon receptor on hepatocytes as the mediator, includes all key clinical facts, and provides accurate, relevant mechanistic detail without any inaccuracies or omissions."
  },
  "1178": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid (corticosteroid hormone) receptor as the relevant intracellular receptor, explains its mechanism, and accurately relates it to the clinical scenario without any inaccuracies or omissions."
  },
  "1179": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key facts from the reference, clearly stating that there is no known cellular or molecular mechanism, and accurately describes the physical mode of action without introducing inaccuracies or irrelevant content."
  },
  "1180": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies β-tubulin as the direct molecular target, explains the mechanism, and provides relevant drug examples, fully covering all key clinical facts without inaccuracies or omissions."
  },
  "1181": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies transpeptidase (penicillin-binding protein) as the molecular target, fully explains the mechanism, and provides relevant, accurate context without any errors or omissions."
  },
  "1182": {
    "score": 4.0,
    "explanation": "4: The model answer covers all mechanistic details and clinical context, but does not explicitly use the term \"insulin receptor agonists\" as in the reference; instead, it describes the mechanism as \"receptor tyrosine kinase activation,\" which is accurate but less specific. No clinically relevant errors or omissions."
  },
  "1183": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies CYP3A4 as the key enzyme, explains the clinical context, mechanism, and relevance to drug interactions, with no inaccuracies or omissions."
  },
  "1184": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the molecular mechanism (plasminogen to plasmin activation), and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "1185": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies albendazole as the drug, its mechanism (microtubule inhibition), and its induction of hepatic CYP450 enzymes, leading to increased clearance and reduced plasma levels of co-administered drugs. However, it generalizes to \"CYP450 enzymes\" rather than specifying CYP1A as in the reference, which is a minor omission."
  },
  "1186": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies β2-adrenergic (beta-adrenergic) receptors as the relevant GPCR class and provides accurate mechanistic detail, but focuses on cilostazol (a PDE3 inhibitor) rather than a direct beta-agonist, which is a minor deviation from the reference's emphasis on direct receptor stimulation."
  },
  "1187": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the mechanism as enzyme inhibition of cell wall synthesis, and provides additional accurate, clinically relevant details without any inaccuracies or omissions."
  },
  "1188": {
    "score": 3.0,
    "explanation": "3: The model answer accurately describes the clinical scenario, mechanism, and therapy, but does not identify \"enzyme activators\" as the pharmacological class, instead using \"coagulation factor replacement.\" This misses the key classification required by the question, covering most but not all key facts."
  },
  "1189": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies alpha-adrenergic (specifically alpha-1) receptors as the target, explains the mechanism, and provides relevant examples, fully covering all key clinical facts without inaccuracies or omissions."
  },
  "1190": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies zinc and its antiviral actions but does not explicitly mention \"acid-base activity\" or alteration of local pH as the primary molecular mechanism, which is the key fact in the reference answer."
  },
  "1191": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies muscarinic antagonists as the drug class and accurately explains their mechanism in promoting mydriasis by blocking M3 receptors, matching the clinical facts required (even though the reference answer focuses on alpha-antagonists, muscarinic antagonists are the standard and more clinically relevant choice for pharmacologic mydriasis)."
  },
  "1192": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the molecular mechanism, and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "1193": {
    "score": 2.0,
    "explanation": "2: The model answer provides a detailed discussion but ultimately selects muscarinic antagonism, omitting the key fact that dopamine antagonists are the correct answer per the reference; it also introduces some confusion regarding the primary mechanism for motion sickness treatment, constituting a moderate factual omission."
  },
  "1194": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies nuclear receptors as the primary target, explains their intracellular location and role in gene transcription, and provides clinically relevant context without any inaccuracies or omissions."
  },
  "1195": {
    "score": 3.0,
    "explanation": "3: The model answer covers the uncertainty of the mechanism and provides plausible hypotheses, but adds speculative mechanisms (e.g., correction of misfolded proteins, stabilization of mutant proteins) not present in the reference, and does not clearly state that the mechanism is unknown, as required by the reference answer."
  },
  "1196": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies HIV-1 protease as the target, explains its role in polyprotein cleavage and viral maturation, and clearly describes how inhibition leads to non-infectious virions and reduced viral load, fully covering all key clinical facts without errors or omissions."
  },
  "1197": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the receptor interaction, and provides additional accurate and clinically relevant details without any inaccuracies or omissions."
  },
  "1198": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the molecular mechanism (dopamine receptor agonism causing vasodilation and increased renal perfusion), and provides additional correct and clinically relevant detail without any inaccuracies or omissions."
  },
  "1199": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key facts from the reference, accurately states that the exact mechanism is unknown, and provides clinically relevant, correct context about PPS’s proposed action without inaccuracies or irrelevant content."
  },
  "1200": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the glucocorticoid/corticosteroid receptor pathway, and provides relevant, accurate, and clinically pertinent additional detail without any inaccuracies or omissions."
  },
  "1201": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the pharmacological class as \"biological response modifier,\" provides accurate supporting details, and includes only clinically relevant, factually correct information with no omissions or inaccuracies."
  },
  "1202": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describing the enzymatic activity of PEG-ADA in metabolizing toxic adenosine metabolites to support lymphocyte survival, with additional correct and relevant mechanistic detail."
  },
  "1203": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the enzyme cofactor role of thiamine, and provides relevant, correct additional details without any inaccuracies or omissions."
  },
  "1204": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the mechanism as inhibition of viral DNA polymerase by nucleoside analogs, covering over 90% of key facts, but adds extra detail (\"nucleoside analogs\") not strictly required by the reference and slightly expands the class name; there are no clinically significant errors or omissions."
  },
  "1205": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies glucocorticoid receptor agonists, and provides accurate, relevant mechanistic detail without any inaccuracies or omissions."
  },
  "1206": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies \"antihistamines (histamine H1 receptor antagonists)\" as the class, explains the mechanism, and links to the clinical scenario; all content is accurate and clinically relevant with no omissions."
  },
  "1207": {
    "score": 5.0,
    "explanation": "5: Fully covers all key clinical facts from the reference answer, correctly identifies the mechanism as inhibition of protein synthesis via 50S ribosomal binding, and provides relevant, accurate elaboration without any errors or omissions."
  },
  "1208": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the histamine H1 receptor as the molecular target, and provides accurate, relevant explanations without any inaccuracies or omissions."
  },
  "1209": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies the medication as IVIG instead of aminobenzoate potassium, which is the agent referenced in the question. While the discussion of IVIG's mechanism is accurate, it is irrelevant here, resulting in a moderate factual error and coverage of less than 70% of key facts."
  },
  "1210": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies ARBs as the drug class and the AT1 receptor as the primary molecular target, covering all key clinical facts; the mention of ACE inhibitors is accurate but appropriately qualified, and the explanation is clinically relevant with no inaccuracies."
  },
  "1211": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies miltefosine and its general mechanism involving membrane phospholipids and lipid receptors, but it does not specifically mention \"lysophospholipid receptors,\" which is the key target class in the reference. The answer covers most, but not all, key facts."
  },
  "1212": {
    "score": 5.0,
    "explanation": "5: Fully covers all key clinical facts from the reference answer, accurately describing protein synthesis inhibition via 30S ribosomal subunit blockade, with additional correct and relevant explanation and no inaccuracies."
  },
  "1213": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies prostaglandin E1 as the drug, its use, and the relevant receptor subtype (EP2/EP4), and accurately describes the mechanism. However, it does not explicitly state \"prostaglandin receptor agonists\" as the class, which is the direct answer required, making this a minor omission."
  },
  "1214": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies phosphodiesterases as the target, explains the mechanism, and provides relevant clinical context without inaccuracies or omissions."
  },
  "1215": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies inhibition of lanosterol 14α-demethylase (14-alpha demethylase) as the specific enzymatic mechanism, provides accurate context, and contains no inaccuracies or omissions."
  },
  "1216": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies VEGF-A inhibition as the mechanism, and provides relevant, accurate additional details without any inaccuracies or omissions."
  },
  "1217": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the mechanism (biotin as a cofactor for carboxylases), and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "1218": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies nicotine as the agent, accurately describes its action as a nicotinic cholinergic receptor agonist, and clearly distinguishes it from muscarinic agonists, covering all key clinical facts without errors or omissions."
  },
  "1219": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and accurate explanation of the clinical scenario, the use of acetazolamide, and its mechanism as a carbonic anhydrase inhibitor (an enzyme inhibitor), but it does not explicitly use the reference's broader mechanistic category \"biological macromolecular activity,\" instead focusing on \"enzyme inhibition.\" This covers most key facts but misses the precise mechanistic category requested."
  },
  "1220": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the molecular mechanism, and provides relevant, correct additional details without any inaccuracies or omissions."
  },
  "1221": {
    "score": 5.0,
    "explanation": "5: Fully covers the key fact (\"protein synthesis inhibition\") and provides additional correct, clinically relevant detail about aminoglycosides and their mechanism, with no inaccuracies or omissions."
  },
  "1222": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies H1-antihistamines (histamine H1 receptor antagonists) as the drug class, explains the mechanism, and provides relevant clinical context without any inaccuracies or omissions."
  },
  "1223": {
    "score": 2.0,
    "explanation": "2: The model answer misidentifies the key transporter as P-glycoprotein rather than OCT2 and focuses on triazole class effects and CYP3A4, omitting the specific OCT2 inhibition by isavuconazole and its clinical significance; only about half the key facts are addressed."
  },
  "1224": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the role of vitamin B12 as a cofactor for methylmalonyl-CoA mutase and methionine synthase, and provides clinically relevant details without inaccuracies or omissions."
  },
  "1225": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies transpeptidase (penicillin-binding protein) as the primary target, explains the mechanism, and provides relevant clinical context without any inaccuracies or omissions."
  },
  "1226": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies CYP3A4 instead of CYP2C9 as the key enzyme to monitor, which is a moderate factual error. While the explanation is otherwise accurate and relevant, the main clinical fact is missed."
  },
  "1227": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the mechanism (blockade of voltage-gated sodium channels), and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "1228": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies thionamides as the drug class, explains their mechanism, lists examples, and provides relevant clinical context without inaccuracies or omissions."
  },
  "1229": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies protease inhibitors as the class, accurately explains the mechanism, clinical effect, and provides relevant examples with no errors or omissions."
  },
  "1230": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the specific class (β-lactam antibiotics) and accurately describes the mechanism, but it omits the broader pharmacological class \"enzyme inhibitors\" as required by the reference answer, thus missing a key fact."
  },
  "1231": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies antimuscarinic agents as the drug class, and provides accurate, relevant explanations without any inaccuracies or omissions."
  },
  "1232": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the drug class and mechanism (DNA crosslinking/alkylation suppressing immune cell proliferation), and provides relevant, accurate elaboration without any inaccuracies or omissions."
  },
  "1233": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key facts from the reference, clearly stating that the cellular or molecular mechanism is unknown, and provides accurate, relevant elaboration without inaccuracies or omissions."
  },
  "1234": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies viral DNA polymerase as the direct target, explains the drug activation and mechanism, and provides relevant clinical context without inaccuracies or omissions."
  },
  "1235": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the histamine H1 receptor as the primary molecular target, covers all key clinical facts, and provides relevant, accurate clinical context without any inaccuracies or omissions."
  },
  "1236": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies cyclooxygenase inhibition as the mechanism, and provides accurate, relevant clinical context without any inaccuracies or omissions."
  },
  "1237": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly identifies the cofactor role of riboflavin in flavoprotein-catalyzed redox reactions, and provides accurate, relevant additional explanation without any inaccuracies or omissions."
  },
  "1238": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "1239": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the molecular fusion and its pharmacological mechanism (FcRn-mediated recycling), and clearly links this to the clinical benefit; all additional content is correct and clinically relevant."
  },
  "1240": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies HMG-CoA reductase as the inhibited enzyme and provides accurate, clinically relevant explanation without any errors or omissions."
  },
  "1241": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the drug class, mechanism, and clinical context, and provides relevant, accurate additional explanation without any inaccuracies or omissions."
  },
  "1242": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately details the aminoglycoside mechanism (binding 30S, misreading mRNA, inhibition of protein synthesis), and provides relevant clinical context without any inaccuracies or omissions."
  },
  "1243": {
    "score": 5.0,
    "explanation": "5: Fully covers all key facts from the reference answer, correctly identifies the glucocorticoid (corticosteroid hormone) receptor as the target, and provides accurate, relevant mechanistic detail without inaccuracies or omissions."
  },
  "1244": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the thyroid hormone receptor as the molecular target, and provides additional accurate, relevant clinical and mechanistic details without any inaccuracies or omissions."
  },
  "1245": {
    "score": 3.0,
    "explanation": "3: The model answer provides a thorough discussion of both antimicrobial and anti-inflammatory mechanisms, correctly identifying suppression of neutrophil chemotaxis as the relevant therapeutic effect in pyoderma gangrenosum. However, it omits the key reference fact—direct inhibition of PABA utilization in folate synthesis—as the molecular mechanism, thus missing the most direct answer required by the question."
  },
  "1246": {
    "score": 3.0,
    "explanation": "3: The model answer correctly explains the mechanism and identifies \"cell wall synthesis inhibitors,\" but it does not use the broader class \"enzyme inhibitors\" as in the reference; thus, it misses a key fact about the general pharmacological classification."
  },
  "1247": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes GnRH receptor antagonism, and provides additional correct and clinically relevant mechanistic detail without any inaccuracies or omissions."
  },
  "1248": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the molecular mechanism, and adds correct, clinically relevant details about enzyme uptake and trafficking without any inaccuracies or omissions."
  },
  "1249": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies sodium oxybate, its clinical use, and its partially understood mechanism, covering nearly all key facts; however, it provides more mechanistic detail than the reference, which is accurate and relevant, but the reference specifically emphasizes the mechanism is \"unknown,\" so the model's elaboration is a minor wording inaccuracy."
  },
  "1250": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes transpeptidase inhibition, and provides additional correct and relevant mechanistic detail without any inaccuracies or omissions."
  },
  "1251": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the mechanism (inhibition of transpeptidases/penicillin-binding proteins), and provides relevant, correct elaboration without any inaccuracies or omissions."
  },
  "1252": {
    "score": 3.0,
    "explanation": "3: The model answer provides a thorough discussion of possible mechanisms and correctly identifies recombinant cytokines (such as interferons) as biological response modifiers that modulate immune responses, but it does not explicitly use the term \"biological response modifier\" as in the reference. While the mechanistic detail is accurate and relevant, the answer is less concise and omits the direct drug class terminology required by the reference."
  },
  "1253": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the clinical scenario, the agent (cantharidin), and its mechanism as a protein phosphatase inhibitor, which is a type of enzyme inhibitor, thus covering ≥90% of key facts. However, it does not explicitly state \"enzyme inhibitor\" as the pharmacologic class, which is a minor omission."
  },
  "1254": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies CYP2B6 induction, and provides accurate, relevant explanations without any inaccuracies or omissions."
  },
  "1255": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies muscarinic acetylcholine receptor antagonism as the mechanism, and provides relevant, accurate additional detail without any inaccuracies or omissions."
  },
  "1256": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describing antigen neutralization by passive antibody transfer and providing additional correct, relevant details about IVIG's mechanisms without any inaccuracies or omissions."
  },
  "1257": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies transpeptidases/penicillin-binding proteins as the target, restates the mechanism, and includes all key facts with no errors or omissions."
  },
  "1258": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the mechanism as enzyme inhibition, specifies cytochrome P450 monooxygenases, and provides relevant, accurate elaboration without inaccuracies or omissions."
  },
  "1259": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the mechanistic pathway as modulation of intracellular proteins involved in glucose metabolism (specifically via AMPK activation), fully aligning with the reference answer and providing clinically relevant, accurate detail without any errors or omissions."
  },
  "1260": {
    "score": 5.0,
    "explanation": "5: The model answer accurately describes the physiochemical (cerumenolytic) mechanism, including effervescence, softening, and breakdown of cerumen, fully aligning with the reference answer and adding correct, relevant detail."
  },
  "1261": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the mechanism as inhibition of bacterial cell wall synthesis via PBPs, and provides relevant, accurate elaboration without any errors or omissions."
  },
  "1262": {
    "score": 5.0,
    "explanation": "5: Fully covers all key facts, correctly identifies VMAT2 inhibitors as the drug class, explains the mechanism, and provides relevant examples without any inaccuracies or omissions."
  },
  "1263": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies inhibition of cyclooxygenase (COX) as the key mechanism, explains its role in prostaglandin synthesis, and relates this to symptom relief, fully covering all key clinical facts without inaccuracies or omissions."
  },
  "1264": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes antimuscarinic (muscarinic acetylcholine receptor antagonism) as the mechanism, and provides relevant, correct additional detail without inaccuracies or omissions."
  },
  "1265": {
    "score": 2.0,
    "explanation": "2: The model answer identifies CYP2C19 instead of CYP2C8, missing the key fact required by the reference. While the explanation is detailed and relevant, the main factual error (wrong CYP enzyme) is moderate and central to the question, warranting a score of 2."
  },
  "1266": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies glucocorticoids/corticosteroids as the drug class, accurately describes their mechanism of action, and covers all key clinical facts from the reference answer without any inaccuracies or omissions."
  },
  "1267": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the histamine H1 receptor as the molecular target, explains the mechanism, and provides relevant clinical context without inaccuracies or omissions."
  },
  "1268": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key facts and provides accurate, relevant mechanistic detail about receptor-mediated endocytosis and lysosomal delivery, but it slightly overemphasizes the uptake mechanism rather than directly stating \"restoring deficient lysosomal enzyme activity\" as the most direct pharmacological mechanism, which is a minor wording inaccuracy."
  },
  "1269": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the mechanism as nucleoside analogs and explains their action, but it omits the broader pharmacological class \"enzyme inhibitors\" as specified in the reference, covering about 70-89% of key facts."
  },
  "1270": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key facts and provides accurate, relevant elaboration on the mechanism, but it does not explicitly use the reference term \"biological macromolecular activity,\" instead describing the process as \"metabolic supplementation.\" This is a minor wording inaccuracy that does not alter the clinical meaning."
  },
  "1271": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key facts from the reference, accurately states the mechanism is not well characterized, and provides additional correct, clinically relevant mechanistic details without inaccuracies or omissions."
  },
  "1272": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies fluoroquinolones as DNA gyrase inhibitors, and provides accurate, relevant additional explanation without any inaccuracies or omissions."
  },
  "1273": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies topoisomerase IV and provides accurate, relevant explanation, but includes DNA gyrase (topoisomerase II) as an additional target, which is not the primary answer requested; this is a minor wording inaccuracy but does not alter the clinical meaning."
  },
  "1274": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies PPAR and FXR agonists as the most likely mechanism, omitting the key fact that the agent is a thyroid hormone receptor agonist; this is a moderate factual error, though the general nuclear receptor mechanism is described."
  },
  "1275": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describing adenosine’s action on A1 receptors in the AV node, the resulting transient AV block, and the molecular mechanism; all additional details are correct and clinically relevant."
  },
  "1276": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the general class as protein synthesis inhibitors, specifies the 50S ribosomal subunit, and provides relevant examples without inaccuracies or omissions."
  },
  "1277": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies free radical scavenging as the key antioxidative mechanism, explains the role of the free thiol group, and provides accurate, clinically relevant detail without any inaccuracies or omissions."
  },
  "1278": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the mechanism, and provides relevant additional detail without any inaccuracies or omissions."
  },
  "1279": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key facts from the reference (DNA gyrase/topoisomerase II as the main target, inhibition prevents DNA replication, leading to cell death), adds correct and clinically relevant detail about topoisomerase IV, and provides an accurate, expanded mechanism with no inaccuracies or omissions."
  },
  "1280": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describing inhibition of cell wall synthesis via binding to PBPs/transpeptidases, with correct and relevant additional detail and no inaccuracies or omissions."
  },
  "1281": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies somatostatin receptors as the primary molecular target, specifically noting SSTR2, and provides accurate, relevant additional information without any inaccuracies or omissions."
  },
  "1282": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the blockade of voltage-gated sodium channels, and provides relevant, correct additional explanation without any inaccuracies or omissions."
  },
  "1283": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the molecular drug target as penicillin-binding proteins (bacterial transpeptidase enzyme), covers all key clinical facts, and provides relevant, accurate additional context without any inaccuracies or omissions."
  },
  "1284": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies CYP3A4 inhibitors and the mechanism of increased vasoconstriction due to impaired drug metabolism, but incorrectly attributes the interaction to triptans rather than dihydroergotamine, missing the key fact that ergot derivatives (not triptans) are the relevant intranasal medication with this interaction."
  },
  "1285": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies Fc receptor interaction (specifically FcRn), and provides additional accurate, clinically relevant detail without inaccuracies or omissions."
  },
  "1286": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the syndrome, the drug (recombinant growth hormone), and its mechanism as a growth hormone receptor agonist, but does not explicitly use the broader class term \"pituitary hormone receptor agonists\" as in the reference; otherwise, all key facts are present and accurate."
  },
  "1287": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies blockade of cardiac fast sodium channels as the primary molecular interaction, covers all key clinical facts, and provides accurate, relevant additional detail without any inaccuracies or omissions."
  },
  "1288": {
    "score": 5.0,
    "explanation": "5: Fully covers the key fact (\"protein synthesis inhibitor\") and provides correct, relevant additional detail about tetracyclines and their mechanism; no inaccuracies or omissions."
  },
  "1289": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key facts, correctly identifies the mechanism as unknown, and provides relevant, accurate context about amantadine without any inaccuracies or omissions."
  },
  "1290": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the mechanism as blockade of neuronal voltage-gated sodium channels, and provides relevant, accurate elaboration without any inaccuracies or omissions."
  },
  "1291": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key facts from the reference (enzyme modulation by retinoids affecting mucin and epithelial enzymes), and provides accurate, relevant mechanistic detail. However, it emphasizes nuclear receptor-mediated gene transcription rather than direct enzyme modulation, which is a minor wording inaccuracy but does not alter the clinical meaning."
  },
  "1292": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the pharmacological principle, and provides relevant, correct additional details without any inaccuracies or omissions."
  },
  "1293": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the mineralocorticoid (aldosterone) receptor as the target, provides accurate and clinically relevant explanation, and contains no inaccuracies or omissions."
  },
  "1294": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the IGF-1 receptor as the molecular target, provides accurate and clinically relevant context, and contains no inaccuracies or omissions."
  },
  "1295": {
    "score": 3.0,
    "explanation": "3: The answer correctly identifies rifampin and its mechanism (inhibition of bacterial RNA polymerase), but it does not use the broader pharmacologic class \"Nucleic Acid Synthesis Inhibitors\" as required by the reference; instead, it gives a more specific subclass, omitting the key fact needed for full credit."
  },
  "1296": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies thyroid peroxidase as the primary molecular target, explains its role, and provides relevant clinical context without any inaccuracies or omissions."
  },
  "1297": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies aminoglycosides and accurately describes their mechanism, but it does not provide the broader pharmacological class (\"protein synthesis inhibitors\") as requested, covering about 70-89% of the key facts."
  },
  "1298": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies that the precise molecular mechanism is not fully established and provides accurate, relevant details about interferon-α’s general immunomodulatory actions, but it slightly overelaborates beyond the reference’s focus on the mechanism being unknown, which could be seen as a minor wording inaccuracy."
  },
  "1299": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies DNA gyrase (topoisomerase II) as the direct molecular target, provides accurate and relevant additional context about fluoroquinolones and their mechanism, and contains no inaccuracies or omissions."
  },
  "1300": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the molecular target (transpeptidase/PBP), explains the mechanism, and provides relevant clinical context without inaccuracies or omissions."
  },
  "1301": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the mechanism as protein synthesis inhibition via the 50S ribosomal subunit, and provides relevant, accurate elaboration without any inaccuracies or omissions."
  },
  "1302": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the drug class and mechanism, and provides relevant, accurate additional details without any inaccuracies or omissions."
  },
  "1303": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key facts from the reference, accurately identifies guanylate cyclase activation via the nitric oxide pathway, and provides additional correct and clinically relevant mechanistic details without any inaccuracies or omissions."
  },
  "1304": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies CYP2C19 as the key enzyme system, provides accurate and clinically relevant context, and contains no inaccuracies or omissions."
  },
  "1305": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies ergosterol as the molecular target and explains the mechanism of polyenes, but it does not explicitly state \"inhibition of ergosterol synthesis\" as the reference answer does; instead, it focuses on membrane disruption via binding to ergosterol, which is slightly different from inhibiting its synthesis."
  },
  "1306": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, accurately describes the pharmacologic chaperone mechanism, and provides relevant, correct additional context without any inaccuracies or omissions."
  },
  "1307": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the pharmacologic class as Selective Estrogen Receptor Modulator (SERM), explains the mechanism, and provides a relevant example, with no omissions or inaccuracies."
  },
  "1308": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, accurately describes the enzymatic degradation of collagen by collagenase, and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "1309": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts in the reference, accurately explains the pharmacological mechanism (restoration of cobalamin-dependent enzyme activity), and provides relevant, correct additional detail without inaccuracies or omissions."
  },
  "1310": {
    "score": 5.0,
    "explanation": "5: Fully covers all key clinical facts from the reference answer, correctly identifies COX inhibition and decreased prostaglandin synthesis, and provides relevant, accurate additional context without any errors or omissions."
  },
  "1311": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the primary molecular interaction as binding to and activating parasite voltage-gated calcium channels, leading to increased calcium influx, matching all key clinical facts in the reference answer with accurate and relevant additional detail."
  },
  "1312": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies GABA B receptor agonism as the mechanism, and provides accurate, relevant additional explanation without any inaccuracies or omissions."
  },
  "1313": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the mechanism and links it to beta-lactam antibiotics, but it omits the broader class \"enzyme inhibitors\" as specified in the reference answer, covering about 70-89% of key facts."
  },
  "1314": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the Na⁺-K⁺-2Cl⁻ cotransporter (NKCC2) as the molecular target, matches all key clinical facts, and provides additional accurate, relevant explanation without any inaccuracies or omissions."
  },
  "1315": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies blockade of fast voltage-gated sodium channels as the mechanism, explains its effect on phase 0 in fast-response tissue, and relates this to arrhythmia suppression, with all content factually accurate and clinically relevant."
  },
  "1316": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the clinical syndrome, mechanism, and relevant drug (interferon-alpha as an immunomodulator), but does not use the precise reference term \"Biological Response Modifiers.\" The explanation is accurate and relevant, with only a minor wording deviation."
  },
  "1317": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies tecovirimat, its target (VP37), the inhibited process (formation and release of extracellular enveloped virions), and the clinical effect, with no inaccuracies or omissions."
  },
  "1318": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the enzyme-mediated conversion, the role of vitamin A derivatives in epithelial health and mucin production, and provides additional correct and relevant mechanistic detail without inaccuracies or omissions."
  },
  "1319": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the target as a small molecule splicing modifier acting on pre-mRNA and provides relevant details about SMA and risdiplam, but it does not explicitly mention the spliceosome or splicing machinery as in the reference; this is a minor omission."
  },
  "1320": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the principal mechanism, and provides relevant additional detail without any inaccuracies or omissions."
  },
  "1321": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies norepinephrine as the primary neurotransmitter whose reuptake is inhibited, provides accurate clinical context, and includes only relevant, factually correct information without omissions or inaccuracies."
  },
  "1322": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies acetylcholinesterase inhibitors as the drug class, accurately explains the mechanism, and provides relevant clinical context without any inaccuracies or omissions."
  },
  "1323": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the drug class (dihydropyridine calcium channel blockers), provides accurate examples, and explains the mechanism in clinically relevant detail with no inaccuracies or omissions."
  },
  "1324": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies pituitary hormone receptor agonism (specifically ACTH acting on MC2R) as the mechanism, covering over 90% of key facts, but does not explicitly state \"pituitary hormone receptor agonism\" as the final mechanism, instead focusing on downstream effects; otherwise, content is accurate and relevant."
  },
  "1325": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the pharmacological mechanism, and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "1326": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the lipid-based agent as vitamin E and thoroughly explains its antioxidant mechanism involving direct interaction with large biomolecules (cell membranes), matching the reference’s focus. However, it introduces some extra clinical detail (e.g., neurologic dysfunction, hemolytic anemia) that, while accurate, is not strictly necessary for the mechanism, and the answer could be more concise in directly stating the fundamental mechanism as in the reference. No major omissions or inaccuracies are present."
  },
  "1327": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies P-glycoprotein (an ABC transporter) as the key class affected, explains its role in drug absorption and elimination, and provides clinically relevant detail without inaccuracies or omissions."
  },
  "1328": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies that the polymer (povidone) has no intrinsic antifungal activity or specific cellular/molecular mechanism, and its role is solely as a carrier for iodine; this fully matches the reference answer with accurate, relevant elaboration and no errors."
  },
  "1329": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key facts about the mechanism (enzyme inhibition of transpeptidases), provides correct and relevant extra detail, but does not explicitly use the general term \"enzyme inhibitors\" as in the reference answer, which is a minor wording inaccuracy."
  },
  "1330": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies nuclear receptors as the primary class, and provides accurate, relevant elaboration without any inaccuracies or omissions."
  },
  "1331": {
    "score": 5.0,
    "explanation": "5: Thoroughly covers all key facts from the reference answer, accurately describes the drug class and mechanism, and provides additional correct and clinically relevant details without any inaccuracies or omissions."
  },
  "1332": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the specific molecular interaction (increased calcium influx via voltage-gated calcium channels), and provides relevant, accurate additional detail without any inaccuracies or omissions."
  },
  "1333": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies CYP3A4 induction as the mechanism, and provides relevant, accurate elaboration without any inaccuracies or omissions."
  },
  "1334": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies leucovorin and explains its mechanism of bypassing DHFR inhibition to restore folate-dependent DNA synthesis, covering most key facts. However, it does not mention \"phosphate chelating activity,\" which is the specific mechanism cited in the reference answer, representing a moderate omission."
  },
  "1335": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the relevant enzyme interactions, and provides additional correct and clinically relevant mechanistic detail without inaccuracies or omissions."
  },
  "1336": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the biochemical transformation as reduction/cleavage of cystine disulfide bonds, and provides accurate, relevant mechanistic and clinical context without inaccuracies or omissions."
  },
  "1337": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies alpha-adrenergic receptors as the target, explains tolazoline’s mechanism, and provides relevant clinical context without inaccuracies or omissions."
  },
  "1338": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies alpha-1 adrenergic receptors as mediating the effect, explains the mechanism, and provides relevant examples, fully covering all key clinical facts without inaccuracies or omissions."
  },
  "1339": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the agent and its antioxidant/free radical scavenging mechanism, and provides relevant, accurate elaboration without any inaccuracies or omissions."
  },
  "1340": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies cyclooxygenase inhibitors as the drug class, explains the mechanism, and relates it to NSAIDs, covering all key clinical facts with no inaccuracies or omissions."
  },
  "1341": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies prostacyclin (IP) receptor agonism as the mechanism, and provides accurate, relevant molecular details without inaccuracies or omissions."
  },
  "1342": {
    "score": 5.0,
    "explanation": "5: Fully covers all key facts from the reference answer, correctly identifies the drug, its mechanism, and the general class (cell wall synthesis inhibitors), with all additional details accurate and clinically relevant."
  },
  "1343": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies heme synthesis as the key cellular process enhanced by iron supplementation and provides accurate, relevant explanation, but it omits explicit mention of iron transport/utilization and the role of electrolyte activity as stated in the reference."
  },
  "1344": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the mechanism (inhibition of acetylcholine release from presynaptic terminals), and provides additional correct and relevant mechanistic detail without any inaccuracies or omissions."
  },
  "1345": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the pharmacologic class, mechanism, and clinical use, and provides relevant, accurate additional detail without any inaccuracies or omissions."
  },
  "1346": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes DNA alkylation/crosslinking, its effect on lymphocyte proliferation, and the clinical relevance to autoantibody production, with no inaccuracies or omissions."
  },
  "1347": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies carbohydrates (monosaccharides) as the class replenished and explains glucose metabolism, but omits the key reference detail that glucose is stored as glycogen (a polysaccharide), thus missing the specific structural macromolecule replenished."
  },
  "1348": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the histamine H1 receptor as the molecular target, provides accurate and clinically relevant explanation, and includes no inaccuracies or omissions."
  },
  "1349": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies cytochrome P450 enzymes as the relevant class and explains their role in albendazole metabolism, but incorrectly emphasizes CYP3A4 rather than the reference's CYP1A subfamily, and introduces flavin-containing monooxygenase, which is not mentioned in the reference. This constitutes a minor inaccuracy and a minor irrelevant addition, covering about 70-89% of key facts."
  },
  "1350": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the β2-adrenergic receptor mechanism, and provides relevant, correct mechanistic detail without any inaccuracies or omissions."
  },
  "1351": {
    "score": 5.0,
    "explanation": "5: Fully covers all key facts from the reference answer, correctly identifies H1 receptor antagonism as the mechanism, and provides relevant, accurate clinical context without any inaccuracies or omissions."
  },
  "1352": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the role of riboflavin as a precursor for FMN and FAD, details their function as essential cofactors for flavoprotein enzymes, and clearly links this to the rapid clinical improvement; all additional content is correct and clinically relevant."
  },
  "1353": {
    "score": 5.0,
    "explanation": "5: Fully covers all key facts—correctly identifies antimuscarinics as the drug class and muscarinic (specifically M3) receptor blockade as the molecular target, with relevant, accurate elaboration and no errors."
  },
  "1354": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately identifies estrogen receptor agonists, details the molecular mechanism, and provides additional correct and clinically relevant information without any inaccuracies or omissions."
  },
  "1355": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the general mechanism as inhibition of cell wall synthesis and accurately explains the role of PBPs, but it omits explicitly stating \"enzyme inhibition\" as the general class, which is the key fact in the reference answer."
  },
  "1356": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the GABA\\(_A\\) receptor as the primary target, thoroughly explains the clinical reasoning, and provides accurate, relevant pharmacological details without any inaccuracies or omissions."
  },
  "1357": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies transpeptidases (penicillin-binding proteins) as the target, explains their role in cell wall synthesis, and provides accurate, relevant additional detail without any errors or omissions."
  },
  "1358": {
    "score": 3.0,
    "explanation": "3: The model answer accurately describes the mechanism of polyene antifungals (binding ergosterol and disrupting membrane integrity) but does not identify inhibition of ergosterol synthesis, which is the specific molecular process asked for in the reference answer; thus, it covers 70-89% of key facts but misses the precise process."
  },
  "1359": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the mechanism as serine proteinase inhibition, and provides accurate, relevant elaboration without any inaccuracies or omissions."
  },
  "1360": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the key mechanism—presynaptic acetylcholine release inhibition—and provides accurate, relevant details about botulinum toxin and its use. However, it introduces \"neuromuscular-blocking agent\" as a drug class, which is broader and less precise than \"acetylcholine release inhibitor,\" causing a minor wording inaccuracy."
  },
  "1361": {
    "score": 5.0,
    "explanation": "5: Fully covers the key fact (blockade of voltage-gated sodium channels) with accurate, relevant elaboration and no errors or omissions."
  },
  "1362": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately identifies the drug class and mechanistic target, and provides additional correct and clinically relevant details without any inaccuracies or omissions."
  },
  "1363": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describing the physiochemical disruption of keratin structure and hydration of the stratum corneum, with correct and clinically relevant additional detail and no inaccuracies or omissions."
  },
  "1364": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the specific molecular target as lanosterol 14-α-demethylase (fungal 14-alpha demethylase), provides accurate clinical context, and includes only relevant, factually correct information with no omissions or inaccuracies."
  },
  "1365": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the mechanism as irreversible inhibition of bacterial transpeptidases (penicillin-binding proteins), covers all key clinical facts, and provides additional accurate and relevant clinical context without any inaccuracies or omissions."
  },
  "1366": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the drug class and mechanism, and provides relevant, correct additional context without any inaccuracies or omissions."
  },
  "1367": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key facts in the reference, accurately describes the current understanding of cysteamine’s mechanism, and explicitly notes that the precise molecular details remain incompletely understood; there are no inaccuracies or omissions."
  },
  "1368": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the mineralocorticoid receptor as the target, and provides accurate, relevant explanations without any inaccuracies or omissions."
  },
  "1369": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the drug and its mechanism (increased calcium permeability leading to paralysis), and provides relevant, accurate clinical context without any inaccuracies or omissions."
  },
  "1370": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the mechanism, names examples, and provides relevant clinical context without any inaccuracies or omissions."
  },
  "1371": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the pharmacologic class as a cytochrome P450 2C8 inhibitor and clearly explains the clinical significance regarding increased plasma concentrations and risk of toxicity for CYP2C8 substrates, fully covering all key facts in the reference answer."
  },
  "1372": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies dihydrofolate reductase inhibitors as the drug class, and provides accurate, relevant clinical context without any inaccuracies or omissions."
  },
  "1373": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies free radical scavenging (antioxidant) activity as the key pharmacological property, provides accurate and relevant additional explanation, and contains no inaccuracies or omissions."
  },
  "1374": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies sucralfate, thoroughly explains its local action and mechanism (forming a protective barrier by binding to ulcerated mucosa), and accurately notes its lack of effect on gastric pH or systemic physiology, fully covering all key clinical facts without errors or omissions."
  },
  "1375": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies methylxanthines as PDE inhibitors, explains the mechanism, provides examples, and acknowledges PDE4 inhibitors like roflumilast, fully covering all key facts in the reference answer with relevant, accurate elaboration."
  },
  "1376": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the drug class as phosphodiesterase-3 inhibitors, accurately explains the mechanism, and provides a relevant example (milrinone) without any inaccuracies or omissions."
  },
  "1377": {
    "score": 4.0,
    "explanation": "4: The model answer covers all clinical facts and provides a detailed, accurate explanation of the current understanding of ursodeoxycholic acid’s mechanism, while clearly stating that the precise mechanism is incompletely understood. The extra mechanistic detail is correct and relevant, but the reference answer emphasizes \"unknown\" as the best descriptor, so the model’s elaboration is a minor wording inaccuracy."
  },
  "1378": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the mechanism (binding to 30S subunit, inhibition of protein synthesis), and provides relevant, correct elaboration without any inaccuracies or omissions."
  },
  "1379": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies estrogen receptor agonism as the key pathway, accurately describes the mechanism, and provides relevant, factually correct details without any omissions or inaccuracies."
  },
  "1380": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies antibody-mediated neutralization as the key process and provides accurate, relevant detail, but it omits explicit mention of Fc receptor engagement and immune modulation, which are part of the reference answer."
  },
  "1381": {
    "score": 4.0,
    "explanation": "4: The model answer covers the key fact that the drug’s mechanism is not formally classified in major pharmacological references and provides relevant, accurate context about metronidazole’s presumed mechanism. There is a minor addition of mechanistic detail, but no clinically significant omissions or inaccuracies."
  },
  "1382": {
    "score": 5.0,
    "explanation": "5: Thoroughly covers all key clinical facts from the reference, accurately describing modulation of connective tissue macromolecules and providing relevant, correct additional details about the mechanism of action. No inaccuracies or omissions."
  },
  "1383": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies viral DNA polymerase as the primary molecular target, thoroughly explains the mechanism of action, and provides clinically relevant context without any inaccuracies or omissions."
  },
  "1384": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies povidone-iodine, accurately describes its broad mechanism (oxidation and iodination of microbial components), and explicitly notes that the precise molecular targets remain incompletely defined, fully aligning with the reference answer."
  },
  "1385": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies aminoglycosides as the adjunctive class and explains their mechanism, but does not use the broader class term \"protein synthesis inhibitors\" as in the reference; otherwise, all key facts are present and explanations are accurate."
  },
  "1386": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the drug class as a receptor agonist, and provides accurate, relevant clinical and mechanistic details without any inaccuracies or omissions."
  },
  "1387": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies codeine, specifies agonism at μ-opioid receptors in the CNS, and accurately explains the mechanism without any omissions or inaccuracies."
  },
  "1388": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the molecular mechanism, and provides relevant additional details without any inaccuracies or omissions."
  },
  "1389": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies cytochrome P450 enzymes as the target and discusses competitive inhibition, but it does not specify CYP2A6 as in the reference, and includes some ambiguity regarding the specific drug and isoenzyme involved; overall, it covers most but not all key facts."
  },
  "1390": {
    "score": 5.0,
    "explanation": "5: Fully covers all key facts—identifies the insulin receptor as a transmembrane tyrosine kinase receptor, explains the mechanism, and specifies the receptor class; no inaccuracies or omissions."
  },
  "1391": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies corticosteroid/glucocorticoid receptor agonism as the primary mechanism, and provides accurate, relevant mechanistic detail without inaccuracies or omissions."
  },
  "1392": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies 5-lipoxygenase inhibitors as the relevant drug class, and provides accurate, clinically relevant mechanistic detail without any inaccuracies or omissions."
  },
  "1393": {
    "score": 3.0,
    "explanation": "3: The model answer identifies DNA gyrase (topoisomerase II) as the inhibited enzyme, which is correct for many gram-negative bacteria, but the question specifically asks about interference with chromosome separation, which is mediated by topoisomerase IV. The answer omits this key fact, though the explanation is otherwise accurate and relevant."
  },
  "1394": {
    "score": 5.0,
    "explanation": "5: The model answer fully explains the mechanism—MAO inhibition by the antimicrobial leading to impaired tyramine metabolism—and provides accurate, clinically relevant details without any errors or omissions."
  },
  "1395": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies CXCR4 as the target, provides a thorough and accurate clinical and mechanistic explanation, and includes only relevant, factually correct information with no omissions or inaccuracies."
  },
  "1396": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies CYP450 inhibitors (specifically CYP3A), explains the mechanism, and provides relevant examples without inaccuracies or omissions."
  },
  "1397": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the drug mechanism, and provides relevant, correct additional context without any inaccuracies or omissions."
  },
  "1398": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies CYP3A4 inducers as the relevant pharmacologic class, provides accurate and clinically relevant context about Friedreich ataxia and omaveloxolone, and explains the mechanism of drug-drug interactions without any inaccuracies or omissions."
  },
  "1399": {
    "score": 3.0,
    "explanation": "3: The model answer correctly explains corticosteroid action and the inhibition of phospholipase A2, but it does not directly identify \"lipoxygenase inhibitors\" as in the reference answer, and focuses on an upstream enzyme rather than the specific enzyme class asked for, missing a key fact."
  },
  "1400": {
    "score": 3.0,
    "explanation": "3: The model answer provides a thorough explanation of phenothiazine mechanisms, correctly emphasizing dopamine D₂ antagonism for antiemetic and antipsychotic effects, but it fails to identify adrenergic alpha-antagonism as the most relevant mechanism per the reference answer, thus missing the key fact required."
  },
  "1401": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key facts, clearly stating that the precise cellular mechanism is incompletely understood, and provides correct, relevant background on beta-blockers' proposed actions; the only minor issue is some extra detail about class I agents, which is not directly relevant but does not detract from accuracy."
  },
  "1402": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed summary of proposed cellular and molecular mechanisms from preclinical studies, but does not clearly state that the mechanism in chronic hepatitis is unknown, as required by the reference. This constitutes a moderate omission, though the content is otherwise accurate and relevant."
  },
  "1403": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies histamine H1 receptor antagonism as the primary mechanism, explains the role of first-generation antihistamines, and provides relevant, accurate clinical context without any inaccuracies or omissions."
  },
  "1404": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies HPPD as the target, explains the mechanism, names the drug, and details the clinical benefit without inaccuracies or omissions."
  },
  "1405": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key facts from the reference, accurately stating that the precise cellular or molecular target is not well defined and providing a correct, clinically relevant summary of ciclopirox’s proposed mechanism without inaccuracies or omissions."
  },
  "1406": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key facts from the reference, accurately stating that iodoquinol's mechanism in cystinuria is not well defined, and any additional content is correct and clinically relevant."
  },
  "1407": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describing phosphate binding/chelation in the GI tract, the formation of insoluble complexes, and reduced absorption, with no inaccuracies or omissions."
  },
  "1408": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately identifies C5a receptor antagonists, explains the molecular mechanism, and provides relevant, correct additional detail without inaccuracies or omissions."
  },
  "1409": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies dopamine antagonists (antipsychotics) as the drug class, and accurately explains D2 receptor blockade in the basal ganglia as the mechanism. Additional details are correct and clinically relevant, with no inaccuracies or omissions."
  },
  "1410": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key facts from the reference, accurately states that the exact mechanism is not fully elucidated, and provides correct, clinically relevant details about the presumed mechanism of permethrin without any inaccuracies or omissions."
  },
  "1411": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the mechanism (inhibition of viral DNA polymerase and halting DNA replication), and provides additional correct, clinically relevant details without any inaccuracies or omissions."
  },
  "1412": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies cyclooxygenase (COX) inhibitors as the molecular class, explains the mechanism, and provides relevant, accurate extra detail without any errors or omissions."
  },
  "1413": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the pharmacological class (tetracyclines), and provides relevant, accurate additional information without any errors or omissions."
  },
  "1414": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies lipoxygenases as the enzyme class, explains their role in leukotriene synthesis, distinguishes them from cyclooxygenases, and provides a relevant example, with no inaccuracies or omissions."
  },
  "1415": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and accurate description of the likely diagnosis, drug, and general mechanism (DNA disruption), but it does not directly state that the mechanism is \"unknown cellular or molecular interaction\" as required; instead, it classifies the mechanism based on partial knowledge, missing the key fact that the mechanism is best classified as unknown."
  },
  "1416": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the diagnosis, drug, mechanism, and pharmacologic class, and provides relevant, accurate additional detail without any inaccuracies or omissions."
  },
  "1417": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the disorder and therapy, and accurately describes the mechanism as regulation of gene transcription via JAK-STAT signaling, matching the reference answer's focus on transcription factor activity."
  },
  "1418": {
    "score": 5.0,
    "explanation": "5: The model answer accurately and thoroughly explains that selective antagonism of the CGRP receptor is the core pharmacological principle, covering all key facts from the reference answer with correct and clinically relevant elaboration."
  },
  "1419": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the mechanism (inhibition of cell wall synthesis via PBPs/transpeptidases), and provides additional correct and relevant detail without any inaccuracies or omissions."
  },
  "1420": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies prostacyclin analogs as the drug class and accurately describes their mechanism via G protein-coupled IP receptors, covering nearly all key facts. However, it does not explicitly use the term \"prostaglandin receptor agonists\" as in the reference, which is a minor wording inaccuracy."
  },
  "1421": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the inhibited process as bacterial protein synthesis (translation) via 30S ribosomal subunit inhibition, matches all key facts, and provides clinically relevant elaboration without inaccuracies or omissions."
  },
  "1422": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, accurately explains the molecular mechanism (inhibition of thyroid peroxidase-mediated organification and coupling), and provides relevant, correct additional context without any inaccuracies or omissions."
  },
  "1423": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies CYP3A4 as the primary enzyme inhibited, whereas the reference specifies CYP2C19. While the explanation is detailed and relevant, this represents a moderate factual error, and only some key facts are addressed."
  },
  "1424": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key facts from the reference, explicitly states that the precise mechanism is unknown, and provides additional correct and clinically relevant details about pentoxifylline’s proposed actions without inaccuracies or omissions."
  },
  "1425": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies CYP3A4 inducers as the responsible class, accurately explains the mechanism (increased hepatic metabolism leading to reduced drug levels and efficacy), and provides relevant, factually correct extra detail without any inaccuracies or omissions."
  },
  "1426": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies inhibition of ergosterol synthesis as the disrupted process, explains the mechanism, and provides relevant additional details without inaccuracies or omissions."
  },
  "1427": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the specific intracellular receptor, thoroughly explains the mechanism, and provides clinically relevant context without any inaccuracies or omissions."
  },
  "1428": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies the primary mechanism as direct muscarinic receptor agonism (pilocarpine), whereas the question and reference specify a drug that increases acetylcholine levels via cholinesterase inhibition; this is a moderate factual error, though the explanation is otherwise relevant."
  },
  "1429": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the drug class and receptor mechanism, and provides additional accurate, relevant details and examples without any inaccuracies or omissions."
  },
  "1430": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies IGF-1 receptor blockade as the mechanism, and provides additional accurate and relevant clinical context without any inaccuracies or omissions."
  },
  "1431": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies thiamine as the essential cofactor, and provides clinically relevant, accurate explanations without any inaccuracies or omissions."
  },
  "1432": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers the key fact that the drug’s mechanism is unknown at the cellular or molecular level, matches the reference, and any extra content is accurate and clinically relevant without introducing errors or omissions."
  },
  "1433": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies somatostatin analogs as the class, explains the mechanism, mentions pasireotide and SSTR5, and clarifies why dopamine agonists are not the main agents; there are no inaccuracies or omissions."
  },
  "1434": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the competitive inhibition of Fc receptors by IVIG, and provides relevant clinical context without inaccuracies or omissions."
  },
  "1435": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies proton pump inhibitors as the drug class, explains the clinical context, mechanism, and provides a relevant comparison table, covering all key facts without inaccuracies or omissions."
  },
  "1436": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies MAOI as the relevant property, and accurately explains the associated clinical risks (serotonin syndrome, hypertensive crisis) without any inaccuracies or irrelevant content."
  },
  "1437": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the pharmacologic class as a complement inhibitor, specifically a complement C5 inhibitor, and provides accurate, relevant clinical context without any inaccuracies or omissions."
  },
  "1438": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies CYP3A4 inhibition as the key molecular property, names itraconazole as the likely agent, and accurately explains the mechanism and clinical relevance without any inaccuracies or omissions."
  },
  "1439": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies cytochrome P450 enzymes as responsible for increased metabolic clearance but does not specify CYP1A as in the reference answer, and instead emphasizes CYP3A4, which is less relevant here; otherwise, the explanation is accurate and clinically relevant."
  },
  "1440": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately identifies the drug class and mechanism, and provides additional correct and clinically relevant details without any inaccuracies or omissions."
  },
  "1441": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers all key clinical facts from the reference, correctly identifies glucocorticoid receptor agonism as the mechanism, and provides accurate, relevant mechanistic detail without any inaccuracies or omissions."
  },
  "1442": {
    "score": 3.0,
    "explanation": "3: The answer correctly describes the mechanism as inhibition of cell wall synthesis via PBPs and peptidoglycan cross-linking, but it does not explicitly name \"transpeptidase inhibitors,\" which is the required class; thus, it omits the key fact needed for full credit."
  },
  "1443": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the mechanism, provides relevant examples, and includes correct, clinically relevant extra detail without any inaccuracies or omissions."
  },
  "1444": {
    "score": 2.0,
    "explanation": "2: The model answer provides a detailed, textbook mechanism (T-type calcium channel blockade) that is widely cited, but the reference explicitly states the precise mechanism remains unknown; thus, the model omits this key uncertainty and overstates current knowledge, constituting a moderate factual error."
  },
  "1445": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describing both the mucolytic (disulfide bond cleavage) and antioxidant (glutathione replenishment, ROS neutralization) mechanisms, with no inaccuracies or omissions."
  },
  "1446": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the pharmacologic class as growth hormone analogs, accurately describes the mechanism of action, and provides relevant clinical context without any inaccuracies or omissions."
  },
  "1447": {
    "score": 5.0,
    "explanation": "5: The model answer accurately identifies collagenase as the agent and clearly explains its molecular mechanism—enzymatic hydrolysis of peptide bonds in collagen—matching all key clinical facts in the reference without errors or omissions."
  },
  "1448": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains magnesium’s role as an enzyme cofactor, and provides relevant, correct elaboration without any inaccuracies or omissions."
  },
  "1449": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the principal molecular mechanism (V2 receptor agonism), and provides additional accurate, clinically relevant mechanistic detail without any inaccuracies or omissions."
  },
  "1450": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the molecular interaction (antibody binding and inhibition of VEGF-A), and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "1451": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies hydroxyurea, its mechanism (ribonucleotide reductase inhibition), and its use, but gives \"antimetabolite\" as the drug class rather than the more precise \"nucleic acid synthesis inhibitor\" required by the reference; this is a minor but meaningful omission in terminology."
  },
  "1452": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the mechanism of cinacalcet, and provides relevant clinical context without any inaccuracies or omissions."
  },
  "1453": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key facts from the reference, correctly identifies inhibition of bacterial DNA gyrase (topoisomerase II), and provides additional clinically relevant detail without inaccuracies or omissions."
  },
  "1454": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the molecular mechanism (niacin as precursor for NAD+/NADP+, essential for dehydrogenase/redox enzymes), and provides relevant clinical context without inaccuracies or omissions."
  },
  "1455": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies paromomycin, its luminal action, and its mechanism (binding the 30S ribosomal subunit to inhibit protein synthesis), with additional accurate and relevant details. No inaccuracies or omissions are present."
  },
  "1456": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies cyclooxygenase inhibition as the key mechanism, thoroughly explains the drug action, and provides relevant clinical context without any inaccuracies or omissions."
  },
  "1457": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies pentoxifylline and notes that its precise mechanism is incompletely understood, but provides more detail than the reference by describing proposed mechanisms; this extra content is accurate and relevant, though the answer could more clearly emphasize the uncertainty as the main point."
  },
  "1458": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the Na⁺/Cl⁻ cotransporter in the distal convoluted tubule as the target, which is accurate for thiazide and thiazide-like diuretics, but the reference answer specifies potassium channels, which is incorrect. However, the model answer covers the clinical context and mechanism well, but does not match the reference's key fact, resulting in a moderate mismatch."
  },
  "1459": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the drug (rifamycin), its mechanism (inhibition of bacterial RNA polymerase), and its use in LTBI, but it does not explicitly use the broader class term \"Nucleic Acid Synthesis Inhibitors\" as in the reference answer, instead focusing on \"RNA polymerase inhibitors,\" which is more specific. This covers most, but not all, key facts."
  },
  "1460": {
    "score": 2.0,
    "explanation": "2: The model answer provides detailed mechanisms for cilostazol and pentoxifylline, but fails to emphasize that the precise cellular or molecular mechanism is unknown, as required by the reference answer; this is a moderate omission."
  },
  "1461": {
    "score": 5.0,
    "explanation": "5: Thoroughly covers all key clinical facts from the reference, accurately describing the non-enzymatic Maillard reaction of dihydroxyacetone with stratum corneum proteins, and provides correct, relevant additional detail without inaccuracies or omissions."
  },
  "1462": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies \"lanosterol 14-α-demethylase\" as the enzyme, matching the reference, and provides accurate, relevant explanation without errors or omissions."
  },
  "1463": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies that the precise mechanism of action of pentoxifylline in vascular smooth muscle is not fully characterized, matching the key fact in the reference. It adds relevant, accurate information about pentoxifylline's effects, but introduces cilostazol (not mentioned in the reference), which is a minor irrelevant detail, slightly detracting from focus but not altering the clinical meaning."
  },
  "1464": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately identifies the pharmacologic class, and provides a detailed, correct, and clinically relevant explanation of the molecular mechanism without any inaccuracies or omissions."
  },
  "1465": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the drug class and mechanism, and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "1466": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies phosphodiesterase inhibition as the primary mechanism, covers all key clinical facts, and provides accurate, relevant additional detail without any errors or omissions."
  },
  "1467": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the GABA_B receptor as the mediator, explains the mechanism, and provides relevant clinical context without inaccuracies or omissions."
  },
  "1468": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains thiamine’s cofactor role in carbohydrate metabolism, and provides relevant, correct additional details without inaccuracies or omissions."
  },
  "1469": {
    "score": 4.0,
    "explanation": "4: The model answer correctly states that the precise molecular mechanism is not fully established and describes the general antimicrobial actions of povidone-iodine, matching the reference's emphasis on the unknown mechanism; however, it adds mechanistic details (oxidation/iodination) that, while accurate, go slightly beyond the reference's strict \"unknown\" stance, representing a minor wording inaccuracy."
  },
  "1470": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the mechanism of flucytosine, and provides additional correct and relevant mechanistic detail without any inaccuracies or omissions."
  },
  "1471": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies papaverine, notes its nonselective PDE inhibition, and emphasizes that the precise mechanism is unclear, matching ≥90% of key facts. The extra mechanistic detail is accurate and relevant, but the answer could be slightly more concise in stating that the exact mechanism is unknown, as in the reference."
  },
  "1472": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies cyclooxygenase (COX) as the enzyme class directly inhibited, provides accurate clinical context, and contains no inaccuracies or omissions."
  },
  "1473": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies 5-lipoxygenase inhibitors, provides accurate and relevant additional details, and contains no inaccuracies or omissions."
  },
  "1474": {
    "score": 5.0,
    "explanation": "5: Fully correct—covers all key facts (androgen receptor as the molecular target, its nuclear/intracellular nature, mechanism of gene transcription activation), with additional accurate and relevant explanation; no errors or omissions."
  },
  "1475": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies PPAR-α as the molecular target, explains the mechanism, and provides relevant context without any inaccuracies or omissions."
  },
  "1476": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies antimuscarinic agents as the class, explains mechanism, and provides relevant examples; all content is accurate and clinically relevant."
  },
  "1477": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the lipoxygenase (specifically 5-lipoxygenase) pathway as the one directly suppressed, fully aligns with the reference answer, and provides accurate, relevant additional explanation without any errors or omissions."
  },
  "1478": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies the type I interferon receptor (specifically IFNAR1) as the direct target, with all key facts from the reference included and relevant, accurate elaboration."
  },
  "1479": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies ergosterol as the direct molecular target, provides accurate and clinically relevant explanation, and includes additional correct details without any inaccuracies or omissions."
  },
  "1480": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the mechanism (binding to ergosterol, pore formation, increased permeability, cell death), and provides correct, relevant additional detail without any inaccuracies or omissions."
  },
  "1481": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies muscarinic acetylcholine receptors as the molecular target and provides relevant, accurate detail about the M3 subtype, but specifying only the M3 receptor is a minor inaccuracy since the reference answer does not limit the target to a subtype; otherwise, all key facts are covered."
  },
  "1482": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies lanosterol 14-α-demethylase as the molecular target, provides the alternative name (fungal 14-alpha demethylase), and adds accurate, relevant mechanistic details without any inaccuracies or omissions."
  },
  "1483": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key facts and provides relevant clinical context, but the mechanistic classification is more detailed than the reference and does not use the exact phrase \"unknown cellular or molecular interaction,\" which is the best match per the reference; otherwise, there are no inaccuracies or unsafe statements."
  },
  "1484": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the mechanism (inhibition of protein synthesis via 50S ribosomal subunit binding), and provides correct, relevant additional detail without any inaccuracies or omissions."
  },
  "1485": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies penicillin-binding proteins (PBPs), specifically transpeptidases, as the direct molecular target, and provides accurate, clinically relevant explanation without any errors or omissions."
  },
  "1486": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the principal drug class as interleukin-1 (IL-1) inhibitors and provides relevant explanation, but does not use the precise term \"interleukin 1 receptor antagonists\" as in the reference; this is a minor wording inaccuracy that does not alter the clinical meaning."
  },
  "1487": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies DNA alkylation as the mechanism, and provides clinically relevant, accurate explanations without any inaccuracies or omissions."
  },
  "1488": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key facts from the reference, clearly stating that the precise molecular mechanism is unknown, while providing accurate, relevant context about edaravone’s antioxidant properties and the uncertainty regarding its action in ALS."
  },
  "1489": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately stating that the primary mechanism of action is unclear, and provides correct, clinically relevant elaboration without inaccuracies or omissions."
  },
  "1490": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies fluoroquinolones as the drug class, accurately explains their mechanism (inhibition of DNA gyrase/topoisomerase II), and provides clinically relevant detail with no omissions or inaccuracies."
  },
  "1491": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describing antisense-mediated inhibition of protein synthesis and providing additional correct, clinically relevant details about fomivirsen's mechanism."
  },
  "1492": {
    "score": 2.0,
    "explanation": "2: The model answer does not mention the key fact from the reference—free radical scavenging activity—as a mechanism, and instead focuses on prevention of hypoxia-induced injury, which, while relevant, does not directly address mitigation of oxidative cellular damage via free radical scavenging. There are no unsafe statements, but the main mechanism asked is omitted."
  },
  "1493": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the primary molecular mechanism as regulation of gene transcription via nuclear retinoic acid receptors, explicitly stating that antioxidant activity is not the main mechanism for symptom relief, matching all key clinical facts in the reference."
  },
  "1494": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately identifies the class as glucocorticoid receptor agonists, and provides correct, relevant mechanistic detail without any inaccuracies or omissions."
  },
  "1495": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies transpeptidases (penicillin-binding proteins) as the direct molecular target, covers all key clinical facts, and provides relevant, accurate additional context without any errors or omissions."
  },
  "1496": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains betaine’s role as a methyl donor in homocysteine remethylation, and provides additional correct, relevant details without any inaccuracies or omissions."
  },
  "1497": {
    "score": 3.0,
    "explanation": "3: The model answer accurately describes the mechanism (mast cell membrane stabilization and prevention of degranulation) but does not use or reference the required class term \"Biological Response Modifiers,\" omitting the key classification fact from the reference answer."
  },
  "1498": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the mechanism as binding to ergosterol in the fungal membrane (polyene action), and provides relevant, accurate clinical context without any inaccuracies or omissions."
  },
  "1499": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the clinical scenario, the use of medium-chain triglycerides, and their absorption via the portal vein, but it incorrectly names \"fatty acid transport proteins/monocarboxylate transporters\" as the most direct molecular targets, rather than the structural macromolecules (cellular membrane components of enterocytes) specified in the reference. This represents a moderate factual inaccuracy regarding the primary molecular class involved."
  },
  "1500": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies glucocorticoid receptor agonism as the mechanism, explains the drug’s pharmacology and mechanism of action, and rules out alternatives; all key facts are covered with no inaccuracies or omissions."
  },
  "1501": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describing the mechanism as a peptide hormone (pituitary hormone) receptor agonist, specifically ACTH/melanocortin 2 receptor agonism, with no inaccuracies or omissions."
  },
  "1502": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describing VMAT inhibition, decreased presynaptic dopamine storage and release, and the clinical context; all additional content is correct and clinically relevant."
  },
  "1503": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the molecular target as the Na⁺-K⁺-2Cl⁻ cotransporter (NKCC2), provides relevant context about sulfa allergy and ethacrynic acid, and contains no inaccuracies or omissions. All key clinical facts are covered."
  },
  "1504": {
    "score": 4.0,
    "explanation": "4: The answer correctly states that the precise mechanism is unclear and identifies tafenoquine, but adds speculative details about reactive oxygen species and mitochondrial disruption that, while plausible, go beyond the reference answer; however, these additions are factually correct and relevant, so only a minor wording inaccuracy is present."
  },
  "1505": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies alpha-1-adrenergic receptor antagonism as the cause, explains the mechanism, and distinguishes it from other possible receptor effects; all key clinical facts are covered with no inaccuracies or omissions."
  },
  "1506": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, accurately describes the mechanism of antibody-mediated neutralization of diphtheria toxin, and provides relevant, correct additional context without any inaccuracies or omissions."
  },
  "1507": {
    "score": 5.0,
    "explanation": "5: Fully covers all key facts from the reference answer, correctly identifies estrogen receptors as the relevant nuclear receptor class, and provides accurate, clinically relevant elaboration without any inaccuracies or omissions."
  },
  "1508": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the drug and its mechanism but gives \"antimetabolite\" as the pharmacological class, which is less specific than \"nucleic acid synthesis inhibitor\" and omits the reference class; otherwise, the explanation is accurate and relevant."
  },
  "1509": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the glucocorticoid receptor as the target and specifies \"selective glucocorticoid receptor modulators,\" which is accurate and clinically relevant, but the reference answer uses the broader term \"glucocorticoid receptor agonists.\" The model's answer is more specific but not incorrect; however, since the reference does not require the \"selective\" qualifier, this is a minor wording inaccuracy, so a 4 is appropriate."
  },
  "1510": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the drug class, mechanism, and relevant receptor, and provides additional accurate and clinically relevant details without any inaccuracies or omissions."
  },
  "1511": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the general mechanism as inhibition of bacterial protein synthesis, and provides relevant, accurate elaboration without any inaccuracies or omissions."
  },
  "1512": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains biotin's role as a coenzyme for carboxylases, and provides additional correct and relevant molecular details without any inaccuracies or omissions."
  },
  "1513": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies penicillin-binding proteins (specifically the transpeptidase enzyme) as the direct molecular target, fully explaining their role in peptidoglycan cross-linking and the mechanism of beta-lactam antibiotics, with no inaccuracies or omissions."
  },
  "1514": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the direct molecular target as IL-4Rα, which is accurate for dupilumab, and explains its role in blocking both IL-4 and IL-13 signaling; however, it does not directly name IL-13 as the antagonized cytokine as in the reference, representing a minor omission in focus."
  },
  "1515": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the enzymatic regeneration of retinal in the visual cycle, and provides correct, clinically relevant additional detail without inaccuracies or omissions."
  },
  "1516": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the drug and its mechanism (disruption of parasite calcium ion channels), and provides additional clinically relevant detail without inaccuracies or omissions."
  },
  "1517": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies penicillin-binding proteins (PBPs), specifically transpeptidase, as the direct molecular target, and provides accurate, relevant clinical context without any inaccuracies or omissions."
  },
  "1518": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the class as vasopressin (ADH) receptor agonists, fully explains the clinical reasoning, and provides relevant, accurate details without any errors or omissions."
  },
  "1519": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies blockade of voltage-gated sodium channels as the primary mechanism, provides accurate context, and includes only relevant, factually correct details without omissions or inaccuracies."
  },
  "1520": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the mechanism (inhibition of protein synthesis via 30S ribosomal subunit binding), and provides relevant, correct elaboration without any inaccuracies or omissions."
  },
  "1521": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies topoisomerase IV as the direct molecular target involved in decatenation, thoroughly explains the reasoning, and contains no inaccuracies or omissions."
  },
  "1522": {
    "score": 4.0,
    "explanation": "4: The model answer covers over 90% of the key facts, correctly describing the mechanism and providing relevant examples, but does not explicitly use the class name \"DNA polymerase inhibitors\" as in the reference answer, which is a minor wording inaccuracy."
  },
  "1523": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly explaining antibody-mediated neutralization of tetanus toxin by human immunoglobulin, and provides additional accurate, relevant details without any inaccuracies or omissions."
  },
  "1524": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the mechanism as free radical scavenging via glutathione replenishment, fully covering the key clinical fact in the reference answer with accurate and relevant detail."
  },
  "1525": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the mechanism, and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "1526": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key facts from the reference, accurately describes the mechanism as adrenergic agonism, and provides correct, clinically relevant elaboration without any inaccuracies or omissions."
  },
  "1527": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies glucocorticoid receptor agonism as the mechanism, and provides additional accurate, clinically relevant detail without any inaccuracies or omissions."
  },
  "1528": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the drug class, explains the mechanism, and provides relevant examples without inaccuracies or omissions."
  },
  "1529": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the drug class and mechanism, and provides relevant, correct additional details without any inaccuracies or omissions."
  },
  "1530": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers the key fact—direct inhibition of viral DNA polymerase—and provides additional, accurate, and clinically relevant mechanistic detail without any inaccuracies or omissions."
  },
  "1531": {
    "score": 5.0,
    "explanation": "5: Fully covers all key facts from the reference answer, correctly identifies the class as complement inhibitors, and provides accurate, relevant explanation without any errors or omissions."
  },
  "1532": {
    "score": 5.0,
    "explanation": "5: All key facts from the reference are included, with additional correct and clinically relevant explanation of the mechanism and examples; there are no inaccuracies or omissions."
  },
  "1533": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the molecular mechanism (competitive inhibition of dihydropteroate synthase via PABA antagonism), and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "1534": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies azoles as the other class, explains their mechanism, and accurately states that ergosterol is the shared molecular target, covering all key clinical facts with relevant, accurate elaboration."
  },
  "1535": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed discussion of the clinical scenario, correctly identifies clofazimine as the agent described, and explains its mechanism as a DNA intercalating agent, but it does not explicitly state \"nucleic acid synthesis inhibitors\" as the broad pharmacological class, which is the key fact required by the reference answer."
  },
  "1536": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the molecular target, thoroughly explains the mechanism, and matches all key clinical facts from the reference without any inaccuracies or omissions."
  },
  "1537": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key clinical facts, correctly identifies interferon-gamma, and explains its mechanism in terms of osteoclast and macrophage activation. However, it does not explicitly use the term \"biological response modification (via immune modulation)\" as in the reference, which is a minor wording omission."
  },
  "1538": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the mechanism of action, and provides relevant additional detail without any inaccuracies or omissions."
  },
  "1539": {
    "score": 5.0,
    "explanation": "5: Fully covers all key clinical facts, accurately describing the agent's mechanism as binding dietary phosphate in the GI tract to prevent absorption, with correct and relevant additional details; no errors or omissions."
  },
  "1540": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the drug class (dihydrofolate reductase inhibitors) and provides accurate, relevant clinical context, but it omits the broader class term \"folic acid metabolism inhibitors\" used in the reference, which is slightly more inclusive; otherwise, all key facts are covered."
  },
  "1541": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies \"inhibition of bacterial protein synthesis\" as the broad class of antimicrobial mechanism, covers all key facts, and provides accurate, relevant elaboration without any errors or omissions."
  },
  "1542": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the principal mechanism as inhibition of penicillin-binding proteins (transpeptidases) essential for peptidoglycan cross-linking, fully matching the reference answer with accurate and clinically relevant elaboration."
  },
  "1543": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the mechanism, names examples, and contains no inaccuracies or omissions."
  },
  "1544": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the molecular mechanism (one-carbon donation for thymidine and purine synthesis), and provides relevant, correct additional detail without inaccuracies or omissions."
  },
  "1545": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the drug, mechanism, and class of enzymatic inhibition (competitive inhibition), and provides relevant clinical context, but does not explicitly state \"PABA inhibitors\" as the class, which is the key fact in the reference answer; this is a minor omission."
  },
  "1546": {
    "score": 2.0,
    "explanation": "2: The model answer provides a detailed and accurate description of metronidazole’s mechanism (DNA damage via reactive intermediates), but this directly contradicts the reference answer, which states the molecular target is unknown; this is a moderate factual discrepancy."
  },
  "1547": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies cyclooxygenase (COX-1 and COX-2) as the molecular target, covers all key facts, and provides accurate, relevant additional explanation without any inaccuracies or omissions."
  },
  "1548": {
    "score": 2.0,
    "explanation": "2: The model answer focuses on CGRP receptor antagonism, which is accurate for modern migraine prophylaxis but does not address the reference answer's key fact: serotonin (5-HT2) receptor antagonism by methysergide. It omits the reference's main mechanism and target, covering less than 70% of key facts."
  },
  "1549": {
    "score": 5.0,
    "explanation": "5: Fully covers all key clinical facts, correctly identifies amphotericin B, its binding to ergosterol, pore formation, increased membrane permeability, and resultant cell death; all additional details are accurate and clinically relevant."
  },
  "1550": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies CYP1A2 as the inhibited enzyme, explains the clinical scenario, theophylline metabolism, and the interaction with fluoroquinolones, with all key facts present and no inaccuracies."
  },
  "1551": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key facts from the reference, accurately emphasizing the uncertain mechanism, the generation of free radicals, and the lack of a clearly established molecular target, with no inaccuracies or omissions."
  },
  "1552": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the histamine H1 receptor as the target and provides a clear, clinically relevant explanation without inaccuracies or omissions."
  },
  "1553": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies the primary mechanism as β-adrenergic (norepinephrine) receptor stimulation, whereas the reference specifies serotonin receptor modulation; this is a moderate factual error, though the rest of the explanation is relevant."
  },
  "1554": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies antithrombin deficiency, details the mechanism as serine protease inhibition, and provides accurate, relevant explanations without inaccuracies or omissions."
  },
  "1555": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies serotonin 3 (5-HT₃) receptor antagonism as the mechanism, and provides accurate, relevant clinical context without any inaccuracies or omissions."
  },
  "1556": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the pharmacologic class as a protein synthesis inhibitor, and provides accurate, relevant additional detail without any inaccuracies or omissions."
  },
  "1557": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies dihydropteroate synthase as the direct molecular target, explains the mechanism of sulfonamides, and provides relevant clinical context without inaccuracies or omissions."
  },
  "1558": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the clinical context, the role of botulinum toxin, and the inhibition of acetylcholine release, and specifies SNARE proteins (SNAP-25) as the molecular target. However, it omits explicit mention of \"acetylcholine transporter interactions\" as in the reference, which is a minor omission but does not alter the clinical meaning."
  },
  "1559": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies \"glucocorticoid\" as the pharmacological class and provides a thorough, accurate explanation of the diagnosis, pathophysiology, and mechanism. However, it omits the more precise term \"glucocorticoid receptor agonist\" as used in the reference, which is a minor wording inaccuracy."
  },
  "1560": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies L-type calcium channel antagonism in vascular smooth muscle as the primary mechanism, fully explains the process, and provides relevant clinical context without inaccuracies or omissions."
  },
  "1561": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies coenzyme Q10, details its role as a cofactor in the mitochondrial respiratory chain, and explains how it enhances ATP production to alleviate symptoms, fully covering all key clinical facts in the reference answer with accurate and relevant elaboration."
  },
  "1562": {
    "score": 5.0,
    "explanation": "5: The model answer correctly explains that corticosteroids inhibit phospholipase A2, not lipoxygenase, and provides accurate, clinically relevant detail without any inaccuracies or omissions."
  },
  "1563": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describing the medication's local adhesion to ulcerated mucosal proteins and barrier formation, with correct and clinically relevant additional details and no inaccuracies or omissions."
  },
  "1564": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies bacterial transpeptidase (penicillin-binding protein) as the direct molecular target, covers all key clinical facts, and provides relevant, accurate additional context without any errors or omissions."
  },
  "1565": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies NSAIDs as cyclooxygenase inhibitors, and provides accurate, relevant additional detail without any inaccuracies or omissions."
  },
  "1566": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the FcRn mechanism, and provides relevant, correct additional details without any inaccuracies or omissions."
  },
  "1567": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies echinocandins as the class, accurately describes their mechanism, and provides relevant clinical context without any inaccuracies or omissions."
  },
  "1568": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describing free radical scavenging/ROS neutralization as the primary mechanism, and provides additional correct and relevant mechanistic detail without any inaccuracies or omissions."
  },
  "1569": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies DNA gyrase as the direct molecular target, provides accurate and clinically relevant context, and contains no inaccuracies or omissions compared to the reference answer."
  },
  "1570": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key facts from the reference, accurately clarifies that Povidone K30 lacks intrinsic antibacterial activity, and provides clinically relevant context without inaccuracies or omissions."
  },
  "1571": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the clinical scenario, the mechanism of corticosteroids, and the role of phospholipase A₂, but it does not select \"lipoxygenase inhibition\" as the most direct answer as in the reference. It covers most key facts but misses the specific enzyme asked for, which is a moderate omission."
  },
  "1572": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies DNA gyrase as the directly inhibited enzyme, with accurate, relevant elaboration on fluoroquinolones and their mechanism; no errors or omissions."
  },
  "1573": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the mechanism as inhibition of penicillin-binding proteins, and provides accurate, relevant elaboration without any inaccuracies or omissions."
  },
  "1574": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the molecular process as inhibition of calcium influx via ion channel modulation, and provides relevant, accurate context without any inaccuracies or omissions."
  },
  "1575": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, including the diagnosis, mechanism of action (serotonin reuptake inhibition), and clinical rationale, but introduces norepinephrine reuptake inhibition as an alternative mechanism, which is not specified in the reference and dilutes the focus. This constitutes a minor error/omission, as the reference answer is specific to serotonin reuptake inhibition."
  },
  "1576": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the mechanism as enzyme inhibition (specifically feedback inhibition of δ-aminolevulinate synthase), and provides accurate, relevant clinical context without inaccuracies or omissions."
  },
  "1577": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and accurate description of the drug’s known mechanism (binding the alpha-2-delta subunit, reducing calcium influx, and neurotransmitter release), but it omits the key reference point that the full cellular or molecular mechanism underlying pain relief is incompletely characterized/unknown; thus, it does not directly address the uncertainty emphasized in the reference answer."
  },
  "1578": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the mechanism (methyl group donation for remethylation of homocysteine to methionine), and provides relevant, accurate additional detail without any inaccuracies or omissions."
  },
  "1579": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies alpha-adrenergic receptors as mediating the rapid benefit, provides accurate pathophysiological reasoning, and appropriately distinguishes the roles of alpha- and beta-adrenergic effects in croup, matching all key clinical facts in the reference."
  },
  "1580": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the mechanism as CYP2C9 (and CYP3A4) inhibition by azole antifungals, and provides relevant, accurate, and clinically pertinent explanations without any inaccuracies or omissions."
  },
  "1581": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the mechanism (nuclear receptor binding, gene transcription modulation), and provides relevant, correct additional detail without inaccuracies or omissions."
  },
  "1582": {
    "score": 5.0,
    "explanation": "5: Fully identifies ergosterol as the molecular target, explains the mechanism, and correctly contextualizes the clinical scenario; all content is accurate and clinically relevant."
  },
  "1583": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describing estrogen receptor agonism and providing additional correct and clinically relevant mechanistic detail without any inaccuracies or omissions."
  },
  "1584": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies β-1,3-D-glucan synthase as the molecular target, explains its role, and provides relevant context about echinocandins, with no inaccuracies or omissions."
  },
  "1585": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies risdiplam and its mechanism of action but incorrectly names BCRP/ABCG2 as the transporter inhibited, rather than the required MATE2-K; otherwise, the explanation is accurate and relevant, covering most key facts."
  },
  "1586": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies azoles as the drug class, thoroughly explains their mechanism, and distinguishes them from other antifungal classes, covering all key clinical facts in the reference without inaccuracies or omissions."
  },
  "1587": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies muscarinic acetylcholine receptors as the target, and provides relevant, accurate, and clinically appropriate additional explanation without any inaccuracies or omissions."
  },
  "1588": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the pharmacological mechanism (iron chelation and urinary excretion), and provides relevant clinical context without any inaccuracies or omissions."
  },
  "1589": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies glucocorticoids as the drug class, specifies their use in nephrotic syndrome, and accurately describes their mechanism via intracellular glucocorticoid receptors altering gene transcription to reduce immune and inflammatory activity, with no inaccuracies or omissions."
  },
  "1590": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately identifies chondroitin sulfate, details its interaction with extracellular matrix components, and provides additional correct, clinically relevant mechanisms without inaccuracies or omissions."
  },
  "1591": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the mechanism (binding to the 30S ribosomal subunit to inhibit protein synthesis), and provides additional accurate and relevant explanation without any inaccuracies or omissions."
  },
  "1592": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the pharmacologic class as beta-adrenergic agonists, provides accurate and clinically relevant mechanistic details, and contains no inaccuracies or omissions compared to the reference answer."
  },
  "1593": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and relevant additional explanation, and contains no inaccuracies or omissions."
  },
  "1594": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies cytochrome P450 induction and specifically mentions CYP3A4, but omits the reference answer's focus on CYP1A enzymes, which is the key fact required; otherwise, the explanation is accurate and relevant."
  },
  "1595": {
    "score": 5.0,
    "explanation": "5: All key clinical facts are covered, including the correct receptor class (muscarinic acetylcholine receptors), relevant subtype (M3), and mechanism; extra explanation is accurate and clinically relevant with no inaccuracies or omissions."
  },
  "1596": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies dopamine D2 receptor antagonism as the key mechanism, specifies the nigrostriatal pathway, and accurately explains the link to extrapyramidal symptoms without any inaccuracies or omissions."
  },
  "1597": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the molecular mechanism (binding to 23S rRNA of the 50S subunit, blocking translocation), and provides relevant, correct additional context without any inaccuracies or omissions."
  },
  "1598": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the mechanism (chronic GnRH agonist use leads to receptor downregulation and decreased LH/FSH), and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "1599": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies insulin receptor activation as the mechanism, and provides additional accurate, clinically relevant mechanistic detail without any inaccuracies or omissions."
  },
  "1600": {
    "score": 2.0,
    "explanation": "2: The model answer focuses on increased ROS/RNS production and their bactericidal effects, but omits the reference answer's key mechanism—free radical scavenging activity. While the answer is detailed and relevant, it does not address the primary molecular mechanism specified in the reference."
  },
  "1601": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the mechanism (enzyme inhibition of penicillin-binding proteins), and provides relevant, correct additional context without any inaccuracies or omissions."
  },
  "1602": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies albumin and its oncotic (osmotic) activity, and provides accurate, relevant mechanistic detail without inaccuracies or omissions."
  },
  "1603": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes methylene blue’s role as an electron carrier, details the reduction of Fe³⁺ to Fe²⁺, and correctly explains the involvement of NADPH; all additional content is correct and clinically relevant."
  },
  "1604": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies inhibition of dihydropteroate synthase as the mechanism, which is the specific enzymatic step underlying the reference answer's \"inhibition of PABA utilization.\" It covers all key facts and provides relevant, accurate elaboration, but does not explicitly state \"inhibition of PABA utilization\" as in the reference, representing a minor wording inaccuracy."
  },
  "1605": {
    "score": 5.0,
    "explanation": "5: The model answer correctly states that there is no established cellular or molecular mechanism for appetite stimulation by the herbal product, clarifies the likely identity (Hoodia gordonii), and accurately explains that available evidence pertains to appetite suppression, not stimulation, with no inaccuracies or omissions."
  },
  "1606": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies free radical scavenging/antioxidant activity via glutathione replenishment as the key property, with accurate and relevant explanation; however, the summary could more directly state \"free radical scavenging activity\" as in the reference, making this a minor wording inaccuracy."
  },
  "1607": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key facts from the reference, correctly identifies NSAIDs as the primary class, explains their mechanism as cyclooxygenase inhibition, and provides relevant clinical context without inaccuracies or omissions."
  },
  "1608": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies inhibition of TNF-α synthesis as the key mechanism, provides accurate and clinically relevant detail about thalidomide’s action (enhanced TNF-α mRNA degradation), and contains no inaccuracies or omissions."
  },
  "1609": {
    "score": 4.0,
    "explanation": "4: The model answer correctly explains the mechanism of inhibiting heme detoxification and links it to disruption of nucleic acid synthesis, but the primary pharmacological action per the reference is inhibition of nucleic acid synthesis; the model emphasizes heme detoxification as the main action, which is a minor wording inaccuracy."
  },
  "1610": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the drug class as NS5B RNA-dependent RNA polymerase inhibitors, and provides accurate, relevant additional details without any inaccuracies or omissions."
  },
  "1611": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the supplement as an enzyme inhibitor, explains the mechanism of nitisinone in tyrosine catabolism, and provides relevant clinical context without inaccuracies or omissions."
  },
  "1612": {
    "score": 5.0,
    "explanation": "5: Fully covers all key facts from the reference answer, correctly identifies the drug class, mechanism, and clinical benefits, with relevant and accurate additional details."
  },
  "1613": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the mechanism as inhibition of bacterial protein synthesis, and provides relevant, accurate elaboration without any inaccuracies or omissions."
  },
  "1614": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key facts from the reference, accurately states that the mechanism is not fully characterized, and provides clinically relevant, correct elaboration without inaccuracies or omissions."
  },
  "1615": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies polyene antifungals, specifically amphotericin B, and accurately explains the mechanism of action, matching all key clinical facts in the reference with relevant, factually correct additional context."
  },
  "1616": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies transpeptidase (penicillin-binding protein) as the direct molecular target, thoroughly explains the mechanism, and provides only relevant, accurate, and clinically appropriate additional details with no omissions or inaccuracies."
  },
  "1617": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the GABA_A receptor as the primary molecular target, accurately explains the mechanism, and provides clinically relevant context without any inaccuracies or omissions."
  },
  "1618": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies transpeptidation (peptide cross-linking) as the inhibited process, explains the role of transpeptidases (PBPs), and accurately describes the mechanism and consequence, with all content factually correct and clinically relevant."
  },
  "1619": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies protein (specifically albumin) as the key molecule, explains its role in oncotic pressure and fluid balance, and contains no inaccuracies or omissions."
  },
  "1620": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the mechanism (enzyme inhibition of PBPs/transpeptidases), and provides relevant, correct elaboration without any inaccuracies or omissions."
  },
  "1621": {
    "score": 5.0,
    "explanation": "5: Fully covers all key clinical facts from the reference answer, correctly identifies the drug and its mechanism, and provides relevant, accurate additional explanation without any errors or omissions."
  },
  "1622": {
    "score": 2.0,
    "explanation": "2: The answer focuses on AMPK activation as the key property, which is not the specific mechanism referenced in the question or the reference answer (iron chelation). While it mentions trace metal sequestration, it does not identify iron chelation as the main pharmacological property, and the main emphasis is on a different mechanism, representing a moderate omission."
  },
  "1623": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the direct molecular target, covers all key clinical facts, and provides accurate, relevant explanations without any inaccuracies or omissions."
  },
  "1624": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies ergosterol as the target, explains the clinical context, mechanism of action, and provides accurate, relevant extra information without any errors or omissions."
  },
  "1625": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies protein synthesis inhibition as the key mechanism, accurately describes ciclopirox's unique action, and provides relevant mechanistic detail without inaccuracies or omissions."
  },
  "1626": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor, provides accurate and clinically relevant explanation, and contains no inaccuracies or omissions."
  },
  "1627": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies penicillin-binding proteins (PBPs) as the primary molecular target, explains their role as transpeptidases involved in cell wall cross-linking, and provides relevant, accurate clinical context without any errors or omissions."
  },
  "1628": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies dihydropyridine calcium channel blockers as first-line therapy for Raynaud phenomenon and accurately describes their molecular mechanism, but it does not answer the specific question regarding GPCR blockade or alpha-antagonists, omitting the key fact that the drug class described in the question is adrenergic alpha-antagonists."
  },
  "1629": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies penicillin-binding proteins (transpeptidases) as the direct molecular target, provides accurate and relevant explanation, and contains no inaccuracies or omissions."
  },
  "1630": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies bradykinin B2 receptor antagonism as the mechanism, provides accurate clinical context, and includes only relevant, factually correct information. No omissions or inaccuracies."
  },
  "1631": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies the pharmacological class as beta-1 adrenergic agonists rather than dopamine agonists, which is a moderate factual error. While the mechanism described is accurate for beta-1 agonists, it does not match the reference answer's focus on dopamine receptor activation, resulting in only partial coverage of key facts."
  },
  "1632": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the drug class and mechanism, and provides relevant, accurate additional details without any inaccuracies or omissions."
  },
  "1633": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies SNARE proteins (including SNAP-25), and provides accurate, relevant additional details without inaccuracies or omissions."
  },
  "1634": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the agent and explains the mechanism, including binding of bile acids and interruption of enterohepatic circulation, but emphasizes downstream effects (hepatic conversion and LDL receptor upregulation) rather than focusing solely on the primary mechanism of bile acid binding as in the reference; this is a minor wording inaccuracy but does not alter the clinical meaning."
  },
  "1635": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies β-1,3-D-glucan synthase as the molecular target, provides accurate and clinically relevant additional information about echinocandins, and contains no inaccuracies or omissions."
  },
  "1636": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key facts from the reference, correctly identifies suramin, its use in early-stage African trypanosomiasis, and accurately states that its precise cellular/molecular target is not fully understood, with no inaccuracies or omissions."
  },
  "1637": {
    "score": 5.0,
    "explanation": "5: All key facts are covered, including the identification of ergosterol as the target and a correct, clinically relevant explanation; there are no inaccuracies or omissions."
  },
  "1638": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key facts, clearly stating that the precise cellular or molecular mechanism is unknown, and any additional content is accurate and clinically relevant without introducing inaccuracies or omissions."
  },
  "1639": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and relevant additional explanation, and contains no inaccuracies or omissions."
  },
  "1640": {
    "score": 5.0,
    "explanation": "5: Fully identifies the correct class (Rho kinase inhibitor), explains the mechanism, and correctly matches the drug to the description; all content is accurate and clinically relevant with no omissions or errors."
  },
  "1641": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies tetracyclines as the pharmacological class and provides accurate clinical reasoning, but it omits the broader class \"protein synthesis inhibitors\" as in the reference, which is a minor omission."
  },
  "1642": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the drug class (glucocorticoids), the molecular mechanism (cytoplasmic receptor binding, nuclear translocation, gene transcription alteration), and provides relevant, correct additional details without inaccuracies or omissions."
  },
  "1643": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the antibiotic and its mechanism (inhibition of transpeptidase/penicillin-binding proteins), and provides relevant, accurate additional explanation without any errors or omissions."
  },
  "1644": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the mechanism as inhibition of cell wall synthesis via transpeptidase inhibition, and provides relevant, accurate elaboration without any errors or omissions."
  },
  "1645": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies inhaled muscarinic antagonists (anticholinergics), explains their mechanism, clinical use, and provides relevant examples, fully covering all key facts in the reference answer without inaccuracies or omissions."
  },
  "1646": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies cyclophosphamide and its mechanism (alkylation/cross-linking of DNA), and provides clinically relevant, accurate elaboration without any errors or omissions."
  },
  "1647": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes chelation and its purpose, and provides relevant clinical context without inaccuracies or omissions."
  },
  "1648": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies adenosine, specifies its action on adenosine (A1) receptors (a type of GPCR) on cardiac cells, and accurately describes the mechanism and class of biological target, fully covering all key facts in the reference answer with relevant, accurate detail."
  },
  "1649": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the pharmacologic class and mechanism, and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "1650": {
    "score": 2.0,
    "explanation": "2: The model answer identifies the correct drug (diethylcarbamazine) and its mechanism but fails to name the drug class \"cyclooxygenase inhibitors\" as required by the question and reference; instead, it focuses on the specific drug and its chemical class, omitting the key fact about cyclooxygenase inhibition."
  },
  "1651": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies \"androgen receptor agonists\" as the pharmacologic class, fully explains the mechanism, and provides accurate, clinically relevant elaboration without any errors or omissions."
  },
  "1652": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the mechanism (inhibition of bacterial protein synthesis), and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "1653": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the thyroid hormone receptor as the molecular target, thoroughly explains the mechanism, provides relevant historical context, and contains no inaccuracies or omissions."
  },
  "1654": {
    "score": 5.0,
    "explanation": "5: Fully covers all key clinical facts from the reference, accurately describes the drug class and mechanism, and provides relevant, correct additional detail without any errors or omissions."
  },
  "1655": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the mechanism as inhibition of bacterial cell wall synthesis via binding to transpeptidases, and provides relevant, accurate elaboration without any errors or omissions."
  },
  "1656": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, adds correct and relevant details (examples, receptor subtype, pathophysiology, and symptom relief), and contains no inaccuracies or omissions."
  },
  "1657": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and accurate explanation of corticosteroid action via phospholipase A2 inhibition, but it does not directly identify the \"lipoxygenase pathway\" as the most directly responsible for leukotriene reduction, as required by the question and reference answer. It covers most key facts but misses the directness of the lipoxygenase pathway's role."
  },
  "1658": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the mechanism of action, and provides relevant clinical context without any inaccuracies or omissions."
  },
  "1659": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies iron metabolism as the directly affected process and discusses relevant monitoring, but it omits the key reference point about electrolyte activity and neuronal/muscular excitability, which is central to the reference answer."
  },
  "1660": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts in the reference, correctly identifies phospholipase A₂ as the key enzyme inhibited by corticosteroids, and provides accurate, relevant mechanistic detail without inaccuracies or omissions."
  },
  "1661": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the 5-HT2A serotonin receptor as the molecular target, provides accurate and clinically relevant explanation about pimavanserin, and contains no inaccuracies or omissions."
  },
  "1662": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the drug class and mechanism, and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "1663": {
    "score": 4.0,
    "explanation": "4: The answer correctly identifies the principal pharmacodynamic effect as antioxidant activity and reduction of oxidative stress, with accurate mechanistic details, but does not explicitly mention disruption of disulfide bonds, which is a key fact in the reference answer."
  },
  "1664": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the antibiotic class, details its binding to the 30S ribosomal subunit, explains disruption of protein synthesis, and describes the resulting bactericidal effect, fully covering all key clinical facts with relevant, accurate elaboration."
  },
  "1665": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately identifies the pharmacologic class, and provides a detailed, correct, and clinically relevant explanation of the mechanism without any inaccuracies or omissions."
  },
  "1666": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies dopamine D2 receptors as the principal target, explains the rationale for drug choice in porphyria, and provides relevant, accurate extra information without any errors or omissions."
  },
  "1667": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key clinical facts and provides accurate, relevant extra detail about the mechanism and differential antibiotics, but the final answer specifies \"tetracyclines\" rather than the broader class \"protein synthesis inhibitors\" as in the reference; this is a minor wording inaccuracy that does not alter the clinical meaning."
  },
  "1668": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the mechanism as inhibition of bacterial transpeptidases (penicillin-binding proteins), and provides additional relevant and accurate explanation without any inaccuracies or omissions."
  },
  "1669": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the viral protease as the target, explains the mechanism in detail, and adds accurate, clinically relevant information without any inaccuracies or omissions."
  },
  "1670": {
    "score": 3.0,
    "explanation": "3: The model answer provides a thorough and accurate explanation of vitamin A’s role in photopigment regeneration and night vision, but it does not directly identify \"free radical scavenging activity (antioxidant effect)\" as the mechanism, which is the key fact in the reference answer; instead, it emphasizes the photopigment pathway, covering about 70-89% of the required content."
  },
  "1671": {
    "score": 5.0,
    "explanation": "5: Fully covers all key facts—identifies the class as alpha-adrenergic agonists, explains the mechanism, and provides relevant examples; no inaccuracies or omissions."
  },
  "1672": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies carbamazepine as the likely drug and explains its induction of CYP2C9, which is relevant to warfarin metabolism, but it omits CYP2C19, the specific enzyme asked for in the reference answer, and instead emphasizes CYP2C9 and CYP3A4, missing the key fact."
  },
  "1673": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the clinical scenario, the specific factor deficiency, and the mechanism of action, but does not explicitly use the reference's required general pharmacological class term \"enzyme activators,\" instead focusing on \"recombinant clotting factor replacement\" and \"procoagulant biologic.\" This constitutes a minor omission in terminology, covering most but not all key facts."
  },
  "1674": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies β-tubulin as the principal target, and provides accurate, relevant additional detail without any inaccuracies or omissions."
  },
  "1675": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies sodium channel blockade as the principal mechanism, accurately describes lidocaine’s state-dependent binding, and provides clinically relevant, factually correct elaboration without any inaccuracies or omissions."
  },
  "1676": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies interferon-alpha and thoroughly explains its mechanism, but it does not use the reference class term \"Biological Response Modifiers\" and instead focuses on \"cytokine receptor agonist\" and \"interferon,\" which are accurate but less encompassing. This represents a moderate omission of the key classification term required by the question."
  },
  "1677": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies cyclooxygenase as the inhibited enzyme class, and provides relevant, accurate additional explanation without any errors or omissions."
  },
  "1678": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explaining that the mixture acts by altering the local acid-base environment (pH) to disrupt viral replication, with additional correct and relevant mechanistic detail and no inaccuracies or omissions."
  },
  "1679": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies PABA utilization in folate synthesis, details the enzyme and drug class, and accurately explains the downstream effects on nucleotide synthesis and bacterial viability, with no inaccuracies or omissions."
  },
  "1680": {
    "score": 3.0,
    "explanation": "3: The model answer provides a plausible mechanistic classification (\"keratolytic agent\") and explains the general action of salicylates, but it does not directly state that the specific cellular or molecular mechanism is unknown, as required by the reference. It covers most key facts but omits the explicit acknowledgment of the mechanism being unknown."
  },
  "1681": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers all key clinical facts, correctly identifies chelation as the relevant pharmacological property, and provides accurate, clinically relevant elaboration without any inaccuracies or omissions."
  },
  "1682": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the mechanism as inhibition of bacterial protein synthesis, and provides additional accurate and relevant clinical context without any inaccuracies or omissions."
  },
  "1683": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies voltage-gated sodium channels as the molecular target, provides accurate and clinically relevant explanation, and includes additional correct context without any inaccuracies or omissions."
  },
  "1684": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies corticosteroids as the class, accurately describes their intracellular receptor-mediated mechanism, and provides relevant, factually correct elaboration without any inaccuracies or omissions."
  },
  "1685": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies 5-lipoxygenase as the enzyme inhibited and provides a clear, relevant explanation, but it omits the broader enzyme class term \"lipoxygenase inhibitors\" used in the reference, which is a minor wording inaccuracy."
  },
  "1686": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the specific class (beta-lactam antibiotics) and provides relevant examples, but it omits the broader pharmacological class \"enzyme inhibitors\" as specified in the reference answer, covering about 70-89% of key facts."
  },
  "1687": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the supplement, summarizes proposed but unproven mechanisms, and clearly states that the precise molecular mechanism is unknown, fully aligning with the reference answer and adding clinically relevant detail without inaccuracies."
  },
  "1688": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies the glucocorticoid receptor as the molecular target, provides accurate and relevant explanation, and contains no errors or omissions."
  },
  "1689": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies DNA gyrase as a fluoroquinolone target and provides relevant clinical context, but omits that topoisomerase IV is the principal enzyme responsible for decatenation of daughter chromosomes, which is the key fact in the reference answer."
  },
  "1690": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describing enzyme interactions and modulation of mitochondrial energy metabolism, and provides additional correct and clinically relevant details without inaccuracies or omissions."
  },
  "1691": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and accurate mechanistic explanation (anaplerotic action, substrate provision) but does not explicitly state the general pharmacological action as \"biological macromolecular activity,\" missing the key general category required by the reference answer."
  },
  "1692": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies beta-adrenergic agonists as the drug class, accurately explains their mechanism, and provides relevant examples without any inaccuracies or omissions."
  },
  "1693": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key facts (cholinomimetic agents, acetylcholinesterase inhibitors, increased acetylcholine, detrusor contraction), and provides additional correct, relevant detail. However, it introduces direct muscarinic agonists as an alternative, which, while accurate, slightly diverges from the reference's focus on acetylcholinesterase inhibitors, constituting a minor wording inaccuracy."
  },
  "1694": {
    "score": 2.0,
    "explanation": "2: The model answer correctly identifies corticosteroids and their inhibition of phospholipase A2 (a hydrolase), but fails to mention lipoxygenase inhibitors, which is the specific enzyme class referenced in the question and reference answer. This represents a moderate factual omission."
  },
  "1695": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the pharmacological mechanism as enzyme activation within the coagulation cascade, and provides correct, relevant additional detail without inaccuracies or omissions."
  },
  "1696": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the mechanism as cofactor replacement, and provides relevant, correct elaboration without any inaccuracies or omissions."
  },
  "1697": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies nafcillin, details its mechanism as irreversible inhibition of transpeptidases (penicillin-binding proteins), and explains the effect on peptidoglycan cross-linking, fully covering all key clinical facts with accurate and relevant elaboration."
  },
  "1698": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the key property—high echogenicity/acoustic impedance mismatch of the microbubbles—as responsible for ultrasound contrast enhancement, fully covering all reference points with accurate and clinically relevant detail."
  },
  "1699": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the drug and its mechanism (dopamine reuptake inhibition via DAT), and provides relevant, accurate clinical context without any inaccuracies or omissions."
  },
  "1700": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies antithrombin III as the molecular target, thoroughly explains the mechanism, and provides relevant clinical context without any inaccuracies or omissions."
  },
  "1701": {
    "score": 5.0,
    "explanation": "5: Fully covers all key clinical facts, correctly identifies sodium channel blockade as the mechanism, and provides relevant, accurate elaboration without any errors or omissions."
  },
  "1702": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies inhibition of cell wall synthesis via transpeptidases (PBPs), and provides additional accurate, relevant detail without any errors or omissions."
  },
  "1703": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides additional correct and clinically relevant mechanistic detail, and contains no inaccuracies or omissions."
  },
  "1704": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, accurately describes the mechanism (inhibition of mast cell degranulation via blockade of calcium influx), and provides relevant, correct additional explanation without any inaccuracies or omissions."
  },
  "1705": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies thyroid hormone receptor agonism as the mechanism, and provides additional accurate and relevant explanation without any inaccuracies or omissions."
  },
  "1706": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the primary molecular target, thoroughly explains the clinical scenario, pathophysiology, and treatment rationale, and contains no inaccuracies or omissions compared to the reference."
  },
  "1707": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies alpha-1 adrenergic receptor blockade as the mechanism, thoroughly explains the clinical reasoning, and provides relevant, accurate additional context without any errors or omissions."
  },
  "1708": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the drug as a growth hormone receptor agonist, and accurately explains the mechanism, including IGF-1 production and effects on bone growth, with no inaccuracies or omissions."
  },
  "1709": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the pharmacologic class as cytochrome P450 3A inhibitors, and provides accurate, relevant additional detail without any inaccuracies or omissions."
  },
  "1710": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that the precise mechanism is unknown, and provides correct, relevant context about sodium oxybate’s proposed actions without inaccuracies or omissions."
  },
  "1711": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies bedaquiline, accurately describes its mechanism, and classifies it as an ATP synthase inhibitor, which is a specific type of enzyme inhibitor; however, it does not explicitly use the broader term \"enzyme inhibitor\" as in the reference, representing a minor omission in generalization."
  },
  "1712": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the general pharmacologic mechanism as inhibition of bacterial protein synthesis, provides accurate and clinically relevant details about the drug class, target, and mechanism, and contains no inaccuracies or omissions."
  },
  "1713": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key facts from the reference, accurately describes the incomplete understanding of ibutilide’s mechanism, and provides correct, clinically relevant details without inaccuracies or omissions."
  },
  "1714": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies imiquimod, its mechanism via TLR7 activation, cytokine induction (including interferons), and the resulting immune-mediated clearance of HPV-infected cells, with no inaccuracies or omissions."
  },
  "1715": {
    "score": 3.0,
    "explanation": "3: The model answer provides a thorough clinical explanation and correctly identifies interferon-alpha and its signaling via the JAK-STAT pathway, but it does not mention RNA replicase enzymes, which is the specific class referenced in the reference answer. Thus, it covers about 70-89% of key facts but misses the precise molecular target required."
  },
  "1716": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies insulin receptor agonists as the drug class, accurately explains the mechanism, and distinguishes from other injectables; all key clinical facts are covered with no inaccuracies or omissions."
  },
  "1717": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies ethambutol, details its mechanism (inhibition of arabinosyl transferase and arabinogalactan synthesis), and provides relevant, accurate clinical context without any inaccuracies or omissions."
  },
  "1718": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the enzyme (transpeptidase/PBP), the drug class (beta-lactam), and the precise molecular mechanism, with no inaccuracies or omissions."
  },
  "1719": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, explicitly states the mechanism is not fully elucidated, and provides additional correct and clinically relevant details about pentoxifylline’s actions and uncertainties in erectile tissue, with no inaccuracies or omissions."
  },
  "1720": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the drug class and mechanism, and provides additional accurate, relevant details without any inaccuracies or omissions."
  },
  "1721": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the molecular mechanism as increased hydrolysis of glycogen within lysosomes due to enzyme replacement, fully aligning with the reference answer and including all key clinical and mechanistic details without inaccuracies or omissions."
  },
  "1722": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly identifying endothelial injury as the central pharmacological property, and provides accurate, relevant elaboration without any inaccuracies or omissions."
  },
  "1723": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the mechanism of action, and provides relevant clinical context without any inaccuracies or omissions."
  },
  "1724": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the alkylating and DNA crosslinking mechanism, and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "1725": {
    "score": 2.0,
    "explanation": "2: The model answer focuses on chloride channel activation and increased intestinal fluid secretion, which is not the key property described in the reference (stool bulking activity). While factually correct for certain IBS agents, it omits the main mechanism relevant to the scenario and introduces moderate factual error regarding the agent’s primary action."
  },
  "1726": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the mechanism (increased stool water content and mass), and provides relevant clinical context without inaccuracies or omissions."
  },
  "1727": {
    "score": 2.0,
    "explanation": "2: The model answer correctly explains corticosteroid action and the role of phospholipase A₂, but it fails to identify lipoxygenase as the principal enzyme whose inhibition leads to reduced leukotriene synthesis, as specified in the reference answer. This represents a moderate factual omission."
  },
  "1728": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly assumes the drug is a calcineurin inhibitor, providing an in-depth but irrelevant mechanism, while the reference states the mechanism of clioquinol is unknown; this is a moderate factual error and covers less than 70% of key facts."
  },
  "1729": {
    "score": 3.0,
    "explanation": "3: The model answer correctly describes the mechanism of action and classifies the antibiotic as a cell wall synthesis inhibitor/β-lactam, but it does not explicitly state \"enzyme inhibitor\" as required by the reference answer, missing the key fact that the primary mechanism is enzyme inhibition."
  },
  "1730": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the Na⁺-Cl⁻ cotransporter (NCC) in the distal convoluted tubule as the primary target, covers all key facts, and provides clinically relevant, accurate additional information without any errors or omissions."
  },
  "1731": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately identifies CYP450-mediated metabolism as the mechanism, and provides relevant, correct elaboration without inaccuracies or omissions."
  },
  "1732": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies beta-adrenergic agonists as the drug class, explains the mechanism, and relates it to the clinical scenario, but omits the specific reference to beta2-agonists as in the reference answer; otherwise, it is accurate and clinically relevant."
  },
  "1733": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the mechanism (binding to the 50S subunit and inhibiting protein synthesis), and provides relevant, correct additional details without any inaccuracies or omissions."
  },
  "1734": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies PPAR-α activation as the primary pathway, provides accurate and clinically relevant mechanistic details, and contains no inaccuracies or omissions."
  },
  "1735": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies transpeptidases/penicillin-binding proteins, and provides accurate, relevant explanation with no errors or omissions."
  },
  "1736": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the receptor as an intracellular (cytoplasmic) steroid hormone receptor, a nuclear receptor, and accurately describes its mechanism, but does not explicitly name the \"glucocorticoid receptor\" as in the reference answer, which is a minor omission."
  },
  "1737": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the drug class and mechanism, and provides additional correct and relevant details without any inaccuracies or omissions."
  },
  "1738": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the enzyme (dihydropteroate synthase), the substrate (PABA), and the mechanism (competitive inhibition), with additional accurate and relevant explanation. No inaccuracies or omissions."
  },
  "1739": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies nitrate vasodilators (organic nitrates) as the pharmacologic class, explains their mechanism (NO donation, cGMP increase, smooth muscle relaxation), and relates this to the clinical scenario without inaccuracies or omissions."
  },
  "1740": {
    "score": 3.0,
    "explanation": "3: The model answer correctly explains that corticosteroids reduce leukotriene-mediated inflammation by inhibiting phospholipase A2, but it does not identify \"lipoxygenase inhibitors\" as the direct pharmacological class, missing the specific key fact required by the question."
  },
  "1741": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies transpeptidase (penicillin-binding protein) as the molecular target, thoroughly explains the mechanism, and includes only factually accurate and clinically relevant information with no omissions or inaccuracies."
  },
  "1742": {
    "score": 2.0,
    "explanation": "2: The model answer focuses on NF-κB pathway components rather than interleukin-6 antagonists, omitting the specific cytokine target required by the question. While the mechanistic explanation is relevant, it does not directly identify the class specified in the reference, constituting a moderate omission."
  },
  "1743": {
    "score": 5.0,
    "explanation": "5: Fully correct; all key facts from the reference are included, with accurate and clinically relevant elaboration on aminoglycosides, their mechanism, and clinical use."
  },
  "1744": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies IVIG, and accurately explains its mechanism of antigen neutralization via inactivation of autoantibodies and immune complexes, with additional relevant details and no inaccuracies."
  },
  "1745": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies glucocorticoid receptor activation as the pathway, and provides accurate, relevant mechanistic detail without inaccuracies or omissions."
  },
  "1746": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies lipoxygenase inhibitors as the class, explains the relevant enzyme pathways, and distinguishes them from COX inhibitors and corticosteroids, fully covering all key clinical facts without inaccuracies or omissions."
  },
  "1747": {
    "score": 4.0,
    "explanation": "4: The answer correctly identifies the mechanism and provides relevant clinical context, but the final drug class given is \"NSAIDs\" rather than the more specific \"cyclooxygenase inhibitors\" as in the reference; this is a minor wording inaccuracy that does not alter the clinical meaning."
  },
  "1748": {
    "score": 3.0,
    "explanation": "3: The model answer correctly explains corticosteroid action and identifies phospholipase A2 as the inhibited enzyme, but fails to name lipoxygenase, which is specifically asked for in the question and reference; this is a moderate omission."
  },
  "1749": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the general class as melatonin receptor agonists and provides accurate, relevant explanation, but does not explicitly use the broader term \"hormone receptor agonists\" as in the reference, representing a minor omission in generalization."
  },
  "1750": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies glucocorticoid receptor agonism as the mechanism, thoroughly explains the receptor-mediated action, and provides relevant clinical context without inaccuracies or omissions."
  },
  "1751": {
    "score": 5.0,
    "explanation": "5: Fully covers all key facts from the reference answer, accurately describes the mechanism, clinical context, and provides relevant examples; no inaccuracies or omissions."
  },
  "1752": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the mechanism of MCT absorption, and provides relevant additional detail without inaccuracies or omissions."
  },
  "1753": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describing anti-D immunoglobulin binding to fetal RhD-positive erythrocytes and preventing maternal alloimmunization, with additional correct and relevant mechanistic detail."
  },
  "1754": {
    "score": 5.0,
    "explanation": "5: Thoroughly covers all key clinical facts—phosphate binding/chelation in the GI tract, non-absorbable nature, mechanism of reducing absorption, and excretion in feces—with accurate, relevant elaboration and no inaccuracies or omissions."
  },
  "1755": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the mechanism (inhibition of cell wall synthesis via penicillin-binding proteins), and provides relevant, correct elaboration without any inaccuracies or omissions."
  },
  "1756": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies glutamine, details its role as a nitrogen source, and accurately explains its primary mechanism via mTOR pathway activation, covering all key clinical facts and providing relevant, accurate elaboration without errors or omissions."
  },
  "1757": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the role of vitamin C as a cofactor for hydroxylase enzymes in collagen synthesis, and clearly explains the restored molecular process and its clinical relevance, with no inaccuracies or omissions."
  },
  "1758": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately identifies antioxidant/free radical scavenging as the mechanism, and provides additional correct and clinically relevant details without any inaccuracies or omissions."
  },
  "1759": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the histamine H2 receptor as the direct target, provides accurate and clinically relevant explanation, and contains no inaccuracies or omissions."
  },
  "1760": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies drotrecogin alfa (activated protein C), details its mechanism as proteolytic inactivation of factors Va and VIIIa, and explains its anti-inflammatory effects, fully covering all key clinical facts in the reference answer with accurate and relevant elaboration."
  },
  "1761": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the receptor class (intracellular steroid hormone/nuclear/glucocorticoid receptor), and provides relevant, accurate mechanistic detail without any inaccuracies or omissions."
  },
  "1762": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the molecular mechanism (disruption of bacterial cell membranes), and provides relevant clinical context without any inaccuracies or omissions."
  },
  "1763": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the mechanism (binding to 30S subunit and inhibition of protein synthesis), and provides relevant, correct additional context without any inaccuracies or omissions."
  },
  "1764": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies metal chelation as the key pharmacological property, explains the mechanism, and relates it to the clinical context without inaccuracies or omissions."
  },
  "1765": {
    "score": 3.0,
    "explanation": "3: The model answer provides a thorough and accurate explanation of vancomycin’s mechanism of action, but the reference answer specifically states that the precise molecular mechanism of metronidazole (not vancomycin) in this context is unclear. The model answer focuses on vancomycin, which is not the drug referenced in the question, resulting in a moderate factual error and omission of the key point."
  },
  "1766": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies voltage-gated sodium channels as the direct neurophysiological target, provides accurate and clinically relevant explanation, and contains no inaccuracies or omissions."
  },
  "1767": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies lanosterol 14-α-demethylase as the directly inhibited enzyme, provides accurate alternative names, and clearly explains the mechanism, matching all key clinical facts in the reference without errors or omissions."
  },
  "1768": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the 5-HT₂C (serotonin 2C) receptor as the target, thoroughly explains the mechanism, and provides relevant clinical context without any inaccuracies or omissions."
  },
  "1769": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the pharmacologic class (antimuscarinic agents/anticholinergics), accurately explains the mechanism, and provides relevant examples without any inaccuracies or omissions."
  },
  "1770": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies viral DNA polymerase as the molecular target, explains the mechanism of action, and provides relevant clinical context without any inaccuracies or omissions."
  },
  "1771": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies transpeptidases (penicillin-binding proteins) as the principal target, provides accurate and clinically relevant explanation, and includes only correct, relevant extra content without any inaccuracies or omissions."
  },
  "1772": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the nuclear vitamin D receptor as the primary molecular target, provides accurate and clinically relevant mechanistic detail, and contains no inaccuracies or omissions."
  },
  "1773": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the molecular mechanism, and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "1774": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the mechanism (enzyme inhibition of transpeptidases), and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "1775": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies transpeptidase (a penicillin-binding protein) as the direct molecular target, fully explains the mechanism, and contains no inaccuracies or omissions."
  },
  "1776": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and accurate explanation of the mechanism (increased presynaptic dopamine release via ion channel blockade) but does not explicitly state \"ion channel interactions\" as the pharmacological interaction, which is the key fact in the reference answer; instead, it focuses on \"indirect agonism,\" which is less precise for this question."
  },
  "1777": {
    "score": 5.0,
    "explanation": "5: The model answer accurately and thoroughly explains the mechanism, including Fc receptor blockade on splenic macrophages by anti-D–opsonized erythrocytes, and correctly relates this to reduced platelet destruction; all key facts are present with relevant, correct elaboration."
  },
  "1778": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describing the agent's adsorptive and chelating mechanism in the GI tract to prevent toxin absorption, with additional correct and relevant mechanistic detail."
  },
  "1779": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies H₁ receptor antagonists as the relevant class, accurately describes their mechanism, and provides clinically relevant context without any inaccuracies or omissions."
  },
  "1780": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the pharmacologic mechanism (alkalinization via bicarbonate generation), and provides relevant, correct additional context without any inaccuracies or omissions."
  },
  "1781": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies VEGF as the primary pathway, and provides accurate, relevant additional details about the drug and mechanisms without any inaccuracies or omissions."
  },
  "1782": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the ergosterol biosynthesis pathway as the target, explains the mechanism for both azoles and allylamines, and provides relevant, accurate, and clinically pertinent details without any inaccuracies or omissions."
  },
  "1783": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies enzyme inhibition (transpeptidases/PBPs), and provides additional accurate, clinically relevant detail without any inaccuracies or omissions."
  },
  "1784": {
    "score": 5.0,
    "explanation": "5: Fully covers all key facts from the reference answer, accurately identifies the drug class, and provides correct, clinically relevant additional explanation without any errors or omissions."
  },
  "1785": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the mechanism as inhibition of cell wall synthesis via PBPs, and provides relevant, accurate detail without any inaccuracies or omissions."
  },
  "1786": {
    "score": 4.0,
    "explanation": "4: The model answer is thorough and clinically accurate, correctly identifying colchicine and its mechanism, but the final answer lists \"microtubule\" as the principal target rather than \"tubulin\" as in the reference; this is a minor wording inaccuracy since colchicine binds tubulin to inhibit microtubule assembly, but the principal pharmacologic target is tubulin."
  },
  "1787": {
    "score": 3.0,
    "explanation": "3: The model answer covers the key point that the mechanism is incompletely understood and mentions disruption of fungal cell membrane integrity, but it incorrectly identifies the agent as undecylenic acid rather than clioquinol, which is specifically referenced in the question and reference answer. This constitutes a moderate factual error."
  },
  "1788": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the molecular mechanism, and provides relevant, correct additional detail about osmotic water shifts and cerebral edema reversal, with no inaccuracies or omissions."
  },
  "1789": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies transpeptidase (penicillin-binding protein) as the target, and provides relevant, accurate clinical context without any inaccuracies or omissions."
  },
  "1790": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the CGRP receptor as the primary molecular target, provides accurate clinical context, and includes only relevant, factually correct information without any omissions or inaccuracies."
  },
  "1791": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies DNA gyrase (topoisomerase II) as the direct molecular target, explains the mechanism, and provides relevant context without inaccuracies or omissions."
  },
  "1792": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies bacterial topoisomerase IV as the molecular target, explains the drug class, mechanism, and clinical relevance, with no inaccuracies or omissions."
  },
  "1793": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies TNF-α inhibition via receptor blockade as the molecular mechanism, names adalimumab, and provides accurate, clinically relevant detail without any inaccuracies or omissions."
  },
  "1794": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and accurate clinical explanation and correctly identifies the recombinant therapy as a procoagulant agent and recombinant coagulation factor, but it does not explicitly use the term \"enzyme activators,\" which is the required general pharmacological class per the reference answer. The mechanistic explanation is correct, but the key terminology is missing."
  },
  "1795": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the osmotic mechanism, and provides relevant, correct additional context without any inaccuracies or omissions."
  },
  "1796": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the drug and its mechanism, and provides relevant, accurate additional details without any inaccuracies or omissions."
  },
  "1797": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key facts, correctly identifies tolnaftate as the agent with an unknown mechanism, and provides relevant, accurate context without any inaccuracies or omissions."
  },
  "1798": {
    "score": 3.0,
    "explanation": "3: The answer correctly identifies demeclocycline (a tetracycline) and explains its use in SIADH, but it does not state the drug class mechanism as \"protein synthesis inhibitors,\" which is the key fact in the reference answer; instead, it focuses on the downstream effect on cAMP and aquaporin-2, omitting the fundamental mechanism of protein synthesis inhibition."
  },
  "1799": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describing adsorption as the primary mechanism and providing correct, relevant additional detail without any inaccuracies or omissions."
  },
  "1800": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies DNA methyltransferase inhibitors as the drug class, fully explains the clinical context, mechanism, and provides relevant examples, with no inaccuracies or omissions."
  },
  "1801": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describing progestin action via progesterone receptor activation and its antagonism of estrogen-driven proliferation, with additional correct and relevant mechanistic detail."
  },
  "1802": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the organism, drug, and its mechanism (inhibition of the electron transport chain via PFOR), but fails to use the key term \"uncouplers\" as required by the reference answer, instead describing the mechanism in detail; this constitutes a significant omission of the specific class name requested."
  },
  "1803": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies nuclear receptors as the broad class of biological targets, provides accurate and clinically relevant context, and contains no inaccuracies or omissions."
  },
  "1804": {
    "score": 4.0,
    "explanation": "4: The model answer correctly explains that povidone-iodine acts via nonspecific cytotoxicity without a well-defined molecular target, matching the reference answer's key point. The extra detail is accurate and relevant, but the answer could be more concise and directly state \"unknown cellular or molecular interaction\" as the most accurate term, representing a minor wording inaccuracy."
  },
  "1805": {
    "score": 4.0,
    "explanation": "4: The model answer correctly explains the mechanism (COX inhibition) and clinical context, but does not explicitly use the term \"cyclooxygenase inhibitors\" as the class of drug action, instead focusing on \"enzyme inhibition\" and NSAIDs; this is a minor wording inaccuracy."
  },
  "1806": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the pharmacological action as free radical scavenging/antioxidant activity, and provides relevant, accurate elaboration without any inaccuracies or omissions."
  },
  "1807": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies adamantanes as M2 protein inhibitors, explains their mechanism, specificity for influenza A, and clinical limitations, covering all key facts in the reference answer with accurate and relevant additional details."
  },
  "1808": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies alpha-2 adrenergic receptors as the relevant GPCR subtype and explains their role in increasing aqueous outflow, but it omits that the reference answer specifies \"adrenergic beta2-agonist\" as the correct class, which is a key fact; the model also provides some extraneous but accurate information."
  },
  "1809": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the direct molecular target, thoroughly explains the mechanism of action, and provides relevant clinical context without any inaccuracies or omissions."
  },
  "1810": {
    "score": 3.0,
    "explanation": "3: The answer correctly identifies μ-opioid receptor agonism (codeine) but also emphasizes NMDA antagonism (dextromethorphan), which is not the reference mechanism; this introduces some inaccuracy and distracts from the key fact that the reference answer requires—μ-opioid receptor agonism."
  },
  "1811": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describing heparin’s mechanism via antithrombin activation leading to thrombin inhibition, with no inaccuracies or omissions."
  },
  "1812": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the molecular mechanism (enzyme cofactor role), and provides clinically relevant, correct elaboration without inaccuracies or omissions."
  },
  "1813": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers all key facts from the reference, accurately describes beta1-adrenergic antagonism as the mechanism, and provides additional correct and clinically relevant details without any inaccuracies or omissions."
  },
  "1814": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the therapy as silver-containing dressings, accurately summarizes the incomplete understanding of its mechanism, and details the known cellular targets, fully covering all key facts in the reference without inaccuracies or omissions."
  },
  "1815": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the drug class (peptide hormone/protein), mechanism, and provides relevant clinical context without inaccuracies or omissions."
  },
  "1816": {
    "score": 3.0,
    "explanation": "3: The model answer accurately describes vitamin A’s role in phototransduction and epithelial maintenance, but it omits the reference answer’s key mechanism—antioxidant (free radical scavenging) activity—thus missing the specific molecular protection cited in the reference."
  },
  "1817": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the pharmacologic class and mechanism, and provides relevant, correct additional detail about symptom improvement and examples, with no inaccuracies or omissions."
  },
  "1818": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies CYP3A4 inhibition by a macrolide, and provides relevant, accurate, and clinically pertinent explanations without any inaccuracies or omissions."
  },
  "1819": {
    "score": 5.0,
    "explanation": "5: Fully covers all key clinical facts from the reference, accurately describing modulation of extracellular matrix and cartilage metabolism, with additional correct and relevant mechanistic details; no inaccuracies or omissions."
  },
  "1820": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies mitotane, accurately describes its clinical use, and clearly states that its precise cellular or molecular target is unknown, matching all key facts in the reference without inaccuracies or omissions."
  },
  "1821": {
    "score": 5.0,
    "explanation": "5: Fully covers all key clinical facts from the reference answer, accurately describes the mechanism, names the drug class, and provides relevant examples without any inaccuracies or omissions."
  },
  "1822": {
    "score": 5.0,
    "explanation": "5: The model answer accurately covers all key clinical facts from the reference, clearly explaining neutralization via spike protein binding and prevention of viral entry, with no omissions or inaccuracies."
  },
  "1823": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies GABA B receptors as the relevant class, explains the clinical context, mechanism of action, and provides only factually correct and clinically relevant additional information with no inaccuracies or omissions."
  },
  "1824": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the drug class as opioid (receptor) antagonists, explains the mechanism, and provides relevant clinical context without inaccuracies or omissions."
  },
  "1825": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers all key facts from the reference (alkylation and cross-linking of DNA), accurately describes the molecular mechanism, and provides clinically relevant additional detail without any inaccuracies or omissions."
  },
  "1826": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the mechanism (restoring lysosomal α-glucosidase activity for glycogen degradation), and provides additional correct, clinically relevant details without any inaccuracies or omissions."
  },
  "1827": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies 5-lipoxygenase inhibitors as the relevant enzyme class, covers all key facts from the reference, and provides accurate, clinically relevant explanations without any inaccuracies or omissions."
  },
  "1828": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies inhibition of PABA utilization in folic acid synthesis, and provides additional accurate, relevant detail without any inaccuracies or omissions."
  },
  "1829": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies glycoprotein IIb/IIIa receptor inhibition as the mechanism, names relevant drugs, and accurately explains the receptor's role in platelet aggregation, matching all key clinical facts in the reference without errors or omissions."
  },
  "1830": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies bacterial transpeptidase (penicillin-binding protein) as the molecular target, explains the mechanism, and provides relevant clinical context without inaccuracies or omissions."
  },
  "1831": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies transpeptidase enzymes (penicillin-binding proteins) as the primary molecular target, provides accurate and relevant clinical context, and contains no inaccuracies or omissions."
  },
  "1832": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies \"enzyme inhibitors\" as the pharmacological class, explains the mechanism, and provides relevant clinical context without inaccuracies or omissions."
  },
  "1833": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies \"lanosterol 14-α-demethylase\" as the enzyme, provides accurate and clinically relevant explanation, and includes a helpful summary table without any inaccuracies or omissions."
  },
  "1834": {
    "score": 3.0,
    "explanation": "3: The model answer correctly explains the anti-inflammatory mechanism of glucocorticoids (phospholipase A2 inhibition) but does not identify \"lipoxygenase inhibitors\" as the class specifically asked for in the question, missing the key fact required by the reference answer."
  },
  "1835": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies dopamine receptor antagonists as the drug class, whereas the reference specifies dopamine agonists and direct stimulation of dopamine receptors; this is a moderate factual error, though the explanation is otherwise relevant and accurate for typical Tourette's treatment."
  },
  "1836": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies agonism of progesterone receptors as the mechanism, accurately describes nuclear receptor binding and downstream effects (decidualization, atrophy), and links these to symptom relief, with no inaccuracies or omissions."
  },
  "1837": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies transpeptidases (penicillin-binding proteins) as the enzyme class inhibited, provides accurate and relevant additional explanation, and contains no inaccuracies or omissions."
  },
  "1838": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies glucocorticoid receptors, and provides accurate, relevant explanations without any inaccuracies or omissions."
  },
  "1839": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies GABA-A receptors as the relevant receptor class, explains the clinical context, discusses the mechanism of action for both benzodiazepines and valproic acid, and provides accurate, clinically relevant details with no inaccuracies or omissions."
  },
  "1840": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies the pharmacologic class as alpha-2 adrenergic agonists, accurately describes the mechanism, and provides relevant examples without any errors or omissions."
  },
  "1841": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies the enzyme target as lanosterol 14-α-demethylase (target of azoles) rather than squalene monooxygenase, and thus does not address the reference answer's key fact; while the clinical reasoning is sound, the main mechanism and enzyme class are not correctly matched, constituting a moderate factual error."
  },
  "1842": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the mechanism of recombinant factor VIII, and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "1843": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the chemical mechanism, and explicitly states that the precise molecular target is not fully defined, with no inaccuracies or omissions."
  },
  "1844": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies prostaglandin receptor agonism as the primary mechanism, explains the role of PGE₁, and accurately describes the molecular pathway (EP receptor activation, cAMP increase, smooth muscle relaxation) with no inaccuracies or omissions."
  },
  "1845": {
    "score": 5.0,
    "explanation": "5: The model answer accurately and thoroughly explains the key mechanism—neutralization of viral particles by antibody binding to the spike protein—and adds correct, clinically relevant detail about blocking viral entry, with no inaccuracies or omissions."
  },
  "1846": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies NS3/4A protease inhibitors and P-glycoprotein as most relevant, omitting the key fact that velpatasvir (an NS5A inhibitor) inhibits BCRP, not P-gp; this is a moderate factual error and misses the principal transporter and drug class specified in the reference."
  },
  "1847": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides additional correct and clinically relevant details (such as effects on remodeling and mortality), and contains no inaccuracies or omissions."
  },
  "1848": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the V2 receptor as the primary target, explains the mechanism of action, and provides relevant clinical context without any inaccuracies or omissions."
  },
  "1849": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the pharmacologic class (sympathomimetic amines) and the mechanism (increased norepinephrine release in the hypothalamus suppressing appetite), covering over 90% of key facts. However, it emphasizes β-adrenergic rather than alpha-adrenergic receptors, which is a minor inaccuracy in receptor specificity but does not alter the overall clinical meaning."
  },
  "1850": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the intracellular nuclear hormone receptor pathway and explains the mechanism, but it equivocates between estrogen and progesterone receptors rather than specifying \"progestational hormone receptor agonists\" as in the reference. This represents a minor omission in specificity, but the overall explanation is accurate and clinically relevant."
  },
  "1851": {
    "score": 4.0,
    "explanation": "4: The model answer correctly explains that the therapy degrades TTR mRNA via RNA interference, matching the reference, and provides accurate, relevant detail. However, it emphasizes disruption of \"translation\" rather than directly stating \"degradation of TTR mRNA\" as the primary disrupted process, which is a minor wording inaccuracy."
  },
  "1852": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key clinical facts and provides accurate, relevant extra detail about the antibiotic class and mechanism, but does not explicitly use the general term \"enzyme inhibitors\" as in the reference answer, which is a minor wording inaccuracy."
  },
  "1853": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describing increased tear film stability and retention time, and provides additional correct, clinically relevant details without inaccuracies or omissions."
  },
  "1854": {
    "score": 5.0,
    "explanation": "5: Fully covers all key facts from the reference answer, correctly identifies the drug class and mechanism, and provides additional accurate, relevant clinical context without any inaccuracies or omissions."
  },
  "1855": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the clinical scenario, mechanism of action, and specifies \"macrolide antibiotic,\" which is a correct and more specific subclass of \"protein synthesis inhibitors.\" However, it does not explicitly state the broader class \"protein synthesis inhibitors\" as in the reference, representing a minor omission."
  },
  "1856": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid (corticosteroid hormone) receptor as the relevant class, accurately describes its intracellular/nuclear location and mechanism, and provides clinically relevant, factually correct elaboration without any inaccuracies or omissions."
  },
  "1857": {
    "score": 3.0,
    "explanation": "3: The model answer provides a plausible and widely cited mechanism (Nrf2 pathway activation) but does not align with the reference answer, which emphasizes that the precise molecular mechanism is unknown; thus, the model omits the key fact that the mechanism is not fully elucidated and overstates current consensus."
  },
  "1858": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the drug class, mechanism, and clinical context, and provides relevant, accurate additional information without any errors or omissions."
  },
  "1859": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies transpeptidase inhibition as the drug action, and provides accurate, relevant additional detail without any inaccuracies or omissions."
  },
  "1860": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the drug as dopamine (or possibly epinephrine), details its adrenergic receptor agonism, and explains the GPCR/cAMP pathway, but omits explicit mention of dopamine receptor agonism, which is a minor omission compared to the reference."
  },
  "1861": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the lack of clear mechanistic understanding, and provides relevant, correct context without inaccuracies or omissions."
  },
  "1862": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies transpeptidases/penicillin-binding proteins as the target, with accurate and relevant explanation; no omissions or inaccuracies."
  },
  "1863": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies transcriptional activation (transcription factor activity) as the key process, accurately explains the JAK-STAT pathway, and provides relevant clinical context without any inaccuracies or omissions."
  },
  "1864": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and accurate description of radioactive iodine's uptake and general cytotoxic mechanism (DNA damage via beta emission), but it goes beyond the reference, which emphasizes that the precise cellular or molecular interaction is unknown; thus, the model overstates the certainty of the mechanism and does not fully align with the reference's emphasis on the unknown details."
  },
  "1865": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the drug class, enzyme, substrate analog, and mechanism, with additional relevant and accurate clinical context and no inaccuracies or omissions."
  },
  "1866": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the class as immunomodulators (specifically interferon alpha), and provides accurate, relevant explanations without any inaccuracies or omissions."
  },
  "1867": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the drug class and mechanism, and provides additional accurate, relevant detail without any errors or omissions."
  },
  "1868": {
    "score": 3.0,
    "explanation": "3: The model answer correctly explains the downstream effect (upregulation of LDL receptors) and mentions statins inhibit HMG-CoA reductase, but it does not explicitly state that the main molecular mechanism is inhibition of HMG-CoA reductase, as required by the reference answer."
  },
  "1869": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately identifies the drug class and mechanism, and provides relevant, correct additional details without any inaccuracies or omissions."
  },
  "1870": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the class as cap-dependent endonuclease inhibitors, explains the mechanism, and specifically mentions inhibition of the viral polymerase acidic (PA) protein’s endonuclease activity, fully matching the reference answer with no errors or omissions."
  },
  "1871": {
    "score": 3.0,
    "explanation": "3: The model answer covers the mechanism of nucleic acid synthesis inhibition and correctly identifies quinidine/quinine as relevant, but it introduces significant ambiguity by discussing multiple drug classes, overemphasizes secondary mechanisms, and includes some inaccuracies (e.g., overstates DNA intercalation as the primary effect), which may confuse the core answer."
  },
  "1872": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the drug class and mechanism, and provides additional accurate, relevant detail without any inaccuracies or omissions."
  },
  "1873": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describing the molecular mechanism as agonism of the thyroid hormone receptor, and provides additional correct and clinically relevant detail without any inaccuracies or omissions."
  },
  "1874": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the pharmacologic class as an aldosterone (mineralocorticoid) antagonist, covers all key clinical facts, and provides relevant, accurate additional details without any errors or omissions."
  },
  "1875": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the molecular process (interaction with nuclear receptors to modulate gene expression), and provides additional correct and relevant mechanistic details without any inaccuracies or omissions."
  },
  "1876": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies pyrantel pamoate and its action as a nicotinic acetylcholine receptor agonist causing persistent depolarization and spastic paralysis, but it omits the key reference fact that the mechanism in question is cholinesterase inhibition, not direct nAChR agonism."
  },
  "1877": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the pharmacological principle (enzyme interactions/substitution), and provides relevant, correct additional detail without inaccuracies or omissions."
  },
  "1878": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the target as enzymes (transpeptidases/penicillin-binding proteins), and provides relevant, accurate elaboration without any errors or omissions."
  },
  "1879": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the primary mediator, thoroughly explains the clinical context, mechanism of action, and provides relevant, accurate extra details without any errors or omissions."
  },
  "1880": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key facts from the reference (bisphosphonates, localization to bone, inhibition of osteoclast-mediated resorption) and adds correct, relevant molecular detail, but slightly overemphasizes the specific molecular pathway (FPP synthase inhibition), which, while accurate for nitrogen-containing bisphosphonates, is not strictly required by the reference answer. No clinically significant omissions or inaccuracies."
  },
  "1881": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the general mechanism (inhibition of bacterial protein synthesis), and provides correct, relevant elaboration without any inaccuracies or omissions."
  },
  "1882": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the molecular mechanism, and adds correct, clinically relevant details about mannose-6-phosphate–mediated uptake and lysosomal targeting, with no inaccuracies or omissions."
  },
  "1883": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately details the molecular mechanism (binding to 50S subunit, blocking translocation, inhibiting protein synthesis), and provides relevant, correct clinical context without any inaccuracies or omissions."
  },
  "1884": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes dopamine D2 receptor antagonism as the primary mechanism, and provides relevant, correct additional context without any inaccuracies or omissions."
  },
  "1885": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the molecular mechanism (antibody-mediated inhibition of VEGF-A), and provides relevant clinical context without any inaccuracies or omissions."
  },
  "1886": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the mechanism (dopamine agonist acting on D1 receptors) and provides the general class as \"sympathomimetic agent (dopamine receptor agonist)\" and \"adrenergic/dopaminergic agonist,\" which is accurate but slightly less direct than \"adrenergic agonist\" alone; minor wording variation but no clinically significant omissions."
  },
  "1887": {
    "score": 2.0,
    "explanation": "2: The model answer correctly identifies the clinical scenario and the use of triclabendazole, but it incorrectly specifies CYP1A2 instead of CYP2B6 and focuses on competitive inhibition rather than the specific CYP2B6 inhibition asked in the reference. This represents a moderate factual error and covers only part of the key facts."
  },
  "1888": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies cytochrome P450 enzymes and describes the induction mechanism, but it overgeneralizes by emphasizing CYP3A4 (not specifically implicated for benzimidazoles) and does not specify CYP1A as the most relevant subtype, missing a key detail from the reference answer."
  },
  "1889": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the prostacyclin (IP) receptor as the molecular target, provides accurate and clinically relevant explanation, and contains no inaccuracies or omissions compared to the reference answer."
  },
  "1890": {
    "score": 5.0,
    "explanation": "5: Fully covers all key facts—identifies glucocorticoid receptor agonism, details intracellular/nuclear receptor mechanism, gene transcription modulation, and clinical relevance; no inaccuracies or omissions."
  },
  "1891": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies neuraminidase inhibitors as the relevant class, explains their mechanism of action, and provides accurate examples, fully covering all key clinical facts without errors or omissions."
  },
  "1892": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the clinical scenario, the next-line agent (fidaxomicin), and its mechanism (RNA polymerase inhibition), but does not explicitly use the broader drug class term \"Nucleic Acid Synthesis Inhibitors\" as in the reference answer; this is a minor wording inaccuracy."
  },
  "1893": {
    "score": 4.0,
    "explanation": "4: The model answer covers over 90% of the key facts, accurately stating that the precise mechanism is unknown but providing correct, relevant details about central action and possible serotonergic involvement; there are no major omissions or inaccuracies, though some mechanistic specifics (e.g., \"inhibiting both gamma and alpha motor neurons\") are somewhat speculative and could be considered a minor wording inaccuracy."
  },
  "1894": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies lanosterol 14α-demethylase (CYP51A) as the target, explains its role in ergosterol synthesis, and describes how inhibition disrupts membrane integrity; all key facts are covered with relevant, accurate elaboration."
  },
  "1895": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies inhibition of translocation during protein synthesis at the 50S ribosomal subunit, provides accurate mechanistic detail, and includes only relevant, factually correct explanations with no omissions or inaccuracies."
  },
  "1896": {
    "score": 3.0,
    "explanation": "3: The answer correctly identifies opioid receptor agonists and μ-receptor activation as the main mechanism, but introduces dextromethorphan, which is not a full opioid agonist and acts via different receptors, potentially causing confusion and a minor inaccuracy relative to the reference."
  },
  "1897": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the molecular mechanism (restoration of β-glucocerebrosidase activity to degrade accumulated substrate), and provides additional correct and clinically relevant details without any inaccuracies or omissions."
  },
  "1898": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the medication class and mechanism, and provides relevant, correct additional details and examples without any inaccuracies or omissions."
  },
  "1899": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describing endothelial injury as the primary mechanism and providing additional correct, clinically relevant detail about the downstream processes leading to vessel obliteration."
  },
  "1900": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies sodium channel inhibition as the key mechanism, omitting the reference answer's focus on calcium channel interactions, which are more directly involved in neurotransmitter release modulation; while some correct context is provided, the main pharmacological interaction is misidentified."
  },
  "1901": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies cytochrome P450 enzymes as the induced class and mentions CYP3A4, but omits the specific reference to CYP1A inducers, which is the key fact in the reference answer. The explanation is otherwise accurate and relevant."
  },
  "1902": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the L-type calcium channel as the molecular target, and provides relevant, accurate clinical context without any inaccuracies or omissions."
  },
  "1903": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies anti-VEGF agents as the class, accurately explains the mechanism, and provides relevant examples without any inaccuracies or omissions."
  },
  "1904": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key facts from the reference, clearly stating that the precise mechanism is unknown, while providing accurate, relevant context about witch hazel and its proposed effects without introducing inaccuracies or irrelevant content."
  },
  "1905": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies niacin deficiency, its biochemical role, and the clinical context, but does not explicitly use the term \"enzyme activators\" as the pharmacological class, which is the key fact required; instead, it provides related but less precise terminology."
  },
  "1906": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the enzymatic mechanism of asparaginase, and provides relevant clinical context without any inaccuracies or omissions."
  },
  "1907": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the mechanism and specifies \"tetracyclines,\" which is a more specific subclass within the broader \"protein synthesis inhibitors.\" There is a minor omission in not explicitly stating the broader class as requested, but the answer is otherwise accurate and relevant."
  },
  "1908": {
    "score": 5.0,
    "explanation": "5: Fully covers all key facts from the reference, accurately describing the pharmacologic class as a protein synthesis inhibitor (macrolide) and specifying the 50S ribosomal subunit mechanism; all additional explanation is correct and clinically relevant."
  },
  "1909": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies isoniazid, details its activation by KatG, inhibition of enoyl-ACP reductase (InhA), and the resulting block in mycolic acid synthesis, with no inaccuracies or omissions."
  },
  "1910": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies DNA gyrase (bacterial topoisomerase II) as the primary molecular target, covers all key clinical facts, and provides accurate, relevant additional explanation without any inaccuracies or omissions."
  },
  "1911": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the mechanism as direct disruption of bacterial cell membranes, explains the physiochemical (not metabolic or nucleic acid-based) nature of the action, and provides relevant, accurate detail without any errors or omissions."
  },
  "1912": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the GnRH receptor as the target, explains the mechanism of action (agonist, desensitization with continuous use), and provides relevant details about the receptor pathway; all content is accurate and clinically relevant with no omissions."
  },
  "1913": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the mechanism (agonism of estrogen receptors), and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "1914": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the mechanism (ergosterol synthesis inhibition via azoles), specifies the enzyme, and provides relevant examples without inaccuracies or omissions."
  },
  "1915": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies cytochrome P450 1A2 (CYP1A2) as the inhibited enzyme class, covers all key clinical facts, and provides relevant, accurate additional context without any inaccuracies or omissions."
  },
  "1916": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies ergosterol as the main target, thoroughly explains the clinical context, mechanism of action, and distinguishes from other antifungal targets, with no inaccuracies or omissions."
  },
  "1917": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the glucocorticoid (corticosteroid) receptor as the relevant intracellular/nuclear receptor and accurately describes its mechanism, but does not explicitly use the term \"corticosteroid hormone receptors\" as in the reference; this is a minor wording inaccuracy."
  },
  "1918": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately identifies the drug class and mechanism, and provides additional correct and relevant details without any inaccuracies or omissions."
  },
  "1919": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the direct molecular target, thoroughly explains the clinical scenario, and accurately describes the mechanism of action without any inaccuracies or omissions."
  },
  "1920": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, accurately explains the mechanism of action (disruption of cell membrane integrity via cationic interaction), and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "1921": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies blockade of voltage-gated sodium channels as the mechanism, provides accurate and clinically relevant detail, and contains no inaccuracies or omissions."
  },
  "1922": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and accurate explanation of the presumed mechanism of chloroquine, but it does not directly state that the mechanism is \"unknown\" or \"not fully elucidated\" as required by the reference answer, thus missing the key fact that the precise cellular or molecular interaction is unknown."
  },
  "1923": {
    "score": 5.0,
    "explanation": "5: Fully covers all key facts, correctly identifies the class as protein synthesis inhibitors, and provides accurate, relevant detail about the aminoglycoside mechanism without any errors or omissions."
  },
  "1924": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies DNA gyrase as the primary target, provides accurate and relevant explanation, and contains no inaccuracies or omissions."
  },
  "1925": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the key pharmacological property (formation of a protective barrier/demulcent activity) and provides accurate, relevant details about bismuth subsalicylate and sucralfate, but does not explicitly use the term \"demulcent activity\" as in the reference; this is a minor wording omission."
  },
  "1926": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies hepatic cytochrome P450 enzyme induction as the relevant property, and provides accurate, clinically relevant explanations without any inaccuracies or omissions."
  },
  "1927": {
    "score": 5.0,
    "explanation": "5: Fully covers all key clinical facts from the reference answer, correctly identifies muscarinic receptor antagonism as the drug action, and provides relevant, accurate explanations without any errors or omissions."
  },
  "1928": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the Na⁺/Cl⁻ cotransporter (NCC) as the primary molecular target, specifies its location, and provides accurate, relevant explanation without any errors or omissions."
  },
  "1929": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies statins (HMG-CoA reductase inhibitors) as the drug class, accurately explains the mechanism of action, and matches all key clinical facts from the reference answer without any errors or omissions."
  },
  "1930": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the mechanism (inhibition of transpeptidases/PBPs), and provides additional correct and relevant detail without any inaccuracies or omissions."
  },
  "1931": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key facts from the reference, correctly identifies the drug class and mechanism, and provides additional accurate, clinically relevant details without any inaccuracies or omissions."
  },
  "1932": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies antimuscarinic agents (anticholinergics) as the drug class, explains the mechanism, provides relevant examples, and includes only accurate, clinically relevant information with no omissions or inaccuracies."
  },
  "1933": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies insulin/insulin preparations as the class, explains the mechanism, and provides relevant supporting details without inaccuracies or omissions."
  },
  "1934": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the histamine H1 receptor as the molecular target, thoroughly explains the clinical context, mechanism, and rationale, and contains no inaccuracies or omissions."
  },
  "1935": {
    "score": 3.0,
    "explanation": "3: The model answer provides a correct diagnosis and a detailed, accurate explanation of the mechanism of PDE3 inhibitors, but it does not identify the reference answer's drug class (alpha-adrenergic antagonists) or their mechanism (alpha-receptor blockade), thus missing a key fact. The explanation is otherwise thorough and free of unsafe statements."
  },
  "1936": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the molecular mechanism (restoration of factor VIII activity to activate the coagulation cascade), and provides additional correct and relevant clinical context without any inaccuracies or omissions."
  },
  "1937": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the molecular mechanism, and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "1938": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and accurate description of povidone-iodine’s general antimicrobial actions but does not explicitly state that the mechanism is \"unknown\" or \"not fully established\" as required; instead, it suggests a partially understood mechanism, thus missing the key fact emphasized in the reference."
  },
  "1939": {
    "score": 4.0,
    "explanation": "4: The model answer correctly states that the precise molecular mechanism is not fully elucidated in pharmacology texts, matching the reference. It adds relevant, accurate context about possible non-specific effects and mechanical cleansing, which is factually correct and clinically relevant. There are no inaccuracies, but the answer could be slightly more concise in directly stating \"unknown mechanism\" as in the reference."
  },
  "1940": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the mechanism, site of action, and transporter involved, and provides relevant additional information without any inaccuracies or omissions."
  },
  "1941": {
    "score": 3.0,
    "explanation": "3: The model answer identifies DNA gyrase (topoisomerase II) as the primary target, but the reference specifies topoisomerase IV, which is the main target in Streptococcus pneumoniae; while the model mentions both enzymes, it incorrectly emphasizes DNA gyrase, resulting in a moderate factual inaccuracy."
  },
  "1942": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the pharmacological class as serine protease inhibitors, and provides accurate, relevant clinical context without any inaccuracies or omissions."
  },
  "1943": {
    "score": 5.0,
    "explanation": "5: Fully covers all key clinical facts, correctly identifies increased oncotic pressure as the mechanism, and provides relevant, accurate explanation without errors or omissions."
  },
  "1944": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies transpeptidases (penicillin-binding proteins) as the direct molecular targets, matches all key facts from the reference, and provides accurate, clinically relevant additional explanation without any errors or omissions."
  },
  "1945": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies povidone-iodine, accurately describes its general antimicrobial mechanism, and clearly states that the precise antiviral mechanism in ocular infections is not fully defined, matching all key points in the reference answer."
  },
  "1946": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies inhibition of TNF-α binding to its receptor as the key molecular interaction, provides accurate supporting rationale, and includes only relevant, factually correct details without omissions or inaccuracies."
  },
  "1947": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the diagnosis, explains the mechanism as enzyme activation within the coagulation cascade, and provides relevant, accurate additional details without any inaccuracies or omissions."
  },
  "1948": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the drug class as direct thrombin inhibitors, explains their mechanism, provides relevant examples, and distinguishes them from other anticoagulant classes, with no inaccuracies or omissions."
  },
  "1949": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the insulin receptor as a tyrosine kinase receptor, explains the clinical scenario, mechanism of action, and links the molecular target to the clinical effects, covering all key facts with no inaccuracies or omissions."
  },
  "1950": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the drug and its mechanism (competitive inhibition of PABA incorporation into folate synthesis), and provides additional relevant, accurate, and clinically useful context without any inaccuracies or omissions."
  },
  "1951": {
    "score": 4.0,
    "explanation": "4: The model answer correctly states that the precise target is unknown and provides accurate, relevant mechanistic context about reductive activation and radical formation, with only a minor addition beyond the reference; no clinically significant omissions or inaccuracies are present."
  },
  "1952": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key facts from the reference, accurately describes the molecular mechanism (VEGF antagonism via antibody binding), and provides additional clinically relevant detail without any inaccuracies or omissions."
  },
  "1953": {
    "score": 3.0,
    "explanation": "3: The model answer correctly explains the glucocorticoid mechanism (PLA2 inhibition via lipocortin), but omits the specific reference answer's focus on direct inhibition of the lipoxygenase pathway; it covers most key facts but misses the precise molecular target asked."
  },
  "1954": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies protein synthesis inhibition as the mechanism, accurately explains ciclopirox’s action, and provides relevant comparisons to other antifungals without inaccuracies or omissions."
  },
  "1955": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the mechanism as inhibition of cell wall synthesis and details the action on PBPs, but does not explicitly use the term \"enzyme inhibitors\" as in the reference; otherwise, it is accurate and thorough."
  },
  "1956": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies rifamycins, their mechanism (inhibition of bacterial DNA-dependent RNA polymerase), and their clinical use, but does not explicitly use the broader class term \"nucleic acid synthesis inhibitors\" as in the reference; this is a minor omission."
  },
  "1957": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies inhibition of topoisomerase IV (and DNA gyrase) as the mechanism, fully explains the clinical context, and provides accurate, relevant details without any errors or omissions."
  },
  "1958": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies deferasirox as the chelator, CYP1A2 as the inhibited enzyme, and clearly explains the clinical pharmacology and relevance of drug-drug interactions, with no omissions or inaccuracies."
  },
  "1959": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies H1 receptor antagonism as the mechanism, and provides relevant, accurate additional explanation without any inaccuracies or omissions."
  },
  "1960": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the molecular mechanism, and provides additional correct and clinically relevant context without any inaccuracies or omissions."
  },
  "1961": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the mechanism (inhibition of bacterial transpeptidase), and provides additional correct and relevant detail without any inaccuracies or omissions."
  },
  "1962": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the clinical syndrome and the general mechanism of enhancing inhibitory neurotransmission, but incorrectly specifies the GABA_A receptor instead of the GABA_B receptor, which is the primary target of sodium oxybate; this is a moderate factual error."
  },
  "1963": {
    "score": 4.0,
    "explanation": "4: The model answer correctly states that the precise mechanism is unknown, matching the reference, and provides accurate, relevant details about thalidomide’s general immunomodulatory actions; however, it could be more concise and places slightly more emphasis on possible mechanisms than the reference, which simply states the mechanism is unknown."
  },
  "1964": {
    "score": 5.0,
    "explanation": "5: All key facts from the reference answer are included, with correct and clinically relevant additional details about the drugs, mechanism, and distinction from other therapies; no inaccuracies or omissions."
  },
  "1965": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the key pharmacological property as antioxidant (free radical scavenging) activity via glutathione replenishment, but is somewhat verbose and introduces minor ambiguity by discussing multiple possible agents and mechanisms; however, it covers ≥90% of key facts with no clinically significant errors."
  },
  "1966": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the drug class (nAChR agonists/pyrantel pamoate) and accurately describes the molecular mechanism (persistent activation of nAChRs causing spastic paralysis), but it does not mention cholinesterase inhibitors as in the reference; this is a minor omission since pyrantel pamoate is the clinically relevant agent, but the reference's mechanism is not directly addressed."
  },
  "1967": {
    "score": 5.0,
    "explanation": "5: Fully covers all key facts—identifies penicillin-binding protein as the target, explains its role in transpeptidation and peptidoglycan synthesis, and describes the mechanism of inhibition; all additional details are accurate and clinically relevant."
  },
  "1968": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the mechanism as inhibition of bacterial protein synthesis, and provides accurate, relevant elaboration without any inaccuracies or omissions."
  },
  "1969": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the NNRTI class and its mechanism, and provides relevant, correct additional details and examples without any inaccuracies or omissions."
  },
  "1970": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies ACTH and its mechanism but does not explicitly state \"pituitary hormone receptor agonist\" as the pharmacological class, missing the key reference terminology; otherwise, the explanation is accurate and relevant."
  },
  "1971": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "1972": {
    "score": 3.0,
    "explanation": "3: The model answer accurately describes metronidazole’s general mechanism and its activation in anaerobic environments, but it fails to directly state that the exact molecular or cellular interactions responsible for its effectiveness in deep tissue abscesses are unknown, as required by the reference answer."
  },
  "1973": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the drug class as long-acting β2-adrenergic agonists, explains the mechanism, clinical use, and provides examples, fully covering all key facts in the reference answer with no inaccuracies or omissions."
  },
  "1974": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "1975": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies cyclooxygenase (COX) inhibition as the targeted pathway, and provides additional accurate and clinically relevant context without any inaccuracies or omissions."
  },
  "1976": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies serotonin receptor modulation (primarily antagonism at 5-HT2A/2C) as the key mechanism, covering over 90% of the reference content, but adds some unnecessary speculation about specific drugs and includes minor extraneous details that do not alter the core meaning."
  },
  "1977": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies viral DNA polymerase as the primary target, provides accurate and clinically relevant explanation, and contains no inaccuracies or omissions."
  },
  "1978": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the mechanism as mast cell stabilization, explains the inhibition of mediator release, and relates it to type I hypersensitivity; all additional details are accurate and clinically relevant."
  },
  "1979": {
    "score": 5.0,
    "explanation": "5: Thoroughly explains the physiochemical (absorption and dissipation) mechanism, covers all key facts, and provides clinically relevant detail without inaccuracies or omissions."
  },
  "1980": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies muscarinic M3 cholinergic receptors as the pharmacologic target and provides a clinically relevant explanation without inaccuracies or omissions."
  },
  "1981": {
    "score": 3.0,
    "explanation": "3: The model answer covers the majority of key facts, correctly identifying cyclobenzaprine and its central action, but goes beyond the reference by detailing possible neurotransmitter involvement and specific CNS sites, which are speculative and not established; the reference emphasizes that the mechanism is unknown, so the model overstates current understanding, representing a minor inaccuracy."
  },
  "1982": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describing the osmotic mechanism, the movement of water, and the reduction of cellular edema, with all additional details being correct and clinically relevant."
  },
  "1983": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts in the reference, accurately explains the primary molecular mechanism (restoration of methylmalonyl-CoA mutase activity and myelin synthesis), and provides additional correct and clinically relevant details without inaccuracies or omissions."
  },
  "1984": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the mechanism (transpeptidase inhibition via PBPs), and provides relevant, correct additional context without any inaccuracies or omissions."
  },
  "1985": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the mechanism (inhibition of purine synthesis in lymphocytes), and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "1986": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the molecular mechanism, and adds correct, clinically relevant details about receptor-mediated uptake and lysosomal delivery without any inaccuracies or omissions."
  },
  "1987": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the drug class, mechanism, and clinical relevance, with no inaccuracies or omissions."
  },
  "1988": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies β-tubulin as the molecular target, fully explains the mechanism, and provides relevant clinical context without any inaccuracies or omissions."
  },
  "1989": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional explanation, and contains no inaccuracies or omissions."
  },
  "1990": {
    "score": 5.0,
    "explanation": "5: Fully covers the key fact that the mechanism is unknown, and any additional content is accurate, relevant, and does not introduce errors or omissions."
  },
  "1991": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies sulfonamides as PABA analogs, details their competitive inhibition of dihydropteroate synthase, and accurately describes the molecular class of action without any inaccuracies or omissions."
  },
  "1992": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the inhibition of cyclooxygenase (COX) enzymes, and provides additional correct and relevant mechanistic details without any inaccuracies or omissions."
  },
  "1993": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the molecular mechanism (antagonism of presynaptic voltage-gated calcium channels), and provides relevant, correct additional context without any inaccuracies or omissions."
  },
  "1994": {
    "score": 4.0,
    "explanation": "4: The model answer correctly states that the precise molecular target is unknown and provides additional, factually accurate and clinically relevant mechanisms that are widely cited as possible actions of gold compounds; there are no inaccuracies, but the reference answer is more concise, and the model's extra details, while correct, slightly exceed the minimal requirement."
  },
  "1995": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies FXR as the primary molecular target instead of PPAR-delta, which is specified in the reference answer; while the mechanistic explanation is accurate for FXR agonists in PBC, this represents a moderate factual error regarding the agent in question."
  },
  "1996": {
    "score": 5.0,
    "explanation": "5: Fully covers all key facts, correctly identifies the general class as protein synthesis inhibition, and provides accurate, relevant mechanistic detail without any inaccuracies or omissions."
  },
  "1997": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes selective beta-1 antagonism as the mechanism, and provides correct, relevant elaboration without any inaccuracies or omissions."
  },
  "1998": {
    "score": 5.0,
    "explanation": "5: Fully covers all key facts from the reference answer, correctly identifies the pharmacologic class as serotonin (5-HT2) receptor antagonist, and provides relevant, accurate clinical context without any inaccuracies or omissions."
  },
  "1999": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the disease and treatment, thoroughly explains the glucocorticoid receptor pathway, and provides relevant mechanistic detail without inaccuracies or omissions."
  },
  "2000": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the histamine H1 receptor as the molecular target, thoroughly explains the reasoning, and includes only factually accurate and clinically relevant information without any omissions or inaccuracies."
  },
  "2001": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional explanation, and contains no inaccuracies or omissions."
  },
  "2002": {
    "score": 5.0,
    "explanation": "5: Fully covers all key facts from the reference answer, accurately names the pharmacological class, describes the mechanism, and provides clinically relevant additional explanation without any inaccuracies or omissions."
  },
  "2003": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the primary pathway, explains the mechanism of gene transcription modulation, and provides relevant, accurate extra detail without any inaccuracies or omissions."
  },
  "2004": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor, thoroughly explains the clinical context, mechanism of action, and contrasts with dapsone, with all content factually accurate and clinically relevant."
  },
  "2005": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the drug class, mechanism, and clinical context, with additional accurate and relevant details; there are no inaccuracies or omissions."
  },
  "2006": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately identifies the drug class and mechanism, and provides additional correct and clinically relevant details without any inaccuracies or omissions."
  },
  "2007": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the pharmacologic class as anticholinergic (antimuscarinic) agents, accurately explains the mechanism, and provides relevant examples, fully covering all key clinical facts without errors or omissions."
  },
  "2008": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies selenium sulfide and its mechanism, and provides relevant, accurate additional context without any inaccuracies or omissions."
  },
  "2009": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies enzyme inhibition as the pharmacological principle, accurately describes the mechanism involving hormone-sensitive lipase, and links this to improved lipid profiles, fully covering all key clinical facts in the reference answer without inaccuracies or omissions."
  },
  "2010": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies beta-lactam antibiotics as the relevant class and accurately explains their mechanism, covering over 90% of the key facts. However, it does not explicitly use the broader term \"enzyme inhibitors\" as in the reference, which is a minor omission in generalization."
  },
  "2011": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies GnRH antagonists as the relevant class and accurately explains their mechanism and clinical effect, but introduces GnRH agonists as an alternative, which is not supported by the question's focus on a novel oral agent; this constitutes a minor inaccuracy in wording."
  },
  "2012": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the physiochemical mechanism (disruption of cell membrane integrity), and provides accurate, relevant additional detail without inaccuracies or omissions."
  },
  "2013": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies CYP3A4 as the enzyme inhibited, provides accurate and clinically relevant details about avacopan, and explains the clinical consequence without any inaccuracies or omissions."
  },
  "2014": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the mechanism (inhibition of protein synthesis via 30S ribosomal subunit blockade), and provides relevant, correct additional context without any inaccuracies or omissions."
  },
  "2015": {
    "score": 5.0,
    "explanation": "5: Fully covers all key clinical facts from the reference answer, including the correct pharmacological class, mechanism, clinical context, and relevant examples, with no inaccuracies or omissions."
  },
  "2016": {
    "score": 3.0,
    "explanation": "3: The model answer correctly explains the mechanism of ammonia trapping via acidification but omits the key pharmacologic property asked for—osmotic activity—focusing instead on acidification; thus, it covers about 70-89% of key facts but misses the primary property specified in the question."
  },
  "2017": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately identifies the drug class and mechanism, and provides additional correct and relevant molecular detail without any inaccuracies or omissions."
  },
  "2018": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describing the direct restoration of serum phosphate via absorption of bioavailable phosphate ions, with relevant and correct additional detail and no inaccuracies."
  },
  "2019": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the molecular mechanism (potentiation of GABA_A receptor activity), and provides additional correct and clinically relevant details without any inaccuracies or omissions."
  },
  "2020": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies viral DNA polymerase as the direct molecular target, thoroughly explains the drug’s mechanism, and provides relevant clinical context without any inaccuracies or omissions."
  },
  "2021": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies antithrombin III as the molecular target and provides a thorough, accurate explanation, but it does not explicitly state that thrombin is the primary factor inactivated for the antithrombotic effect, which is a minor omission compared to the reference."
  },
  "2022": {
    "score": 2.0,
    "explanation": "2: The model answer identifies interferons, which are a type of biological response modifier, but does not explicitly name the broader class as required by the reference answer. It provides some relevant mechanistic detail but omits the key fact that the class is \"biological response modifiers,\" and focuses too narrowly on interferons, which are not standard therapy for neovascular AMD."
  },
  "2023": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies β-1,3-D-glucan synthase as the molecular target, explains the mechanism, and provides relevant additional context about echinocandins and their action, with no inaccuracies or omissions."
  },
  "2024": {
    "score": 5.0,
    "explanation": "5: Fully covers all key facts from the reference, correctly identifies the drug class as antimuscarinic/anticholinergic, accurately describes central muscarinic receptor inhibition, and clearly explains the mechanism of symptom relief; all additional details are correct and clinically relevant."
  },
  "2025": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies vancomycin, its pharmacological class (glycopeptide antibiotic), and its mechanism of action as a cell wall synthesis inhibitor, but does not explicitly use the term \"enzyme inhibitors\" as in the reference answer, which is a minor wording inaccuracy."
  },
  "2026": {
    "score": 3.0,
    "explanation": "3: The answer correctly identifies the drug (albendazole), its mechanism, and its pharmacological class (benzimidazoles/anthelmintics), but does not explicitly state \"enzyme inhibitors\" as required by the reference; thus, it covers most but not all key facts."
  },
  "2027": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key facts from the reference, correctly identifies the uncertainty of the mechanism, and provides clinically relevant, accurate additional detail about povidone-iodine without introducing errors or irrelevant content."
  },
  "2028": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies cyclooxygenase (COX) as the molecular target, explains the mechanism, and provides relevant context without inaccuracies or omissions."
  },
  "2029": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies CYP3A4 as the key enzyme, explains the mechanism, and relates it to warfarin and drug interactions; all content is accurate and clinically relevant."
  },
  "2030": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies CaSR as the target, explains the mechanism, and provides relevant clinical context; all content is accurate and clinically pertinent with no omissions or errors."
  },
  "2031": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies cinacalcet, details its action on CaSR, and accurately explains the downstream Gq/11-PLC-IP₃/DAG pathway leading to reduced PTH secretion; all additional content is factually correct and clinically relevant."
  },
  "2032": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key facts from the reference, accurately states that the precise mechanism is not fully understood, and provides clinically relevant, correct additional detail about cyclosporine’s proposed podocyte effects without introducing inaccuracies."
  },
  "2033": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies glatiramer acetate and thoroughly explains its mechanism, but it does not use the reference term \"immunologic adjuvant\" and instead uses \"immunomodulator,\" which is less specific; this represents a minor but meaningful omission in terminology."
  },
  "2034": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the mechanism (inhibition of protein synthesis via 30S binding), and provides correct, relevant additional details without any inaccuracies or omissions."
  },
  "2035": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describing local binding to mucosal surfaces to form a protective barrier, and provides additional correct and clinically relevant mechanistic detail without any inaccuracies or omissions."
  },
  "2036": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the enzymatic cofactor role of vitamin C in collagen synthesis, and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "2037": {
    "score": 3.0,
    "explanation": "3: The model answer correctly explains that corticosteroids inhibit phospholipase A2, reducing arachidonic acid-derived mediators, but it does not identify lipoxygenase inhibitors as the class most directly responsible per the reference; thus, it covers the mechanism but not the specific key fact required."
  },
  "2038": {
    "score": 5.0,
    "explanation": "5: Fully covers all key facts (PBPs/transpeptidases as the direct target), provides correct and clinically relevant extra detail, and contains no inaccuracies or omissions."
  },
  "2039": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the mechanism (blockade of fast voltage-gated sodium channels), and provides relevant, correct additional context without any inaccuracies or omissions."
  },
  "2040": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies glucocorticoids as the drug class, and accurately describes their mechanism as agonism of intracellular (glucocorticoid) receptors leading to altered gene transcription; all additional details are factually correct and clinically relevant."
  },
  "2041": {
    "score": 3.0,
    "explanation": "3: The answer provides a thorough explanation of the mechanism and clinical context, but the final class given is \"cholinergic (muscarinic) agonists\" or \"cholinomimetics,\" which is broader and not as specific as \"cholinesterase inhibitors\" (the reference answer). This is a minor but important inaccuracy in wording, as the question asks for the class of the drug used, not the downstream effectors."
  },
  "2042": {
    "score": 2.0,
    "explanation": "2: The model answer identifies PDE3 inhibitors (cilostazol) rather than the reference's beta-agonists, and describes a different mechanism (PDE3 inhibition vs. beta-adrenergic stimulation), missing the key fact of the reference answer; while the explanation is detailed and correct for PDE3 inhibitors, it does not match the reference's required pharmacological class or mechanism."
  },
  "2043": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies VMAT2 inhibition as the mechanism, accurately explains the role of VMAT2, and clearly links reduced dopamine release to symptom relief in tardive dyskinesia, with all content factually correct and clinically relevant."
  },
  "2044": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explaining that magnesium restores neuromuscular stability by inhibiting presynaptic calcium channels and reducing acetylcholine release; all additional details are correct and clinically relevant."
  },
  "2045": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key facts from the reference and provides additional, accurate, and clinically relevant mechanistic detail about gabapentin’s action on α2δ subunits of voltage-gated calcium channels. The only minor issue is that it goes slightly beyond the reference’s emphasis on the mechanism being unknown, but this is not misleading or clinically unsafe."
  },
  "2046": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies muscarinic acetylcholine receptors as the target, explains their role in GI physiology, and provides relevant examples of antagonists, fully covering all key clinical facts without inaccuracies or omissions."
  },
  "2047": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies PBPs as the target, explains the mechanism in detail, and provides clinically relevant elaboration without inaccuracies or omissions."
  },
  "2048": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes corticosteroid (glucocorticoid) receptor agonism, and provides correct, clinically relevant mechanistic detail without any inaccuracies or omissions."
  },
  "2049": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the molecular mechanism, and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "2050": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies transpeptidase (penicillin-binding protein) as the molecular target, provides accurate clinical context, and includes only relevant, factually correct information with no omissions or inaccuracies."
  },
  "2051": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies CYP3A4 inhibitors and provides a detailed, accurate explanation, but it misses the key fact from the reference answer, which specifies CYP2D6 inhibitors; thus, it covers about 70-89% of the key facts but omits the specific enzyme cited in the reference."
  },
  "2052": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describing antibody–antigen binding, neutralization of the spike protein, and prevention of viral entry, with additional correct and relevant mechanistic detail and no inaccuracies or omissions."
  },
  "2053": {
    "score": 4.0,
    "explanation": "4: The model answer correctly states that the precise molecular mechanism of coal tar is not fully understood and provides accurate, relevant details about its proposed anti-proliferative and anti-inflammatory effects; however, it slightly overemphasizes speculative mechanisms (e.g., DNA synthesis suppression) that are not definitively established, but this does not alter the core meaning."
  },
  "2054": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describing phosphate supplementation as the direct pharmacological activity, with correct and relevant additional explanation; there are no inaccuracies or omissions."
  },
  "2055": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the mechanism, and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "2056": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the biological target as a cell-surface purinergic (A1) receptor, a type of GPCR, and provides accurate, clinically relevant explanation without any inaccuracies or omissions."
  },
  "2057": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately identifies echinocandins as glucan synthase inhibitors, explains their mechanism, and provides relevant clinical context without any inaccuracies or omissions."
  },
  "2058": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the mechanism (inhibition of transpeptidases/PBPs and disruption of cell wall synthesis), and adds correct, relevant details without any errors or omissions."
  },
  "2059": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies glucocorticoids as the class with a similar mechanism, rather than lipoxygenase inhibitors, and provides excessive, somewhat confusing detail; while it covers some relevant pharmacology, it omits the key fact that lipoxygenase inhibitors are the correct answer and contains a moderate factual error regarding the mechanism."
  },
  "2060": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the drug class and mechanism, and clearly explains how acid suppression promotes mucosal healing; all additional details are correct and clinically relevant."
  },
  "2061": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies glucocorticoids (corticosteroids) as the pharmacological class, accurately describes their mechanism of action, and relates this to the clinical scenario without any inaccuracies or omissions."
  },
  "2062": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies 5-lipoxygenase as the enzyme, provides accurate and clinically relevant explanation, and includes additional correct information about the drug and related pharmacology without any inaccuracies or omissions."
  },
  "2063": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies kallikreins as the target, and provides accurate, relevant clinical context without inaccuracies or omissions."
  },
  "2064": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies antimuscarinic agents as the class, accurately explains the mechanism (competitive inhibition of muscarinic acetylcholine receptors), and provides relevant examples and distinctions from other classes without any inaccuracies or omissions."
  },
  "2065": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key facts from the reference, clearly stating that the mechanism is unknown at the cellular/molecular level, and provides relevant, accurate context without introducing inaccuracies or irrelevant information."
  },
  "2066": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the pharmacological class as calcium channel blockers, accurately explains the mechanism, clinical context, and provides relevant examples, with no omissions or inaccuracies."
  },
  "2067": {
    "score": 2.0,
    "explanation": "2: The model answer provides a detailed and accurate description of the general mechanism of vitamin K (menadiol) in coagulation factor carboxylation, but it fails to emphasize that the precise cellular or molecular mechanism by which menadiol treats Factor II deficiency in this context is not clearly defined, as required by the reference answer."
  },
  "2068": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides additional accurate and clinically relevant detail (criteria for SLNB, supporting trials/guidelines), and contains no inaccuracies or omissions."
  },
  "2069": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains why concurrent chemoradiation is inappropriate in this scenario, and appropriately discusses alternative strategies without any inaccuracies or omissions."
  },
  "2070": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "2071": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that orthopedic stabilization and palliative radiotherapy are indicated based on clinical risk and not molecular subtype, with no inaccuracies or omissions."
  },
  "2072": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that SRS alone is appropriate for most patients with mild neurological symptoms, whereas the reference specifies that surgical resection is preferred in symptomatic cases; this represents a moderate factual error and a key clinical omission."
  },
  "2073": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional explanations, and contains no inaccuracies or omissions."
  },
  "2074": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "2075": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains staging, operability, and standard management, and provides relevant, correct additional details without any inaccuracies or omissions."
  },
  "2076": {
    "score": 3.0,
    "explanation": "3: The model answer provides a thorough and accurate discussion of diagnostic and staging steps, but it incorrectly states that local interventions are not routinely indicated as first-line therapy in asymptomatic patients, whereas the reference answer clearly prefers local intervention for isolated, asymptomatic endobronchial obstruction. This represents a moderate factual error regarding the preferred initial management."
  },
  "2077": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional details, and contains no inaccuracies or omissions."
  },
  "2078": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly recommends endocrine therapy alone, explains the low-risk features, and appropriately notes that chemotherapy is not indicated; additional details are accurate and clinically relevant."
  },
  "2079": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately stating that neoadjuvant therapy is not mandatory, both approaches are acceptable, and surgery first is an option in selected patients; additional content is correct, relevant, and guideline-based."
  },
  "2080": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant explanations, and contains no inaccuracies or omissions."
  },
  "2081": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional details, and contains no inaccuracies or omissions."
  },
  "2082": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including the rationale, guideline recommendations, and the specific scenario where testing may not be essential; it adds relevant detail without inaccuracies or omissions."
  },
  "2083": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that pathologic confirmation is required and imaging alone is insufficient, and provides additional, accurate, and relevant rationale without any inaccuracies or omissions."
  },
  "2084": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that T1cN0 TNBC alone is sufficient for preoperative systemic therapy without needing additional high-risk features, and provides accurate, relevant explanations and supporting guidelines with no inaccuracies or omissions."
  },
  "2085": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, including the rarity of RET fusions in squamous NSCLC, limited supporting data, and the need for multidisciplinary discussion, but it incorrectly states that RET-targeted therapy is a valid first-line option and that squamous histology does not exclude use, which overstates current standard practice and omits that such use is not standard outside clinical trials."
  },
  "2086": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains guideline recommendations, the sufficiency of non-contrast low-dose CT, and the rationale regarding CKD. Additional details about surveillance frequency and radiation are correct and clinically relevant. No inaccuracies or omissions."
  },
  "2087": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant explanations, and includes correct guideline-based rationale without any inaccuracies or omissions."
  },
  "2088": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and provides relevant, correct additional detail without any omissions or inaccuracies."
  },
  "2089": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "2090": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and provides relevant, correct additional details without any inaccuracies or omissions."
  },
  "2091": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional rationale, and contains no inaccuracies or omissions."
  },
  "2092": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately cites guidelines, and clearly explains that routine FDG-PET/CT is not indicated, with no inaccuracies or omissions."
  },
  "2093": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant explanations, cites guidelines, and contains no inaccuracies or omissions."
  },
  "2094": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant explanations, and includes guideline support without any inaccuracies or omissions."
  },
  "2095": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including osimertinib’s preference over chemotherapy for EGFR S768I mutations, its CNS efficacy, and the need for local therapy for symptomatic brain metastases; all additional content is accurate and clinically relevant."
  },
  "2096": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes standard management, exceptions, and the need for individualized assessment, with additional correct and relevant guideline-based detail and no inaccuracies."
  },
  "2097": {
    "score": 4.0,
    "explanation": "4: The model answer correctly prioritizes definitive radiotherapy over surgery in a medically inoperable stage IIIB (T3N2) NSCLC patient and explains why surgery is contraindicated, but it incorrectly suggests SABR as a preferred modality for this stage, which is not standard for N2 disease—this is a minor but clinically relevant inaccuracy."
  },
  "2098": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, cites relevant guidelines, and contains no inaccuracies or omissions."
  },
  "2099": {
    "score": 4.0,
    "explanation": "4: The model answer correctly explains that mediastinal (N2) involvement changes nodal staging and impacts perioperative therapy eligibility, but it inaccurately states that T4N2 remains stage IIIA (per AJCC 8th edition, T4N2 is still IIIA, but the reference answer upgrades to IIIB, which is a point of contention). The answer is otherwise thorough and clinically relevant, with only a minor staging discrepancy."
  },
  "2100": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides additional relevant rationale, and cites guidelines; there are no inaccuracies or omissions."
  },
  "2101": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the risks of re-irradiation, emphasizes systemic therapy as the preferred approach, and notes that re-irradiation is reserved for select cases; there are no inaccuracies or omissions."
  },
  "2102": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizes the necessity of confirmed germline BRCA mutation for olaparib use, and provides relevant context without inaccuracies or omissions."
  },
  "2103": {
    "score": 1.0,
    "explanation": "1: The model answer directly contradicts the reference by stating that radiological N3 is sufficient for stage IIIB/IIIC treatment, whereas the reference emphasizes the need for pathological confirmation before upstaging; this is a major inaccuracy with potential clinical implications."
  },
  "2104": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, and includes relevant guideline citations and examples without any inaccuracies or omissions."
  },
  "2105": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, and includes relevant supporting guidelines without any inaccuracies or omissions."
  },
  "2106": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and relevant guideline-based rationale, and contains no inaccuracies or omissions."
  },
  "2107": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, emphasizes the contraindication due to ILD, and suggests appropriate alternative strategies without any inaccuracies or omissions."
  },
  "2108": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately stating that plasma-based testing is sufficient if positive, and tissue confirmation is not inherently required; it also provides relevant, correct context about guidelines and reflex testing, with no inaccuracies or omissions."
  },
  "2109": {
    "score": 3.0,
    "explanation": "3: The model answer is well-structured and evidence-based but directly contradicts the reference answer by recommending chemotherapy as the preferred option, whereas the reference states further endocrine therapy may still be considered until options are exhausted or visceral crisis develops. This represents a moderate factual error regarding the appropriateness of further endocrine therapy, despite otherwise accurate rationale and supporting details."
  },
  "2110": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that EGFR-targeted therapy is not appropriate in the presence of a coexisting KRAS mutation, which is a moderate factual error and contradicts current guidelines; it also overstates the predictive value of KRAS mutations for resistance to EGFR inhibitors, leading to a clinically misleading recommendation."
  },
  "2111": {
    "score": 3.0,
    "explanation": "3: The model answer accurately describes the rationale for switching to an ALK inhibitor and cites guidelines, but it omits that completing the current regimen is also an acceptable option per guidelines, thus missing a key fact and overstating the exclusivity of immediate switch."
  },
  "2112": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, including the importance of considering molecular testing in never-smokers with squamous NSCLC, but it incorrectly states that testing is \"not generally necessary\" and \"not mandatory,\" which underplays current recommendations for broad molecular profiling regardless of histology or smoking status if tissue is available. This represents a moderate omission and some wording inaccuracies."
  },
  "2113": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that chest CT every 3–6 months for 3 years is appropriate, whereas guidelines recommend every 6 months for 2–3 years in this scenario; it also overstates guideline flexibility and does not clarify that more frequent imaging is for those who had radiotherapy or higher-stage disease."
  },
  "2114": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, correctly cites guidelines, and explains that both every 6 months and annually are acceptable per some sources, but it does not clearly state that every 6 months is the preferred recommendation (as in the reference), and slightly overemphasizes annual imaging as equally acceptable, which is a minor inaccuracy."
  },
  "2115": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, accurately describes the default metastatic classification, the exception for separate primaries, and the need for comprehensive evaluation, with no inaccuracies or omissions."
  },
  "2116": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant elaboration, and contains no inaccuracies or omissions."
  },
  "2117": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including the appropriateness of immunotherapy in PD-L1 positive, biomarker-negative NSCLC, and the need to prioritize local therapy for diffuse brain metastases before or with immunotherapy; it adds relevant, accurate detail without inaccuracies or omissions."
  },
  "2118": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional explanations, and contains no inaccuracies or omissions."
  },
  "2119": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, cites current guidelines, and contains no inaccuracies or omissions."
  },
  "2120": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that MET inhibitors are appropriate first-line therapy in this scenario, and provides additional correct and clinically relevant details without any inaccuracies or omissions."
  },
  "2121": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that adjuvant pembrolizumab is still indicated regardless of pCR, and provides correct, relevant supporting details without any inaccuracies or omissions."
  },
  "2122": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly emphasizes the need for orthopedic stabilization prior to radiotherapy, and provides relevant details and exceptions without inaccuracies or omissions."
  },
  "2123": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and relevant additional detail, cites guidelines, and contains no inaccuracies or omissions."
  },
  "2124": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly prioritizing adjuvant radiotherapy over re-resection in the context of poor pulmonary reserve, and provides accurate, relevant guideline-based rationale without any inaccuracies or omissions."
  },
  "2125": {
    "score": 2.0,
    "explanation": "2: The model answer covers some relevant surveillance recommendations and recurrence risk factors, but it incorrectly denies that radiotherapy as part of initial treatment is the key determinant for more intensive follow-up, which is the central point of the reference answer. This represents a moderate factual error and a significant omission regarding the role of radiotherapy in determining surveillance intensity."
  },
  "2126": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale and relevant guideline citations, and contains no inaccuracies or omissions."
  },
  "2127": {
    "score": 5.0,
    "explanation": "5: The model answer accurately covers all key clinical facts, clearly stating that preoperative systemic therapy is specifically recommended for tumors ≥1 cm (T1c), and not for tumors <1 cm, with no inaccuracies or omissions."
  },
  "2128": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including the clear prioritization of SABR over conventional fractionated radiotherapy, supporting evidence, guideline recommendations, and relevant outcome data, with no inaccuracies or omissions."
  },
  "2129": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, correctly noting that chemoradiation is preferred in clinically stable patients and stenting is reserved for severe symptoms, but it overstates chemoradiation as the initial approach and underemphasizes that stenting is often prioritized for rapid symptom relief even in stable but symptomatic patients, which is a minor but clinically relevant omission."
  },
  "2130": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and relevant additional rationale and guideline support, and contains no inaccuracies or omissions."
  },
  "2131": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional rationale, and includes no inaccuracies or omissions."
  },
  "2132": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the standard of care, the role of surgery in oligometastatic disease, and the need for multidisciplinary evaluation, with relevant, up-to-date references and no inaccuracies or omissions."
  },
  "2133": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the rationale, includes relevant guideline citations, and contains no inaccuracies or omissions."
  },
  "2134": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, includes relevant guidelines, and contains no inaccuracies or omissions."
  },
  "2135": {
    "score": 4.0,
    "explanation": "4: The model answer covers over 90% of the key facts, correctly noting that adjuvant chemo/trastuzumab is generally recommended for 0.6–1.0 cm tumors and not routinely for <0.6 cm, but can be considered in select high-risk cases. However, it slightly overstates the routine consideration for tumors just below 0.6 cm, whereas the reference emphasizes that benefit is not well established and it is not routinely recommended, making this a minor wording inaccuracy."
  },
  "2136": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the staging rationale, diagnostic work-up, and treatment implications, with no omissions or inaccuracies."
  },
  "2137": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains current guideline recommendations, and provides relevant rationale without any inaccuracies or omissions."
  },
  "2138": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "2139": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately prioritizing EBRT for immediate symptom control in severe hemoptysis and airway obstruction, and provides correct, relevant rationale without any inaccuracies or omissions."
  },
  "2140": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, adds relevant detail about exceptions (targetable mutations), and cites guidelines; there are no inaccuracies or omissions."
  },
  "2141": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies that afatinib is preferred over erlotinib for EGFR S768I mutations and provides detailed, accurate rationale, but it incorrectly states that erlotinib should not be used as first-line therapy, which contradicts the reference answer that allows erlotinib as appropriate; this represents a moderate factual inaccuracy."
  },
  "2142": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "2143": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, correctly noting the standard role of brain MRI with contrast and the alternative of non-contrast MRI if contrast is contraindicated, but its initial statement that contrast MRI is \"still mandatory\" is misleading given the clinical scenario; this is a minor wording inaccuracy that does not alter the overall meaning."
  },
  "2144": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the staging, surgical candidacy, and when systemic therapy is preferred, and provides relevant, correct additional details without inaccuracies or omissions."
  },
  "2145": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including the inappropriateness of observation alone, the need for further local and systemic therapy, and guideline recommendations; all additional details are accurate and clinically relevant."
  },
  "2146": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail about diagnostic considerations and multidisciplinary evaluation, and contains no inaccuracies or omissions."
  },
  "2147": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately identifies concurrent chemoradiation as the preferred option, provides relevant rationale, and includes no inaccuracies or omissions. Additional content is correct and clinically relevant."
  },
  "2148": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that routine brain MRI is not indicated without symptoms, and correctly describes appropriate surveillance; additional content is factually correct and clinically relevant."
  },
  "2149": {
    "score": 1.0,
    "explanation": "1: The model answer directly contradicts the reference by recommending immediate initiation of ROS1-targeted therapy rather than completing the current regimen, which is a major inaccuracy and could lead to unsafe clinical practice."
  },
  "2150": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately stating there is no clear preference, and details the main factors influencing choice (efficacy, toxicity, comorbidities, drug interactions, availability). Additional content is correct, relevant, and enhances clinical context without introducing inaccuracies."
  },
  "2151": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional details, cites supporting evidence and guidelines, and contains no inaccuracies or omissions."
  },
  "2152": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including the indication for endocrine therapy, the impact of severe liver dysfunction on agent selection and safety, the need for multidisciplinary discussion, and the possibility of omission in certain cases. All additional content is accurate and clinically relevant."
  },
  "2153": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant explanations, cites guidelines, and contains no inaccuracies or omissions."
  },
  "2154": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, adds accurate and clinically relevant detail, and contains no inaccuracies or omissions."
  },
  "2155": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizing that negative imaging does not rule out underlying carcinoma and that histopathological evaluation is essential; all additional explanations are correct and clinically relevant."
  },
  "2156": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly prioritizing re-resection with systemic therapy and appropriately recommending chemoradiation only if re-resection is not feasible; all additional content is accurate, relevant, and guideline-based."
  },
  "2157": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale for preferring nonsurgical therapy in this high-risk patient, and adds relevant, correct details about surgical contraindications and alternative therapies without any inaccuracies or omissions."
  },
  "2158": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the staging change to IV (M1a/IVA), and clearly justifies the need for metastatic disease management; there are no omissions or inaccuracies."
  },
  "2159": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately stating that routine FDG-PET/CT or brain MRI is not indicated for surveillance in asymptomatic patients, and correctly outlines the appropriate use of these modalities if recurrence is suspected. There are no inaccuracies or omissions."
  },
  "2160": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that severe pulmonary dysfunction shifts the standard from surgery to SBRT, and provides accurate, relevant elaboration without any inaccuracies or omissions."
  },
  "2161": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that routine FDG-PET/CT or brain MRI is not indicated, details standard surveillance recommendations, and provides correct rationale and references without any inaccuracies or omissions."
  },
  "2162": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, cites guidelines, and contains no inaccuracies or omissions. All additional content is clinically relevant and correct."
  },
  "2163": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that PMRT can generally be omitted, despite the tumor size exceeding 5 cm, which does not meet established omission criteria; while it provides relevant guideline context and acknowledges individualization, it omits the key fact that omission is not indicated per standard criteria, constituting a moderate factual error."
  },
  "2164": {
    "score": 1.0,
    "explanation": "1: The model answer directly contradicts the reference by recommending continued HER2-targeted therapy after progression on multiple prior lines, which is not clinically indicated per the reference; this is a major inaccuracy that could lead to inappropriate treatment."
  },
  "2165": {
    "score": 4.0,
    "explanation": "4: The model answer covers over 90% of the key facts, accurately describing the default approach (treat as metastatic disease) and the rare exception (curative intent if proven to be independent primaries), with appropriate emphasis on multidisciplinary evaluation; the only minor issue is a slightly more conservative tone than the reference, but no clinically significant omissions or inaccuracies."
  },
  "2166": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately addresses both the stage IB NSCLC context and the impact of ILD, and provides correct, clinically relevant explanations without any inaccuracies or omissions."
  },
  "2167": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "2168": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including the necessity of obtaining EGFR, ALK, and PD-L1 status before initiating therapy, the rationale for waiting, exceptions for urgent cases, and recommendations for re-biopsy or liquid biopsy; it also cites guidelines and provides a clear summary without inaccuracies or omissions."
  },
  "2169": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional explanation, cites guidelines, and contains no inaccuracies or omissions."
  },
  "2170": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and provides relevant supporting details without any inaccuracies or omissions."
  },
  "2171": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional details (trial data, guideline names, efficacy rates), and contains no inaccuracies or omissions."
  },
  "2172": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, adds relevant and accurate clarifications, and contains no inaccuracies or omissions."
  },
  "2173": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly states the requirement for absence of EGFR, ALK, or ROS1 alterations, and provides accurate, relevant explanations and supporting references without any inaccuracies or omissions."
  },
  "2174": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, emphasizes the necessity of PFTs before perioperative assessment, and provides additional accurate, relevant guideline-based rationale without any inaccuracies or omissions."
  },
  "2175": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately stating that sotorasib and adagrasib are only appropriate after progression on prior systemic therapy and not as first-line treatment, with no inaccuracies or omissions."
  },
  "2176": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant explanations, cites appropriate guidelines and trials, and contains no inaccuracies or omissions."
  },
  "2177": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "2178": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional details, and contains no inaccuracies or omissions."
  },
  "2179": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "2180": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts but overstates that prior RT is not an absolute contraindication, potentially underemphasizing the significant risks and typical preference for systemic therapy or observation; it provides relevant detail but may mislead regarding standard practice, representing a moderate omission."
  },
  "2181": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly distinguishing when SVC stenting versus chemoradiation should be prioritized, and provides accurate, clinically relevant explanations without any inaccuracies or omissions."
  },
  "2182": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, adds relevant rationale and guideline support, and includes no inaccuracies or omissions."
  },
  "2183": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, including the limited benefit of durvalumab in EGFR-mutant NSCLC and the lack of approval for osimertinib after chemoradiation, but incorrectly prioritizes durvalumab over osimertinib, which contradicts the reference answer's clear recommendation to prioritize osimertinib due to mutation status; this represents a moderate factual error."
  },
  "2184": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale for avoiding surgery, details relevant PFT thresholds, and appropriately prioritizes alternative local therapies without any inaccuracies or omissions."
  },
  "2185": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including appropriateness of BCS with axillary staging, perioperative imaging considerations, and the need to defer radiotherapy; additional details are accurate and clinically relevant."
  },
  "2186": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, including the distinction between BCS and mastectomy, relevant trial data, and the lack of standardization for omitting axillary surgery after mastectomy, but it overstates the restriction to BCS and underplays that omission is allowable in mastectomy if the undissected axilla is intentionally irradiated, as per the reference."
  },
  "2187": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and provides relevant, correct additional details without any inaccuracies or omissions."
  },
  "2188": {
    "score": 3.0,
    "explanation": "3: The model answer correctly explains that both lesions must be resectable with curative intent but overemphasizes that surgical management does not require classification as two primaries, missing the key point that surgical management presupposes both are individually curable and typically managed as two primaries; overall, it covers most but not all key facts."
  },
  "2189": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describing the role of mediastinal nodal status in surgical candidacy and the shift to chemoradiation with N2 disease, with no inaccuracies or omissions."
  },
  "2190": {
    "score": 2.0,
    "explanation": "2: The model answer correctly notes the importance of nodal assessment and the risk of understaging, but incorrectly asserts that adjuvant therapy is still indicated without adequate mediastinal nodal evaluation, missing the key fact that accurate pathologic staging (which requires systematic nodal assessment) is a prerequisite for adjuvant therapy; this is a moderate factual error."
  },
  "2191": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that omission of axillary lymph node dissection is appropriate after neoadjuvant therapy with a positive sentinel node, which contradicts the reference answer and current standard guidelines; while it provides supporting evidence and references, this represents a moderate factual error regarding the criteria for ALND omission in this context."
  },
  "2192": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, adds correct and clinically relevant detail about exceptions and rationale, and contains no inaccuracies or omissions."
  },
  "2193": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizes the high risk of radiation pneumonitis in ILD, and correctly states that adjuvant radiotherapy is generally not appropriate, with appropriate mention of alternative strategies and guideline recommendations; no inaccuracies or omissions are present."
  },
  "2194": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and appropriately discusses exceptions and current standards without any inaccuracies or omissions."
  },
  "2195": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and relevant supporting evidence, and includes no inaccuracies or omissions. Additional content is accurate and clinically pertinent."
  },
  "2196": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional details, and contains no inaccuracies or omissions."
  },
  "2197": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately prioritizing systemic therapy over lung resection, correctly noting the upstaging to stage IV, and appropriately discussing the role of local therapy for brain metastasis; all additional details are relevant and factually correct."
  },
  "2198": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant elaboration, cites supporting evidence and guidelines, and contains no inaccuracies or omissions."
  },
  "2199": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, cites relevant guidelines, and contains no inaccuracies or omissions."
  },
  "2200": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "2201": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "2202": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, correctly noting that broad molecular profiling is not routinely recommended for classic squamous cell carcinoma in smokers, but should be considered in never/light smokers, young patients, or when histology is uncertain. It omits the explicit statement that molecular testing should not be omitted solely based on squamous histology, but this is implied; overall, there are no clinically significant errors."
  },
  "2203": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly distinguishing between locoregional-only recurrence and cases with oligometastatic disease, and correctly emphasizes the need for individualized, multidisciplinary management without any inaccuracies or omissions."
  },
  "2204": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key clinical facts, correctly distinguishing between satellite nodules (T3) and synchronous primaries, and explains that treatment may or may not change depending on this distinction. There is a minor omission: it does not explicitly state that, if synchronous primaries are confirmed, each lesion must be staged and managed individually, as emphasized in the reference."
  },
  "2205": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, emphasizing the preference for pathological confirmation and the need to exhaust alternative diagnostic strategies, but it incorrectly states that empiric treatment based on imaging alone is generally acceptable, which contradicts the reference's insistence on tissue confirmation before stage-specific therapy."
  },
  "2206": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately cites relevant trials and guidelines, and provides correct, clinically relevant explanations without any inaccuracies or omissions."
  },
  "2207": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, correctly stating that FDG-PET/CT is appropriate in the initial evaluation of a new suspicious nodule and that brain MRI is generally reserved for symptomatic patients or those being considered for curative therapy. There is a minor wording inaccuracy suggesting PET/CT can be used before recurrence is confirmed, but this aligns with guidelines for suspected recurrence, so the answer is comprehensive with no clinically significant omissions."
  },
  "2208": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately distinguishing between indications for adjuvant osimertinib after surgery versus after chemoradiation/durvalumab, and cites relevant guidelines and trial data without inaccuracies or omissions."
  },
  "2209": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the appropriate follow-up schedule, clearly distinguishes it from the schedule used after radiotherapy, and provides correct, relevant references without any inaccuracies or omissions."
  },
  "2210": {
    "score": 4.0,
    "explanation": "4: The model answer covers over 90% of the key facts, correctly emphasizing that adjuvant radiotherapy is not routine for all but is strongly considered with positive margins, and that the decision depends on clinicopathological factors and multidisciplinary input. There is a minor wording inaccuracy in stating \"generally indicated\" and \"largely independent of systemic therapy,\" which could be misinterpreted as more routine than the reference suggests, but overall the answer is accurate and thorough."
  },
  "2211": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and adds relevant details about SBRT and operability criteria without any inaccuracies or omissions."
  },
  "2212": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately cites current guidelines, and provides relevant, correct explanations without any inaccuracies or omissions."
  },
  "2213": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, including the rationale for re-biopsy and guideline recommendations, but it incorrectly states that confirmation is \"not required,\" which contradicts the reference's emphasis on the necessity of confirming HER2 status on metastatic tissue; this represents a moderate omission."
  },
  "2214": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, cites guidelines, and includes relevant details without inaccuracies or omissions."
  },
  "2215": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant explanations, and includes no inaccuracies or omissions."
  },
  "2216": {
    "score": 4.0,
    "explanation": "4: The model answer correctly states that durvalumab is not recommended for EGFR-mutant patients and provides rationale and guideline references, but it omits the key fact that osimertinib is now preferred as consolidation therapy in this setting, which is a clinically relevant omission."
  },
  "2217": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the appropriateness of surgery after preoperative therapy, clarifies when chemoradiation is preferred, and provides relevant guideline references without any inaccuracies or omissions."
  },
  "2218": {
    "score": 4.0,
    "explanation": "4: The model answer covers all major key facts and provides a thorough rationale, but omits mention of several additional recommended molecular targets (BRAF, NTRK, MET exon 14, RET, HER2) included in the reference answer; otherwise, it is accurate and clinically relevant."
  },
  "2219": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly distinguishing between management with and without distant metastases, and provides accurate, relevant rationale without any inaccuracies or omissions."
  },
  "2220": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, trial data, and guidelines, and contains no inaccuracies or omissions."
  },
  "2221": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "2222": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "2223": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including the contraindication of standard HER2-directed and chemotherapy regimens in severe liver dysfunction, the need for hepatic assessment, and the alternative of primary surgery. All additional content is accurate and clinically relevant, with no inaccuracies or omissions."
  },
  "2224": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and cites authoritative guidelines; there are no inaccuracies or omissions."
  },
  "2225": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the contraindication to surgery, discusses alternative treatments, and adds relevant detail about multidisciplinary evaluation and PFT thresholds without any inaccuracies or omissions."
  },
  "2226": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional details, and contains no inaccuracies or omissions."
  },
  "2227": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides additional relevant details (toxicity profiles, guideline citations), and contains no inaccuracies or omissions."
  },
  "2228": {
    "score": 1.0,
    "explanation": "1: The model answer directly contradicts the reference by recommending trastuzumab-based chemotherapy for metaplastic histology, whereas the reference states it is not routinely indicated and is an exception to standard recommendations; this is a major inaccuracy."
  },
  "2229": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that routine surveillance should not include FDG-PET/CT or brain MRI without symptoms or suspicious findings, and provides relevant, correct guideline-based rationale without any inaccuracies or omissions."
  },
  "2230": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that endocrine therapy remains recommended in this scenario, and provides relevant, correct additional details without any inaccuracies or omissions."
  },
  "2231": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and relevant guideline-based details, and contains no inaccuracies or omissions."
  },
  "2232": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "2233": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, cites relevant guidelines, and contains no inaccuracies or omissions."
  },
  "2234": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and relevant guideline-based details, and includes no inaccuracies or omissions. Additional content is correct and clinically pertinent."
  },
  "2235": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains staging, management rationale, and provides relevant guidelines, with no omissions or inaccuracies."
  },
  "2236": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, cites relevant guidelines, and contains no inaccuracies or omissions."
  },
  "2237": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that HR-positive, HER2-negative cT1c, cN0 tumors are not standard candidates for preoperative systemic therapy, and provides accurate, relevant rationale without any inaccuracies or omissions."
  },
  "2238": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, adds relevant and accurate details about risks of systemic therapy (e.g., antiangiogenic agents), and correctly prioritizes local control of bleeding without any inaccuracies or omissions."
  },
  "2239": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizes the necessity of pathological confirmation before definitive treatment, and appropriately notes exceptions and guideline support without any inaccuracies or omissions."
  },
  "2240": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that trastuzumab/pertuzumab is contraindicated with LVEF <50%, explains the rationale, cites guidelines, and appropriately suggests alternative approaches without any inaccuracies or omissions."
  },
  "2241": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional details, and contains no inaccuracies or omissions."
  },
  "2242": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including the contraindication of bisphosphonates in severe renal impairment, the appropriateness of denosumab, and the need for hypocalcemia monitoring. Additional content is accurate and clinically relevant."
  },
  "2243": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts and provides detailed rationale and references, but it incorrectly asserts that intensive surveillance is recommended for all stage III patients regardless of radiotherapy, whereas the reference specifies that the rationale for intensive surveillance is less clear without radiotherapy and suggests the less intensive schedule is reasonable. This represents a moderate factual inaccuracy."
  },
  "2244": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly prioritizing surgical resection for urgent decompression, explaining the rationale, and appropriately describing the role of SRS. Additional content is accurate, relevant, and guideline-based, with no inaccuracies or omissions."
  },
  "2245": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly explains why SABR is inappropriate for central, N2 disease, and provides relevant, accurate, and guideline-based details without any inaccuracies or omissions."
  },
  "2246": {
    "score": 1.0,
    "explanation": "1: The model answer incorrectly states that external-beam radiotherapy is appropriate regardless of pulmonary function, directly contradicting the reference, which emphasizes that poor pulmonary function may preclude radiotherapy and favor stenting alone; this is a major inaccuracy with potential clinical implications."
  },
  "2247": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that adjuvant systemic therapy is generally not indicated after neoadjuvant therapy and R0 resection, which contradicts the reference answer and current guidelines; while it provides some relevant context, this represents a moderate factual error and omits the key recommendation that adjuvant therapy remains indicated if the patient can tolerate it."
  },
  "2248": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly distinguishes between micrometastasis and macrometastasis, accurately cites guideline criteria, and contains no inaccuracies or omissions."
  },
  "2249": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizes the necessity of pathologic confirmation, and provides relevant, guideline-based rationale without inaccuracies or omissions."
  },
  "2250": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, cites relevant guidelines, and contains no inaccuracies or omissions."
  },
  "2251": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that routine FDG-PET/CT or brain MRI is not indicated, details appropriate surveillance, and provides correct, relevant guideline-based explanations without any inaccuracies or omissions."
  },
  "2252": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly states that concurrent chemoradiation is preferred, and provides accurate, relevant rationale and guideline references without any inaccuracies or omissions."
  },
  "2253": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that the recommendation assumes no evidence of distant metastasis, and provides additional, accurate, and relevant explanation without any inaccuracies or omissions."
  },
  "2254": {
    "score": 2.0,
    "explanation": "2: The model answer omits the key fact that adjuvant chemotherapy is indicated for premenopausal women with this recurrence score and tumor size, as per guidelines; it incorrectly recommends endocrine therapy alone, which is not standard for this scenario, constituting a moderate factual error."
  },
  "2255": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, cites relevant guidelines, and appropriately individualizes surveillance recommendations based on patient comorbidities and life expectancy, with no inaccuracies or omissions."
  },
  "2256": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that routine brain MRI is not indicated, details standard surveillance, and appropriately cites guidelines; there are no inaccuracies or omissions."
  },
  "2257": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, cites supporting guidelines and evidence, and contains no inaccuracies or omissions."
  },
  "2258": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the exclusion of this regimen for squamous histology, and provides relevant supporting details without any inaccuracies or omissions."
  },
  "2259": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts but incorrectly states that BRAF-targeted therapy should not be prioritized in first-line for squamous histology, which contradicts the reference's emphasis on prioritizing targeted therapy for actionable mutations regardless of histology. It provides relevant supporting details but omits the current shift toward molecularly driven therapy and overstates the lack of evidence, resulting in a moderate factual inaccuracy."
  },
  "2260": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately stating that sotorasib and adagrasib are indicated for ECOG 0–2 (with caveats for ECOG 2), and not recommended for ECOG ≥3 due to lack of data; all additional details are correct and clinically relevant."
  },
  "2261": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale and guideline citations, and contains no inaccuracies or omissions."
  },
  "2262": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly explains why concurrent chemoradiation is not appropriate, discusses toxicity risks, alternative options, and provides relevant clinical context without inaccuracies or omissions."
  },
  "2263": {
    "score": 1.0,
    "explanation": "1: The model answer incorrectly asserts that palliative chemotherapy in this context assumes absence of metastatic disease, directly contradicting the reference, which states systemic therapy is appropriate regardless of metastasis status; this is a major inaccuracy."
  },
  "2264": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and relevant guideline-based rationale, and contains no inaccuracies or omissions."
  },
  "2265": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the equivalence of EBUS and mediastinoscopy for pathologic confirmation, and correctly notes that stage IIIB (N3) is not eligible for perioperative therapy regardless of biopsy method; there are no inaccuracies or omissions."
  },
  "2266": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly explains the contraindication of concurrent chemoradiation in renal impairment, discusses alternative strategies, and provides accurate, relevant detail without inaccuracies or omissions."
  },
  "2267": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant rationale, cites guidelines, and contains no inaccuracies or omissions."
  },
  "2268": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that serial imaging surveillance is preferred over immediate invasive intervention, and provides correct, relevant guideline-based rationale without any inaccuracies or omissions."
  },
  "2269": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that surveillance alone is not appropriate, explaining the rationale, and outlining recommended adjuvant therapies; all additional content is accurate, guideline-based, and clinically relevant."
  },
  "2270": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key facts from the reference, clearly stating MRI is optional (not mandatory) if the tumor is visible on mammography, and provides accurate, relevant guideline-based context without any inaccuracies or omissions."
  },
  "2271": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly emphasizes that standard guidelines do not apply to immunosuppressed patients, and appropriately recommends individualized follow-up; all additional content is accurate and clinically relevant."
  },
  "2272": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately stating that mastectomy with axillary staging is standard and that immediate reconstruction may be considered if appropriate; it adds relevant, correct details without any inaccuracies or omissions."
  },
  "2273": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts but incorrectly states that surveillance should be every 6 months (rather than every 3–6 months) and that more frequent surveillance is not recommended, missing the nuance that intervals can be as short as 3 months based on recurrence risk. This is a minor but clinically relevant omission, so the answer does not reach the 4-point threshold."
  },
  "2274": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides additional relevant and accurate detail regarding pulmonary function thresholds, risk assessment, and alternative therapies, and contains no inaccuracies or omissions."
  },
  "2275": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including the role of re-resection, the importance of clinical factors, and when chemoradiation or PORT is appropriate. It adds relevant, accurate detail and guideline references without inaccuracies or omissions."
  },
  "2276": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, cites relevant guidelines and studies, and contains no inaccuracies or omissions."
  },
  "2277": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes endocrine therapy options (including ovarian suppression/ablation), and provides relevant guideline context without inaccuracies or omissions."
  },
  "2278": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains why perioperative therapy is not appropriate, and provides relevant, correct additional context about standard management and the impact of poor pulmonary function."
  },
  "2279": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately addresses selpercatinib’s appropriateness in the presence of brain metastases, and provides correct, clinically relevant supporting details without any inaccuracies or omissions."
  },
  "2280": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant explanations, and contains no inaccuracies or omissions."
  },
  "2281": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly explains that PORT is not routinely recommended after R0 resection and chemotherapy for N2 disease, and provides relevant, up-to-date evidence and guideline context without inaccuracies or omissions."
  },
  "2282": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately stating that curative intent is not automatically precluded and providing relevant, guideline-based explanations without inaccuracies or omissions."
  },
  "2283": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant explanations, cites supporting guidelines and evidence, and contains no inaccuracies or omissions."
  },
  "2284": {
    "score": 5.0,
    "explanation": "5: Fully covers all key clinical facts from the reference, accurately states that routine PET/CT or brain MRI is not indicated for surveillance in asymptomatic patients with R1 margins, and provides relevant, guideline-based rationale without inaccuracies or omissions."
  },
  "2285": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately distinguishes between synchronous primaries and intrapulmonary metastases, correctly explains staging implications, and clearly states that systemic therapy for metastatic disease is not always indicated; there are no inaccuracies or omissions."
  },
  "2286": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately addresses the scenario, and provides additional correct and clinically relevant details without any inaccuracies or omissions."
  },
  "2287": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including the standard role of surgery, the impact of restrictive impairment, the need for multidisciplinary evaluation, and alternative treatments if surgery is unsafe. Additional details are accurate and clinically relevant."
  },
  "2288": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, cites guidelines, and offers relevant additional detail without inaccuracies or omissions."
  },
  "2289": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that palliative chemotherapy does not preclude later local interventions, and provides relevant, correct additional explanation without any inaccuracies or omissions."
  },
  "2290": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts but incorrectly states that surveillance schedules are essentially the same after surgery and definitive radiotherapy, missing the reference's point that post-radiotherapy follow-up is more intensive (every 3–6 months for 3 years, then every 6 months for 2 years). This is a moderate omission, though the rest of the content is accurate and relevant."
  },
  "2291": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides additional relevant and accurate details, and contains no inaccuracies or omissions."
  },
  "2292": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant rationale, and includes correct guideline references without any inaccuracies or omissions."
  },
  "2293": {
    "score": 5.0,
    "explanation": "5: The model answer correctly states that concurrent chemoradiation is not routinely recommended solely for R1 status, accurately describes the standard approach (sequential therapy), and cites relevant guidelines, fully covering all key clinical facts in the reference without inaccuracies or omissions."
  },
  "2294": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the eligibility criteria, and provides relevant supporting details without any inaccuracies or omissions."
  },
  "2295": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly prioritizing interventional bronchoscopy for acute airway compromise and explaining the rationale and timing for both interventions; all additional content is accurate and clinically relevant."
  },
  "2296": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional explanation, and contains no inaccuracies or omissions."
  },
  "2297": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that routine PET/CT or brain MRI is not indicated, and provides correct, relevant guideline-based details without any inaccuracies or omissions."
  },
  "2298": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizes the necessity of ongoing ovarian suppression, and appropriately addresses exceptions (permanent ovarian ablation), with no inaccuracies or omissions."
  },
  "2299": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that routine brain MRI is not required in asymptomatic patients, and provides relevant, guideline-based context without any inaccuracies or omissions."
  },
  "2300": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant guideline-based rationale, and contains no inaccuracies or omissions."
  },
  "2301": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, clearly distinguishes between M1a metastatic disease and synchronous primaries, accurately describes management implications, and provides correct, relevant references without inaccuracies or omissions."
  },
  "2302": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant explanations, cites guidelines, and contains no inaccuracies or omissions."
  },
  "2303": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that such lesions should be managed as intrapulmonary metastases by default, contradicting the reference answer, which supports management as two primaries in the absence of nodal or distant metastases; while the model provides detailed staging rationale, this represents a moderate factual error."
  },
  "2304": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the restriction of pemetrexed to nonsquamous histology, and correctly states that osimertinib monotherapy is standard for EGFR-mutant squamous NSCLC, with no inaccuracies or omissions."
  },
  "2305": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "2306": {
    "score": 4.0,
    "explanation": "4: The model answer covers over 90% of the key facts, correctly stating that surgery remains standard if operable, but adds nuanced, guideline-based discussion about individualized decision-making, surgical modifications, and SBRT as an alternative. There is a minor omission in not explicitly stating that non-surgical options are reserved for when operative risk is unacceptable, but this is implied; all content is accurate and clinically relevant."
  },
  "2307": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, includes relevant guideline references, and contains no inaccuracies or omissions."
  },
  "2308": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that surgical resection alone is insufficient and that PMRT is required, with accurate rationale and no inaccuracies or omissions."
  },
  "2309": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and provides relevant guideline context without any inaccuracies or omissions."
  },
  "2310": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "2311": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately addresses both de novo and recurrent scenarios, emphasizes the importance of no prior radiation, and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "2312": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, adds correct and relevant examples of high-risk features, and cites supporting guidelines; there are no inaccuracies or omissions."
  },
  "2313": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the contraindication of surgery in the context of severe COPD, and appropriately recommends definitive radiotherapy as the preferred alternative, with no inaccuracies or omissions."
  },
  "2314": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly explains when a contralateral nodule may represent a second primary rather than metastatic disease, and details the clinical implications and criteria for distinction, with no inaccuracies or omissions."
  },
  "2315": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and provides relevant guideline context without any inaccuracies or omissions."
  },
  "2316": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, provides relevant guideline citations, and contains no inaccuracies or omissions."
  },
  "2317": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key facts and provides additional relevant detail about increased cancer risk and guideline references, but it overstates that fibrosis \"fundamentally alters\" the surveillance strategy, whereas the reference says the interval is not fundamentally changed—this is a minor wording inaccuracy."
  },
  "2318": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, addresses guidelines, and includes relevant nuances about risk, histology, and shared decision-making, with no inaccuracies or omissions."
  },
  "2319": {
    "score": 1.0,
    "explanation": "1: The model answer directly contradicts the reference by recommending immediate transition to EGFR TKI rather than completion of initial therapy, which is a major inaccuracy and could lead to inappropriate management."
  },
  "2320": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional details, and contains no inaccuracies or omissions."
  },
  "2321": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and contains no inaccuracies or omissions."
  },
  "2322": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant rationale, cites guidelines, and contains no inaccuracies or omissions."
  },
  "2323": {
    "score": 5.0,
    "explanation": "5: Fully covers all key clinical facts from the reference, accurately explains the rationale, and provides relevant supporting details without any inaccuracies or omissions."
  },
  "2324": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant elaboration, and contains no inaccuracies or omissions."
  },
  "2325": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "2326": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional details, and contains no inaccuracies or omissions."
  },
  "2327": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly states that moderate CKD is not a contraindication, and appropriately emphasizes perioperative precautions; all additional details are accurate and clinically relevant."
  },
  "2328": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts but incorrectly states that concurrent chemoradiation is generally preferred, whereas the reference specifies both are equally appropriate with no established superiority; this is a moderate factual inaccuracy. The rest of the content is accurate and relevant."
  },
  "2329": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and provides relevant guideline references without any inaccuracies or omissions."
  },
  "2330": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the role of adjuvant therapy, appropriately cites guidelines, and provides relevant additional details without any inaccuracies or omissions."
  },
  "2331": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "2332": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, emphasizes the need for individualized, multidisciplinary decision-making, and includes correct, relevant guideline-based context without any inaccuracies or omissions."
  },
  "2333": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional details (including evidence, guidelines, and newer adjuvant options), and contains no inaccuracies or omissions."
  },
  "2334": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, cites relevant guidelines, and contains no inaccuracies or omissions."
  },
  "2335": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "2336": {
    "score": 3.0,
    "explanation": "3: The model answer correctly states that immediate brain MRI is not indicated and provides appropriate context, but incorrectly recommends FDG-PET/CT as the next step for all new asymptomatic radiographic abnormalities, which is more aggressive than standard guidelines for stage I NSCLC; this oversteps the reference answer, which reserves advanced imaging for suspicious or symptomatic findings, not all new abnormalities."
  },
  "2337": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately addresses histology and smoking status, and provides correct, relevant additional details without any inaccuracies or omissions."
  },
  "2338": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains why surgery is not appropriate, details the standard of care, and provides relevant rationale without any inaccuracies or omissions."
  },
  "2339": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that routine FDG-PET/CT or brain MRI is not indicated, and appropriately details current guidelines and indications for these modalities; no inaccuracies or omissions are present."
  },
  "2340": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant explanations, cites appropriate guidelines and studies, and contains no inaccuracies or omissions."
  },
  "2341": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately prioritizing bronchoscopic intervention for immediate airway relief and appropriately relegating EBRT to a secondary role. Additional details and references are correct and clinically relevant, with no inaccuracies or omissions."
  },
  "2342": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly emphasizes that prior multifocality and initial ineligibility for local therapy do not preclude concurrent chemoradiation, and adds relevant, accurate clinical context without any inaccuracies or omissions."
  },
  "2343": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate supporting data, guideline context, and a clear recommendation with no inaccuracies or omissions."
  },
  "2344": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately addresses the need for individualized therapy, highlights the risks of surgery in the context of poor pulmonary function, and appropriately suggests non-surgical alternatives; all additional content is clinically relevant and correct."
  },
  "2345": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale and supporting evidence, and contains no inaccuracies or omissions."
  },
  "2346": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains that M1a (contralateral nodules) is metastatic and not routinely surgically resected, and appropriately notes rare exceptions without suggesting unsafe practice."
  },
  "2347": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional details, and contains no inaccuracies or omissions."
  },
  "2348": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, adds relevant guideline-based context, and contains no inaccuracies or omissions."
  },
  "2349": {
    "score": 5.0,
    "explanation": "5: The model answer correctly states that surveillance for stage I NSCLC after primary radiotherapy aligns with that for stage I post-surgery, not with the more intensive stage IIIB protocol. It provides accurate details, guideline references, and a summary table, with no inaccuracies or omissions."
  },
  "2350": {
    "score": 5.0,
    "explanation": "5: Fully covers all key clinical facts from the reference, accurately cites relevant guidelines, and provides correct, clinically relevant additional detail without any inaccuracies or omissions."
  },
  "2351": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "2352": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains why surgery is contraindicated, discusses the role of non-surgical therapies, and provides relevant, correct additional detail without inaccuracies or omissions."
  },
  "2353": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, accurately describes the evidence and guideline landscape, and correctly notes the lack of prospective data for osimertinib in this setting; however, it does not clearly state that osimertinib is preferred for EGFR-mutant cases (as in the reference), instead emphasizing durvalumab as the current standard, which is a minor omission in prioritization."
  },
  "2354": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant guideline-based explanations, and contains no inaccuracies or omissions."
  },
  "2355": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, addresses imaging considerations, and emphasizes the importance of localization, with no inaccuracies or omissions."
  },
  "2356": {
    "score": 5.0,
    "explanation": "5: Fully covers all key clinical facts from the reference, provides accurate and relevant additional explanation, and cites appropriate guidelines; no inaccuracies or omissions."
  },
  "2357": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides additional correct and clinically relevant details about endocrine therapy options, and contains no inaccuracies or omissions."
  },
  "2358": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, emphasizes the necessity of brain MRI for accurate staging, explains the rationale, cites relevant guidelines, and contains no inaccuracies or omissions."
  },
  "2359": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the necessity of PFTs before treatment planning, and provides additional relevant details without any inaccuracies or omissions."
  },
  "2360": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly explains the rationale, discusses perioperative risk, and appropriately recommends SBRT as the alternative; there are no inaccuracies or omissions."
  },
  "2361": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional details, and contains no inaccuracies or omissions."
  },
  "2362": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that adjuvant chemotherapy is indicated due to nodal micrometastasis in triple-negative breast cancer, regardless of small tumor size, and provides accurate, guideline-based rationale without any inaccuracies or omissions."
  },
  "2363": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "2364": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately prioritizing re-resection and correctly describing the role of adjuvant radiotherapy, with no omissions or inaccuracies."
  },
  "2365": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "2366": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant rationale, and contains no inaccuracies or omissions."
  },
  "2367": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, clearly distinguishes between stage IIIB (M0) and oligometastatic (M1) disease, accurately describes standard and potential treatment options, and provides relevant, correct additional context without inaccuracies or omissions."
  },
  "2368": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and provides relevant, evidence-based details without any inaccuracies or omissions."
  },
  "2369": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "2370": {
    "score": 4.0,
    "explanation": "4: The model answer covers over 90% of the key facts, is detailed, and provides correct, relevant extra information, but introduces a minor caveat about determining the primary oncogenic driver when co-mutations are present, which is not explicitly stated in the reference and could slightly alter the intended meaning."
  },
  "2371": {
    "score": 1.0,
    "explanation": "1: The model answer directly contradicts the reference by recommending immediate switching to a TRK inhibitor before completing initial therapy, which is not standard practice per the reference; this is a major inaccuracy with potential clinical implications."
  },
  "2372": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale for surveillance, addresses the impact of renal impairment on chemotherapy choice, and provides relevant guideline references without any inaccuracies or omissions."
  },
  "2373": {
    "score": 3.0,
    "explanation": "3: The model answer correctly explains that adjuvant chemotherapy with trastuzumab is indicated regardless of nodal status and provides nuanced discussion about pertuzumab, but it contradicts the reference answer’s key point that dual HER2 blockade (chemo + trastuzumab + pertuzumab) is primarily indicated when pN+ is confirmed, thus missing the main clinical fact and introducing some ambiguity."
  },
  "2374": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, emphasizes the necessity of pathologic confirmation for N3 disease, and correctly states that stage I–IIIA treatment is appropriate without such confirmation; all additional content is accurate and clinically relevant."
  },
  "2375": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that PS 3 excludes patients from curative-intent concurrent chemoradiotherapy regardless of N3 status, and provides accurate, relevant explanations without any inaccuracies or omissions."
  },
  "2376": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that routine PET/CT or brain MRI is not indicated, and appropriately details recommended surveillance; all additional content is correct and clinically relevant."
  },
  "2377": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and provides relevant details about staging and management changes without any inaccuracies or omissions."
  },
  "2378": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, cites relevant guidelines, and makes no errors or omissions. All additional content is correct and clinically relevant."
  },
  "2379": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional explanations, and contains no inaccuracies or omissions."
  },
  "2380": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that adjuvant chemotherapy with trastuzumab is indicated for HER2-positive, node-positive breast cancer regardless of hormone receptor status, and that endocrine therapy is only added if ER/PR positive. Additional content is accurate, relevant, and guideline-based."
  },
  "2381": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the ECOG 0–2 requirement, references relevant trials, and provides appropriate clinical context without inaccuracies or omissions."
  },
  "2382": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly emphasizes avoidance of routine contrast in renal insufficiency, and provides relevant, accurate guideline-based context without any inaccuracies or omissions."
  },
  "2383": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional details, and contains no inaccuracies or omissions."
  },
  "2384": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that non-contrast CT is sufficient, and that contrast is not mandatory. Additional content is correct, guideline-based, and clinically relevant, with no inaccuracies or omissions."
  },
  "2385": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional rationale, and contains no inaccuracies or omissions."
  },
  "2386": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant rationale, cites guidelines, and contains no inaccuracies or omissions."
  },
  "2387": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately addresses the scenario regardless of prior therapy, and provides relevant, guideline-based detail without inaccuracies or omissions."
  },
  "2388": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and relevant additional rationale, and contains no inaccuracies or omissions."
  },
  "2389": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "2390": {
    "score": 5.0,
    "explanation": "5: Fully covers all key clinical facts from the reference, accurately explains why N3 status precludes surgery, and correctly describes standard management; additional details are relevant and factually correct."
  },
  "2391": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and relevant additional explanation, and contains no inaccuracies or omissions."
  },
  "2392": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant explanations, and cites appropriate guidelines; there are no inaccuracies or omissions."
  },
  "2393": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that non-contrast chest CT is sufficient, and that FDG-PET/CT and brain MRI are not routinely indicated. Additional content is correct, guideline-based, and clinically relevant, with no inaccuracies or omissions."
  },
  "2394": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that immediate annual CT is within protocol boundaries, omitting the key fact that more frequent (every 6–12 months) imaging is required for the first 2–3 years post-treatment; this is a moderate factual error, though the rest of the content is accurate and well-referenced."
  },
  "2395": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, cites relevant guidelines, and contains no inaccuracies or omissions."
  },
  "2396": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "2397": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly explains the CPS+EG threshold, and clearly states that olaparib is not indicated; all additional content is accurate and clinically relevant, with no omissions or inaccuracies."
  },
  "2398": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and appropriately recommends SBRT as the preferred alternative; there are no inaccuracies or omissions."
  },
  "2399": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly explaining that EBRT is not always the initial intervention for severe hemoptysis and detailing when alternative local control methods should take precedence, with no inaccuracies or omissions."
  },
  "2400": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the reasoning, and provides correct, relevant additional details without any inaccuracies or omissions."
  },
  "2401": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides additional accurate and clinically relevant details, and contains no inaccuracies or omissions."
  },
  "2402": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the roles of systemic therapy and palliative radiotherapy, and provides relevant, correct additional details without any inaccuracies or omissions."
  },
  "2403": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that RET inhibitors are preferred first-line regardless of PD-L1, and provides additional correct, relevant guideline-based context without inaccuracies or omissions."
  },
  "2404": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "2405": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, cites guidelines, and clearly delineates when molecular testing is appropriate, with no inaccuracies or omissions."
  },
  "2406": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that perioperative therapy is only appropriate if the patient is a surgical candidate, and that significant PFT impairment contraindicates surgery and thus perioperative therapy. Additional content is accurate, relevant, and enhances clinical understanding without introducing errors."
  },
  "2407": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "2408": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizes the necessity of pathological confirmation, explains the limitations of imaging, and references relevant guidelines; there are no inaccuracies or omissions."
  },
  "2409": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key clinical facts, correctly explains the mutual exclusivity of driver mutations, and emphasizes the need for comprehensive molecular testing before starting an ALK inhibitor. However, the initial \"No\" is a wording inaccuracy that could cause confusion, as the rest of the answer aligns with the reference's \"Yes\" rationale; this minor inconsistency prevents a perfect score."
  },
  "2410": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that metaplastic carcinoma is included, directly contradicting the reference answer, which specifies that metaplastic carcinoma is not eligible; this is a moderate factual error, though the rest of the content is otherwise accurate."
  },
  "2411": {
    "score": 4.0,
    "explanation": "4: The model answer covers over 90% of the key facts, accurately explains the rationale for best supportive care, and appropriately notes rare exceptions where systemic therapy may be considered, though it could more clearly emphasize that best supportive care is the standard and systemic therapy is rarely appropriate. No clinically significant errors are present."
  },
  "2412": {
    "score": 5.0,
    "explanation": "5: The model answer accurately states that routine FDG-PET/CT or brain MRI is not indicated in asymptomatic patients post-treatment, aligns with guideline recommendations, and contains no inaccuracies or omissions."
  },
  "2413": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizes the need for orthopedic stabilization prior to radiotherapy in cases of significant fracture risk, and provides additional relevant detail without inaccuracies or omissions."
  },
  "2414": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, cites relevant guidelines, and contains no inaccuracies or omissions."
  },
  "2415": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and provides relevant guideline references without any inaccuracies or omissions."
  },
  "2416": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional rationale, and contains no inaccuracies or omissions."
  },
  "2417": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that routine brain MRI is not indicated, emphasizes the focus on H&P and chest CT, and correctly reserves brain imaging for new neurological symptoms, with no inaccuracies or omissions."
  },
  "2418": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and provides relevant, correct additional details without any omissions or inaccuracies."
  },
  "2419": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and includes relevant, correct additional details without any inaccuracies or omissions."
  },
  "2420": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly explains staging, the impact of N2 disease, and guideline recommendations, with no inaccuracies or omissions."
  },
  "2421": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that systemic therapy is standard, and appropriately notes that surgery is not generally preferred but may be considered in highly selected cases, consistent with guidelines; there are no inaccuracies or omissions."
  },
  "2422": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that routine FDG-PET/CT or brain MRI is not indicated, and appropriately cites guidelines and standard surveillance practices without any inaccuracies or omissions."
  },
  "2423": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "2424": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant explanations, and contains no inaccuracies or omissions."
  },
  "2425": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately prioritizing local interventions over systemic therapy, and provides additional correct and clinically relevant detail without any inaccuracies or omissions."
  },
  "2426": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and relevant additional detail, and contains no inaccuracies or omissions."
  },
  "2427": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately prioritizing EGFR TKI over ICI monotherapy, provides correct rationale, guideline support, and relevant evidence, with no inaccuracies or omissions."
  },
  "2428": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate, guideline-based recommendations, and includes relevant, correct additional detail without any omissions or inaccuracies."
  },
  "2429": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explaining that HER2-targeted therapy consideration in squamous cell carcinoma presumes broad molecular profiling has been performed, and clarifies why this is not routine in squamous histology. No inaccuracies or omissions are present."
  },
  "2430": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional details, and contains no inaccuracies or omissions."
  },
  "2431": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant elaboration, and includes supporting guideline references without any inaccuracies or omissions."
  },
  "2432": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "2433": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly explains the rationale, and provides relevant, accurate additional detail without any inaccuracies or omissions."
  },
  "2434": {
    "score": 4.0,
    "explanation": "4: The model answer covers over 90% of the key facts, correctly emphasizing that indeterminate or suspicious residual abnormalities warrant more frequent imaging, while benign/stable findings do not. It introduces minor nuance about multidisciplinary review and guideline specifics, but this does not alter the core recommendation; however, the reference answer is more direct in recommending increased surveillance for any residual abnormality, making the model answer slightly less aligned."
  },
  "2435": {
    "score": 2.0,
    "explanation": "2: The model answer covers the presence of both mutations and discusses the impact of concurrent KRAS mutations on EGFR TKI efficacy, but it incorrectly states that erlotinib/gefitinib are not appropriate, directly contradicting the reference answer. This is a moderate factual error, as current guidelines still recommend EGFR TKI therapy based on EGFR mutation status regardless of KRAS, so the answer misses the key clinical fact."
  },
  "2436": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizes the necessity of pathological confirmation of metastatic disease, and provides relevant, correct rationale and supporting details without any inaccuracies or omissions."
  },
  "2437": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, adds accurate and clinically relevant detail about molecular features and modern systemic therapy, and clearly explains the factors determining prioritization without any inaccuracies or omissions."
  },
  "2438": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional explanation, and contains no inaccuracies or omissions."
  },
  "2439": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale regarding chemotherapy, radiation, and surveillance, and adds relevant, correct details about immunotherapy and guideline-based surveillance intervals without any inaccuracies or omissions."
  },
  "2440": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately stating that adjuvant endocrine therapy is recommended regardless of nodal status and providing relevant, correct additional context without any inaccuracies or omissions."
  },
  "2441": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that FDG-PET/CT is appropriate for all asymptomatic patients with new radiographic abnormalities, which overstates guideline recommendations; PET/CT is not routinely indicated in this scenario and should be reserved for cases with clinical suspicion, making this a moderate factual error."
  },
  "2442": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant explanations, cites appropriate guidelines, and contains no inaccuracies or omissions."
  },
  "2443": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional details, and contains no inaccuracies or omissions."
  },
  "2444": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly prioritizing systemic/palliative therapy over perioperative therapy in poor performance status, and provides relevant, accurate rationale and supporting references without any inaccuracies or omissions."
  },
  "2445": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the evidence and guidelines, and clearly states that multifocality precludes omission of radiation regardless of age; there are no inaccuracies or omissions."
  },
  "2446": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, cites relevant guidelines, and includes no inaccuracies or omissions."
  },
  "2447": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the upstaging, the shift from surgery to chemoradiation, and the rationale, with additional relevant detail and no inaccuracies or omissions."
  },
  "2448": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant rationale, cites guidelines, and contains no inaccuracies or omissions."
  },
  "2449": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including the standard use of post-operative chemoradiation for R1 resection, the increased risk of pulmonary toxicity with COPD, the need for individualized assessment, and that chemotherapy alone may be considered if pulmonary function is inadequate. There are no inaccuracies or omissions."
  },
  "2450": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately prioritizes surgery for resectable T4N1 NSCLC, and provides relevant, guideline-based rationale without inaccuracies or omissions."
  },
  "2451": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly states the necessity of FDG-PET/CT before perioperative therapy, and provides accurate, relevant rationale without any omissions or inaccuracies."
  },
  "2452": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "2453": {
    "score": 3.0,
    "explanation": "3: The model answer incorrectly states that the recommendation \"implicitly assumes\" absence of thromboembolic risk, whereas the reference clarifies that the recommendation does not universally assume this and that alternatives (aromatase inhibitors) are preferred in high-risk patients; otherwise, the answer covers most key facts and provides relevant detail."
  },
  "2454": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the appropriateness of surgery after neoadjuvant therapy, and correctly positions chemoradiation as an alternative for non-surgical candidates; all additional content is relevant, guideline-based, and free of inaccuracies."
  },
  "2455": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional details, and contains no inaccuracies or omissions."
  },
  "2456": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, including the distinction between metastatic disease and separate primaries, the need for multidisciplinary evaluation, and appropriate management for each scenario. It adds relevant detail about staging and guidelines, but slightly overemphasizes the default to metastatic disease and the need for \"proof\" to treat as two primaries, which could be seen as a minor wording inaccuracy. No clinically unsafe advice is present."
  },
  "2457": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant explanations, and includes supporting guideline references without any inaccuracies or omissions."
  },
  "2458": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that re-resection is preferred and radiotherapy is a secondary option, with supporting guideline references and no inaccuracies or omissions."
  },
  "2459": {
    "score": 5.0,
    "explanation": "5: The model answer accurately covers all key clinical facts, correctly explains the impact of N2 involvement on staging, and provides relevant, factually correct details without any inaccuracies or omissions."
  },
  "2460": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and relevant supporting evidence, and includes no inaccuracies or omissions; extra content is correct and enhances clinical understanding."
  },
  "2461": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that routine FDG-PET/CT or brain MRI is not indicated, and provides correct, relevant guideline-based explanations without any inaccuracies or omissions."
  },
  "2462": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts in the reference, provides accurate, clinically relevant additional detail (notably RxPONDER trial results and current guidelines), and contains no inaccuracies or omissions."
  },
  "2463": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately stating that pathological confirmation of metastases is preferred but not required, and that systemic therapy can proceed based on clinical and imaging evidence; all additional content is correct, relevant, and guideline-based."
  },
  "2464": {
    "score": 5.0,
    "explanation": "5: Fully correct—covers all key facts, clearly states that routine brain MRI is not indicated, specifies appropriate surveillance methods, and accurately notes that brain imaging is reserved for symptomatic patients; extra guideline references are correct and relevant."
  },
  "2465": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly prioritizing systemic therapy, explaining the rationale, and noting that local thoracic treatment is not standard initially in metastatic disease. Additional details are accurate and clinically relevant."
  },
  "2466": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and provides relevant guideline context without any inaccuracies or omissions."
  },
  "2467": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes standard therapy and exceptions, and adds relevant, correct detail without any inaccuracies or omissions."
  },
  "2468": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the expanded treatment options, and provides additional relevant context about the rarity and evidence base in squamous histology without any inaccuracies or omissions."
  },
  "2469": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and provides relevant guideline context without any inaccuracies or omissions."
  },
  "2470": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional rationale, and contains no inaccuracies or omissions."
  },
  "2471": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, including the role of EGFR TKIs and when to consider radiotherapy, but it does not prioritize palliative radiotherapy for symptom relief in all cases of diffuse brain metastases as the reference does, and instead suggests deferring radiotherapy unless severe symptoms are present, which is a minor but clinically relevant deviation from the reference."
  },
  "2472": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including the recommendation for broad molecular profiling in advanced NSCLC regardless of histology, the rationale, relevant exceptions, and guideline references, with no inaccuracies or omissions."
  },
  "2473": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate, relevant guideline-based explanations, and includes no inaccuracies or omissions. Additional content is correct and clinically pertinent."
  },
  "2474": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the importance of distinguishing between metastatic and synchronous primary tumors, details the diagnostic approach, and discusses implications for management and prognosis without any inaccuracies or omissions."
  },
  "2475": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "2476": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately prioritizing MET-targeted therapy over immunotherapy regardless of PD-L1 status, and provides additional correct, relevant context without inaccuracies or omissions."
  },
  "2477": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains why perioperative therapy is not appropriate, and provides relevant, guideline-based rationale without any inaccuracies or omissions."
  },
  "2478": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly states that adjuvant olaparib is indicated regardless of nodal status, and provides accurate, relevant supporting evidence without any inaccuracies or omissions."
  },
  "2479": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that EGFR-targeted therapy is valid in squamous histology with a sensitizing mutation, and provides accurate, relevant guideline-based rationale without any inaccuracies or omissions."
  },
  "2480": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly stating that brain metastases do not preclude palliative chemotherapy, and adds clinically relevant details about management without inaccuracies or omissions."
  },
  "2481": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, correctly states that adjuvant chemotherapy with trastuzumab should be routinely considered for T1bN0 HER2-positive tumors, and provides relevant guideline references. However, it slightly overstates the routine nature of the recommendation (implying it is more standard than the reference, which emphasizes case-by-case evaluation), representing a minor wording inaccuracy."
  },
  "2482": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, cites relevant guidelines, and contains no inaccuracies or omissions."
  },
  "2483": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that re-resection is preferred if feasible and that radiotherapy is appropriate when surgery is not possible or advisable. It adds relevant, accurate detail and guideline references without any inaccuracies or omissions."
  },
  "2484": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "2485": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including guideline recommendations, rationale for non-contrast CT, the impact of renal insufficiency, and appropriate use of contrast. There are no inaccuracies or omissions."
  },
  "2486": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate staging details, rationale, and guideline references, and contains no inaccuracies or omissions."
  },
  "2487": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, emphasizing the need for detailed functional assessment and possible modification of therapy, but slightly overstates that moderate impairment alone does not generally require modification, which could underplay the potential for contraindication in some cases; otherwise, it is thorough and accurate."
  },
  "2488": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, correctly prioritizing systemic therapy over observation in the setting of a growing nodule when local therapy is not feasible, but introduces some equivocation about observation that is less definitive than the reference; otherwise, content is accurate and relevant."
  },
  "2489": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that definitive radiotherapy (including SABR) is only for localized (M0) disease and not offered in the presence of distant metastases, with accurate and relevant additional explanation."
  },
  "2490": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that surgery is preferred when feasible, details patient selection, alternatives, and guideline support, and adds relevant, correct context without inaccuracies or omissions."
  },
  "2491": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes current guidelines, provides rationale, and includes relevant references without any inaccuracies or omissions."
  },
  "2492": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and relevant guideline-based rationale, and contains no inaccuracies or omissions."
  },
  "2493": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate staging rationale, clarifies the distinction between metastases and separate primaries, and cites relevant guidelines; there are no inaccuracies or omissions."
  },
  "2494": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly prioritizing urgent EBRT (± SVC stent) for acute SVC syndrome and deferring concurrent chemoradiation until after stabilization; all additional content is accurate, relevant, and well-structured."
  },
  "2495": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that routine FDG-PET/CT or brain MRI is not recommended, and provides relevant guideline-based surveillance details without inaccuracies or omissions."
  },
  "2496": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, accurately noting that molecular testing is not exclusive to non-squamous subtypes and should be considered in metastatic squamous cell carcinoma in specific clinical scenarios; all additional content is correct and clinically relevant."
  },
  "2497": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale for preferring SBRT in high-risk patients, and provides relevant, correct additional detail without inaccuracies or omissions."
  },
  "2498": {
    "score": 1.0,
    "explanation": "1: The model answer directly contradicts the reference by stating that definitive chemoradiation to the thoracic disease is not appropriate, which is a major inaccuracy and could mislead clinical decision-making; it also omits the key point that local thoracic control may still be beneficial in selected cases."
  },
  "2499": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant rationale, and includes correct additional details without any inaccuracies or omissions."
  },
  "2500": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "2501": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the staging distinctions, and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "2502": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional details, and contains no inaccuracies or omissions."
  },
  "2503": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly distinguishing between routine surveillance and diagnostic use of PET/CT, and provides accurate, guideline-based rationale without any inaccuracies or omissions."
  },
  "2504": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and provides relevant additional details without inaccuracies or omissions."
  },
  "2505": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "2506": {
    "score": 5.0,
    "explanation": "5: The model answer accurately identifies that a contralateral pulmonary nodule constitutes M1a (stage IV) disease, clearly explains the staging implications, and provides correct, relevant references with no omissions or inaccuracies."
  },
  "2507": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "2508": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional details, and contains no inaccuracies or omissions."
  },
  "2509": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and relevant rationale, cites guidelines, and contains no inaccuracies or omissions."
  },
  "2510": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the resistance of exon 20 insertions to standard EGFR TKIs, prioritizes chemotherapy, and correctly notes the status of exon 20-specific agents; all additional content is factually correct and clinically relevant."
  },
  "2511": {
    "score": 5.0,
    "explanation": "5: Fully covers all key clinical facts, accurately describes current guideline recommendations, addresses the impact of positive margins, and provides correct, relevant references without any inaccuracies or omissions."
  },
  "2512": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that observation alone is insufficient and that additional local therapy (radiotherapy, possibly chemotherapy) is preferred; it provides accurate, relevant details and guideline references without any inaccuracies or omissions."
  },
  "2513": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that routine FDG-PET/CT or brain MRI is not indicated, and correctly describes standard surveillance with history, physical, and chest CT; additional content is relevant, guideline-based, and free of inaccuracies."
  },
  "2514": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the irrelevance of PD-L1 status when a RET rearrangement is present, and provides additional, correct, and clinically relevant context without any inaccuracies or omissions."
  },
  "2515": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, correctly noting the limited evidence for EGFR-TKIs in SCC with G719X, the preference for chemotherapy as standard, and the possible use of afatinib, but slightly overstates the appropriateness of EGFR-targeted therapy as a primary option rather than emphasizing chemotherapy as preferred, which is a minor wording inaccuracy."
  },
  "2516": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, correctly states that comprehensive molecular profiling is recommended in advanced squamous NSCLC if adequate tissue is available, and explains the rationale. However, it introduces guideline-based qualifiers (age, smoking status) that, while accurate, slightly overemphasize selectivity compared to the reference, which more broadly recommends testing when tissue is available; this constitutes a minor wording inaccuracy."
  },
  "2517": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies chest CT as the preferred modality, and appropriately excludes routine FDG-PET/CT; additional details and references are accurate and clinically relevant."
  },
  "2518": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including the inappropriateness of ado-trastuzumab emtansine in ECOG 3, the rationale regarding toxicity and lack of benefit, and the recommendation for supportive care; additional details are accurate and clinically relevant."
  },
  "2519": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "2520": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "2521": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately cites relevant guidelines, and provides correct, clinically relevant additional detail without any inaccuracies or omissions."
  },
  "2522": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant explanations, cites appropriate guidelines, and contains no inaccuracies or omissions."
  },
  "2523": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, includes relevant selection criteria, and cites authoritative guidelines; there are no inaccuracies or omissions."
  },
  "2524": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the evidence, clarifies the reduced benefit without radiotherapy, and provides appropriate guideline context without any inaccuracies or omissions."
  },
  "2525": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, cites guidelines, and contains no inaccuracies or omissions."
  },
  "2526": {
    "score": 5.0,
    "explanation": "5: Fully covers all key facts from the reference, accurately explains the rationale, and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "2527": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail (including recent trial evidence and risk stratification), and contains no inaccuracies or omissions."
  },
  "2528": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, and includes relevant guideline references and context without any inaccuracies or omissions."
  },
  "2529": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant explanations, cites guidelines, and contains no inaccuracies or omissions."
  },
  "2530": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizes the need to wait for biomarker results, and appropriately notes the exception for urgent cases; all additional content is correct, relevant, and guideline-based."
  },
  "2531": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional details, and contains no inaccuracies or omissions."
  },
  "2532": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and relevant supporting evidence, and contains no inaccuracies or omissions."
  },
  "2533": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that more frequent imaging (every 3–6 months or 6–12 months) is required in the first three years, and provides relevant, correct guideline-based details without inaccuracies or omissions."
  },
  "2534": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately distinguishes between preferred and alternative options, addresses ECOG status, and provides correct, relevant supporting data and guideline references without inaccuracies or omissions."
  },
  "2535": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional explanation, and contains no inaccuracies or omissions."
  },
  "2536": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that sotorasib and adagrasib can be used regardless of PD-L1 status, and provides accurate, relevant supporting details without any inaccuracies or omissions."
  },
  "2537": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional details, and contains no inaccuracies or omissions."
  },
  "2538": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional rationale, and contains no inaccuracies or omissions."
  },
  "2539": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "2540": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes current guideline recommendations, and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "2541": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and relevant guideline-based details, and contains no inaccuracies or omissions."
  },
  "2542": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including the need for caution due to hepatic metabolism, lack of data in significant impairment, and the recommendation to consider alternatives or specialist input; all additional content is accurate and clinically relevant."
  },
  "2543": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately prioritizing surgical resection for resectable locoregional recurrence and appropriately reserving radiotherapy/SABR for non-surgical candidates; all additional content is correct, relevant, and well-supported by guidelines."
  },
  "2544": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and relevant guideline-based rationale, and includes no inaccuracies or omissions."
  },
  "2545": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including prioritizing NTRK inhibitors for NTRK1 fusion-positive NSCLC with brain metastases, the exception for urgent neurological compromise, and provides accurate, relevant rationale and guideline support without inaccuracies or omissions."
  },
  "2546": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional explanation, and contains no inaccuracies or omissions."
  },
  "2547": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, and includes relevant guideline-based details without any inaccuracies or omissions."
  },
  "2548": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, and cites relevant guidelines without any inaccuracies or omissions."
  },
  "2549": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, cites relevant guidelines, and includes no inaccuracies or omissions."
  },
  "2550": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the limited efficacy and CNS penetration of EGFR TKIs (including newer agents), and correctly prioritizes palliative radiotherapy for immediate symptom control, with no inaccuracies or omissions."
  },
  "2551": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the risks, mentions guideline recommendations, and appropriately emphasizes multidisciplinary assessment and alternative strategies, with no inaccuracies or omissions."
  },
  "2552": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizing that surgical re-resection is preferred and radiotherapy is only considered if re-resection is not feasible; all additional content is correct, relevant, and guideline-based, with no omissions or inaccuracies."
  },
  "2553": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including bisphosphonates being contraindicated in severe renal impairment and denosumab being an alternative with the need for calcium/vitamin D supplementation and monitoring; additional content is accurate and clinically relevant."
  },
  "2554": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizes the need for individualized assessment based on prior dose, interval, and toxicity risk, and adds relevant, correct details about guidelines and multidisciplinary evaluation without any inaccuracies or omissions."
  },
  "2555": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and provides relevant guideline-based context without any inaccuracies or omissions."
  },
  "2556": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the TNM staging, the distinction between metastasis and independent primaries, and the need for pathological evidence to classify as two primaries; there are no inaccuracies or omissions."
  },
  "2557": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "2558": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including the unresectability of N3 disease, the contraindication of surgery due to severe pulmonary dysfunction, and the preference for external-beam radiation therapy; all additional explanations are accurate and clinically relevant."
  },
  "2559": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately stating that non-contrast chest CT is appropriate for surveillance and that CKD does not alter the standard imaging schedule; all additional explanations are correct and clinically relevant."
  },
  "2560": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that known germline BRCA1/2 mutation is required for olaparib, and provides accurate, relevant guideline context without any inaccuracies or omissions."
  },
  "2561": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that sotorasib and adagrasib are not first-line treatments and are reserved for use after prior systemic therapy, with accurate and relevant additional detail and no inaccuracies or omissions."
  },
  "2562": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that chemotherapy is preferred over targeted therapy in this scenario, and provides correct, relevant guideline-based rationale without any inaccuracies or omissions."
  },
  "2563": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "2564": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including appropriateness of trastuzumab deruxtecan for HER2-mutant NSCLC with ECOG 0–2 regardless of brain metastases, the need for stability of CNS disease, and the potential requirement for local CNS therapy; all additional content is accurate and clinically relevant."
  },
  "2565": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including the standard indication for PMRT with ≥4 positive nodes, the heightened risk and need for individualized multidisciplinary assessment in the context of poorly controlled heart failure, and the possibility of modifying or omitting radiotherapy if cardiac risk outweighs benefit. All additional content is accurate and clinically relevant."
  },
  "2566": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and provides guideline-based recommendations without any inaccuracies or omissions."
  },
  "2567": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately addresses guideline recommendations, tumor size thresholds, and the relevance of histology, with no inaccuracies or omissions."
  },
  "2568": {
    "score": 4.0,
    "explanation": "4: The model answer correctly states that it is appropriate and standard to continue HER2-targeted therapy postoperatively, but it omits explicit mention of concurrent administration with radiation and endocrine therapy, and does not specify the total one-year duration, resulting in a minor omission."
  },
  "2569": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately addresses the impact of severe thrombocytopenia on both orthopedic stabilization and radiotherapy, and provides correct, clinically relevant additional detail without inaccuracies or omissions."
  },
  "2570": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, correctly emphasizing the need for ovarian suppression/ablation before most endocrine therapies and noting the exception for tamoxifen. However, it introduces nuance about tamoxifen monotherapy that could be interpreted as a minor omission regarding the strict requirement stated in the reference, but overall remains accurate and clinically relevant."
  },
  "2571": {
    "score": 3.0,
    "explanation": "3: The model answer overstates the routine indication for broad molecular profiling in all advanced SCC cases, missing the key nuance that such testing is generally not routinely indicated except in select populations (e.g., never-smokers, young patients); it covers most key facts but contains a moderate inaccuracy regarding current standard practice."
  },
  "2572": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "2573": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that pleurodesis alone is insufficient and systemic therapy targeting the ERBB2 mutation is necessary; additional details and references are accurate and clinically relevant."
  },
  "2574": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional explanation, and contains no inaccuracies or omissions."
  },
  "2575": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly states that micropapillary subtype alone does not justify omission of the 21-gene assay, and provides relevant, accurate guideline-based context without any inaccuracies or omissions."
  },
  "2576": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that neoadjuvant therapy is justified for cT1c, cN0, HER2-positive disease, and provides additional correct, relevant details without any inaccuracies or omissions."
  },
  "2577": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "2578": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that routine surveillance brain MRI is not indicated, cites relevant guidelines, and provides correct rationale without any inaccuracies or omissions."
  },
  "2579": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately stating that adjuvant systemic therapy is not mandatory and that observation is acceptable, while providing relevant, guideline-based details and emphasizing individualized decision-making without any inaccuracies or omissions."
  },
  "2580": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant rationale, cites guidelines, and includes a helpful summary table without any inaccuracies or omissions."
  },
  "2581": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, adds relevant supporting details (clinical trial and guideline context), and contains no inaccuracies or omissions."
  },
  "2582": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "2583": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly prioritizing local bronchoscopic intervention for airway obstruction before systemic therapy, and provides accurate, relevant rationale without any inaccuracies or omissions."
  },
  "2584": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly states that targeted therapy can be initiated before completing the current regimen, and provides additional, accurate, and clinically relevant explanations without any inaccuracies or omissions."
  },
  "2585": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "2586": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes exceptions for molecular testing in SCC, and correctly emphasizes universal PD-L1 testing; additional details are correct and clinically relevant."
  },
  "2587": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, correctly emphasizing that chemoradiation is preferred over chemotherapy alone and discussing the rationale and guideline support. However, it incorrectly states that chemotherapy alone is not acceptable, whereas the reference answer specifies that both approaches are considered acceptable, though chemoradiation is preferred. This represents a moderate factual omission."
  },
  "2588": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, guideline recommendations, and the roles of re-excision and systemic therapy, with no omissions or inaccuracies."
  },
  "2589": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly prioritizing bisphosphonates/denosumab in the absence of symptoms or fracture risk, and appropriately reserving radiotherapy for symptomatic or high-risk lesions. There are no inaccuracies or omissions."
  },
  "2590": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional explanation, and contains no inaccuracies or omissions."
  },
  "2591": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional details, and contains no inaccuracies or omissions."
  },
  "2592": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately prioritizing re-resection if feasible and reserving chemoradiation for inoperable cases, with correct, relevant guideline references and no inaccuracies or omissions."
  },
  "2593": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and relevant additional detail, and contains no inaccuracies or omissions."
  },
  "2594": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes exceptions, provides relevant guideline references, and adds correct, clinically relevant context without any inaccuracies or omissions."
  },
  "2595": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately prioritizing TRK inhibitors over chemotherapy, addresses the irrelevance of prior radiotherapy, and provides correct, relevant rationale and guideline references without any inaccuracies or omissions."
  },
  "2596": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale and supporting evidence, and contains no inaccuracies or omissions."
  },
  "2597": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, includes relevant guideline recommendations, and appropriately addresses rare exceptions without any inaccuracies or omissions."
  },
  "2598": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that chest wall radiotherapy is indicated for any positive margin regardless of size or nodal status, and provides relevant, guideline-based rationale without inaccuracies or omissions."
  },
  "2599": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional details, and contains no inaccuracies or omissions."
  },
  "2600": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, including the indication for brain MRI in staging, the risks of gadolinium in severe CKD, and alternative imaging options. However, it initially states that contrast-enhanced MRI is \"still indicated\" without immediately clarifying that contrast is contraindicated in severe CKD, which could be misleading; this minor inaccuracy prevents a perfect score."
  },
  "2601": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the implications of R2 resection, and clearly states that observation alone is not standard; all additional details are correct and clinically relevant."
  },
  "2602": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, correctly noting the rarity of EGFR exon 20 insertions in squamous histology, the need for confirmation, and the appropriateness of specific targeted agents (amivantamab, mobocertinib), while cautioning about histological misclassification. However, it slightly overstates guideline support for routine use in squamous histology, where evidence and recommendations remain more cautious, representing a minor wording inaccuracy."
  },
  "2603": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, cites relevant guidelines, and contains no inaccuracies or omissions."
  },
  "2604": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly prioritizing re-resection with systemic therapy when feasible, and appropriately relegates chemoradiation to cases where surgery is not possible. Additional content is accurate, guideline-based, and clinically relevant, with no inaccuracies or omissions."
  },
  "2605": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant explanations, and includes supporting evidence and guidelines without any inaccuracies or omissions."
  },
  "2606": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "2607": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the shift to stage IV disease and prioritizes systemic therapy, but it omits the key reference recommendation of combining local therapy for the metastatic site with standard concurrent chemoradiation for locoregional disease in oligometastatic cases, thus missing a central management principle."
  },
  "2608": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, cites guidelines, and provides relevant details without inaccuracies or omissions."
  },
  "2609": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately stating that ALK inhibitor therapy is appropriate if an ALK rearrangement is confirmed, regardless of squamous histology. Additional content is factually correct, clinically relevant, and provides useful context without introducing inaccuracies or omissions."
  },
  "2610": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that significant hepatic dysfunction is a contraindication to T-DM1 regardless of age, and provides accurate, clinically relevant elaboration without any inaccuracies or omissions."
  },
  "2611": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and provides correct, clinically relevant additional details without any inaccuracies or omissions."
  },
  "2612": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizing that adjuvant therapy consideration is not strictly limited by histology or molecular markers, and provides additional, relevant clinical context without inaccuracies or omissions."
  },
  "2613": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, adds relevant rationale and guideline citations, and contains no inaccuracies or omissions."
  },
  "2614": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides additional accurate and relevant details, and contains no inaccuracies or omissions."
  },
  "2615": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly states that switching to an EGFR TKI upon mutation detection is appropriate, and provides additional, accurate, and clinically relevant context about mutation sensitivity and TKI selection without any inaccuracies or omissions."
  },
  "2616": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the concurrent and individualized approach, and provides relevant, correct additional details without any inaccuracies or omissions."
  },
  "2617": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and relevant guideline-based details, and contains no inaccuracies or omissions."
  },
  "2618": {
    "score": 5.0,
    "explanation": "5: Fully covers all key clinical facts from the reference, clearly explains rationale, cites guidelines, and includes no inaccuracies or omissions."
  },
  "2619": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional explanation, and contains no inaccuracies or omissions."
  },
  "2620": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, correctly noting that adjuvant therapy is standard but may be precluded by significant pulmonary impairment, and emphasizes individualized assessment and surveillance if therapy is unsafe. However, it is less direct than the reference in stating that significant impairment is a contraindication, and could be clearer that observation is favored in such cases, representing a minor omission."
  },
  "2621": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the upstaging to at least stage IIIA, the impact on management, and the need for multidisciplinary input, with no inaccuracies or omissions."
  },
  "2622": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly states that systemic therapy alone is insufficient, and that chemoradiation (sequential or concurrent) is preferred due to the need for local control. Additional content is accurate, relevant, and guideline-based, with no inaccuracies or omissions."
  },
  "2623": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly prioritizing laser/photic therapy for immediate bleeding control and explaining the delayed effect of RT; all additional content is accurate, relevant, and enhances clinical understanding without any omissions or inaccuracies."
  },
  "2624": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional details, cites guidelines, and contains no inaccuracies or omissions."
  },
  "2625": {
    "score": 1.0,
    "explanation": "1: The model answer directly contradicts the reference by recommending immediate initiation of alectinib rather than completing current systemic therapy first, which is a major inaccuracy and could lead to inappropriate treatment sequencing."
  },
  "2626": {
    "score": 4.0,
    "explanation": "4: The model answer correctly states that N3 disease generally precludes surgery as initial therapy and that surgery is not recommended, but its initial \"No\" and phrasing could be misinterpreted as allowing for exceptions outside of clinical trials or highly selected cases, which is a minor wording inaccuracy. Otherwise, it covers ≥90% of key facts."
  },
  "2627": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and provides relevant guideline support without any inaccuracies or omissions."
  },
  "2628": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly explains that RNI is still recommended based on initial clinical N2 status regardless of final node count, and provides accurate, relevant guideline references with no inaccuracies or omissions."
  },
  "2629": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "2630": {
    "score": 2.0,
    "explanation": "2: The model answer recommends immediate switching to a TRK inhibitor and explicitly advises against completing planned systemic therapy, which contradicts the reference answer stating both options are acceptable and should be individualized; this is a moderate factual omission and overstates the guideline preference."
  },
  "2631": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts in the reference, provides accurate and clinically relevant rationale, and cites current guidelines and evidence; there are no inaccuracies or omissions."
  },
  "2632": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "2633": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the contraindication, provides rationale, cites guidelines, and appropriately suggests alternative approaches without any inaccuracies or omissions."
  },
  "2634": {
    "score": 5.0,
    "explanation": "5: Fully covers all key clinical facts from the reference, provides accurate and relevant guideline-based rationale, and contains no inaccuracies or omissions."
  },
  "2635": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly states that concurrent chemoradiation is preferred over chemotherapy alone for R2 margins, and provides accurate, relevant rationale and guideline support without any inaccuracies or omissions."
  },
  "2636": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that preoperative systemic therapy is indicated for cT1c, cN0, triple-negative breast cancer without need for additional high-risk pathology, and provides relevant, correct guideline-based context without inaccuracies or omissions."
  },
  "2637": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that annual low-dose non-contrast chest CT is sufficient after 2–3 years, and that contrast is not routinely required. Additional content is correct, relevant, and guideline-based, with no inaccuracies or omissions."
  },
  "2638": {
    "score": 1.0,
    "explanation": "1: The model answer directly contradicts the reference by stating that treating both lesions as separate primaries does not require both to be potentially curable, which is a major inaccuracy and misses the key clinical fact that this approach is only considered if both are potentially curable."
  },
  "2639": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that routine FDG-PET/CT or brain MRI is not indicated, details standard surveillance with chest CT, and provides relevant guideline references without any inaccuracies or omissions."
  },
  "2640": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately lists relevant high-risk features, and provides correct, clinically relevant additional context without inaccuracies or omissions."
  },
  "2641": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that RET-targeted therapy is standard first-line regardless of PD-L1, and provides correct, relevant additional details without any inaccuracies or omissions."
  },
  "2642": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly prioritizing systemic therapy, explaining the rationale, and appropriately discussing the role of local therapies for both brain and thoracic disease, with no inaccuracies or omissions."
  },
  "2643": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains both the staging and pulmonary contraindications, and correctly identifies chemoradiotherapy as the standard of care, with no inaccuracies or omissions."
  },
  "2644": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizes the necessity of pathologic exclusion of N2–3 disease before surgery, and provides relevant, correct elaboration without any inaccuracies or omissions."
  },
  "2645": {
    "score": 2.0,
    "explanation": "2: The model answer directly contradicts the reference by stating adjuvant systemic therapy is generally not indicated after neoadjuvant therapy and resection, regardless of N0 or N1 status, which is a moderate factual error and omits the key recommendation that adjuvant therapy is indicated in this scenario; however, it does not provide unsafe advice."
  },
  "2646": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, cites guidelines, and contains no inaccuracies or omissions."
  },
  "2647": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant guideline-based rationale, and contains no inaccuracies or omissions."
  },
  "2648": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, correctly stating that re-resection is preferred and radiotherapy is considered if re-resection is not possible, but it incorrectly asserts that radiotherapy is only recommended when re-resection is not feasible, omitting that radiotherapy may be considered as an alternative even if re-resection is possible (albeit as a lower-category option)."
  },
  "2649": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, adds correct and clinically relevant details (e.g., pCR, adjuvant capecitabine, guideline references), and contains no inaccuracies or omissions."
  },
  "2650": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant rationale, and includes no inaccuracies or omissions. Additional content is correct and enhances understanding."
  },
  "2651": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, cites relevant guidelines, and provides additional clinically relevant context without inaccuracies or omissions."
  },
  "2652": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional details on efficacy, toxicity, and guidelines, and contains no inaccuracies or omissions."
  },
  "2653": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale and guideline citations, and contains no inaccuracies or omissions."
  },
  "2654": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, accurately explains the distinction between metastatic disease and synchronous primaries, and provides relevant, guideline-based detail without inaccuracies or omissions."
  },
  "2655": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, including the distinction between metastatic disease and synchronous primaries, and the criteria for differentiating them. However, it incorrectly states that the default is to manage as metastatic (M1a) disease unless proven otherwise, whereas the reference emphasizes that if both lesions are potentially curable, they should be managed as two primaries despite M1a staging. This represents a moderate omission in clinical nuance."
  },
  "2656": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "2657": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale for the sequence, and includes relevant details about indications and timing without any inaccuracies or omissions."
  },
  "2658": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, including the need for dose reduction and close monitoring, but overstates appropriateness by suggesting TRK inhibitor initiation is standard in Child-Pugh B without emphasizing that use is not routinely appropriate and requires careful risk assessment; this is a moderate omission."
  },
  "2659": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes guideline recommendations, relevant patient subgroups, and the rationale for testing, with no inaccuracies or omissions."
  },
  "2660": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes current guideline recommendations, and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "2661": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, correctly recommends broad molecular profiling regardless of prior radiotherapy, and lists most relevant targets, but omits explicit mention of PD-L1 and HER2/ERBB2 testing, and slightly overemphasizes selective testing based on clinical features, which is less aligned with current broad testing recommendations."
  },
  "2662": {
    "score": 4.0,
    "explanation": "4: The model answer covers over 90% of the key facts, correctly stating that PET/CT and brain MRI are not part of routine surveillance but are indicated for further evaluation of a new nodule; however, it goes beyond the reference by recommending PET/CT in this scenario, which is reasonable but not strictly within the \"routine surveillance\" context asked, making the answer slightly less precise."
  },
  "2663": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes current guidelines, and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "2664": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional details about surveillance intervals and indications for PET/CT or brain MRI, and cites appropriate guidelines with no inaccuracies or omissions."
  },
  "2665": {
    "score": 2.0,
    "explanation": "2: The model answer covers the staging and criteria for distinguishing metastatic disease from synchronous primaries, but it directly contradicts the reference answer's key clinical fact: that technically resectable solitary contralateral nodules (N0, M1a) should be managed as synchronous primaries. This is a moderate factual error and a major omission of the recommended management approach."
  },
  "2666": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant explanations, cites guidelines, and appropriately notes rare exceptions without introducing any inaccuracies or omissions."
  },
  "2667": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional explanations, and contains no inaccuracies or omissions."
  },
  "2668": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, clearly stating that ALK and ROS1 rearrangements must be excluded before recommending EGFR-targeted therapy, and provides accurate, relevant rationale without any inaccuracies or omissions."
  },
  "2669": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the tumor profile, guideline recommendations, and rationale for neoadjuvant therapy, and provides relevant, correct additional details without any inaccuracies or omissions."
  },
  "2670": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, accurately cites guidelines and pivotal trials, and correctly explains that chemo-immunotherapy can be initiated without known PD-L1 status; all additional content is factually correct and clinically relevant."
  },
  "2671": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that neoadjuvant systemic therapy is indicated and standard of care, and provides relevant, correct rationale without any inaccuracies or omissions."
  },
  "2672": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, discusses alternative options, and provides relevant references without any inaccuracies or omissions."
  },
  "2673": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately cites guideline recommendations, and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "2674": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that ALND is the standard of care for a single biopsy-proven axillary node in early-stage breast cancer, omitting that SLN mapping and excision remain appropriate in this scenario per current guidelines; this is a moderate factual error that could lead to overtreatment."
  },
  "2675": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that routine FDG-PET/CT is not recommended, and appropriately describes when PET/CT may be considered; all additional content is correct and clinically relevant."
  },
  "2676": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains that M1c does not alter eligibility, and provides correct, relevant details about indications and criteria for KRAS G12C inhibitors without any inaccuracies or omissions."
  },
  "2677": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, adds relevant and accurate details about risk, multidisciplinary evaluation, and alternative options, and contains no inaccuracies or omissions."
  },
  "2678": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional context, and contains no inaccuracies or omissions."
  },
  "2679": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately stating that nodal involvement is not required for adjuvant chemotherapy with trastuzumab in this scenario, and provides correct, relevant guideline-based explanations without any inaccuracies or omissions."
  },
  "2680": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizes RET-targeted therapy as first-line, addresses brain metastases, provides relevant rationale, and includes no inaccuracies or omissions."
  },
  "2681": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately cites guidelines, and provides relevant rationale without any inaccuracies or omissions."
  },
  "2682": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale for broad molecular profiling, lists relevant targetable alterations, and cites guideline recommendations, with no inaccuracies or omissions."
  },
  "2683": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, cites relevant guidelines, and makes no errors or omissions."
  },
  "2684": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant rationale, cites guidelines, and contains no inaccuracies or omissions."
  },
  "2685": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly explains why omission of ALND is not appropriate post-neoadjuvant chemotherapy, references relevant guidelines and trials, and includes no inaccuracies or omissions."
  },
  "2686": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately prioritizing palliative radiotherapy for symptomatic diffuse brain metastases and appropriately noting exceptions for CNS-active targeted therapies; all additional content is clinically relevant and correct."
  },
  "2687": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that concurrent chemoradiation is only recommended if distant metastases are excluded, and provides accurate, relevant rationale without any inaccuracies or omissions."
  },
  "2688": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts and provides strong guideline-based rationale for switching to ALK-targeted therapy, but it omits the reference answer's nuance that either completing current therapy or switching immediately are both valid, and that the decision should be individualized based on response and tolerability."
  },
  "2689": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "2690": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, adds accurate and clinically relevant details (including guideline citations and supporting evidence), and contains no inaccuracies or omissions."
  },
  "2691": {
    "score": 3.0,
    "explanation": "3: The model answer correctly explains that classification as two primaries is based on clinical and pathological criteria, not curability, but it omits the key clinical fact that management as two primaries is only pursued if both lesions are potentially curable; this is a moderate omission."
  },
  "2692": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts and provides strong rationale for switching to ROS1-targeted therapy, but it incorrectly states that ongoing therapy should be interrupted immediately, omitting that completing current therapy is also an acceptable option per guidelines; this is a moderate omission."
  },
  "2693": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states the preference for RET-targeted therapy, provides correct rationale, cites relevant guidelines, and includes no inaccuracies or omissions."
  },
  "2694": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describing current guidelines, the rationale for selective testing in squamous NSCLC, and the clinical scenarios where molecular profiling is appropriate, with no inaccuracies or omissions."
  },
  "2695": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, including the appropriateness of local therapy in select oligometastatic NSCLC cases, but incorrectly states that immediate local therapy instead of systemic therapy is not standard, which contradicts the reference answer's acceptance of local therapy as an initial approach in carefully staged patients. This represents a moderate omission and some overemphasis on systemic therapy as mandatory first-line, lowering the score."
  },
  "2696": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides additional accurate and clinically relevant detail, and contains no inaccuracies or omissions."
  },
  "2697": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the role of HER2 status in therapy selection, and provides relevant, correct additional details without any inaccuracies or omissions."
  },
  "2698": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that surveillance frequency does not differ, missing the key fact that post-radiotherapy surveillance is recommended every 3–6 months, while post-surgical surveillance is every 6 months; this is a moderate factual omission, though the rest of the content is accurate and well-referenced."
  },
  "2699": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the limited utility of the 21-gene assay in this low-risk subgroup, and provides relevant guideline-based context without inaccuracies or omissions."
  },
  "2700": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizes the necessity of HER2-targeted therapy, and provides relevant, guideline-based details without inaccuracies or omissions."
  },
  "2701": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including the inappropriateness of systemic therapy for ECOG 3, the primacy of best supportive care, and the rare exception if PS decline is reversible. Additional content is accurate, relevant, and guideline-based, with no inaccuracies or omissions."
  },
  "2702": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately distinguishing between follow-up after surgery versus radiotherapy and after resected oligometastatic disease, and provides correct, relevant guideline-based details without inaccuracies or omissions."
  },
  "2703": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant explanations, and contains no inaccuracies or omissions."
  },
  "2704": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately cites relevant guidelines, and clearly states that low-dose non-contrast chest CT is sufficient for surveillance in this context, with no inaccuracies or omissions."
  },
  "2705": {
    "score": 1.0,
    "explanation": "1: The model answer directly contradicts the reference by recommending immediate initiation of targeted therapy rather than completing planned systemic therapy first, which is a major inaccuracy and could lead to inappropriate clinical decisions."
  },
  "2706": {
    "score": 5.0,
    "explanation": "5: Fully covers all key facts from the reference, clearly states that preoperative pulmonary function assessment is mandatory, and provides correct, relevant reasoning without inaccuracies or omissions."
  },
  "2707": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizes the need to exclude distant metastases before concurrent chemoradiation, and provides relevant, correct explanations without any inaccuracies or omissions."
  },
  "2708": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, adds relevant and accurate details about performance status, guideline support, and molecularly targeted therapies, and contains no inaccuracies or omissions."
  },
  "2709": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional details (trial data, guideline recommendations, rationale), and contains no inaccuracies or omissions."
  },
  "2710": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately cites supporting evidence and guidelines, and provides clear, clinically relevant recommendations without any inaccuracies or omissions."
  },
  "2711": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the staging implications, management changes, and provides correct, relevant additional detail without any inaccuracies or omissions."
  },
  "2712": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "2713": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides additional correct and clinically relevant explanations, and contains no inaccuracies or omissions."
  },
  "2714": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly distinguishes between resected and unresectable stage III disease, accurately references current guidelines, and provides relevant, factually correct explanations without any inaccuracies or omissions."
  },
  "2715": {
    "score": 2.0,
    "explanation": "2: The model answer covers the trial-based exclusion of ECOG 2 and real-world considerations, but it incorrectly states that ECOG 2 is an exclusion criterion for treatment, missing that guidelines and clinical practice do allow use in ECOG 2; this is a moderate factual omission."
  },
  "2716": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately addresses the indication for adjuvant therapy, the impact of renal insufficiency, and the need for individualized, multidisciplinary decision-making, with no inaccuracies or omissions."
  },
  "2717": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and relevant guideline-based details, and contains no inaccuracies or omissions."
  },
  "2718": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains current guidelines, and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "2719": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and adds relevant details about restaging and management shifts without any inaccuracies or omissions."
  },
  "2720": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that adjuvant systemic therapy is not routinely indicated, and provides additional relevant, correct context regarding guidelines and evidence without any inaccuracies or omissions."
  },
  "2721": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including the preference for surgery in operable patients, the rationale, and guideline support, with no inaccuracies or omissions."
  },
  "2722": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that surgical resection assumes absence of distant metastasis, and provides accurate, relevant rationale without any inaccuracies or omissions."
  },
  "2723": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains current surveillance guidelines, and provides relevant rationale without any inaccuracies or omissions."
  },
  "2724": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale regarding cumulative toxicity, and clearly states that concurrent chemoradiation presumes no prior such therapy; there are no inaccuracies or omissions."
  },
  "2725": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional details, and contains no inaccuracies or omissions."
  },
  "2726": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, cites relevant guidelines, and includes additional correct and clinically relevant details about margin status and risk factors, with no inaccuracies or omissions."
  },
  "2727": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, and appropriately outlines alternative management; there are no inaccuracies or omissions."
  },
  "2728": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, adds relevant detail about patient selection and multidisciplinary evaluation, and contains no inaccuracies or omissions."
  },
  "2729": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly explains that SVC stenting and/or EBRT are appropriate and that repeating concurrent chemoradiation is not indicated after prior definitive treatment; additional details are accurate and clinically relevant."
  },
  "2730": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly states that concurrent chemoradiation is standard for stage IIIC NSCLC, addresses the relevance of mild, well-controlled COPD, and adds accurate, relevant detail without inaccuracies or omissions."
  },
  "2731": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, and includes relevant guideline references and clarifications without any inaccuracies or omissions."
  },
  "2732": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including the contraindication of radiation during pregnancy, the necessity of radiation after BCS, the risks of delaying radiation, and the recommendation for mastectomy with axillary staging; all additional explanations are accurate and clinically relevant."
  },
  "2733": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant elaboration, and contains no inaccuracies or omissions."
  },
  "2734": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, including the aggressive nature of triple-negative, node-positive disease and the general guideline recommendations, but it omits the important nuance that uncommon subtypes like tubular carcinoma may require further pathological risk assessment due to their distinct prognosis and sensitivity to therapy, as highlighted in the reference."
  },
  "2735": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional details, and contains no inaccuracies or omissions."
  },
  "2736": {
    "score": 2.0,
    "explanation": "2: The model answer covers less than 70% of the key facts, incorrectly stating that RET-targeted therapy should not be prioritized first-line in squamous histology despite FDA histology-agnostic approval and the reference's clear recommendation to prioritize RET-targeted therapy; it overemphasizes the lack of trial data and guideline conservatism, constituting a moderate factual omission."
  },
  "2737": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that routine brain MRI is not indicated, and provides relevant, correct guideline-based explanations without any inaccuracies or omissions."
  },
  "2738": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional explanation, and cites appropriate guidelines without any inaccuracies or omissions."
  },
  "2739": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the contraindication of standard chemotherapy due to renal impairment, and appropriately addresses the limited role of radiotherapy post-R0 resection. There are no inaccuracies or omissions, and extra content is correct and clinically relevant."
  },
  "2740": {
    "score": 0.0,
    "explanation": "0: The model answer directly contradicts the reference by stating brain MRI is not mandatory in asymptomatic stage II NSCLC, which is a clinically significant inaccuracy that could lead to under-staging and inappropriate management."
  },
  "2741": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizes the preference for systemic therapy plus radiotherapy over systemic therapy alone, and provides correct, guideline-based rationale without inaccuracies or omissions."
  },
  "2742": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "2743": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly explains the rationale against repeat concurrent chemoradiation, and appropriately discusses alternative management options without any inaccuracies or omissions."
  },
  "2744": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, including the appropriateness of adjuvant chemotherapy and the general lack of routine indication for PORT in N1, R0 disease, but it introduces nuanced discussion about PORT that may confuse the core message and slightly overcomplicates the answer compared to the reference, which is more direct and clear."
  },
  "2745": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that axillary lymph node dissection is mandatory in this scenario, which is a moderate factual error, as current guidelines allow for omission of ALND when only one node is positive post-neoadjuvant therapy; otherwise, the answer is detailed and relevant."
  },
  "2746": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "2747": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, and includes relevant supporting details and references without any inaccuracies or omissions."
  },
  "2748": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, includes relevant guideline references, and clearly states the exception for urgent cases; there are no inaccuracies or omissions."
  },
  "2749": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that sublobar resection may be preferred in high-risk patients, while also providing accurate, relevant context and supporting evidence without inaccuracies or omissions."
  },
  "2750": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale for contraindication, and appropriately discusses alternative options without any inaccuracies or omissions."
  },
  "2751": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that adjuvant radiation is standard after R1 resection even if chemotherapy was given, and that surveillance alone is not appropriate; all additional content is accurate and clinically relevant."
  },
  "2752": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizes that systemic therapy is indicated regardless of T stage, and provides additional correct and relevant clinical context without any inaccuracies or omissions."
  },
  "2753": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly prioritizing local stabilization/radiotherapy for imminent fracture risk and appropriately sequencing EGFR-targeted therapy. Additional explanations and references are accurate and clinically relevant, with no omissions or inaccuracies."
  },
  "2754": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "2755": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, adds accurate and clinically relevant details (criteria for distinguishing primaries vs. metastasis), and contains no inaccuracies or omissions."
  },
  "2756": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "2757": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizes the necessity of biomarker testing before initiating therapy, and appropriately notes exceptions for unstable patients; all additional content is correct and clinically relevant."
  },
  "2758": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional context, and contains no inaccuracies or omissions."
  },
  "2759": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that adjuvant pembrolizumab is appropriate only if prior immune-related adverse events do not contraindicate further use, and provides accurate, clinically relevant detail without inaccuracies or omissions."
  },
  "2760": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly states that routine FDG-PET/CT and brain MRI are not indicated, and provides accurate, relevant explanations without any inaccuracies or omissions."
  },
  "2761": {
    "score": 5.0,
    "explanation": "5: Comprehensive answer that covers all key facts from the reference, accurately cites relevant guidelines, and provides clear rationale without any inaccuracies or omissions."
  },
  "2762": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly prioritizing immediate local management for bone lesions at high fracture risk and recommending systemic ALK-targeted therapy after stabilization. Additional details are accurate and clinically relevant, with no omissions or inaccuracies."
  },
  "2763": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly explaining when surgery may be preferred over EBRT, and adds relevant, accurate clinical context without inaccuracies or omissions."
  },
  "2764": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, including the rarity of MET exon 14 mutations in squamous histology, the lack of FDA approval for crizotinib in this setting, and current guideline recommendations. However, it incorrectly states that crizotinib is not preferred, whereas the reference answer affirms MET-targeted therapy as preferred based on mutation-specific efficacy, leading to a significant interpretive discrepancy."
  },
  "2765": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately prioritizing systemic therapy before surgery and explaining the rationale; additional details are correct and clinically relevant, with no omissions or inaccuracies."
  },
  "2766": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the upstaging to stage IV, prioritization of systemic therapy, and the role of local brain radiotherapy, with additional relevant and correct details and no inaccuracies or omissions."
  },
  "2767": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant guideline-based details, and contains no inaccuracies or omissions."
  },
  "2768": {
    "score": 4.0,
    "explanation": "4: The model answer covers over 90% of the key facts, accurately distinguishing between pre- and postmenopausal recommendations and noting the appropriateness of tamoxifen and aromatase inhibitors. However, it omits the specific preference for aromatase inhibitors in postmenopausal women under 60 or with thromboembolic risk, which is a minor omission."
  },
  "2769": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including the rationale for broad profiling, examples of other actionable mutations, therapeutic implications, and guideline recommendations, with no inaccuracies or omissions."
  },
  "2770": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, clearly stating that adjuvant endocrine therapy with ovarian suppression is recommended regardless of nodal status, and provides accurate, relevant rationale and guideline references without any inaccuracies or omissions."
  },
  "2771": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly prioritizing EBRT in the context of high surgical risk, and provides accurate, relevant explanations without any inaccuracies or omissions."
  },
  "2772": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional rationale, and includes no inaccuracies or omissions."
  },
  "2773": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant guideline-based rationale, and contains no inaccuracies or omissions."
  },
  "2774": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly stating that PORT is generally considered but contraindicated with severe pulmonary dysfunction, and suggests alternative management options without any inaccuracies or omissions."
  },
  "2775": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that routine brain MRI is not indicated, and provides correct, relevant guideline-based rationale without any inaccuracies or omissions."
  },
  "2776": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, emphasizes the necessity of PFTs before perioperative therapy, and provides relevant guideline references without inaccuracies or omissions."
  },
  "2777": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately prioritizing cytotoxic chemotherapy for symptomatic visceral disease and explaining the rationale. Additional content is factually correct, clinically relevant, and guideline-based, with no inaccuracies or omissions."
  },
  "2778": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and relevant additional detail, and contains no inaccuracies or omissions."
  },
  "2779": {
    "score": 3.0,
    "explanation": "3: The model answer incorrectly states that CT every 6 months is guideline-concordant, omitting that every 3–6 months is recommended and that 6-monthly alone is insufficient; it also incorrectly asserts that more frequent imaging is not supported, missing the nuance that more frequent (every 3–6 months) is preferred early post-treatment."
  },
  "2780": {
    "score": 3.0,
    "explanation": "3: The model answer is thorough and evidence-based but asserts a clear preference for re-resection plus systemic therapy, whereas the reference states there is no definitive evidence of superiority and that both are acceptable options. This overstates the evidence and omits the need for individualized decision-making, missing a key nuance."
  },
  "2781": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes current guideline recommendations, and provides relevant additional detail without inaccuracies or omissions."
  },
  "2782": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides additional relevant and accurate details about specific agents, and contains no inaccuracies or omissions."
  },
  "2783": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional details, and contains no inaccuracies or omissions."
  },
  "2784": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately stating that observation remains appropriate and systemic therapy is not mandated in the absence of metastasis, while providing additional, relevant clinical context without inaccuracies or omissions."
  },
  "2785": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "2786": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that perioperative therapy requires operability and that inoperable patients should receive definitive chemoradiation; there are no inaccuracies or omissions."
  },
  "2787": {
    "score": 5.0,
    "explanation": "5: The model answer accurately covers all key clinical facts from the reference, including appropriateness of capmatinib or tepotinib use in this setting and the irrelevance of smoking status; there are no omissions or inaccuracies."
  },
  "2788": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that olaparib is not appropriate without confirmed germline BRCA1/2 mutation, and provides correct, relevant rationale and references without any inaccuracies or omissions."
  },
  "2789": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly prioritizes olaparib over capecitabine, provides accurate rationale and supporting evidence, and includes only relevant, factually correct additional details without any inaccuracies or omissions."
  },
  "2790": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, guideline support, and relevant details about the role of MRI, with no omissions or inaccuracies."
  },
  "2791": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizes that eligibility is based on molecular status and not smoking history, and provides additional correct and relevant context without any inaccuracies or omissions."
  },
  "2792": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the lack of evidence for sotorasib in ECOG PS 3, and appropriately emphasizes that it is not a standard option, with no inaccuracies or omissions."
  },
  "2793": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts and provides relevant, up-to-date evidence, but it overstates the acceptability of omitting ALND in this scenario, whereas the reference states ALND is generally mandated if residual nodal disease is present; this represents a moderate factual inaccuracy regarding standard practice."
  },
  "2794": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, lists relevant high-risk features, and provides correct, clinically relevant additional detail without any inaccuracies or omissions."
  },
  "2795": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that the indication for concurrent chemoradiation assumes no prior such therapy, and explains the rationale regarding toxicity; there are no inaccuracies or omissions."
  },
  "2796": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, cites relevant guidelines and trials, and contains no inaccuracies or omissions."
  },
  "2797": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately cites guidelines, and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "2798": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately addresses the appropriateness of non-contrast CT in CKD, and provides relevant guideline-based context without any inaccuracies or omissions."
  },
  "2799": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional details, and contains no inaccuracies or omissions."
  },
  "2800": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, cites relevant guidelines, and contains no inaccuracies or omissions."
  },
  "2801": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, adds accurate and relevant details (guidelines, drug names, histology considerations), and contains no inaccuracies or omissions."
  },
  "2802": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, details the evaluation process, and appropriately prioritizes SBRT for patients with significant PFT impairment; there are no inaccuracies or omissions."
  },
  "2803": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately prioritizing concurrent chemoradiation, discussing exceptions, and providing relevant context for SVC obstruction management without inaccuracies or omissions."
  },
  "2804": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "2805": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that ovarian suppression with endocrine therapy is the primary treatment and that bone-modifying agents should be added concurrently, not instead of systemic therapy. Additional explanations are accurate, relevant, and there are no inaccuracies or omissions."
  },
  "2806": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant rationale, cites guidelines, and contains no inaccuracies or omissions."
  },
  "2807": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including the default metastatic classification, the exception for distinct primaries, criteria for distinction, and the importance of multidisciplinary evaluation, with no inaccuracies or omissions."
  },
  "2808": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant explanations, and includes no inaccuracies or omissions. Additional content is correct and enhances clarity."
  },
  "2809": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately details the staging change, surgical considerations, and the need for multidisciplinary evaluation, with no inaccuracies or omissions."
  },
  "2810": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly explains why observation is inappropriate in symptomatic locoregional recurrence, and discusses appropriate alternative interventions; there are no inaccuracies or omissions."
  },
  "2811": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the nuanced decision-making for T1b HER2+ tumors, and provides correct, clinically relevant additional detail without inaccuracies or omissions."
  },
  "2812": {
    "score": 5.0,
    "explanation": "5: The model answer correctly states that current smoking and COPD increase risk and that follow-up imaging is recommended for high-risk patients per Fleischner 2017 guidelines, accurately reflecting the nuanced guideline distinction and providing appropriate recommendations for this clinical scenario."
  },
  "2813": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides additional relevant details (e.g., specific markers, rationale, exceptions), and contains no inaccuracies or omissions."
  },
  "2814": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and provides relevant guideline context without any inaccuracies or omissions."
  },
  "2815": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that routine FDG-PET/CT or brain MRI is not indicated, and provides relevant guideline-based details without inaccuracies or omissions."
  },
  "2816": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional details, cites supporting evidence and guidelines, and contains no inaccuracies or omissions."
  },
  "2817": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and provides relevant guideline references; additional content is correct and clinically relevant, with no inaccuracies or omissions."
  },
  "2818": {
    "score": 2.0,
    "explanation": "2: The model answer covers the staging and standard management for M1a disease but directly contradicts the reference by stating management assumes metastatic disease, not potentially resectable primaries; it omits the key fact that, in select N0M1a cases with solitary contralateral nodules, management may presume distinct primaries amenable to curative treatment."
  },
  "2819": {
    "score": 3.0,
    "explanation": "3: The model answer correctly explains that EBRT is standard for unresectable stage IIIA NSCLC and not solely for obstruction or recurrence, but it misses the key reference point that EBRT in this specific context \"typically implies\" such issues, thus omitting the nuance that its use is not routine for all stage IIIA solitary nodules."
  },
  "2820": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, cites relevant guidelines, and contains no inaccuracies or omissions."
  },
  "2821": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "2822": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides relevant guideline details, and includes correct, clinically pertinent additional information without inaccuracies or omissions."
  },
  "2823": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the indication for amivantamab-vmjw, addresses the role of molecular profiling, and provides relevant, correct additional context without any inaccuracies or omissions."
  },
  "2824": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "2825": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, cites guidelines, and includes no inaccuracies or omissions. Additional content is correct and clinically relevant."
  },
  "2826": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that BRAF inhibitors can be used first-line in BRAF V600E-mutant SCC, and provides relevant, correct additional context without any inaccuracies or omissions."
  },
  "2827": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly explains the dependence on HR and HER2 status, and affirms that cT1c, cN0 triple-negative tumors are routinely considered for preoperative systemic therapy, with correct and relevant elaboration and no inaccuracies."
  },
  "2828": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states the preference for ROS1 inhibitors, addresses the rarity in squamous histology, cites relevant guidelines, and provides correct, clinically relevant additional details without inaccuracies or omissions."
  },
  "2829": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale and relevant guideline references, and contains no inaccuracies or omissions."
  },
  "2830": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, provides accurate and clinically relevant explanations, cites appropriate guidelines, and contains no inaccuracies or omissions."
  },
  "2831": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant explanations, cites guidelines, and contains no inaccuracies or omissions."
  },
  "2832": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately stating that broad molecular profiling is not required if an NTRK fusion is confirmed, and provides additional, relevant context without introducing inaccuracies or omissions."
  },
  "2833": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, cites relevant guidelines, and contains no inaccuracies or omissions."
  },
  "2834": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "2835": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that observation alone is appropriate, and provides additional relevant context regarding individualized decision-making and guideline recommendations, with no inaccuracies or omissions."
  },
  "2836": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly states that KRAS G12C inhibitors are not appropriate when other actionable drivers are present, and correctly explains the rationale and standard of care without inaccuracies or omissions."
  },
  "2837": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly prioritizing concurrent chemoradiation over chemotherapy alone and providing relevant, accurate additional context without any inaccuracies or omissions."
  },
  "2838": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately distinguishes recommendations for T1b versus T1c, and provides correct, relevant guideline context without inaccuracies or omissions."
  },
  "2839": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that preoperative systemic therapy is justified, and provides additional correct, clinically relevant details without inaccuracies or omissions."
  },
  "2840": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains staging, management, and when systemic therapy for metastatic disease is indicated, with no inaccuracies or omissions."
  },
  "2841": {
    "score": 3.0,
    "explanation": "3: The model answer accurately describes the rarity and resistance profile of EGFR exon 20 insertions in squamous NSCLC and current guideline recommendations, but it omits that amivantamab and mobocertinib are now recommended as first-line options if available, per the reference. It also incorrectly states that these agents are only approved after chemotherapy, missing a key recent update."
  },
  "2842": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "2843": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, cites guidelines, and includes no inaccuracies or omissions; extra content is correct and clinically relevant."
  },
  "2844": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly states that HER2 status does not alter the approach, and provides additional accurate, clinically relevant context without any inaccuracies or omissions."
  },
  "2845": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizes the importance of waiting for biomarker results, details relevant guidelines, and appropriately notes the exception for urgent cases; there are no inaccuracies or omissions."
  },
  "2846": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, cites relevant guidelines, and contains no inaccuracies or omissions. All additional content is correct and clinically relevant."
  },
  "2847": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale and guideline references, and includes relevant additional details without any inaccuracies or omissions."
  },
  "2848": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale and relevant guideline citations, and contains no inaccuracies or omissions."
  },
  "2849": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly states that chemotherapy is not mandatory, discusses the role of clinicopathologic features in the absence of the recurrence score, and emphasizes endocrine therapy as primary; all additional content is accurate and clinically relevant."
  },
  "2850": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, cites guidelines, and makes no omissions or inaccuracies."
  },
  "2851": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that routine FDG-PET/CT or brain MRI is not appropriate, provides correct guideline-based surveillance recommendations, and includes relevant rationale and references without any inaccuracies or omissions."
  },
  "2852": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that surveillance schedules are similar for radiotherapy and surgery, missing the key fact that more intensive follow-up is recommended after definitive radiotherapy. While it cites guidelines and provides some relevant rationale, it omits the specific increased frequency of follow-up required and thus covers less than 70% of key facts."
  },
  "2853": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that routine PET/CT or brain MRI is not justified, and provides relevant, guideline-based details about appropriate surveillance; there are no inaccuracies or omissions."
  },
  "2854": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately addresses the role of micropapillary subtype, and correctly discusses pathologic features that might influence but not preclude endocrine therapy; all additional content is factually correct and clinically relevant."
  },
  "2855": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, explicitly addresses each histological subtype, and provides accurate, relevant guideline-based rationale without any inaccuracies or omissions."
  },
  "2856": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly states that surveillance alone is inappropriate, and details the need for post-operative systemic therapy or chemoradiation. Additional content is accurate, relevant, and guideline-based, with no inaccuracies or omissions."
  },
  "2857": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately addresses the lack of evidence and approval for first-line KRAS G12C inhibitors in squamous histology, and correctly emphasizes standard platinum-based chemotherapy as initial treatment; there are no inaccuracies or omissions."
  },
  "2858": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant explanations, cites guidelines, and contains no inaccuracies or omissions."
  },
  "2859": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate, up-to-date guideline-based recommendations, and includes relevant supporting evidence without any inaccuracies or omissions."
  },
  "2860": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, adds correct and clinically relevant details (trial names, guideline sources), and contains no inaccuracies or omissions."
  },
  "2861": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, adds accurate and clinically relevant details about SBRT, and cites supporting guidelines and evidence without any inaccuracies or omissions."
  },
  "2862": {
    "score": 1.0,
    "explanation": "1: The model answer directly contradicts the reference by recommending immediate switching to targeted therapy rather than completing the initial regimen, which is a major inaccuracy and could lead to inappropriate clinical decisions."
  },
  "2863": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional details, and contains no inaccuracies or omissions."
  },
  "2864": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the contraindication to surgery, and appropriately recommends SBRT as the preferred alternative, with no inaccuracies or omissions."
  },
  "2865": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and relevant guideline-based rationale, and includes no inaccuracies or omissions."
  },
  "2866": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, including the need to complete a year of anti-HER2 therapy and the importance of initial nodal status, but it incorrectly suggests that adjuvant pertuzumab is generally continued regardless of initial nodal status, whereas the reference specifies it is indicated only if initially node-positive; this represents a moderate factual inaccuracy."
  },
  "2867": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale for PORT in the context of positive margins and contraindication to systemic therapy, and cites relevant guidelines; there are no inaccuracies or omissions."
  },
  "2868": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that routine FDG-PET/CT or brain MRI is not indicated, and provides relevant, guideline-based details without inaccuracies or omissions."
  },
  "2869": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies fam-trastuzumab deruxtecan-nxki as the preferred therapy and notes the lack of strong evidence for ado-trastuzumab emtansine in this setting, but it incorrectly states that ado-trastuzumab emtansine is not a standard option even if T-DXd is unavailable or not tolerated, omitting that it is considered an alternative in guidelines; this is a moderate factual omission."
  },
  "2870": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that ALND omission is not supported with 3 positive sentinel lymph nodes, and provides correct, relevant explanations without any inaccuracies or omissions."
  },
  "2871": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the contraindication of both drugs in severe hepatic impairment, and provides relevant, correct additional details without inaccuracies or omissions."
  },
  "2872": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and relevant rationale, cites guidelines, and contains no inaccuracies or omissions."
  },
  "2873": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and relevant supporting evidence, and contains no inaccuracies or omissions."
  },
  "2874": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, cites relevant guidelines, and contains no inaccuracies or omissions."
  },
  "2875": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant rationale, and includes no inaccuracies or omissions. Additional content is correct and enhances understanding."
  },
  "2876": {
    "score": 5.0,
    "explanation": "5: The model answer accurately covers all key clinical facts, correctly explains that limited metastasis-directed therapy can be considered in well-selected M1b patients with a single extrathoracic metastasis, and provides relevant, up-to-date context without inaccuracies or omissions."
  },
  "2877": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that pleurodesis is only for symptom control and systemic therapy is mandatory for stage IV NSCLC, with no inaccuracies or omissions."
  },
  "2878": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, including PD-L1 status, lack of actionable mutations, and comorbidity considerations, but incorrectly states that ICI monotherapy is not appropriate when it is still an option per guidelines for PD-L1 ≥1% and ECOG 0–2; this is a moderate factual error."
  },
  "2879": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and adds relevant, correct details about drug metabolism, risks, and alternative strategies without any inaccuracies or omissions."
  },
  "2880": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale for both systemic and local therapies, and provides relevant, up-to-date details without inaccuracies or omissions."
  },
  "2881": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains guideline recommendations, and provides relevant rationale and references without any inaccuracies or omissions."
  },
  "2882": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, discusses alternative approaches, and contains no inaccuracies or omissions."
  },
  "2883": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that bronchoscopy is essential despite PET/CT, and provides additional, accurate, and clinically relevant rationale without any inaccuracies or omissions."
  },
  "2884": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, cites relevant guidelines, and makes no errors or omissions."
  },
  "2885": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating both technical resectability and absence of disseminated disease, and provides relevant, accurate elaboration without any inaccuracies or omissions."
  },
  "2886": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes current guideline recommendations, and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "2887": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, adds relevant detail about tumor suitability and guidelines, and contains no inaccuracies or omissions."
  },
  "2888": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that preoperative systemic therapy is indicated based on clinical and molecular features regardless of imaging modality, and provides additional correct and relevant context without any inaccuracies or omissions."
  },
  "2889": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant rationale, and includes no inaccuracies or omissions."
  },
  "2890": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including the preference for best supportive care, the lack of evidence for KRAS inhibitors in PS 3, relevant trial and guideline data, and the rare exception for reversible causes; all additional content is accurate and clinically relevant."
  },
  "2891": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant guideline-based details, and contains no inaccuracies or omissions."
  },
  "2892": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional details, and contains no inaccuracies or omissions."
  },
  "2893": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, cites guidelines, and includes a relevant summary table without any inaccuracies or omissions."
  },
  "2894": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, clearly stating that local therapy alone is insufficient and systemic targeted therapy is required, with accurate rationale and no inaccuracies or omissions."
  },
  "2895": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and relevant additional rationale, and contains no inaccuracies or omissions."
  },
  "2896": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the appropriateness of surgery in NYHA class II, and adds relevant, correct details about guidelines, preoperative assessment, and shared decision making without any inaccuracies or omissions."
  },
  "2897": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the impact of severe pulmonary dysfunction on surgical risk, and correctly identifies external-beam radiation therapy as the preferred modality. There are no inaccuracies or omissions."
  },
  "2898": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant rationale, and includes no inaccuracies or omissions."
  },
  "2899": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, cites supporting guidelines and evidence, and includes relevant additional details without inaccuracies or omissions."
  },
  "2900": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that adjuvant systemic therapy is routinely recommended, whereas observation alone is an appropriate option per the reference; this is a moderate factual error, though the rest of the content is accurate and relevant."
  },
  "2901": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the relevance of pN1mi, and provides correct, clinically relevant guideline-based justification without any inaccuracies or omissions."
  },
  "2902": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional details, and contains no inaccuracies or omissions."
  },
  "2903": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and provides relevant, correct additional details without any inaccuracies or omissions."
  },
  "2904": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts but incorrectly suggests that upfront surgery is reasonable and that concurrent chemoradiation is not the first priority, which contradicts the reference stating chemoradiation is generally prioritized; this represents a moderate factual inaccuracy."
  },
  "2905": {
    "score": 2.0,
    "explanation": "2: The model answer covers some relevant facts but incorrectly states that 21-gene RT-PCR is not strongly recommended for a 0.6 cm tumor, whereas guidelines do recommend it for tumors >0.5 cm in this setting; this is a moderate factual omission and misinterpretation of standard recommendations."
  },
  "2906": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including the preference for concurrent chemoradiation, rationale, and detailed clinical factors influencing the choice, with accurate and relevant additional explanations and no inaccuracies or omissions."
  },
  "2907": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides additional relevant detail about surgical candidacy, and accurately reflects current guidelines without any inaccuracies or omissions."
  },
  "2908": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and provides relevant, correct additional details without any inaccuracies or omissions."
  },
  "2909": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "2910": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that orthopedic stabilization is not indicated without fracture risk, and provides relevant, correct additional context without any inaccuracies or omissions."
  },
  "2911": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately stating that HER2 positivity and tumor size alone are sufficient for recommending preoperative systemic therapy, with no need for additional high-risk features. All extra content is correct, relevant, and guideline-based."
  },
  "2912": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately stating that surgery is not standard but may be considered in highly selected cases, and emphasizes systemic therapy as standard. Additional details are correct and clinically relevant, with no inaccuracies or omissions."
  },
  "2913": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately addresses surgical risk in the context of COPD and decreased pulmonary function, and appropriately discusses alternative non-surgical options; all additional details are correct and clinically relevant."
  },
  "2914": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides additional relevant detail about patient selection, sequencing of therapy, supporting evidence, and guidelines, with no inaccuracies or omissions."
  },
  "2915": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, cites relevant guidelines and studies, and contains no inaccuracies or omissions."
  },
  "2916": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains current guidelines, provides rationale, and includes relevant references without any inaccuracies or omissions."
  },
  "2917": {
    "score": 5.0,
    "explanation": "5: The model answer accurately covers all key clinical facts from the reference, including correct TNM staging, the upstaging to Stage IIIA (not beyond), and the continued eligibility for perioperative therapy if resectable; all additional details are correct and clinically relevant."
  },
  "2918": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant explanations, and contains no inaccuracies or omissions."
  },
  "2919": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate staging, rationale, standard of care, and relevant guidelines, with no inaccuracies or omissions. Additional content is correct and clinically relevant."
  },
  "2920": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional explanation, and contains no inaccuracies or omissions."
  },
  "2921": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and includes only relevant, correct, and guideline-based information without any inaccuracies or omissions."
  },
  "2922": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant explanations, cites guidelines, and includes no inaccuracies or omissions."
  },
  "2923": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly clarifies the staging (T4, not T3), and provides accurate, relevant guideline-based management recommendations without inaccuracies or omissions."
  },
  "2924": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly emphasizes the need for orthopedic stabilization and palliative radiotherapy prior to systemic therapy, and provides accurate, relevant additional context without any inaccuracies or omissions."
  },
  "2925": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant rationale, cites guidelines, and contains no inaccuracies or omissions."
  },
  "2926": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and provides relevant, correct additional details without any inaccuracies or omissions."
  },
  "2927": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key facts, correctly emphasizes prioritizing molecular profiling regardless of neurological symptoms, and provides relevant rationale and guideline references. However, it introduces a minor nuance about urgency in severe symptoms, which, while accurate and guideline-based, slightly qualifies the absolute nature of the reference answer, constituting a minor wording inaccuracy."
  },
  "2928": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the low yield and non-essential role of molecular testing in typical squamous NSCLC, and appropriately notes exceptions and the relevance of PD-L1 testing; there are no inaccuracies or omissions."
  },
  "2929": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant explanations, cites supporting evidence and guidelines, and contains no inaccuracies or omissions."
  },
  "2930": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale for excluding targeted and immunotherapy monotherapy, and correctly prioritizes systemic chemotherapy; all additional details are factually correct and clinically relevant."
  },
  "2931": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, cites relevant guidelines, and contains no inaccuracies or omissions."
  },
  "2932": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the impact of prior thoracic radiation on treatment recommendations, and provides relevant, correct additional details without any inaccuracies or omissions."
  },
  "2933": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly explains the rationale, cites relevant guidelines, and accurately recommends SBRT as the preferred option without any inaccuracies or omissions."
  },
  "2934": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant explanations, and includes correct guideline references without any inaccuracies or omissions."
  },
  "2935": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately stating that surgery is not appropriate due to poor pulmonary function and that definitive radiotherapy is preferred; all additional details are correct and clinically relevant."
  },
  "2936": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizes the necessity of pathologic confirmation before stage IIIB management, and provides relevant, correct additional context without any inaccuracies or omissions."
  },
  "2937": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional details (including trial data and guidelines), and contains no inaccuracies or omissions."
  },
  "2938": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional details, and contains no inaccuracies or omissions."
  },
  "2939": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant rationale, and cites appropriate guidelines without any inaccuracies or omissions."
  },
  "2940": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and relevant additional explanations, cites guidelines, and contains no inaccuracies or omissions."
  },
  "2941": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides clear rationale, and includes relevant, accurate additional details without any inaccuracies or omissions."
  },
  "2942": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the role of the 21-gene assay, addresses premenopausal considerations, and provides relevant guideline and trial references without any inaccuracies or omissions."
  },
  "2943": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant explanations, cites appropriate guidelines, and contains no inaccuracies or omissions."
  },
  "2944": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, cites relevant guidelines and trials, and includes no inaccuracies or omissions."
  },
  "2945": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately stating that broad molecular profiling is recommended in advanced squamous NSCLC if tissue is sufficient, and provides correct, clinically relevant elaboration without inaccuracies or omissions."
  },
  "2946": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional explanations, and includes appropriate mention of rare exceptions without inaccuracies or omissions."
  },
  "2947": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale for omitting chemotherapy, and provides relevant guideline references without any inaccuracies or omissions."
  },
  "2948": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly emphasizes the risk of contrast-induced nephropathy, and appropriately recommends non-contrast CT for surveillance; additional content is accurate, relevant, and guideline-based, with no inaccuracies or omissions."
  },
  "2949": {
    "score": 2.0,
    "explanation": "2: The model answer correctly notes that ALK rearrangement is the key biomarker for ceritinib use and that co-occurrence with EGFR mutations is rare, but it incorrectly denies that EGFR negativity is an implicit requirement, missing the clinical standard that ALK inhibitors are indicated only when EGFR mutations are absent; this is a moderate factual omission."
  },
  "2950": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, including the importance of EGFR mutation and tissue insufficiency, but incorrectly states that first-line amivantamab-vmjw plus lazertinib is not appropriate due to pending guideline approval, which contradicts the reference's assertion that it is indicated if EGFR mutation is confirmed. This represents a moderate factual inaccuracy regarding current clinical appropriateness."
  },
  "2951": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly prioritizing local therapy for the brain lesion and providing appropriate nuance regarding performance status and multidisciplinary care, with no inaccuracies or omissions."
  },
  "2952": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and relevant guideline-based rationale, and contains no inaccuracies or omissions."
  },
  "2953": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional detail, cites guidelines, and contains no inaccuracies or omissions."
  },
  "2954": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately prioritizing selpercatinib and pralsetinib over cabozantinib, and provides correct, relevant additional details without inaccuracies or omissions."
  },
  "2955": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that the follow-up schedule assumes no evidence of disease and explaining that active disease would require different management; all additional content is accurate and clinically relevant."
  },
  "2956": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "2957": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that RET-targeted therapy is appropriate and preferred over chemotherapy for RET-rearranged squamous NSCLC, and provides relevant, guideline-based details without inaccuracies or omissions."
  },
  "2958": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the staging, therapeutic implications, and explicitly states that perioperative therapy remains appropriate while systemic therapy for metastatic disease is not indicated; there are no inaccuracies or omissions."
  },
  "2959": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly outlining standard first-line therapy, appropriate exceptions, and the rationale for when endocrine ± HER2 therapy may be used. It is accurate, comprehensive, and clinically relevant, with no omissions or inaccuracies."
  },
  "2960": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "2961": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides additional accurate and clinically relevant details, and contains no inaccuracies or omissions."
  },
  "2962": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the shift to stage IV and systemic therapy, and provides relevant, correct additional details without any inaccuracies or omissions."
  },
  "2963": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that EGFR TKI remains the primary treatment regardless of prior radiotherapy, and provides additional accurate, relevant rationale without any inaccuracies or omissions."
  },
  "2964": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, including the TAILORx trial data, the modest benefit of chemotherapy, and the role of clinical risk and recurrence score, but it overstates the acceptability of endocrine therapy alone in this group. The reference answer is clear that chemotherapy is generally recommended, while the model suggests endocrine therapy alone is appropriate in select cases, which is a minor but clinically relevant deviation."
  },
  "2965": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "2966": {
    "score": 1.0,
    "explanation": "1: The model answer directly contradicts the reference by stating that grade 3 alone does not justify RNI, omitting the key fact that any single high-risk feature (such as grade 3) is sufficient; this is a major inaccuracy despite otherwise detailed discussion."
  },
  "2967": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional details, cites guidelines, and contains no inaccuracies or omissions."
  },
  "2968": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly states that adjuvant HER2-directed therapy is indicated regardless of pCR or initial nodal status, and provides accurate, relevant rationale without any inaccuracies or omissions."
  },
  "2969": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate staging details, management rationale, and emphasizes that surgery remains an option in selected T4N0–1 cases; all additional content is correct and clinically relevant."
  },
  "2970": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, cites relevant guidelines, and contains no inaccuracies or omissions."
  },
  "2971": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant rationale, and contains no inaccuracies or omissions."
  },
  "2972": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the individualized use of adjuvant radiotherapy, addresses margin status, prior chemotherapy, and the need for multidisciplinary discussion, and provides relevant, correct additional detail without inaccuracies or omissions."
  },
  "2973": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that both tumors must be technically and medically curable for this approach, and provides relevant, accurate elaboration without any inaccuracies or omissions."
  },
  "2974": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and provides additional relevant context without inaccuracies or omissions."
  },
  "2975": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizes completing planned systemic therapy unless there is progression or toxicity, and provides correct, relevant additional context about EGFR TKI options and supporting guidelines. No inaccuracies or omissions are present."
  },
  "2976": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the contraindication to surgery due to poor pulmonary reserve, and appropriately discusses alternative management without any inaccuracies or omissions."
  },
  "2977": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, includes relevant guideline references, and clearly states exceptions without any inaccuracies or omissions."
  },
  "2978": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional details, and contains no inaccuracies or omissions."
  },
  "2979": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately details staging implications based on nodule location, and clearly explains the management shift. All additional content is correct and clinically relevant, with no inaccuracies or omissions."
  },
  "2980": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, adds relevant and accurate detail about diagnostic criteria and management, and contains no inaccuracies or omissions."
  },
  "2981": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional details, and contains no inaccuracies or omissions."
  },
  "2982": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional explanation, and contains no inaccuracies or omissions."
  },
  "2983": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "2984": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly distinguishes between post-surgical and post-radiotherapy surveillance intervals, and cites relevant guidelines without any inaccuracies or omissions."
  },
  "2985": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional details, and contains no inaccuracies or omissions."
  },
  "2986": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that omission of further axillary surgery can be considered with 3 positive SLNs, whereas guidelines and evidence restrict omission to cases with only 1–2 positive SLNs; this is a moderate factual error. While the answer is otherwise detailed and references relevant trials, the key clinical fact is misapplied."
  },
  "2987": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly explains why perioperative therapy is inappropriate in the setting of poor pulmonary function, and correctly recommends definitive chemoradiation as the preferred alternative, with no inaccuracies or omissions."
  },
  "2988": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly states that trastuzumab plus endocrine therapy is sufficient for node-negative patients achieving pCR, and that dual HER2 blockade is not required; all additional content is accurate, relevant, and guideline-based."
  },
  "2989": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, including the standard use of durvalumab and the limited evidence for osimertinib in this setting, but it incorrectly states that durvalumab should be prioritized over osimertinib despite the presence of an EGFR mutation, which is a clinically relevant omission compared to the reference answer."
  },
  "2990": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "2991": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and relevant guideline-based explanations, and includes no inaccuracies or omissions."
  },
  "2992": {
    "score": 2.0,
    "explanation": "2: The model answer overstates the preference for adjuvant chemotherapy and incorrectly implies that observation is not an appropriate standard option for fit patients, omitting the guideline-supported acceptability of both approaches; this is a moderate factual error."
  },
  "2993": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, mentions guidelines, and correctly identifies SBRT as the preferred alternative, with no inaccuracies or omissions."
  },
  "2994": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly explains why concurrent chemoradiotherapy is contraindicated, and appropriately discusses alternative options without inaccuracies or omissions."
  },
  "2995": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly explaining that chemotherapy is recommended for both triple-negative and HER2-positive cases (with anti-HER2 therapy if HER2+), and that the recommendation is not limited to HER2-negative status; there are no inaccuracies or omissions."
  },
  "2996": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that contrast-enhanced CT is not required, and that non-contrast CT is sufficient and guideline-supported, especially in the context of a contrast allergy; all additional content is correct and clinically relevant."
  },
  "2997": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately addresses guideline recommendations, the rationale for non-contrast CT, and the relevance of renal impairment, with no inaccuracies or omissions."
  },
  "2998": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale for prioritizing radiotherapy over surgery in high-risk patients, and provides relevant, correct additional details without any inaccuracies or omissions."
  },
  "2999": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that SRS alone is appropriate for asymptomatic patients, and that surgery is reserved for symptomatic cases or when tissue confirmation is needed. Additional content is correct, relevant, and guideline-based, with no inaccuracies or omissions."
  },
  "3000": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that SLN mapping/excision is sufficient and ALND is not required upfront, and provides correct, relevant additional detail without inaccuracies or omissions."
  },
  "3001": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that neoadjuvant therapy is appropriate for cT1c (1.1–2 cm) HER2-positive tumors, and clarifies there is no 2 cm minimum. Additional content is correct, relevant, and guideline-based, with no inaccuracies or omissions."
  },
  "3002": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizing that systemic disease control is generally required before local ablative therapy, while appropriately noting rare exceptions; there are no inaccuracies or omissions."
  },
  "3003": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, correctly stating that surveillance is the same for both post-surgical and post-chemoradiation patients, but it omits the option of every 3–6 months (instead stating every 6 months), which is a clinically relevant detail per the reference; otherwise, the content is accurate and relevant."
  },
  "3004": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that recommendations for further resection or chemoradiation assume medical operability, and appropriately addresses alternative management for inoperable patients; all additional content is accurate and clinically relevant."
  },
  "3005": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately prioritizing re-resection over radiation and providing correct, relevant rationale and guideline references without any inaccuracies or omissions."
  },
  "3006": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional details, cites guidelines, and contains no inaccuracies or omissions."
  },
  "3007": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional explanations, and contains no inaccuracies or omissions."
  },
  "3008": {
    "score": 3.0,
    "explanation": "3: The model answer incorrectly states that RET inhibitors remain \"first-line\" if the rearrangement is found after chemotherapy, which is inaccurate; they become subsequent-line therapy in this scenario. While the answer provides correct and relevant information about the use of RET inhibitors and guideline support, this key misstatement about line of therapy is a moderate factual error."
  },
  "3009": {
    "score": 5.0,
    "explanation": "5: The model answer correctly states that adjuvant systemic chemotherapy is not routinely indicated after adequate neoadjuvant therapy and complete resection in T2, N2, M0 NSCLC, provides guideline-based rationale, and discusses exceptions for targeted/immunotherapy, covering all key clinical facts in the reference with accurate, relevant detail and no inaccuracies."
  },
  "3010": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, cites relevant guidelines, and contains no inaccuracies or omissions."
  },
  "3011": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and provides relevant, correct additional details without any inaccuracies or omissions."
  },
  "3012": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that trastuzumab continuation is indicated regardless of baseline nodal status, and provides accurate, relevant guideline-based context without inaccuracies or omissions."
  },
  "3013": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and relevant guideline-based rationale, and contains no inaccuracies or omissions."
  },
  "3014": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and relevant rationale, cites guidelines, and contains no inaccuracies or omissions."
  },
  "3015": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, accurately describes the size threshold, guideline recommendations, and the rationale for individualized decision-making, with no inaccuracies or omissions."
  },
  "3016": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly prioritizes further endocrine therapy despite clear evidence of endocrine resistance (progression within a year), which is a moderate factual error; while it provides relevant rationale and references, it fails to recognize that chemotherapy should now be prioritized, as per guidelines and the reference answer."
  },
  "3017": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately quantifies the risk, cites guidelines, and clearly explains why omission is appropriate in this scenario; there are no inaccuracies or omissions."
  },
  "3018": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, discusses alternative options, and includes relevant supporting guidelines without any inaccuracies or omissions."
  },
  "3019": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "3020": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes when molecular profiling is indicated or can be omitted, and provides relevant guideline references; there are no inaccuracies or omissions."
  },
  "3021": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that systemic EGFR therapy does not preclude pleurodesis, explains the rationale, and provides guideline-based support without inaccuracies or omissions."
  },
  "3022": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "3023": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains why standard concurrent chemoradiation is not appropriate in the context of renal impairment, and discusses alternative options and relevant considerations without any inaccuracies or omissions."
  },
  "3024": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant rationale, cites supporting guidelines, and contains no inaccuracies or omissions."
  },
  "3025": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that standard EGFR TKIs are not indicated, and correctly prioritizes platinum-based chemotherapy ± immunotherapy as first-line, with newer agents reserved for later lines; all additional content is factually correct and clinically relevant."
  },
  "3026": {
    "score": 5.0,
    "explanation": "5: The model answer includes all key clinical facts from the reference, clearly states the mandatory nature of PFTs before surgery, and provides relevant guideline support without inaccuracies or omissions."
  },
  "3027": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including symptomatic disease, disease progression, and performance status, with additional relevant and accurate details; there are no inaccuracies or omissions."
  },
  "3028": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and provides relevant supporting details without any inaccuracies or omissions."
  },
  "3029": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, correctly stating that adjuvant radiotherapy is generally indicated after R1/R2 resection but that surveillance may be considered in select cases (e.g., after re-resection or with contraindications). It omits explicit mention that surveillance is acceptable after successful re-resection or systemic therapy, but this is implied; overall, there are no major errors or unsafe statements."
  },
  "3030": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and provides relevant supporting details without any inaccuracies or omissions."
  },
  "3031": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, correctly stating that surveillance should be more frequent than annually and providing rationale about recurrence risk, but it recommends a 6–12 month interval (rather than the reference's 3–6 months), which is a moderate omission/inaccuracy. The rest of the content is accurate and relevant."
  },
  "3032": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and relevant additional explanations, and contains no inaccuracies or omissions."
  },
  "3033": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, cites guidelines, discusses rare exceptions appropriately, and contains no inaccuracies or omissions."
  },
  "3034": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately specifying chest CT every 6 months for the first 2 years, and provides correct, relevant references and additional context without any inaccuracies or omissions."
  },
  "3035": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional rationale, and contains no inaccuracies or omissions."
  },
  "3036": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant rationale, and includes no inaccuracies or omissions. Additional content is correct and enhances understanding."
  },
  "3037": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "3038": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the threshold for routine adjuvant chemotherapy with trastuzumab, and provides relevant, guideline-based justification without any inaccuracies or omissions."
  },
  "3039": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly emphasizes the need for more frequent imaging regardless of symptoms, and provides additional relevant, accurate rationale and guideline-based recommendations without any inaccuracies or omissions."
  },
  "3040": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and relevant guideline-based rationale, and includes no inaccuracies or omissions. Additional content is correct and clinically pertinent."
  },
  "3041": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and relevant supporting evidence, and contains no inaccuracies or omissions."
  },
  "3042": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and clearly states that adjuvant therapy assumes no residual disease; it also appropriately describes management changes if residual disease is present, with no inaccuracies or omissions."
  },
  "3043": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the resistance of exon 20 insertions to standard EGFR TKIs, addresses the role of specific agents, and correctly notes that prior radiotherapy does not affect molecular eligibility. No inaccuracies or omissions are present."
  },
  "3044": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly explains the rationale, references relevant trials and guidelines, and makes no errors or omissions."
  },
  "3045": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizes systemic therapy as first-line for M1a (stage IVA) NSCLC, and appropriately notes that surgery is not standard initial therapy. Additional content is factually correct, clinically relevant, and guideline-based, with no inaccuracies or omissions."
  },
  "3046": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly prioritizing targeted therapy with crizotinib over immunotherapy in the presence of a METex14 mutation, and provides additional relevant context without inaccuracies or omissions."
  },
  "3047": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, cites relevant guidelines, and contains no inaccuracies or omissions."
  },
  "3048": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including the standard of care, the need for individualized assessment based on pulmonary function, and alternative options if tolerance is insufficient; all additional content is accurate and clinically relevant."
  },
  "3049": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly states that pathologic confirmation is mandatory, explains the rationale, cites guidelines, and appropriately notes rare exceptions, with no inaccuracies or omissions."
  },
  "3050": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizing that HER2 status dictates preoperative therapy selection regardless of HR or BRCA status, and provides correct, relevant elaboration without inaccuracies or omissions."
  },
  "3051": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, guideline recommendations, and limitations of PET/CT, with no omissions or inaccuracies."
  },
  "3052": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant rationale, and cites appropriate guidelines without any inaccuracies or omissions."
  },
  "3053": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains standard recommendations, the rationale for omission in this scenario, and emphasizes individualized, multidisciplinary decision-making without any inaccuracies or omissions."
  },
  "3054": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly prioritizing urgent airway intervention before cancer-directed therapy, and provides additional relevant, accurate rationale without any omissions or inaccuracies."
  },
  "3055": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, cites guidelines, and includes relevant additional details without any inaccuracies or omissions."
  },
  "3056": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "3057": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale for excluding targeted therapy, and correctly recommends platinum-based chemotherapy plus immunotherapy as first-line treatment; there are no inaccuracies or omissions."
  },
  "3058": {
    "score": 1.0,
    "explanation": "1: The model answer incorrectly states that only patients who have undergone resection qualify for the surveillance schedule, directly contradicting the reference answer. This is a major inaccuracy that could lead to inappropriate exclusion of radiotherapy patients from proper surveillance."
  },
  "3059": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant elaboration, and contains no inaccuracies or omissions."
  },
  "3060": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "3061": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant rationale, and includes appropriate guideline references without any inaccuracies or omissions."
  },
  "3062": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, correctly distinguishing between diagnostic criteria for synchronous primaries and the separate clinical judgment of curability, and emphasizes that curability is not inherent to the diagnosis. However, it could more explicitly state that the decision to treat as two primaries is contingent on both being potentially curable, as in the reference, making this a minor omission."
  },
  "3063": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that brain MRI is mandatory for stage IIIA but not for stage IB, and provides accurate, relevant explanations without any inaccuracies or omissions."
  },
  "3064": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and provides relevant, correct additional details without any inaccuracies or omissions."
  },
  "3065": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant rationale, and includes no inaccuracies or omissions. Additional content is correct and enhances understanding."
  },
  "3066": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale for neoadjuvant therapy in both HER2-positive and triple-negative cT1cN0 breast cancer, and clearly prioritizes preoperative therapy over immediate surgery. There are no inaccuracies or omissions."
  },
  "3067": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly explains the relevant trial criteria, and provides accurate, clinically relevant additional detail without any inaccuracies or omissions."
  },
  "3068": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the presumption of adequate pulmonary function, and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "3069": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale for systemic therapy preference, addresses toxicity and limited benefit of repeat local treatment, and appropriately notes rare exceptions; all additional content is correct and clinically relevant."
  },
  "3070": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that routine brain MRI is not indicated, cites relevant guidelines, and correctly describes appropriate surveillance; there are no inaccuracies or omissions."
  },
  "3071": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the staging implications, management changes, and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "3072": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, correctly emphasizing the need to confirm ALK and ROS1 testing, but it incorrectly states that exclusion is not implied when recommending EGFR TKI therapy, which contradicts the reference answer's assertion that such exclusion is presumed; this represents a moderate omission."
  },
  "3073": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately prioritizing concurrent chemoradiation (with or without SVC stent) over immediate EBRT, and appropriately discusses the role of stenting and EBRT based on symptom severity, with no inaccuracies or omissions."
  },
  "3074": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that KRAS G12C inhibitors are used regardless of PD-L1 status, and provides relevant, correct additional context without any inaccuracies or omissions."
  },
  "3075": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and provides additional relevant staging and management details without any inaccuracies or omissions."
  },
  "3076": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly states that adjuvant chemotherapy with trastuzumab is appropriate for HER2-positive, pN1mi cases regardless of a 0.5 cm tumor size, and provides accurate, relevant guideline-based rationale without inaccuracies or omissions."
  },
  "3077": {
    "score": 4.0,
    "explanation": "4: The model answer covers over 90% of the key facts, correctly stating that surveillance is generally similar to stage III but may be individualized with additional imaging for prior metastatic sites. It introduces minor nuance about guideline ambiguity and possible increased surveillance, which is accurate but not emphasized in the reference; there are no clinically significant omissions or inaccuracies."
  },
  "3078": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant rationale, cites guidelines, and contains no inaccuracies or omissions."
  },
  "3079": {
    "score": 2.0,
    "explanation": "2: The model answer omits the key fact that MRI is mandatory for comprehensive assessment of local invasion in T4 tumors abutting the subclavian vessels, regardless of unremarkable CT/PET findings, and incorrectly suggests MRI is optional; this is a moderate factual error that could impact surgical planning."
  },
  "3080": {
    "score": 0.0,
    "explanation": "0: The model answer directly contradicts the reference by recommending immediate initiation of ALK inhibitor therapy rather than completing planned systemic therapy first, which is a major inaccuracy and could lead to unsafe clinical practice."
  },
  "3081": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and relevant guideline-based details, and contains no inaccuracies or omissions."
  },
  "3082": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and provides relevant guideline-based recommendations without any inaccuracies or omissions."
  },
  "3083": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizes the necessity of pathological confirmation, cites relevant guidelines, and appropriately notes rare exceptions, with no inaccuracies or omissions."
  },
  "3084": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant rationale, and cites appropriate guidelines; there are no inaccuracies or omissions."
  },
  "3085": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that routine FDG-PET/CT or brain MRI is not indicated, details standard surveillance, and correctly notes that positive margins do not alter surveillance modality; all additional content is relevant and guideline-based."
  },
  "3086": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "3087": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly asserts that adjuvant therapy inherently implies additional high-risk features, directly contradicting the reference answer, which states it may be considered based on tumor size or clinical factors alone; while the model provides relevant details about high-risk features, this central error is a moderate factual inaccuracy."
  },
  "3088": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizes the necessity of pathologically negative N2 nodes before surgery, and provides relevant, correct guideline-based rationale without any inaccuracies or omissions."
  },
  "3089": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that both lesions must be potentially curable to justify treating as synchronous primaries, and that this approach is not appropriate if one site is not amenable to curative therapy. There are no inaccuracies or omissions."
  },
  "3090": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant rationale, cites guidelines and literature, and contains no inaccuracies or omissions."
  },
  "3091": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that routine FDG-PET/CT is not indicated without suspicion of recurrence, and provides relevant, guideline-based rationale without any inaccuracies or omissions."
  },
  "3092": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that surveillance is not altered by omission of chemotherapy, and provides relevant, guideline-based details without inaccuracies or irrelevant content."
  },
  "3093": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly states that TRK inhibitor therapy is preferred over platinum-based chemotherapy in the presence of an NTRK1 fusion, and provides accurate, relevant additional details without any inaccuracies or omissions."
  },
  "3094": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "3095": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that compromised pulmonary function precludes perioperative therapy, and adds relevant, accurate details about alternative management and assessment without any inaccuracies or omissions."
  },
  "3096": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant elaboration, and contains no inaccuracies or omissions."
  },
  "3097": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, accurately explains the independence from PD-L1 status, and provides relevant, correct additional context without any inaccuracies or omissions."
  },
  "3098": {
    "score": 2.0,
    "explanation": "2: The model answer contradicts the reference by stating that symptomatic obstruction is not necessary for considering endobronchial interventions, omitting the key fact that these procedures are specifically indicated for symptomatic relief; this represents a moderate factual error."
  },
  "3099": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that durvalumab is only indicated if there is no evidence of progression post-chemoradiation, and provides relevant, correct additional context without any inaccuracies or omissions."
  },
  "3100": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key facts, correctly emphasizing the importance of re-biopsy to confirm hormone receptor status at recurrence, but introduces the nuance that therapy can be based on the primary tumor if biopsy is not feasible—this is a minor addition not present in the reference but aligns with guidelines and is clinically relevant; no inaccuracies or unsafe statements are present."
  },
  "3101": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly advises discontinuing the current endocrine agent in the setting of unacceptable toxicity, continuing ovarian suppression, and switching to an alternative therapy; all additional content is accurate and clinically relevant."
  },
  "3102": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional details, and contains no inaccuracies or omissions."
  },
  "3103": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that routine brain MRI is not indicated unless there was prior brain involvement or new symptoms, and provides relevant guideline-based context without any inaccuracies or omissions."
  },
  "3104": {
    "score": 1.0,
    "explanation": "1: The model answer directly contradicts the reference by recommending immediate initiation of EGFR TKI upon mutation discovery, rather than completing planned systemic and maintenance therapy first; this is a major inaccuracy and could lead to unsafe clinical decisions."
  },
  "3105": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, including the rarity of actionable mutations in squamous cell carcinoma and the importance of PD-L1 testing, but it incorrectly states that broad molecular profiling is generally not recommended, which contradicts current guidelines advocating comprehensive testing in advanced/metastatic cases regardless of histology. This represents a moderate factual inaccuracy."
  },
  "3106": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including prioritization of fam-trastuzumab deruxtecan-nxki, rationale based on efficacy, guideline support, and relative positioning of ado-trastuzumab emtansine; additional details are accurate and clinically relevant."
  },
  "3107": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that annual CT is insufficient, specifies the recommended surveillance interval, cites relevant guidelines, and provides correct rationale without any inaccuracies or omissions."
  },
  "3108": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, addresses the safety of MRI contrast in renal dysfunction, and provides relevant guideline recommendations without any inaccuracies or omissions."
  },
  "3109": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides additional accurate and clinically relevant details, and contains no inaccuracies or omissions."
  },
  "3110": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly emphasizing that ALK-targeted therapy is first-line regardless of histology or smoking history, and provides accurate, relevant guideline-based explanations without any inaccuracies or omissions."
  },
  "3111": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that ongoing systemic therapy should be completed before switching to targeted agents, and provides accurate, relevant rationale and guideline references without any inaccuracies or omissions."
  },
  "3112": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that HER2-targeted therapy is reserved for cases negative for other common driver mutations, and provides accurate, relevant elaboration without any inaccuracies or omissions."
  },
  "3113": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the distinction between resectability, local advancement, and metastasis, and provides relevant, correct additional context without any inaccuracies or omissions."
  },
  "3114": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that SLNB should be deferred until after systemic therapy, and provides correct, relevant rationale and guideline references without any inaccuracies or omissions."
  },
  "3115": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the upstaging to at least stage IIIA (T4), details the impact on perioperative therapy eligibility, and provides relevant, correct additional context without inaccuracies or omissions."
  },
  "3116": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that routine brain MRI and FDG-PET/CT are not recommended for asymptomatic surveillance, details appropriate follow-up with history, exam, and chest CT, and provides relevant guideline references without any inaccuracies or omissions."
  },
  "3117": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately classifies the disease stage, correctly states that systemic therapy for metastatic disease is not indicated, and prioritizes local treatment strategies; all additional content is factually correct and clinically relevant."
  },
  "3118": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly states that dabrafenib plus trametinib is preferred over immune checkpoint inhibitors as first-line therapy, and provides accurate, relevant rationale and supporting evidence without any inaccuracies or omissions."
  },
  "3119": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant explanations, and contains no inaccuracies or omissions."
  },
  "3120": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant rationale, and includes no inaccuracies or omissions."
  },
  "3121": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant elaboration, and contains no inaccuracies or omissions."
  },
  "3122": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, cites relevant guidelines, and contains no inaccuracies or omissions."
  },
  "3123": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional details, cites supporting guidelines and studies, and contains no inaccuracies or omissions."
  },
  "3124": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and relevant rationale, and includes no inaccuracies or omissions. Additional content is factually correct and clinically pertinent."
  },
  "3125": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that routine follow-up should not be modified without clinical or radiographic suspicion, and provides correct, relevant rationale without inaccuracies or omissions."
  },
  "3126": {
    "score": 1.0,
    "explanation": "1: The model answer incorrectly states that surveillance frequency is the same for both groups, directly contradicting the reference, which specifies more intensive imaging for radiotherapy patients; this is a major inaccuracy."
  },
  "3127": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizes the necessity of pathologic confirmation, and appropriately notes rare exceptions; all additional content is correct and clinically relevant."
  },
  "3128": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and provides correct, relevant extra detail about standard first-line therapy; there are no inaccuracies or omissions."
  },
  "3129": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately prioritizing systemic therapy ± radiotherapy over upfront surgery, and adds correct, clinically relevant details about guidelines and rare exceptions without any inaccuracies or omissions."
  },
  "3130": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly states the dependence on absence of other actionable mutations, and provides accurate, relevant guideline-based explanation without any inaccuracies or omissions."
  },
  "3131": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant rationale, cites appropriate guidelines, and contains no inaccuracies or omissions."
  },
  "3132": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "3133": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts and provides strong rationale and guideline support, but it omits that both completing current therapy or switching to selpercatinib are acceptable options and that the decision should be individualized; it presents switching as the only appropriate approach, which is a moderate omission."
  },
  "3134": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate, relevant additional detail, and emphasizes the importance of patient selection and multidisciplinary evaluation without any inaccuracies or omissions."
  },
  "3135": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly prioritizing symptom control with endobronchial therapies or EBRT before surgery, and provides additional relevant detail without inaccuracies or omissions."
  },
  "3136": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately prioritizing systemic therapy, explaining the rationale, and appropriately contextualizing the role of local therapies in oligometastatic disease, with no inaccuracies or omissions."
  },
  "3137": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly asserts that concurrent chemoradiation is generally preferred, whereas the reference states neither approach is universally preferred and the choice depends on patient factors; this is a moderate factual error, though the rest of the content is relevant and accurate."
  },
  "3138": {
    "score": 5.0,
    "explanation": "5: The model answer accurately covers all key clinical facts, correctly stating that surgery is appropriate if neoadjuvant therapy was not planned, and provides relevant, guideline-based rationale without inaccuracies or omissions."
  },
  "3139": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and relevant additional explanations, and contains no inaccuracies or omissions."
  },
  "3140": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the contraindication of concurrent chemoradiation in ILD, and provides relevant, correct additional details without any inaccuracies or omissions."
  },
  "3141": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, cites relevant studies and guidelines, and contains no inaccuracies or omissions."
  },
  "3142": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional details, cites guidelines, and contains no inaccuracies or omissions."
  },
  "3143": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and relevant additional rationale, and contains no inaccuracies or omissions."
  },
  "3144": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that chemotherapy is indicated for a recurrence score of 25, whereas guidelines recommend it only for scores ≥26; this is a moderate factual error. While the answer is otherwise thorough and references relevant studies, the key recommendation is not aligned with current standards."
  },
  "3145": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including the appropriateness of considering two primaries, the need for comprehensive staging, criteria for distinguishing primaries from metastases, and the importance of multidisciplinary evaluation, with additional correct and clinically relevant detail and no inaccuracies."
  },
  "3146": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizes osimertinib’s CNS efficacy, guideline recommendations, and the exception for urgent local intervention, with additional relevant details and no inaccuracies or omissions."
  },
  "3147": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately stating that brain MRI is optional (not mandatory) for asymptomatic stage IB (T2aN0) NSCLC, even with a central tumor, and provides correct, relevant guideline-based context without inaccuracies or omissions."
  },
  "3148": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the role of BRAF-targeted therapy, acknowledges the rarity in squamous histology, and provides relevant guideline and evidence context without inaccuracies or omissions."
  },
  "3149": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key facts, emphasizing the necessity of pathologic confirmation before definitive chemoradiotherapy and referencing guidelines, but introduces an exception (rare cases where sampling is not feasible) that, while accurate, is not mentioned in the reference and could be seen as a minor deviation from the strict standard described. No clinically unsafe statements are present."
  },
  "3150": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately stating that ALK inhibitor therapy is appropriate first-line treatment in ALK-positive squamous cell carcinoma, regardless of histology. Additional content is factually correct, clinically relevant, and includes guideline references and practical considerations without any inaccuracies or omissions."
  },
  "3151": {
    "score": 5.0,
    "explanation": "5: The model answer accurately covers all key clinical facts from the reference, correctly details the upstaging to at least stage IIB (T3, N0), explains the impact on management, and provides relevant, factually correct elaboration without inaccuracies or omissions."
  },
  "3152": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "3153": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and relevant additional detail about pulmonary function thresholds and alternative therapies, and contains no inaccuracies or omissions."
  },
  "3154": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizes the need for pathologic confirmation of N2 disease, and provides relevant, correct explanations without any inaccuracies or omissions."
  },
  "3155": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains current guidelines, cites relevant clinical trials, and provides a clear rationale and summary without any inaccuracies or omissions."
  },
  "3156": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately cites guidelines, and clearly explains that further CT at 18–24 months is required; there are no inaccuracies or omissions."
  },
  "3157": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including appropriateness of EGFR TKI therapy regardless of smoking history, relevant guideline support, and the need for diagnostic confirmation; all additional content is accurate and clinically relevant."
  },
  "3158": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale for shifting away from surgery in N2 disease, and provides relevant supporting details without inaccuracies or omissions."
  },
  "3159": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly explaining that severe pulmonary dysfunction contraindicates surgery and shifts the preferred treatment to definitive radiotherapy, with no inaccuracies or omissions."
  },
  "3160": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant elaboration, and contains no inaccuracies or omissions."
  },
  "3161": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the scenario as stage IV disease, and appropriately recommends metastatic protocols; additional explanations are accurate and clinically relevant, with no inaccuracies or omissions."
  },
  "3162": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states the indication is based on ERBB2 (HER2) mutation regardless of PD-L1 status, and provides additional correct, clinically relevant details without any inaccuracies or omissions."
  },
  "3163": {
    "score": 5.0,
    "explanation": "5: The model answer accurately covers all key clinical facts from the reference, clearly explaining that HER2-targeted therapy is not prioritized over standard first-line regimens in squamous cell NSCLC, and provides correct, relevant details about current guidelines and evidence."
  },
  "3164": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional explanation, and contains no inaccuracies or omissions."
  },
  "3165": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately stating that neoadjuvant therapy is not routinely indicated for cT1bN0 HER2-positive tumors and is reserved for higher-stage or node-positive cases; all additional content is correct and clinically relevant."
  },
  "3166": {
    "score": 1.0,
    "explanation": "1: The model answer directly contradicts the reference by stating that residual radiographic abnormalities do not necessitate more frequent surveillance, which is a major inaccuracy and could lead to under-monitoring; this is a clinically significant error."
  },
  "3167": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly states the requirement for HER2 confirmation prior to therapy, and provides relevant, accurate rationale without any inaccuracies or omissions."
  },
  "3168": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and relevant additional detail, cites guidelines, and contains no inaccuracies or omissions."
  },
  "3169": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant explanations, and includes supporting guideline references without any inaccuracies or omissions."
  },
  "3170": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that routine brain MRI is not indicated, references relevant guidelines, and provides correct, clinically relevant additional context without any inaccuracies or omissions."
  },
  "3171": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that adjuvant therapy is not routinely indicated for T2aN0 (Stage IB, R0), and correctly notes that it is reserved for higher-stage or high-risk cases; all additional details are factually correct and clinically relevant."
  },
  "3172": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and relevant additional detail, and clearly states that pathologic confirmation is required even if imaging suggests N2 disease, with appropriate mention of rare exceptions and supporting guidelines."
  },
  "3173": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately identifies surgery as preferred if operable, and clearly states that operability/surgical fitness is the primary determinant; all additional details are correct and clinically relevant."
  },
  "3174": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including the modest benefit of chemotherapy in small, node-negative TNBC, the contraindication of anthracyclines due to cardiac comorbidity, and the consideration of non-anthracycline regimens with individualized risk–benefit assessment; all additional content is accurate and clinically relevant."
  },
  "3175": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizes the high risk of pulmonary toxicity, and appropriately advises against adjuvant radiotherapy in this context. Additional content is factually correct, clinically relevant, and guideline-based, with no inaccuracies or omissions."
  },
  "3176": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly prioritizing further local therapy over surveillance, and provides additional, accurate, and clinically relevant details without any inaccuracies or omissions."
  },
  "3177": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides additional accurate and clinically relevant details, and contains no inaccuracies or omissions."
  },
  "3178": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the rationale and guidelines, and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "3179": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate staging clarification, and reinforces that concurrent chemoradiation is preferred for unresectable Stage IIIA NSCLC without extrathoracic disease; all additional content is correct and clinically relevant."
  },
  "3180": {
    "score": 5.0,
    "explanation": "5: The model answer accurately covers all key clinical facts from the reference, clearly distinguishing between routine surveillance and the appropriate use of PET/CT when new abnormalities arise, and correctly describes the boundaries of standard imaging follow-up without any inaccuracies or omissions."
  },
  "3181": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional details, and contains no inaccuracies or omissions."
  },
  "3182": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly explaining when a contralateral nodule may be considered a second primary and when it is metastatic, with accurate, relevant detail and no inaccuracies or omissions."
  },
  "3183": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional details, and contains no inaccuracies or omissions."
  },
  "3184": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and relevant guideline-based details, and includes no inaccuracies or omissions; additional content is correct and clinically pertinent."
  },
  "3185": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant explanations, and contains no inaccuracies or omissions."
  },
  "3186": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides additional relevant context about mutation frequency and guideline support, and contains no inaccuracies or omissions."
  },
  "3187": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional details, and contains no inaccuracies or omissions."
  },
  "3188": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale and guideline support, and contains no inaccuracies or omissions."
  },
  "3189": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, correctly emphasizing that adjuvant chemoradiation is not universally standard and that sequential chemotherapy followed by PORT is preferred, regardless of mediastinal lymph node dissection. However, the initial \"No\" could be misleading, as chemoradiation (sequentially) is standard, and the answer could be clearer in affirming that chemoradiation (as sequential chemo then PORT) is indeed indicated for R1, N2 disease."
  },
  "3190": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, cites relevant trials and guidelines, and includes no inaccuracies or omissions."
  },
  "3191": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizes the need for orthopedic stabilization in addition to radiation, and provides relevant rationale and guideline support without any inaccuracies or omissions."
  },
  "3192": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly emphasizing that re-resection is preferred if feasible and that chemoradiation is recommended only when re-resection is not possible; it also accurately discusses concurrent versus sequential chemoradiation, with no inaccuracies or omissions."
  },
  "3193": {
    "score": 1.0,
    "explanation": "1: The model answer directly contradicts the reference by incorrectly stating that ALND is required in this scenario, despite current evidence and guidelines allowing omission if only one node is positive and radiotherapy is planned. This is a major inaccuracy that could lead to overtreatment."
  },
  "3194": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant rationale, and contains no inaccuracies or omissions."
  },
  "3195": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides additional correct and clinically relevant context, and contains no inaccuracies or omissions."
  },
  "3196": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately stating that broad molecular profiling is recommended for all advanced squamous NSCLC patients regardless of smoking status, and provides additional relevant context without inaccuracies or omissions."
  },
  "3197": {
    "score": 2.0,
    "explanation": "2: The model answer omits the key fact that brain MRI is routinely required for stage II and above to exclude occult brain metastases, and incorrectly suggests omission is acceptable in stage II, which contradicts current recommendations; it also introduces some guideline ambiguity and downplays the importance of brain MRI in stage II, constituting a moderate factual error."
  },
  "3198": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, correctly outlining when SRS alone or surgical resection is appropriate, and provides relevant clinical criteria. However, it slightly overemphasizes surgical resection as generally prioritized, whereas the reference states SRS alone suffices unless the lesion is symptomatic or tissue diagnosis is needed; this is a minor wording inaccuracy but does not alter the clinical meaning."
  },
  "3199": {
    "score": 5.0,
    "explanation": "5: Fully covers all key clinical facts from the reference, clearly prioritizing local intervention for severe hemoptysis and correctly stating that chemotherapy alone is insufficient; additional explanations are accurate and clinically relevant."
  },
  "3200": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale and guideline citations, and contains no inaccuracies or omissions."
  },
  "3201": {
    "score": 5.0,
    "explanation": "5: Fully covers all key facts from the reference, accurately states that routine FDG-PET/CT is not recommended, describes appropriate surveillance with chest CT, and correctly notes PET/CT is reserved for suspected recurrence; additional content is guideline-based and clinically relevant."
  },
  "3202": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that surveillance intervals should be the same for both groups, missing the key fact that post-radiation patients require more frequent (every 3–6 months) surveillance than post-surgical patients (every 6 months). This is a moderate factual error and omits the rationale regarding higher recurrence risk after radiation."
  },
  "3203": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and provides relevant additional detail without inaccuracies or omissions."
  },
  "3204": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate staging details, guideline references, and a clear rationale; all additional content is correct and clinically relevant, with no inaccuracies or omissions."
  },
  "3205": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains that surgery is feasible in selected T4, N0–1 cases, and provides relevant, guideline-based detail without inaccuracies or omissions."
  },
  "3206": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, clearly stating that durvalumab is not appropriate for all patients regardless of EGFR status, and correctly identifies that those with sensitizing EGFR mutations should not receive durvalumab. It references relevant guidelines and provides accurate, clinically relevant explanations with no inaccuracies or omissions."
  },
  "3207": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional details (e.g., CDK4/6 inhibitors, guideline references), and contains no inaccuracies or omissions."
  },
  "3208": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional details, and contains no inaccuracies or omissions."
  },
  "3209": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional details, and contains no inaccuracies or omissions."
  },
  "3210": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that routine brain MRI is not indicated, and appropriately specifies that brain imaging is reserved for symptoms or recurrence; all additional content is correct and clinically relevant."
  },
  "3211": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "3212": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that routine surveillance should use chest CT (with or without contrast) and not FDG-PET/CT, and correctly notes PET/CT is reserved for suspicious findings or symptoms; additional details are correct and clinically relevant."
  },
  "3213": {
    "score": 1.0,
    "explanation": "1: The model answer incorrectly states that the same surveillance schedule is appropriate, directly contradicting the reference, which specifies that closer (every 3–6 months) surveillance is needed after radiotherapy. This is a major inaccuracy that could lead to suboptimal follow-up."
  },
  "3214": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly states that adjuvant radiotherapy is indicated regardless of systemic therapy, and provides accurate, relevant rationale and guideline references without any inaccuracies or omissions."
  },
  "3215": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional details, cites guidelines, and contains no inaccuracies or omissions."
  },
  "3216": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the contraindication to chemoradiation due to pulmonary fibrosis, discusses alternative management, and provides relevant, correct additional detail without inaccuracies or omissions."
  },
  "3217": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and provides relevant guideline-based recommendations without any inaccuracies or omissions."
  },
  "3218": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, correctly noting the rarity of actionable mutations in squamous cell carcinoma and outlining exceptions for testing, but it incorrectly implies that broad molecular profiling is generally not indicated, which contradicts current guidelines recommending testing in all advanced cases due to the possibility of rare actionable mutations regardless of histology."
  },
  "3219": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that concurrent chemoradiation is generally not appropriate in severe COPD due to toxicity risk, and suggests individualized or sequential approaches. Additional content is accurate, relevant, and guideline-based, with no inaccuracies or omissions."
  },
  "3220": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, cites guidelines and evidence, and contains no inaccuracies or omissions."
  },
  "3221": {
    "score": 3.0,
    "explanation": "3: The model answer accurately states that either isolated ERBB2 testing or broad profiling can identify eligibility for fam-trastuzumab deruxtecan-nxki, but it omits the reference answer’s key point that broad molecular profiling is the standard for identifying all actionable mutations, not just ERBB2, in advanced squamous cell carcinoma."
  },
  "3222": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including the standard recommendation for one year of HER2-directed therapy, the need to individualize treatment in the setting of severe hepatic dysfunction, and the importance of safety considerations. Additional content is accurate, relevant, and enhances the explanation without introducing errors."
  },
  "3223": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant explanations, cites appropriate guidelines, and contains no inaccuracies or omissions."
  },
  "3224": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly explains why perioperative therapy is unsuitable, and appropriately recommends non-surgical management; there are no inaccuracies or omissions."
  },
  "3225": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, correctly describing the role of SVC stenting for severe/life-threatening symptoms and chemoradiation for less severe cases, but it introduces a conditional approach not present in the reference, which states stenting should be prioritized for all symptomatic SVC obstruction regardless of severity. This represents a minor but clinically relevant omission, as the reference does not support withholding stenting in any symptomatic case."
  },
  "3226": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant rationale, and contains no inaccuracies or omissions."
  },
  "3227": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional guideline-based details, and contains no inaccuracies or omissions."
  },
  "3228": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and includes relevant, correct additional details without any inaccuracies or omissions."
  },
  "3229": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key facts, correctly stating that NTRK-targeted therapy presumes comprehensive molecular profiling regardless of smoking status, and provides accurate, relevant explanations. However, it introduces nuanced guideline distinctions about when profiling is \"increasingly\" recommended in squamous NSCLC, which could be seen as a minor wording inaccuracy compared to the reference's unequivocal stance."
  },
  "3230": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately cites major guidelines, explains the rationale, and provides correct, clinically relevant additional details without any inaccuracies or omissions."
  },
  "3231": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that routine PET/CT or brain MRI is not indicated, and appropriately reserves these modalities for suspected recurrence; additional guideline details are correct and clinically relevant."
  },
  "3232": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional details, and contains no inaccuracies or omissions."
  },
  "3233": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, includes relevant details about the indication, and provides supporting evidence without any inaccuracies or omissions."
  },
  "3234": {
    "score": 4.0,
    "explanation": "4: The model answer correctly states that adjuvant radiotherapy is not a category 1 recommendation and explains the lower level of evidence or consensus, but it inaccurately cites the NCCN as category 2A rather than 2B for this scenario, which is a minor wording inaccuracy that does not alter the overall clinical meaning."
  },
  "3235": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly denies that classifying and treating the lesions as two primaries implicitly presumes curability, which is a key fact in the reference; while it provides relevant background, it omits the central point that this classification assumes both are potentially curable, resulting in a moderate factual omission."
  },
  "3236": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that both lesions must be potentially curable to be managed as two primaries, and adds relevant, accurate clinical context without any inaccuracies or omissions."
  },
  "3237": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional explanations, and contains no inaccuracies or omissions."
  },
  "3238": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and relevant additional details, and contains no inaccuracies or omissions."
  },
  "3239": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly emphasizing that contrast-enhanced CT is not recommended in severe CKD and that non-contrast CT should be used for surveillance; all additional content is accurate and clinically relevant."
  },
  "3240": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides additional relevant and accurate details about rationale and guidelines, and contains no inaccuracies or omissions."
  },
  "3241": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that pulmonary function assessment is mandatory before surgery and providing relevant, accurate explanations without any omissions or inaccuracies."
  },
  "3242": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the lack of indication for sotorasib or adagrasib in ECOG PS 3, and provides relevant context without inaccuracies or omissions."
  },
  "3243": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that ALK rearrangement justifies first-line ALK inhibitor use over standard chemotherapy, and provides accurate, relevant background and guideline references without inaccuracies or omissions."
  },
  "3244": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly emphasizes the limitations of FDG-PET/CT alone, discusses the need for CNS imaging even without contrast, and provides guideline-based recommendations without inaccuracies or omissions."
  },
  "3245": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "3246": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately cites guidelines, and provides relevant supporting details without any inaccuracies or omissions."
  },
  "3247": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and includes relevant guideline-based recommendations without any inaccuracies or omissions."
  },
  "3248": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, adds accurate and clinically relevant detail, and contains no inaccuracies or omissions."
  },
  "3249": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, addresses the role of non-contrast PET/CT, and provides relevant guideline references without any inaccuracies or omissions."
  },
  "3250": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, adds relevant and accurate details about targeted agents and clinical guidelines, and contains no inaccuracies or omissions."
  },
  "3251": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that routine brain MRI and FDG-PET/CT are unnecessary in this context, and provides correct, relevant guideline-based details without any inaccuracies or omissions."
  },
  "3252": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, guideline citations, and clearly states that PMRT is indicated in this scenario; there are no inaccuracies or omissions."
  },
  "3253": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately distinguishes between synchronous primaries and intrapulmonary metastasis, details staging and management implications, and provides relevant, correct additional context without inaccuracies or omissions."
  },
  "3254": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional details, and contains no inaccuracies or omissions."
  },
  "3255": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "3256": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant rationale, and includes no inaccuracies or omissions."
  },
  "3257": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, adds correct and clinically relevant details (e.g., additional actionable mutations, guideline citations), and contains no inaccuracies or omissions."
  },
  "3258": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that EGFR-targeted therapy is appropriate with a confirmed L861Q mutation despite lack of broad profiling, and provides additional relevant, correct, and guideline-based context without any inaccuracies or omissions."
  },
  "3259": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, including staging and the need for robust evidence to consider lesions as separate primaries, but overemphasizes the default metastatic classification and underplays that current practice does allow for curative treatment of both lesions if they are potentially curable, as per the reference. There is a minor omission regarding the support for individualized curative approaches in such cases."
  },
  "3260": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional details, and contains no inaccuracies or omissions."
  },
  "3261": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that systemic therapy is generally prioritized over palliative radiotherapy for symptomatic management, which contradicts the reference's emphasis on immediate local control for symptomatic brain metastases; while it provides relevant details and scenarios, this represents a moderate factual error regarding initial management priorities."
  },
  "3262": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes surgical candidacy criteria, and appropriately positions radiotherapy as an alternative for inoperable patients. All additional details are correct and clinically relevant."
  },
  "3263": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "3264": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant rationale, cites guidelines, and contains no inaccuracies or omissions."
  },
  "3265": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and relevant additional explanation, and contains no inaccuracies or omissions."
  },
  "3266": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and relevant additional details (e.g., chemotherapy regimens, oncologic indications, safety considerations), and contains no inaccuracies or omissions."
  },
  "3267": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly explains the rationale, addresses the role of contrast in surveillance, and appropriately recommends non-contrast CT due to CKD; all additional content is accurate and clinically relevant."
  },
  "3268": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key facts, correctly stating that adjuvant radiation is generally recommended but that surveillance may be considered in select cases where radiotherapy is not feasible; it slightly overstates the strength of the recommendation (\"almost always indicated\") compared to the reference, but this is a minor wording inaccuracy and does not alter the clinical meaning."
  },
  "3269": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains that clinical staging (not pathologic confirmation) guides neoadjuvant therapy decisions, and provides relevant, correct rationale without any inaccuracies or omissions."
  },
  "3270": {
    "score": 4.0,
    "explanation": "4: The model answer covers over 90% of key facts, correctly clarifying that immunotherapy monotherapy is not appropriate and that chemoimmunotherapy is standard, with relevant references and clinical context. However, it slightly overstates the appropriateness of immunotherapy (as part of chemoimmunotherapy) as \"appropriate\" in all cases, whereas the reference emphasizes chemotherapy as standard and immunotherapy is generally reserved for higher PD-L1 or after chemotherapy, making this a minor wording inaccuracy."
  },
  "3271": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, cites supporting evidence and guidelines, and contains no inaccuracies or omissions."
  },
  "3272": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that adjuvant radiation therapy is routinely warranted and that observation is generally not appropriate, which contradicts the reference answer and current guidelines for stage IB (T2a, N0) NSCLC with R1 resection; this represents a moderate factual error and overstates the role of PORT, missing the acceptability of observation alone."
  },
  "3273": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "3274": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "3275": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, provides accurate and relevant guideline-based rationale, and correctly states that clinical suspicion alone warrants targeted ultrasound even if exam and mammogram are unremarkable; there are no inaccuracies or omissions."
  },
  "3276": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, cites relevant guidelines, and includes additional correct and clinically relevant details without any inaccuracies or omissions."
  },
  "3277": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional explanation, and contains no inaccuracies or omissions."
  },
  "3278": {
    "score": 5.0,
    "explanation": "5: The model answer accurately states that fam-trastuzumab deruxtecan-nxki is currently approved and recommended only for non-squamous NSCLC (mainly adenocarcinoma) with ERBB2 mutations, and not for squamous cell carcinoma, matching all key clinical facts in the reference and providing relevant supporting details."
  },
  "3279": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional detail, cites guidelines, and contains no inaccuracies or omissions."
  },
  "3280": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizing that systemic therapy is standard, surgery is not routine, and may only be considered in highly selected cases with multidisciplinary input; all additional content is correct and clinically relevant."
  },
  "3281": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant guideline-based details, and contains no inaccuracies or omissions."
  },
  "3282": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that routine FDG-PET/CT and brain MRI are not indicated, and provides relevant, guideline-based details without inaccuracies or omissions."
  },
  "3283": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, adds accurate and clinically relevant details about histopathologic and molecular criteria, and contains no inaccuracies or omissions."
  },
  "3284": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant guideline-based rationale, and includes no inaccuracies or omissions. Additional content is correct and enhances understanding."
  },
  "3285": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "3286": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional explanation, and contains no inaccuracies or omissions."
  },
  "3287": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "3288": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly states the necessity of marking and retrieving the biopsied node, explains the rationale, and references supporting guidelines and studies. There are no inaccuracies or omissions."
  },
  "3289": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant rationale, and contains no inaccuracies or omissions."
  },
  "3290": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that routine PET/CT or brain MRI is not indicated, and provides correct, relevant guideline-based surveillance details without any inaccuracies or omissions."
  },
  "3291": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly prioritizing surgical resection for resectable, operable patients, and appropriately noting SABR/EBRT as alternatives for non-surgical candidates; all additional content is accurate and clinically relevant."
  },
  "3292": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains staging, treatment intent, and implications, and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "3293": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "3294": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant rationale, cites supporting guidelines and trials, and contains no inaccuracies or omissions."
  },
  "3295": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and provides relevant guideline-based details without any inaccuracies or omissions."
  },
  "3296": {
    "score": 5.0,
    "explanation": "5: Fully covers all key clinical facts from the reference, accurately describes current guidelines, and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "3297": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that adjuvant radiation is generally recommended but observation may be considered in select scenarios (e.g., contraindications or patient refusal), with no inaccuracies or omissions."
  },
  "3298": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and relevant additional details, cites guidelines, and contains no inaccuracies or omissions."
  },
  "3299": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the rationale, guidelines, and radiotherapy options, and includes only relevant, correct additional details without any inaccuracies or omissions."
  },
  "3300": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that the surveillance schedule is unchanged by adjuvant radiotherapy, omitting the need for more intensive CT follow-up (every 3–6 months for 3 years, then every 6 months for 2 years) recommended after radiotherapy; this is a moderate factual omission, though the rest of the content is accurate and relevant."
  },
  "3301": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, emphasizing the importance of molecular profiling and the role of targeted therapies, but it incorrectly suggests deferring radiotherapy in stable patients, whereas the reference states that urgent symptom control with radiotherapy is appropriate regardless of molecular status. This represents a moderate omission regarding the primacy of symptom control."
  },
  "3302": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, cites relevant evidence and guidelines, and contains no inaccuracies or omissions."
  },
  "3303": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the upstaging to T3/stage IIB, confirms that surgery remains standard if operable, and adds relevant, correct details about surgical complexity and multidisciplinary care."
  },
  "3304": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizes the necessity of pathologic confirmation, explains the limitations of imaging, and provides relevant rationale without any inaccuracies or omissions."
  },
  "3305": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizes the need for absence of mediastinal nodal and extrathoracic metastasis, and provides correct, relevant staging details without any inaccuracies or omissions."
  },
  "3306": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, including that adjuvant therapy is not universally indicated after full neoadjuvant therapy and R0 resection, and that surveillance is appropriate in this scenario. However, it overstates the lack of benefit for adjuvant therapy in all such cases and does not clearly state that adjuvant therapy is generally preferred unless contraindicated, as per guidelines, which is a moderate omission."
  },
  "3307": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that significant pulmonary impairment precludes surgery and thus perioperative therapy, and that definitive chemoradiotherapy is preferred; all additional content is accurate and clinically relevant."
  },
  "3308": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately stating that NTRK inhibitor therapy can be initiated based solely on a confirmed NTRK fusion without requiring broad molecular profiling, and provides additional relevant context without any inaccuracies or omissions."
  },
  "3309": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that routine FDG-PET/CT or brain MRI is not indicated, and provides relevant guideline-based details without inaccuracies or omissions."
  },
  "3310": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately prioritizing systemic therapy due to toxicity risks of re-irradiation, and appropriately notes that locoregional treatment may be considered only in highly selected cases with multidisciplinary input. No inaccuracies or omissions are present."
  },
  "3311": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "3312": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional details, and contains no inaccuracies or omissions."
  },
  "3313": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional rationale, and contains no inaccuracies or omissions."
  },
  "3314": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and relevant additional context, and contains no inaccuracies or omissions."
  },
  "3315": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, cites relevant guidelines, and contains no inaccuracies or omissions."
  },
  "3316": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, guideline references, and a helpful summary table, with no inaccuracies or omissions."
  },
  "3317": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, including the rarity of ROS1 rearrangements in squamous histology and guideline recommendations, but it incorrectly downplays the necessity of confirming non-squamous histology prior to TKI initiation, which is a key point in the reference answer. This represents a moderate omission regarding the clinical workflow and appropriateness of molecular testing."
  },
  "3318": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that routine FDG-PET/CT is not indicated, details appropriate surveillance methods, and correctly cites guidelines; there are no inaccuracies or omissions."
  },
  "3319": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides additional relevant and accurate details about specific MET inhibitors, dosing, and monitoring, and contains no inaccuracies or omissions."
  },
  "3320": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately cites relevant guidelines, and provides correct, clinically relevant additional detail without any inaccuracies or omissions."
  },
  "3321": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides additional accurate and clinically relevant detail about best practices (TAD, dual tracer, node count), and cites current guidelines; there are no inaccuracies or omissions."
  },
  "3322": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides additional correct and clinically relevant details, and contains no inaccuracies or omissions."
  },
  "3323": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains why surgery is contraindicated, and appropriately recommends definitive radiotherapy as the preferred alternative, with no inaccuracies or omissions."
  },
  "3324": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately cites relevant guidelines, and provides correct, clinically relevant explanations without any inaccuracies or omissions."
  },
  "3325": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant explanations, and includes no inaccuracies or omissions."
  },
  "3326": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly distinguishing between indications for immediate stenting versus chemoradiation based on symptom severity, with no inaccuracies or omissions and relevant, accurate additional detail."
  },
  "3327": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately cites relevant guidelines, and provides clinically relevant additional detail without any inaccuracies or omissions."
  },
  "3328": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizes the essential role of PD-L1 testing regardless of prior radiotherapy, and provides relevant, correct additional context without any inaccuracies or omissions."
  },
  "3329": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant rationale, cites guidelines, and contains no inaccuracies or omissions."
  },
  "3330": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant elaboration, and contains no inaccuracies or omissions."
  },
  "3331": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly explains the rationale for favoring definitive chemoradiation in patients with severe COPD, and provides relevant guideline references without inaccuracies or omissions."
  },
  "3332": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and relevant guideline-based explanations, and includes no inaccuracies or omissions."
  },
  "3333": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, cites relevant guidelines and trial data, and makes no errors or omissions."
  },
  "3334": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that routine FDG-PET/CT is not indicated, details appropriate follow-up, and provides correct, relevant guideline-based rationale without any inaccuracies or omissions."
  },
  "3335": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, adds correct and clinically relevant details about diagnostic criteria, and accurately explains the clinical significance without any inaccuracies or omissions."
  },
  "3336": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, cites supporting evidence, and contains no inaccuracies or omissions."
  },
  "3337": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant explanations, and contains no inaccuracies or omissions."
  },
  "3338": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly stating that more frequent imaging is indicated for indeterminate or suspicious findings, while standard intervals are appropriate for clearly benign/stable abnormalities; it adds relevant, accurate detail and guideline references without any inaccuracies or omissions."
  },
  "3339": {
    "score": 4.0,
    "explanation": "4: The model answer correctly states that the standard 6–12 month interval applies but emphasizes that COPD increases malignancy risk and suggests follow-up at the earlier end (6 months), which is consistent with guideline nuance. However, it slightly overstates the impact of COPD alone by implying it mandates a shorter interval, rather than simply allowing for it within the recommended range; this is a minor wording inaccuracy."
  },
  "3340": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional rationale, and contains no inaccuracies or omissions."
  },
  "3341": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that routine brain MRI is not indicated, and appropriately references guidelines and indications for brain imaging; there are no inaccuracies or omissions."
  },
  "3342": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly explains the rationale for both re-operation and radiotherapy, addresses the impact of COPD and borderline pulmonary function, and cites relevant guidelines without inaccuracies or omissions."
  },
  "3343": {
    "score": 5.0,
    "explanation": "5: Fully covers all key clinical facts from the reference, provides accurate and clinically relevant rationale, cites guidelines, and contains no inaccuracies or omissions."
  },
  "3344": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly stating that PET/CT is not routinely indicated for asymptomatic surveillance but may be appropriate for evaluating a new radiographic abnormality, even in the absence of symptoms; all additional content is accurate and clinically relevant."
  },
  "3345": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately prioritizing local interventions over systemic therapy for severe hemoptysis, and provides correct, clinically relevant rationale and references without any inaccuracies or omissions."
  },
  "3346": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the impact of brain metastases on management, and appropriately discusses exceptions in oligometastatic cases, with no inaccuracies or omissions."
  },
  "3347": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant explanations, cites guidelines, and emphasizes the necessity of PET/CT and brain MRI before treatment; there are no inaccuracies or omissions."
  },
  "3348": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly prioritizing urgent symptom relief with SVC stenting and EBRT before definitive chemoradiation, and cites relevant guidelines; there are no inaccuracies or omissions."
  },
  "3349": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale for brain MRI, addresses guideline recommendations, and includes relevant supporting details without inaccuracies or omissions."
  },
  "3350": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "3351": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and provides relevant, correct additional detail without any omissions or inaccuracies."
  },
  "3352": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional details, and contains no inaccuracies or omissions."
  },
  "3353": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key clinical facts, accurately distinguishing between T3 and T4 scenarios and emphasizing the more selective approach for T4. However, it slightly overstates the impact of anatomical location on surgical eligibility, as both groups can be considered for surgery if otherwise eligible; this constitutes a minor wording inaccuracy."
  },
  "3354": {
    "score": 1.0,
    "explanation": "1: The model answer directly contradicts the reference by recommending immediate switching to selpercatinib, which is not aligned with the optimal sequencing described; this is a major inaccuracy regarding current standard practice."
  },
  "3355": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and appropriately notes rare exceptions and the need for multidisciplinary evaluation, with no inaccuracies or omissions."
  },
  "3356": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizing the necessity of excluding distant metastases with FDG-PET/CT and brain MRI before surgery, and adds relevant, correct context without any inaccuracies or omissions."
  },
  "3357": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explaining the faster symptomatic relief with SVC stenting versus radiotherapy, and provides additional correct and clinically relevant context without any inaccuracies or omissions."
  },
  "3358": {
    "score": 5.0,
    "explanation": "5: The model answer accurately covers all key clinical facts from the reference, clearly stating that prior platinum-based chemotherapy failure is required, and supports this with correct, relevant guideline and FDA references; there are no inaccuracies or omissions."
  },
  "3359": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizes the need for pathologic confirmation, discusses exceptions, and provides relevant guideline support without inaccuracies or omissions."
  },
  "3360": {
    "score": 1.0,
    "explanation": "1: The model answer directly contradicts the reference by recommending immediate switch to osimertinib, omitting the key fact that current therapy should be completed first; this is a major inaccuracy with potential clinical implications."
  },
  "3361": {
    "score": 2.0,
    "explanation": "2: The model answer covers some relevant considerations about surgical candidacy and multidisciplinary assessment, but it directly contradicts the reference by failing to recognize that \"definitive local therapy not possible\" inherently excludes surgery, which is a form of definitive local therapy; this is a moderate factual error."
  },
  "3362": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately stating that bone-modifying agents can be started before molecular results and that systemic therapy should be based on molecular findings. Additional content is correct, clinically relevant, and guideline-based, with no inaccuracies or omissions."
  },
  "3363": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and relevant rationale, and cites supporting guidelines without any inaccuracies or omissions."
  },
  "3364": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional details, and contains no inaccuracies or omissions."
  },
  "3365": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and provides relevant guideline-based context without any inaccuracies or omissions."
  },
  "3366": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "3367": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the appropriateness of definitive radiotherapy (including SABR) for medically inoperable stage IIB (T3, N0) NSCLC, and provides relevant, correct elaboration on technical considerations without any inaccuracies or omissions."
  },
  "3368": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, cites relevant guidelines, and contains no inaccuracies or omissions."
  },
  "3369": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional rationale, and contains no inaccuracies or omissions."
  },
  "3370": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that selpercatinib is recommended upon RET rearrangement discovery during first-line therapy, even if the initial regimen is incomplete. Additional content is accurate, clinically relevant, and guideline-based, with no inaccuracies or omissions."
  },
  "3371": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly justifying EGFR TKI use in this context, and provides additional, accurate, and clinically relevant details without any inaccuracies or omissions."
  },
  "3372": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly emphasizes that endocrine therapy is indicated based on ER-positivity and nodal status without needing additional adverse features, and provides accurate, relevant rationale with no inaccuracies or omissions."
  },
  "3373": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional rationale, cites guidelines and evidence, and includes appropriate caveats regarding patient fitness, with no inaccuracies or omissions."
  },
  "3374": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes SABR/SBRT as the preferred definitive treatment for medically inoperable stage I NSCLC, and provides relevant, correct additional context without any inaccuracies or omissions."
  },
  "3375": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and provides relevant, up-to-date guideline references without any inaccuracies or omissions."
  },
  "3376": {
    "score": 5.0,
    "explanation": "5: The model answer accurately states that broad molecular profiling is not routinely required in stage III squamous NSCLC without distant metastasis, aligns with current guidelines, and covers all key clinical facts from the reference answer, with additional correct and relevant details about exceptions and PD-L1 testing."
  },
  "3377": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains why surgery is not appropriate, details the nature of N3 disease, and correctly identifies chemoradiotherapy as the standard of care, with no inaccuracies or omissions."
  },
  "3378": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "3379": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately prioritizing repeat resection over adjuvant radiotherapy and specifying that radiotherapy is only considered if re-resection is not feasible; all additional content is correct and clinically relevant."
  },
  "3380": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional explanations, and cites appropriate guidelines without any inaccuracies or omissions."
  },
  "3381": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale for ovarian suppression, details guideline-based options, and correctly notes that tamoxifen monotherapy is acceptable (though suboptimal) if ovarian intervention is refused; there are no inaccuracies or omissions."
  },
  "3382": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional details, and contains no inaccuracies or omissions."
  },
  "3383": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the necessity of PET/CT and PFTs, references relevant guidelines, and contains no inaccuracies or omissions."
  },
  "3384": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, emphasizes the necessity of PFTs regardless of comorbidities, and provides accurate, relevant guideline-based rationale without any inaccuracies or omissions."
  },
  "3385": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that SERMs are contraindicated in serious hepatic dysfunction, provides rationale, and cites guidelines; there are no inaccuracies or omissions."
  },
  "3386": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts in the reference, accurately explains the rationale, and appropriately describes the rare exception for urgent cases, with no inaccuracies or omissions."
  },
  "3387": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, includes relevant guideline citations, and clearly states the only exception (inability to access/tolerate TKIs); there are no inaccuracies or omissions."
  },
  "3388": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, includes relevant guideline context, and contains no inaccuracies or omissions."
  },
  "3389": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately prioritizing local therapy for a solitary brain metastasis and appropriately noting exceptions where systemic therapy may be considered; all additional content is correct and clinically relevant."
  },
  "3390": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant guideline citations, and contains no inaccuracies or omissions."
  },
  "3391": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes guideline recommendations, and provides relevant additional detail without inaccuracies or omissions."
  },
  "3392": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly states that neoadjuvant chemotherapy is appropriate for cT1c, cN0, triple-negative breast cancer, and provides accurate, relevant rationale and guideline support without any inaccuracies or omissions."
  },
  "3393": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key clinical facts, correctly prioritizing endobronchial intervention for acute airway compromise and chemoradiotherapy otherwise, but introduces a nuanced distinction (mild/moderate symptoms) not present in the reference; this is a minor wording difference, not a clinically significant omission."
  },
  "3394": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant guideline-based details, and contains no inaccuracies or omissions."
  },
  "3395": {
    "score": 2.0,
    "explanation": "2: The model answer provides a detailed, guideline-based rationale for administering chemotherapy in the late third trimester, but this directly contradicts the reference answer, which states chemotherapy should be deferred until after delivery. While the model is factually accurate per some guidelines, it omits the reference's clear recommendation to defer, constituting a moderate factual discrepancy."
  },
  "3396": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant explanations, cites guidelines, and contains no inaccuracies or omissions."
  },
  "3397": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly explains that core biopsy is unnecessary without a detectable mass, and correctly emphasizes the need for a nipple-areolar complex biopsy. All additional content is accurate and clinically relevant."
  },
  "3398": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides additional relevant detail about guidelines and rationale, and contains no inaccuracies or omissions."
  },
  "3399": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that routine brain MRI is not indicated, and provides correct, relevant guideline-based rationale without any inaccuracies or omissions."
  },
  "3400": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including the necessity of broad molecular profiling despite a known MET mutation, the rationale (guidelines, detection of co-mutations, impact on prognosis and future therapy), and references to current guidelines, with no inaccuracies or omissions."
  },
  "3401": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant explanations, cites guidelines, and contains no inaccuracies or omissions."
  },
  "3402": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, adds relevant and accurate details about guidelines, monitoring for toxicity, and rationale, with no inaccuracies or omissions."
  },
  "3403": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional explanation, cites guidelines, and contains no inaccuracies or omissions."
  },
  "3404": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly states that both biopsies with clip/marker placement are required, and explains the rationale and consequences of omission. There are no inaccuracies or omissions, and extra content is accurate and clinically relevant."
  },
  "3405": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "3406": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional rationale, and contains no inaccuracies or omissions."
  },
  "3407": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and relevant guideline-based explanations, and contains no inaccuracies or omissions."
  },
  "3408": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts and provides detailed, guideline-based justification, but it incorrectly states that adjuvant therapy is routinely recommended for all stage IIA patients regardless of risk factors, whereas the reference specifies it is typically considered only in the presence of high-risk features; this is a moderate factual inaccuracy."
  },
  "3409": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately cites guidelines, addresses the impact of positive margins, and provides correct, relevant additional detail without any inaccuracies or omissions."
  },
  "3410": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizes the primacy of biomarker testing, discusses the rationale for deferring local therapy unless urgent symptoms are present, and provides relevant guideline references and exceptions without inaccuracies or omissions."
  },
  "3411": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, cites relevant guidelines, and provides a clear summary without any inaccuracies or omissions."
  },
  "3412": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant explanations, and contains no inaccuracies or omissions."
  },
  "3413": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately clarifies that osimertinib is appropriate for all stage IV substages, and provides relevant, correct additional context without any inaccuracies or omissions."
  },
  "3414": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including the appropriateness of preoperative concurrent chemoradiation, the significance of brachial plexus invasion (but not vertebral body or subclavian vessels), and the importance of potential R0 resection. Additional content is accurate, relevant, and guideline-based, with no inaccuracies or omissions."
  },
  "3415": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that immediate switching is not always required, and that completing planned therapy (including maintenance) is acceptable, with targeted therapy initiation at progression also reasonable. Additional content is factually correct and clinically relevant, with no inaccuracies or omissions."
  },
  "3416": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately prioritizing SBRT over surgery in patients with significant pulmonary impairment, and provides additional relevant, correct detail without any inaccuracies or omissions."
  },
  "3417": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizes the need for pathologic confirmation, and provides relevant, correct rationale without any inaccuracies or omissions."
  },
  "3418": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant guideline citations, and contains no inaccuracies or omissions."
  },
  "3419": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly emphasizes that observation is not appropriate, and that systemic therapy is standard; additional details about staging and adjuvant options are accurate and clinically relevant."
  },
  "3420": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that targeted therapy is prioritized, provides relevant guideline context, and includes a clinically appropriate caveat about the rarity of ALK rearrangements in squamous histology, with no inaccuracies or omissions."
  },
  "3421": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately cites major guidelines, and provides relevant additional detail without any inaccuracies or omissions."
  },
  "3422": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, cites guidelines, and includes relevant extra detail without any inaccuracies or omissions."
  },
  "3423": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including prioritizing osimertinib over durvalumab, the rationale regarding limited immunotherapy benefit in EGFR-mutant NSCLC, supporting trial and guideline evidence, and the clinical implications; all additional details are accurate and clinically relevant."
  },
  "3424": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, provides correct and relevant additional details, and contains no inaccuracies or omissions."
  },
  "3425": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that observation alone is acceptable for asymptomatic patients with contraindications to therapy, and appropriately notes that palliative therapy is not mandatory unless symptoms develop. Additional content is correct, relevant, and guideline-based."
  },
  "3426": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, cites relevant guidelines, and contains no inaccuracies or omissions."
  },
  "3427": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly states that a 6 mm nodule is included in surveillance recommendations, and provides accurate, relevant guideline context without any inaccuracies or omissions."
  },
  "3428": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, cites relevant guidelines, and includes no inaccuracies or omissions."
  },
  "3429": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant elaboration, and contains no inaccuracies or omissions."
  },
  "3430": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and provides relevant, correct additional context without any inaccuracies or omissions."
  },
  "3431": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that re-resection is preferred only if pulmonary function allows, and radiotherapy is appropriate for inoperable patients; there are no inaccuracies or omissions."
  },
  "3432": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizes the need for updated histology and molecular testing before systemic therapy, and correctly notes exceptions when biopsy is not feasible; all additional content is relevant, guideline-based, and free of inaccuracies."
  },
  "3433": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and provides relevant guideline context without any inaccuracies or omissions."
  },
  "3434": {
    "score": 5.0,
    "explanation": "5: Covers all key clinical facts, correctly prioritizing surveillance over PET/CT or biopsy, and provides accurate, clinically relevant explanations without inaccuracies or omissions."
  },
  "3435": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that positive margins require adjuvant therapy rather than standard surveillance, and provides accurate, relevant detail without inaccuracies or omissions."
  },
  "3436": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key facts regarding PET/CT (not indicated for routine surveillance) and provides accurate, guideline-based recommendations for chest CT. It correctly notes that routine brain MRI is not standard but may be considered in patients with prior brain metastasis, though this is more nuanced than the reference, which states it is not indicated even in this group. This slight overstatement of brain MRI use constitutes a minor wording inaccuracy, so the score is 4."
  },
  "3437": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains why surgery may be contraindicated, details perioperative risks, and appropriately recommends radiotherapy as an alternative. All additional content is clinically relevant and correct."
  },
  "3438": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, adds relevant and accurate details about patient selection, rationale, and supporting guidelines, and contains no inaccuracies or omissions."
  },
  "3439": {
    "score": 3.0,
    "explanation": "3: The model answer accurately describes current guidelines and the investigational status of osimertinib post-chemoradiation, but it incorrectly states that durvalumab is the standard for EGFR-mutant patients, omitting that durvalumab is not recommended in this subgroup due to lack of benefit; this is a moderate omission affecting clinical priority."
  },
  "3440": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "3441": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key clinical facts, accurately stating that durvalumab is not recommended and that osimertinib is not yet standard but may be considered; it provides additional relevant context and guidelines, with only a minor omission in not explicitly stating osimertinib is preferred over durvalumab in this setting."
  },
  "3442": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including prioritization of MET inhibitors over chemotherapy, applicability in the presence of brain metastases, and relevant clinical trial and guideline support, with no inaccuracies or omissions."
  },
  "3443": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that dabrafenib plus trametinib should only be initiated after completion, interruption, or failure of first-line therapy, and not immediately upon mutation discovery if current treatment is ongoing and effective; there are no inaccuracies or omissions."
  },
  "3444": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, correctly notes that adjuvant chemotherapy should be considered for T1b TNBC, and emphasizes individualized decision-making, but it slightly understates that omission is generally not appropriate except in exceptional cases, as per the reference. No clinically significant errors are present."
  },
  "3445": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that ICI monotherapy is not appropriate and that combination chemotherapy (with or without immunotherapy) is prioritized. It provides accurate rationale, guideline references, and a summary table, with no inaccuracies or omissions."
  },
  "3446": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and provides relevant guideline-based recommendations without any inaccuracies or omissions."
  },
  "3447": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the impact of marginal pulmonary function on surgical candidacy, and provides relevant guideline-based details without inaccuracies or omissions."
  },
  "3448": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the ≥1 cm (T1c) threshold, and provides relevant, correct context without any inaccuracies or omissions."
  },
  "3449": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant elaboration, and includes no inaccuracies or omissions."
  },
  "3450": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains guideline recommendations, addresses the relevance of non-contrast CT in renal impairment, and provides correct, clinically relevant additional details without any inaccuracies or omissions."
  },
  "3451": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and relevant guideline-based rationale, and includes no inaccuracies or omissions."
  },
  "3452": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the necessity of confirming non-small cell, non-neuroendocrine histology before recommending HER2-targeted therapy, and provides relevant, correct elaboration without inaccuracies or omissions."
  },
  "3453": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including the contraindication of bisphosphonates in renal insufficiency, the rationale, and the recommendation of denosumab as an alternative, with no inaccuracies or omissions."
  },
  "3454": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale and guideline citations, and contains no inaccuracies or omissions."
  },
  "3455": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, guideline references, and a clear summary table, with no omissions or inaccuracies."
  },
  "3456": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, provides correct and relevant additional explanations, and contains no inaccuracies or omissions."
  },
  "3457": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant rationale, cites guidelines, and contains no inaccuracies or omissions."
  },
  "3458": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale for preferring SBRT in high-risk patients, and provides relevant, correct additional details without any inaccuracies or omissions."
  },
  "3459": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly prioritizing systemic targeted therapy in asymptomatic or minimally symptomatic patients, specifying exceptions for urgent local intervention, and providing accurate, relevant rationale and guideline support without inaccuracies or omissions."
  },
  "3460": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the lack of efficacy of standard EGFR TKIs for exon 20 insertions, details the approved indication for amivantamab-vmjw, and provides relevant, correct additional context without inaccuracies or omissions."
  },
  "3461": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizes the rarity of actionable mutations in squamous histology, the urgency of systemic therapy in rapid deterioration, and the option to perform molecular profiling concurrently; there are no inaccuracies or omissions."
  },
  "3462": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains why surgery is contraindicated, correctly prioritizes chemoradiotherapy, and adds relevant, factually correct context without any inaccuracies or omissions."
  },
  "3463": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts and provides detailed, accurate staging and management considerations, but it does not clearly state that when both lesions are potentially curable, they should be managed as two primaries, as per the reference; instead, it defaults to metastatic disease unless strict criteria are met, missing the reference's main clinical recommendation."
  },
  "3464": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant elaboration, and contains no inaccuracies or omissions."
  },
  "3465": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, correctly noting that renal insufficiency may require regimen modification and specialist input, but it overstates the impact by implying moderate renal insufficiency generally precludes or significantly limits candidacy, rather than requiring careful selection and adjustment; this is a minor but meaningful inaccuracy."
  },
  "3466": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, references relevant guidelines, and contains no inaccuracies or omissions."
  },
  "3467": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, correctly emphasizing that prior EGFR TKI exposure determines osimertinib's use and detailing scenarios based on prior therapies. There is a minor inaccuracy: osimertinib is not standard as second-line if no prior EGFR TKI was given; it is the preferred first-line, not subsequent, therapy—this slightly unclear wording warrants a minor deduction."
  },
  "3468": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly states that HER2-targeted therapy is contraindicated with LVEF <50%, provides relevant guideline and safety information, and offers appropriate clinical recommendations without inaccuracies or omissions."
  },
  "3469": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, and includes relevant guideline references without any inaccuracies or omissions."
  },
  "3470": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly prioritizing local control for severe hemoptysis, explains the rationale, and lists appropriate interventions without inaccuracies or omissions."
  },
  "3471": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate, clinically relevant elaboration, and includes no inaccuracies or omissions."
  },
  "3472": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant guideline-based details, and contains no inaccuracies or omissions."
  },
  "3473": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and relevant additional details, and contains no inaccuracies or omissions."
  },
  "3474": {
    "score": 5.0,
    "explanation": "5: The model answer correctly states that durvalumab consolidation therapy remains standard of care in this scenario, referencing the PACIFIC trial and specifying the exclusion of EGFR exon 19/L858R mutations, with no inaccuracies or omissions."
  },
  "3475": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and relevant guideline-based recommendations, and includes appropriate rationale and next steps without any inaccuracies or omissions."
  },
  "3476": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and relevant supporting evidence and guidelines, and contains no inaccuracies or omissions."
  },
  "3477": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and relevant rationale, and cites appropriate guidelines without any inaccuracies or omissions."
  },
  "3478": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the risks of repeat thoracic radiation, prioritizes systemic therapy, and adds relevant, correct details about multidisciplinary evaluation and guideline recommendations without any inaccuracies or omissions."
  },
  "3479": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, addresses mutual exclusivity, guideline support, and the appropriateness of starting alectinib without waiting for EGFR results, with no inaccuracies or omissions."
  },
  "3480": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts and provides relevant guideline references, but overstates the appropriateness of osimertinib in classic squamous histology, missing the nuance that EGFR TKI therapy is generally not recommended except in rare or mixed/ambiguous cases; this is a minor but clinically important omission."
  },
  "3481": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately cites relevant guidelines, and provides correct, clinically relevant explanations without any inaccuracies or omissions."
  },
  "3482": {
    "score": 5.0,
    "explanation": "5: The model answer accurately covers all key clinical facts from the reference, clearly stating that durvalumab is only indicated if there is no disease progression during or after chemoradiation, and provides relevant, correct supporting details without any inaccuracies or omissions."
  },
  "3483": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts but incorrectly states that pathologic confirmation is not an absolute requirement, which contradicts the reference answer's clear stance that it is required; this represents a moderate factual inaccuracy, though the rest of the content is accurate and relevant."
  },
  "3484": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant guideline-based details, and contains no inaccuracies or omissions."
  },
  "3485": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including the requirement for core biopsy and clip placement prior to preoperative therapy, and provides accurate, relevant rationale without any inaccuracies or omissions."
  },
  "3486": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including the general indication for chemotherapy, the need to avoid anthracyclines due to cardiac risk, and the possibility of alternative regimens or omission based on comorbidity. All additional content is accurate and clinically relevant."
  },
  "3487": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly prioritizing re-resection and appropriately relegating radiotherapy to a secondary role if re-resection is not feasible; all additional content is accurate, relevant, and guideline-based."
  },
  "3488": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizing that impaired pulmonary function does not automatically preclude perioperative therapy, and elaborates on surgical candidacy, alternative therapies, and the need for multidisciplinary assessment without any inaccuracies or omissions."
  },
  "3489": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, discusses alternative approaches, and includes no inaccuracies or omissions."
  },
  "3490": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains staging nuances, and clearly states that Stage IIB is not excluded from perioperative therapy indications; all additional content is correct and clinically relevant."
  },
  "3491": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the expanded eligibility for targeted therapy, and clearly states that broad molecular profiling is not routinely recommended for all squamous cases, with appropriate nuance and no inaccuracies."
  },
  "3492": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, cites relevant guidelines, and contains no inaccuracies or omissions."
  },
  "3493": {
    "score": 5.0,
    "explanation": "5: Fully covers all key clinical facts, correctly states the indications for osimertinib and durvalumab, and provides accurate, relevant context without any inaccuracies or omissions."
  },
  "3494": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately prioritizing surgical re-exploration for R0 resection if feasible, and reserving chemoradiation for unresectable cases; all additional content is correct, relevant, and guideline-based, with no inaccuracies or omissions."
  },
  "3495": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, adds accurate and relevant details about standard surveillance protocols and guidelines, and contains no inaccuracies or omissions."
  },
  "3496": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, cites relevant guidelines, and contains no inaccuracies or omissions."
  },
  "3497": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that high PD-L1 does not alter the priority of BRAF-targeted therapy, and provides additional correct, clinically relevant context without any inaccuracies or omissions."
  },
  "3498": {
    "score": 3.0,
    "explanation": "3: The model answer correctly emphasizes the need for a full-thickness biopsy of the nipple-areolar complex but incorrectly states that a core biopsy of the breast is not required unless a lesion is detected, omitting that a core biopsy is still indicated to rule out underlying malignancy even with negative imaging."
  },
  "3499": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains N3 versus M1 staging, clarifies the status of supraclavicular nodes, and provides correct, clinically relevant management implications without any inaccuracies or omissions."
  },
  "3500": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately prioritizing surgical resection for diagnosis and symptom relief, and correctly explaining the roles of SRS and WBRT, with no inaccuracies or omissions."
  },
  "3501": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the rationale and guideline-based nuances for molecular profiling in advanced squamous cell carcinoma, and provides relevant, correct additional detail without inaccuracies or omissions."
  },
  "3502": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly explains the rationale, cites relevant guidelines, and contains no inaccuracies or omissions."
  },
  "3503": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant elaboration, and contains no inaccuracies or omissions."
  },
  "3504": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant explanations, includes appropriate guideline references, and clearly addresses the prioritization of biomarker testing in stable patients without any inaccuracies or omissions."
  },
  "3505": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "3506": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, includes relevant guideline recommendations, and appropriately notes rare exceptions without any inaccuracies or omissions."
  },
  "3507": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that olaparib is appropriate with dose adjustment for eGFR 35, whereas the reference answer clearly states it is not recommended for eGFR <40. While the model covers most clinical facts, this moderate factual error regarding the renal threshold for olaparib use warrants a score of 2."
  },
  "3508": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizing that sotorasib is only recommended for patients with adequate (ECOG 0–1) performance status and not for those with poorer status; all additional content is correct and clinically relevant."
  },
  "3509": {
    "score": 5.0,
    "explanation": "5: Fully covers all key facts from the reference, accurately states that routine brain MRI is not indicated, provides correct rationale and guideline references, and outlines appropriate surveillance; no errors or omissions."
  },
  "3510": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately details first-line therapy based on PD-L1 status, correctly places KRAS G12C inhibitors in the second-line setting, and cites relevant guidelines without inaccuracies or omissions."
  },
  "3511": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and correctly identifies SBRT as the preferred treatment; there are no inaccuracies or omissions."
  },
  "3512": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, cites relevant evidence, and contains no inaccuracies or omissions."
  },
  "3513": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "3514": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly prioritizes adjuvant radiation for positive margins, and provides additional relevant, accurate rationale and references without any inaccuracies or omissions."
  },
  "3515": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes guideline recommendations, and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "3516": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, and includes relevant guideline references without any inaccuracies or omissions."
  },
  "3517": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant guideline details, and contains no inaccuracies or omissions."
  },
  "3518": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "3519": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and provides relevant guideline support without any inaccuracies or omissions."
  },
  "3520": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale and relevant guideline references, and contains no inaccuracies or omissions."
  },
  "3521": {
    "score": 3.0,
    "explanation": "3: The model answer covers the rationale for switching to crizotinib and cites guidelines, but it omits that both immediate switch and completion of current therapy are acceptable options; it instead recommends only immediate interruption, missing a key fact from the reference."
  },
  "3522": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately cites current guidelines, and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "3523": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the staging, eligibility, and treatment implications, and provides correct, clinically relevant additional detail without any inaccuracies or omissions."
  },
  "3524": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale for broad molecular profiling and PD-L1 testing, and provides relevant, correct additional context without any inaccuracies or omissions."
  },
  "3525": {
    "score": 4.0,
    "explanation": "4: The model answer covers over 90% of the key facts, accurately emphasizing the need for individualized, multidisciplinary decision-making and noting that surgery is not universally preferred, which aligns with current guidelines. However, it slightly underplays that surgery is generally regarded as preferred when the recurrence is completely resectable and the patient is fit, which is a minor omission."
  },
  "3526": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly delineates when radiotherapy is prioritized, and provides accurate, guideline-based nuance regarding the use of ROS1 inhibitors versus radiotherapy, with no inaccuracies or omissions."
  },
  "3527": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale for therapy selection, and provides relevant, correct additional context without any inaccuracies or omissions."
  },
  "3528": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "3529": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly emphasizes the need for radiotherapy in addition to chemotherapy for R1 margins, discusses sequential versus concurrent chemoradiation, and provides relevant, accurate detail without any inaccuracies or omissions."
  },
  "3530": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "3531": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key clinical facts, correctly identifies BRAF/MEK inhibitors as a reasonable first-line option guided by the BRAF V600E mutation, and adds relevant context about evidence, histology, and other considerations. There is a minor omission in not explicitly stating that targeted therapy is guideline-recommended and prioritized over chemotherapy, but this does not alter the overall meaning."
  },
  "3532": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and relevant additional details, cites guidelines, and includes appropriate caveats without any inaccuracies or omissions."
  },
  "3533": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, and appropriately recommends chemoradiotherapy as the preferred option; there are no inaccuracies or omissions."
  },
  "3534": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and relevant guideline-based details, and contains no inaccuracies or omissions."
  },
  "3535": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and cites supporting guidelines without any inaccuracies or omissions."
  },
  "3536": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly explains the rationale, highlights the need for hypocalcemia monitoring, and provides relevant, accurate additional details without any inaccuracies or omissions."
  },
  "3537": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and adds relevant, guideline-based context without any inaccuracies or omissions."
  },
  "3538": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the requirements for operability and absence of significant comorbidities, and provides relevant, correct additional context without any inaccuracies or omissions."
  },
  "3539": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that adjuvant endocrine therapy is reasonable and not precluded by small tumor size, and provides relevant, guideline-based context without inaccuracies or omissions."
  },
  "3540": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including the necessity of broad molecular and PD-L1 testing in stage IV SCC, rationale, guideline support, and clinical implications, with no inaccuracies or omissions."
  },
  "3541": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, cites relevant guidelines and evidence, and includes correct, clinically relevant additional information without any inaccuracies or omissions."
  },
  "3542": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and provides relevant guideline references without any inaccuracies or omissions."
  },
  "3543": {
    "score": 4.0,
    "explanation": "4: The model answer correctly prioritizes re-resection over chemoradiation if both are feasible and provides appropriate rationale and references, but the phrase \"should always be prioritized\" is slightly stronger than the reference's \"generally preferred,\" omitting the nuance that both are acceptable options."
  },
  "3544": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant explanations, and contains no inaccuracies or omissions."
  },
  "3545": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including the appropriateness of broad molecular profiling for advanced non-squamous NSCLC (adenocarcinoma/large cell), the need for re-biopsy or plasma testing if tissue is insufficient, and relevant guideline support, with no inaccuracies or omissions."
  },
  "3546": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, and includes relevant, correct additional details without any inaccuracies or omissions."
  },
  "3547": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizing the need for pathological confirmation and pulmonary function testing before systemic therapy, with additional relevant explanations and no inaccuracies or omissions."
  },
  "3548": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly emphasizes that noncontrast CT is sufficient, addresses CKD risk, and provides relevant guideline context without inaccuracies or omissions."
  },
  "3549": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, correctly emphasizing that orthopedic stabilization is generally prioritized in cases of high fracture risk but also appropriately notes exceptions based on patient factors and prognosis. There is a minor wording inaccuracy in the initial statement (\"should not always be prioritized\") that could be misinterpreted, but the subsequent explanation aligns with the reference answer."
  },
  "3550": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant explanations, cites guidelines, and contains no inaccuracies or omissions."
  },
  "3551": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the staging implications, and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "3552": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately prioritizing palliative radiotherapy for acute neurological symptoms and appropriately discussing the role and timing of KRAS G12C-targeted therapy, with no inaccuracies or omissions."
  },
  "3553": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately stating that absence of nodal disease does not automatically exclude adjuvant therapy, and that therapy may be considered based on tumor size, high-risk features, and clinical judgment. All additional details are correct and clinically relevant."
  },
  "3554": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that routine brain MRI is not indicated, cites relevant guidelines, and correctly describes appropriate surveillance and indications for brain imaging, with no inaccuracies or omissions."
  },
  "3555": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, provides accurate rationale, cites guidelines, and contains no inaccuracies or omissions."
  },
  "3556": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "3557": {
    "score": 3.0,
    "explanation": "3: The model answer accurately describes the rationale for switching to ALK-targeted therapy upon discovery of an ALK rearrangement and provides supporting evidence, but it omits that either completing current therapy or switching are both acceptable options per guidelines; it presents switching as the only appropriate approach, missing the nuance in the reference answer."
  },
  "3558": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly stating that broad molecular profiling is not routinely essential in squamous cell carcinoma except in select cases, and that PD-L1 testing is sufficient and recommended. There are no inaccuracies or omissions."
  },
  "3559": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides additional relevant details about guidelines, approvals, and evidence, and contains no inaccuracies or omissions."
  },
  "3560": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately prioritizes systemic therapy, correctly states that surgery is not routinely appropriate, and provides relevant, guideline-based rationale without inaccuracies or omissions."
  },
  "3561": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that local treatment is \"typically warranted\" prior to systemic therapy for asymptomatic brain metastases, which contradicts the reference answer that prioritizes systemic therapy and reserves local treatment for symptomatic or select oligometastatic cases; this represents a moderate factual error."
  },
  "3562": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and adds relevant guideline-based details without inaccuracies or omissions."
  },
  "3563": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately prioritizing re-resection and correctly describing the limited role of adjuvant radiotherapy, with no inaccuracies or omissions."
  },
  "3564": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key facts and provides additional, accurate, and relevant detail, but it introduces a minor inaccuracy by stating that re-resection is preferred and should be attempted first, whereas the reference answer does not mandate re-resection and presents chemoradiation as appropriate without requiring re-resection. This is a minor wording inaccuracy that does not alter the overall clinical meaning."
  },
  "3565": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, emphasizes the necessity of pathologic confirmation, explains the rationale, cites guidelines, and appropriately notes rare exceptions; there are no inaccuracies or omissions."
  },
  "3566": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizing systemic therapy as primary management while appropriately noting that urgent local intervention is indicated for life-threatening airway compromise; all additional content is clinically relevant and correct."
  },
  "3567": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, current indications, and standard of care, and makes no clinically unsafe or inaccurate statements."
  },
  "3568": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly explains the stage IV designation, standard first-line therapy, and the rare exception of oligometastatic disease, with no inaccuracies or omissions."
  },
  "3569": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key facts and provides correct, relevant explanations, but introduces guideline-based surveillance intervals (every 6 months for 2-3 years, then annually) not mentioned in the reference, which could be seen as a minor deviation from the reference's focus on annual imaging. No clinically significant errors or omissions are present."
  },
  "3570": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately stating that systemic therapy is generally only considered if there is nodal involvement, and not indicated for node-negative cases, even if triple-negative. Additional explanations are correct and clinically relevant, with no inaccuracies or omissions."
  },
  "3571": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that surgery is not appropriate without PFTs, explaining the rationale, and emphasizing standard of care with no inaccuracies or omissions."
  },
  "3572": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly explains the rationale, and provides relevant guideline-based recommendations without inaccuracies or omissions."
  },
  "3573": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly stating that surveillance frequency does not differ based on chemoradiation sequencing, and provides accurate, relevant guideline-based details without any inaccuracies or omissions."
  },
  "3574": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that absence of distant metastases is required, explaining the rationale, and referencing guidelines; there are no inaccuracies or omissions."
  },
  "3575": {
    "score": 0.0,
    "explanation": "0: The model answer directly contradicts the reference by stating adjuvant pembrolizumab is indicated for all such patients regardless of risk, whereas the reference specifies it is only for those considered high-risk; this is a clinically significant and potentially misleading error."
  },
  "3576": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that ROS1-targeted therapy is recommended regardless of histology, contradicting guidelines that generally exclude squamous histology except in rare, specific circumstances; this is a moderate factual error, though it does provide some relevant context."
  },
  "3577": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizes the necessity of pathologic confirmation, and provides relevant, correct additional context without any inaccuracies or omissions."
  },
  "3578": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that routine FDG-PET/CT or brain MRI is not indicated for asymptomatic patients, and appropriately describes standard surveillance with chest CT; additional details and references are correct and clinically relevant."
  },
  "3579": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant guideline details, and contains no inaccuracies or omissions."
  },
  "3580": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly prioritizing local therapy for symptomatic brain metastases before systemic therapy, and provides additional accurate, relevant details without inaccuracies or omissions."
  },
  "3581": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately addresses the impact of ECOG 2 due to COPD, and provides relevant, correct additional context without any inaccuracies or omissions."
  },
  "3582": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant guideline-based details, and includes correct rationale and references without any inaccuracies or omissions."
  },
  "3583": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, cites guidelines, and includes only relevant, correct additional details without any inaccuracies or omissions."
  },
  "3584": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant elaboration, and contains no inaccuracies or omissions."
  },
  "3585": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly recommends every 6 months rather than every 3–6 months, omitting the key fact that adjuvant radiotherapy aligns surveillance with higher-stage disease; this is a moderate factual omission, though the rest of the content is accurate and relevant."
  },
  "3586": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and provides relevant additional context without any inaccuracies or omissions."
  },
  "3587": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale with relevant guideline citations, and contains no inaccuracies or omissions."
  },
  "3588": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale and supporting evidence, and contains no inaccuracies or omissions."
  },
  "3589": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional details, and contains no inaccuracies or omissions."
  },
  "3590": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately prioritizes ERBB2-targeted therapy if available, and provides relevant, up-to-date guideline references and caveats without any inaccuracies or omissions."
  },
  "3591": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "3592": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizing that entrectinib use is based solely on confirmed ROS1 rearrangement regardless of smoking history, and provides additional correct, clinically relevant context without any inaccuracies or omissions."
  },
  "3593": {
    "score": 1.0,
    "explanation": "1: The model answer directly contradicts the reference answer on the key clinical fact—curability is indeed required for the dual primary approach to be applicable—resulting in a major inaccuracy despite otherwise detailed explanation."
  },
  "3594": {
    "score": 1.0,
    "explanation": "1: The model answer directly contradicts the reference by recommending non–contrast low-dose CT at every interval for five years, omitting the need for contrast-enhanced CT in the first three years and the correct surveillance intervals; this is a major inaccuracy."
  },
  "3595": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional explanation, and contains no inaccuracies or omissions."
  },
  "3596": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, guideline references, and appropriate recommendations, with no omissions or inaccuracies."
  },
  "3597": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional explanations, and contains no inaccuracies or omissions."
  },
  "3598": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that durvalumab use is dependent on EGFR mutation status and is generally not recommended for patients with EGFR exon 19 deletion or L858R, which contradicts the reference answer and current guidelines; while it provides relevant background and cites guidelines, this represents a moderate factual error."
  },
  "3599": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, cites relevant guidelines, and contains no inaccuracies or omissions."
  },
  "3600": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides additional accurate and relevant details, and contains no inaccuracies or omissions."
  },
  "3601": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately addresses the elevated malignancy risk due to both smoking and pulmonary fibrosis, and correctly justifies ongoing surveillance; all additional content is factually correct and clinically relevant."
  },
  "3602": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, cites guidelines, and contains no inaccuracies or omissions."
  },
  "3603": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, correctly emphasizes the strong recommendation (but not absolute requirement) for metastatic biopsy, and cites guidelines; the only minor issue is that it could more clearly state that standard practice presumes reassessment, as in the reference, but this is a minor wording nuance rather than a substantive omission."
  },
  "3604": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant explanations, and contains no inaccuracies or omissions."
  },
  "3605": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, and includes relevant, correct additional details without any omissions or inaccuracies."
  },
  "3606": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, including the roles of re-resection, adjuvant radiotherapy, and surveillance, but incorrectly states that surveillance alone is a reasonable alternative, which contradicts the reference's clear recommendation against surveillance alone due to recurrence risk; this is a moderate factual inaccuracy."
  },
  "3607": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional context, and contains no inaccuracies or omissions."
  },
  "3608": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "3609": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly emphasizes the avoidance of contrast in chronic renal insufficiency, and provides relevant, accurate context without any inaccuracies or omissions."
  },
  "3610": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly explains current guidelines, and clearly states that serial CT follow-up is not recommended for a 5 mm pure GGN in a low-risk patient; there are no inaccuracies or omissions."
  },
  "3611": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional details, cites guidelines, and contains no inaccuracies or omissions."
  },
  "3612": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional context, and contains no inaccuracies or omissions."
  },
  "3613": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant rationale, cites guidelines, and contains no inaccuracies or omissions."
  },
  "3614": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and includes appropriate caveats regarding patient fitness and emergent management, with no inaccuracies or omissions."
  },
  "3615": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant elaboration, and contains no inaccuracies or omissions."
  },
  "3616": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the role of re-resection, individualized decision-making, and scenarios where surveillance is appropriate, with no inaccuracies or omissions."
  },
  "3617": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and cites relevant guidelines; all additional details are correct and clinically pertinent, with no omissions or inaccuracies."
  },
  "3618": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, accurately explains the rationale, references supporting evidence (KATHERINE trial), and clearly states that T-DM1 is indicated only in the presence of residual disease post-neoadjuvant therapy, with no inaccuracies or omissions."
  },
  "3619": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, cites guidelines, and contains no inaccuracies or omissions."
  },
  "3620": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, cites relevant guidelines, and includes only correct and clinically relevant additional details without any inaccuracies or omissions."
  },
  "3621": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "3622": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant rationale, and contains no inaccuracies or omissions."
  },
  "3623": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale and guideline references, and contains no inaccuracies or omissions."
  },
  "3624": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that routine brain MRI or PET/CT is not indicated without symptoms or suspicion, and provides relevant, guideline-based surveillance details without inaccuracies or omissions."
  },
  "3625": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and correctly identifies SBRT as the preferred alternative without any inaccuracies or omissions."
  },
  "3626": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant rationale, and includes no inaccuracies or omissions. Additional details and references are correct and enhance the answer."
  },
  "3627": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that routine FDG-PET/CT and brain MRI are not indicated in this scenario, and provides additional correct and relevant details about surveillance protocols and management of equivocal nodules, with no inaccuracies or omissions."
  },
  "3628": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that re-resection is preferred if feasible and chemoradiation is reserved for unresectable or inoperable cases. Additional content is accurate, relevant, and guideline-based, with no inaccuracies or omissions."
  },
  "3629": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, adds correct and clinically relevant details (e.g., CDK4/6 inhibitors, guideline references), and contains no inaccuracies or omissions."
  },
  "3630": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that surgical resection is preferred for operable, resectable recurrences and that EBRT/SABR are alternatives for non-surgical candidates. Additional content is accurate, relevant, and well-supported by guidelines and literature."
  },
  "3631": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately stating that re-resection is not mandatory and adjuvant therapy can proceed without it; additional content is correct, relevant, and guideline-based, with no inaccuracies or omissions."
  },
  "3632": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and relevant guideline-based rationale, and contains no inaccuracies or omissions."
  },
  "3633": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, including the use of adjuvant chemotherapy and PORT for R1 resection, but incorrectly states that concurrent chemoradiation is generally not recommended, whereas the reference answer affirms it as an appropriate and often preferred option; this represents a moderate omission and a wording inaccuracy regarding standard practice."
  },
  "3634": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes both options as appropriate, and provides relevant, guideline-based rationale without inaccuracies or omissions."
  },
  "3635": {
    "score": 5.0,
    "explanation": "5: Fully covers all key facts from the reference, accurately states that routine FDG-PET/CT or brain MRI is not indicated, and provides correct, relevant guideline-based details without any inaccuracies or omissions."
  },
  "3636": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "3637": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "3638": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that surgery is not appropriate and that definitive concurrent chemoradiation is standard, with correct rationale and no inaccuracies or omissions."
  },
  "3639": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "3640": {
    "score": 5.0,
    "explanation": "5: The model answer accurately covers all key clinical facts, correctly cites current guidelines, and provides a clear, clinically relevant rationale for not shortening the surveillance interval, with no inaccuracies or omissions."
  },
  "3641": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly explains the contraindication of pemetrexed at the given renal function, and provides accurate, relevant details about each drug; there are no inaccuracies or omissions."
  },
  "3642": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale for entrectinib preference (CNS penetration/efficacy), and provides relevant supporting details without inaccuracies or omissions."
  },
  "3643": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that bone involvement alone is sufficient for bone-modifying agent therapy and that hypercalcemia is not required. Additional content is accurate, relevant, and guideline-based, with no omissions or inaccuracies."
  },
  "3644": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly explains the rationale, cites relevant guidelines and trial data, and contains no inaccuracies or omissions."
  },
  "3645": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that no further molecular targets are needed, and appropriately describes standard therapy options; all additional explanations are correct and clinically relevant."
  },
  "3646": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, adds relevant detail about diagnostic criteria and guidelines, and contains no inaccuracies or omissions."
  },
  "3647": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional details, and contains no inaccuracies or omissions."
  },
  "3648": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains guideline recommendations, and provides relevant supporting details without any inaccuracies or omissions."
  },
  "3649": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly prioritizing EGFR mutation for therapy selection, and provides accurate, relevant rationale and supporting guidelines without any inaccuracies or omissions."
  },
  "3650": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that routine FDG-PET/CT or brain MRI is not appropriate without symptoms or radiographic suspicion, and correctly describes recommended surveillance and rationale, with no inaccuracies or omissions."
  },
  "3651": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, cites guidelines, and provides relevant context without any inaccuracies or omissions."
  },
  "3652": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant explanations, and contains no inaccuracies or omissions."
  },
  "3653": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, cites supporting evidence, and contains no inaccuracies or omissions."
  },
  "3654": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including the rationale for SLNB despite negative imaging, relevant guideline recommendations, and the risk of occult invasion; all additional content is accurate and clinically relevant, with no omissions or inaccuracies."
  },
  "3655": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that routine FDG-PET/CT or brain MRI is not indicated, and provides relevant, guideline-based details without inaccuracies or omissions."
  },
  "3656": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, cites guidelines, and includes relevant extra detail without any inaccuracies or omissions."
  },
  "3657": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional details, and contains no inaccuracies or omissions."
  },
  "3658": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale and relevant guideline references, and contains no inaccuracies or omissions."
  },
  "3659": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately discusses the risks of chemoradiation in poor pulmonary function, and appropriately outlines alternative strategies without any inaccuracies or omissions."
  },
  "3660": {
    "score": 5.0,
    "explanation": "5: Fully covers all key clinical facts, provides correct rationale, and includes relevant guideline references; no inaccuracies or omissions."
  },
  "3661": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts but incorrectly states that EGFR-targeted therapy is generally not prioritized, which contradicts the reference answer and current guidelines for EGFR-mutant NSCLC, even in squamous histology. It provides relevant context about rarity and limited data but omits the key point that EGFR mutations predict TKI sensitivity and that targeted therapy is preferred in this molecular subgroup."
  },
  "3662": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, adds accurate and clinically relevant detail about assessment and SBRT, and contains no inaccuracies or omissions."
  },
  "3663": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, and includes relevant, up-to-date guideline references and practical considerations without any inaccuracies or omissions."
  },
  "3664": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that HER2-targeted therapy is now preferred over platinum-based chemotherapy, provides relevant guideline and approval details, and includes correct context for exceptions; there are no inaccuracies or omissions."
  },
  "3665": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that adjuvant T-DM1 is conditional on residual invasive disease and not indicated with pathologic complete response, with accurate and clinically relevant explanations and no inaccuracies or omissions."
  },
  "3666": {
    "score": 5.0,
    "explanation": "5: The model answer accurately covers all key clinical facts, clearly explaining that completion ALND is still required after neoadjuvant therapy and mastectomy if SLN micrometastases are found, and provides relevant guideline references and rationale without inaccuracies or omissions."
  },
  "3667": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that fam-trastuzumab deruxtecan-nxki is only appropriate for patients with adequate performance status (PS 0–2) and not for those with poor PS (≥3), and provides additional, accurate, and clinically relevant detail without inaccuracies or omissions."
  },
  "3668": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant rationale, and includes correct additional detail without any inaccuracies or omissions."
  },
  "3669": {
    "score": 5.0,
    "explanation": "5: The model answer correctly states that brain MRI with contrast is standard for initial staging in T3, N1, M0 NSCLC, citing current guidelines and providing accurate rationale; all key facts are covered with no inaccuracies or omissions."
  },
  "3670": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately stating that adjuvant radiotherapy is not routinely indicated, re-resection is preferred, and radiotherapy may be considered if re-resection is not feasible; all additional content is correct and clinically relevant."
  },
  "3671": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, accurately distinguishing recommendations for non-squamous versus squamous NSCLC, and correctly notes exceptions and the universal role of PD-L1 testing; no inaccuracies or omissions are present."
  },
  "3672": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the impact of poor PFTs on therapy choice, and appropriately discusses alternative strategies without inaccuracies or omissions."
  },
  "3673": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately stating that EGFR-targeted therapy is justified regardless of histology if the mutation is confirmed, and appropriately notes the importance of pathology review to exclude misclassification. There are no inaccuracies or omissions."
  },
  "3674": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including the justification for brain MRI, the appropriateness of non-contrast MRI in renal dysfunction, and relevant guideline recommendations, with no inaccuracies or omissions."
  },
  "3675": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant rationale, cites guidelines, and contains no inaccuracies or omissions."
  },
  "3676": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including the inappropriateness of endocrine therapy alone, the need for rapid disease control, the limitations of endocrine therapy and CDK4/6 inhibitors in CNS disease, and the preference for chemotherapy and/or local therapy. There are no inaccuracies or omissions."
  },
  "3677": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key clinical facts, correctly identifies neoadjuvant chemotherapy as appropriate and guideline-based, and provides relevant rationale and references. However, it slightly overstates the acceptability of immediate surgery as an alternative, which is less preferred per guidelines, constituting a minor wording inaccuracy."
  },
  "3678": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that broad molecular profiling is not routinely required in pure squamous cell carcinoma without atypical features, and correctly notes exceptions. Additional content (PD-L1 testing) is factually correct and clinically relevant. No inaccuracies or omissions."
  },
  "3679": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, outlines standard management options, and includes relevant guideline references without any inaccuracies or omissions."
  },
  "3680": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "3681": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, cites guidelines, and clearly states that afatinib is preferred regardless of PD-L1 status, with no omissions or inaccuracies."
  },
  "3682": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including the necessity of brain MRI before therapy, the impact on staging and management, guideline recommendations, and the rationale for MRI use; all additional details are accurate and clinically relevant."
  },
  "3683": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately stating that SABR remains appropriate despite poor lung function, is not contraindicated by low PFTs, and emphasizes the need for multidisciplinary evaluation and risk assessment. Additional content is correct and clinically relevant."
  },
  "3684": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizing the necessity of negative extrathoracic staging by PET/CT and brain MRI before definitive radiotherapy, with no omissions or inaccuracies."
  },
  "3685": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains ceritinib’s hepatotoxicity and need for dose adjustment/avoidance, and correctly prioritizes alectinib as a safer alternative; all additional content is clinically relevant and factually correct."
  },
  "3686": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant rationale, cites supporting guidelines and evidence, and contains no inaccuracies or omissions."
  },
  "3687": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, cites supporting evidence and guidelines, and contains no inaccuracies or omissions."
  },
  "3688": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizes the contraindication of concurrent chemoradiation after prior thoracic radiotherapy, and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "3689": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key facts, correctly stating that PORT is indicated for R1 resection regardless of prior chemotherapy, and clarifies that sequential (not concurrent) chemoradiation is standard due to toxicity concerns. The only minor inaccuracy is the implication that concurrent chemoradiation is generally avoided postoperatively, whereas the reference allows for either sequential or concurrent; otherwise, the answer is thorough and accurate."
  },
  "3690": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional context, and contains no inaccuracies or omissions."
  },
  "3691": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional context, and contains no inaccuracies or omissions."
  },
  "3692": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, cites relevant guidelines, and includes no inaccuracies or omissions; additional content is correct and clinically relevant."
  },
  "3693": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key clinical facts, correctly identifies fam-trastuzumab deruxtecan-nxki as an appropriate option, and provides relevant context and caveats. However, it introduces a minor inaccuracy by suggesting that pivotal trials only included ECOG 0–1 and that use in ECOG 2 is extrapolated, whereas the reference answer states evidence supports use in ECOG 0–2; this is a minor wording inaccuracy but does not alter the clinical recommendation."
  },
  "3694": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and guideline-based rationale, and contains no inaccuracies or omissions."
  },
  "3695": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizing that cT1c tumor size, triple-negative status, and nodal status are the determinants for preoperative systemic therapy, with no additional clinical characteristics required; all extra content is correct and clinically relevant."
  },
  "3696": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, cites relevant guidelines, and contains no inaccuracies or omissions."
  },
  "3697": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and relevant additional explanations, and contains no inaccuracies or omissions."
  },
  "3698": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately prioritizing concurrent chemoradiation for fit patients and reserving systemic therapy for those unable to tolerate CRT. Additional content is correct, clinically relevant, and there are no inaccuracies or omissions."
  },
  "3699": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "3700": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies non-contrast chest CT as the appropriate modality and provides a suitable surveillance interval (every 6 months), but omits the option of a 3–6 month interval as per guidelines and does not mention clinical examination as part of surveillance; otherwise, it is accurate and relevant."
  },
  "3701": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and provides relevant supporting details without any inaccuracies or omissions."
  },
  "3702": {
    "score": 4.0,
    "explanation": "4: The model answer covers over 90% of the key facts, correctly emphasizes the need for pathologic confirmation, and clarifies that management should not default to metastatic therapy; however, it introduces nuanced guidance about multidisciplinary acceptance of clinical N3, which, while accurate, slightly diverges from the reference's strict requirement for pathologic confirmation, constituting a minor wording inaccuracy."
  },
  "3703": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional context, and contains no inaccuracies or omissions."
  },
  "3704": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, correctly noting that adjuvant chemotherapy with trastuzumab is not routinely recommended for T1a tumors but may be considered in selected high-risk cases, and that endocrine therapy is standard. However, it slightly overemphasizes the \"generally no\" stance compared to the reference's more neutral \"may be considered\" (category 2B), which is a minor wording inaccuracy."
  },
  "3705": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "3706": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the role and limitations of plasma-based ctDNA testing, and emphasizes that systemic therapy should not proceed without molecular profiling; all additional details are correct and clinically relevant."
  },
  "3707": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and provides relevant, correct additional context without any inaccuracies or omissions."
  },
  "3708": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the need for pulmonary function assessment, the risks of surgery in compromised patients, and the role of SBRT as an alternative; all additional content is correct and clinically relevant."
  },
  "3709": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly emphasizes the continued indication for invasive mediastinal evaluation despite prior radiotherapy, and provides relevant, accurate rationale without any omissions or inaccuracies."
  },
  "3710": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "3711": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional context, and contains no inaccuracies or omissions."
  },
  "3712": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly prioritizing urgent orthopedic and radiotherapy interventions before or concurrently with ROS1 inhibitor therapy, and emphasizes multidisciplinary coordination; there are no inaccuracies or omissions."
  },
  "3713": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, cites guidelines, and includes all relevant genes; there are no inaccuracies or omissions."
  },
  "3714": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts and provides relevant guideline references, but it incorrectly states that proceeding with stage III-specific treatment is generally justified based on imaging alone, which contradicts the reference answer's clear requirement for pathological confirmation; this represents a moderate factual inaccuracy."
  },
  "3715": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and relevant additional rationale, and cites current guidelines; there are no inaccuracies or omissions."
  },
  "3716": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that routine FDG-PET/CT is not indicated, and appropriately details standard surveillance and guideline recommendations without any inaccuracies or omissions."
  },
  "3717": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant elaboration, and contains no inaccuracies or omissions."
  },
  "3718": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, cites guidelines, and provides relevant additional detail without inaccuracies or omissions."
  },
  "3719": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately stating that palliative chemotherapy does not require symptoms and can be considered for asymptomatic patients, with additional correct and relevant clinical context and no inaccuracies."
  },
  "3720": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately contrasts surveillance intervals, cites relevant guidelines, and provides correct rationale without any inaccuracies or omissions."
  },
  "3721": {
    "score": 5.0,
    "explanation": "5: Fully covers all key clinical facts from the reference, clearly prioritizing endobronchial techniques for immediate relief and correctly noting the delayed effect of radiotherapy; all additional details are accurate and clinically relevant."
  },
  "3722": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly states that tumors exactly 0.5 cm are included in the recommendation, and provides accurate, relevant guideline-based rationale with no inaccuracies or omissions."
  },
  "3723": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant guideline details, and contains no inaccuracies or omissions."
  },
  "3724": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale against concurrent chemoradiation, discusses toxicity risks, and appropriately outlines alternative management options without any inaccuracies or omissions."
  },
  "3725": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key clinical facts, correctly emphasizes the importance of brain MRI for optimal agent selection, and notes that crizotinib is no longer preferred; however, it initially states that ALK detection alone is sufficient to proceed with targeted therapy, which could be misinterpreted as not requiring CNS assessment prior to agent choice—a minor wording inaccuracy."
  },
  "3726": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, cites guidelines and evidence, and contains no inaccuracies or omissions."
  },
  "3727": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately clarifies that EGFR exon 20 insertion positivity alone is sufficient for amivantamab-vmjw use, and provides additional, relevant context about molecular profiling without introducing inaccuracies or omissions."
  },
  "3728": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that targeted therapy is preferred, addresses relevant guidelines, and provides correct, clinically relevant additional detail without any inaccuracies or omissions."
  },
  "3729": {
    "score": 5.0,
    "explanation": "5: The model answer includes all key clinical facts from the reference, correctly emphasizes the universal requirement for preoperative PFTs, and provides relevant rationale without inaccuracies or omissions."
  },
  "3730": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and provides correct, relevant additional details without any inaccuracies or omissions."
  },
  "3731": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly prioritizes the gene assay, cites supporting evidence and guidelines, and provides relevant, accurate additional context without any inaccuracies or omissions."
  },
  "3732": {
    "score": 2.0,
    "explanation": "2: The model answer provides detailed, guideline-based reasoning but omits the key fact that broad molecular profiling is still recommended in advanced squamous NSCLC to identify rare actionable mutations, as stated in the reference. It overstates the lack of indication for testing and does not reflect the current consensus for advanced disease, constituting a moderate omission."
  },
  "3733": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that palliative chemotherapy is contingent on symptoms or further progression and not routinely recommended for asymptomatic patients without ongoing progression; it also provides relevant, accurate references without inaccuracies or omissions."
  },
  "3734": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly distinguishes denosumab as appropriate and bisphosphonates as contraindicated in dialysis, and adds relevant, accurate details about hypocalcemia risk and monitoring without any inaccuracies or omissions."
  },
  "3735": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, adds accurate and clinically relevant details (guideline support, alternative options, multidisciplinary care), and contains no inaccuracies or omissions."
  },
  "3736": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant rationale, and contains no inaccuracies or omissions. Additional explanations are correct and enhance understanding."
  },
  "3737": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the role of ovarian suppression/ablation and endocrine therapy, clarifies the definition and implications of endocrine resistance, and correctly reserves chemotherapy for visceral crisis or exhaustion of endocrine options, with no inaccuracies or omissions."
  },
  "3738": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale for prioritizing osimertinib over durvalumab, references relevant trials and guidelines, and contains no inaccuracies or omissions."
  },
  "3739": {
    "score": 4.0,
    "explanation": "4: The model answer correctly explains that detection of BRAF V600E does not necessarily imply broad molecular profiling has been done and emphasizes guideline recommendations for comprehensive testing, but it omits the key clinical fact that BRAF V600E is rare in squamous cell carcinoma and typically requires explicit, non-standard testing—an important nuance highlighted in the reference."
  },
  "3740": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "3741": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional details, and contains no inaccuracies or omissions."
  },
  "3742": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the performance status requirement, the rationale for exclusion of PS >2, and provides relevant supporting details and references without any inaccuracies or omissions."
  },
  "3743": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the resistance of exon 20 insertions to standard TKIs, discusses appropriate alternatives, and contains no inaccuracies or omissions."
  },
  "3744": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, adds correct and clinically relevant details about targeted agents and guideline rationale, and contains no inaccuracies or omissions."
  },
  "3745": {
    "score": 1.0,
    "explanation": "1: The model answer incorrectly states that surveillance frequency should be the same after radiotherapy as after surgery, directly contradicting the reference, which specifies more intensive surveillance post-radiotherapy; this is a major inaccuracy."
  },
  "3746": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional rationale, cites appropriate guidelines, and contains no inaccuracies or omissions."
  },
  "3747": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly emphasizing the need for more frequent imaging in the presence of persistent abnormalities and providing relevant guideline-based details without inaccuracies or omissions."
  },
  "3748": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly emphasizes that non-contrast chest CT is acceptable for surveillance in CKD, and provides relevant guideline references without any inaccuracies or omissions."
  },
  "3749": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that a documented germline BRCA1/2 mutation is required, and provides accurate, relevant supporting details without any inaccuracies or omissions."
  },
  "3750": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale for treating as two primaries if supported by evaluation, and adds relevant detail about diagnostic criteria and guidelines without introducing inaccuracies or irrelevant content."
  },
  "3751": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts and provides detailed, guideline-based rationale, but it incorrectly states that FDG-PET/CT is recommended for a new nodule found on surveillance, whereas the reference answer specifies that routine PET/CT is not indicated unless there is suspicion of recurrence or new abnormalities—here, the nodule itself is the abnormality, so the model's recommendation is reasonable but slightly overstates the routine use. Minor over-explanation and slight ambiguity lower the score."
  },
  "3752": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional details, and contains no inaccuracies or omissions."
  },
  "3753": {
    "score": 3.0,
    "explanation": "3: The model answer covers the majority of key facts about preferred endocrine regimens and the role of SERMs, but it omits the critical exception of visceral crisis requiring cytotoxic chemotherapy, which is a major omission in this clinical context."
  },
  "3754": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, including the appropriateness of EGFR TKI therapy for these mutations and the consideration of performance status due to tumor burden, but it omits the important nuance that systemic therapy is generally not recommended if poor performance status is unrelated to tumor burden, which is a clinically significant omission."
  },
  "3755": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, adds relevant and accurate detail about guidelines, therapy specifics, and clinical considerations, and contains no inaccuracies or omissions."
  },
  "3756": {
    "score": 2.0,
    "explanation": "2: The model answer contradicts the reference by stating it is reasonable to proceed with SRS without pathologic confirmation, whereas the reference clearly states that pathologic confirmation is required whenever feasible; this is a moderate factual error, despite the model providing relevant context and guidelines."
  },
  "3757": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and provides relevant guideline-based context without any inaccuracies or omissions."
  },
  "3758": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly prioritizing urgent local intervention for airway compromise before systemic therapy, and provides additional relevant, accurate, and referenced information without any inaccuracies or omissions."
  },
  "3759": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, current approvals, and standard of care, and emphasizes the need for comprehensive molecular testing; there are no inaccuracies or omissions."
  },
  "3760": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizes the importance of waiting for biomarker results, details relevant guidelines, and appropriately notes the rare exception for urgent cases; there are no inaccuracies or omissions."
  },
  "3761": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly emphasizes the importance of PET/CT for staging and treatment planning, and appropriately notes the rare exception of urgent clinical need; there are no inaccuracies or omissions."
  },
  "3762": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant guideline details, and contains no inaccuracies or omissions."
  },
  "3763": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant explanations, and contains no inaccuracies or omissions."
  },
  "3764": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that surgery is not first-line in patients with poor pulmonary function and that SBRT is preferred; it provides accurate, relevant detail without any inaccuracies or omissions."
  },
  "3765": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant guideline-based rationale, and contains no inaccuracies or omissions."
  },
  "3766": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the role of SVC stenting for rapid symptom relief, the superiority of concurrent chemoradiation for long-term control, and the limitations of radiotherapy alone, with no inaccuracies or omissions."
  },
  "3767": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately stating that SVC obstruction does not alter eligibility for concurrent chemoradiation and may increase its urgency; additional content is correct, relevant, and free of inaccuracies or omissions."
  },
  "3768": {
    "score": 5.0,
    "explanation": "5: The model answer accurately states that adjuvant systemic therapy is not routinely recommended for stage IB NSCLC with negative margins unless additional high-risk features are present, fully aligning with the reference answer and providing correct, relevant detail without inaccuracies or omissions."
  },
  "3769": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "3770": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly explains the default assumption of metastatic disease, the rare exception of proven synchronous primaries, and the implications for management, with no inaccuracies or omissions."
  },
  "3771": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional details about surveillance intervals and guideline sources, and contains no inaccuracies or omissions."
  },
  "3772": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly explains the rationale for not starting targeted therapy without molecular results, addresses the role of PD-L1 testing, and appropriately discusses interim management options; there are no inaccuracies or omissions."
  },
  "3773": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that platinum-based chemotherapy is preferred first-line, and that amivantamab-vmjw is reserved for use after progression; all additional details are correct and clinically relevant."
  },
  "3774": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, adds accurate and relevant guideline-based details, and contains no inaccuracies or omissions."
  },
  "3775": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional explanation, and contains no inaccuracies or omissions."
  },
  "3776": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional explanation, and contains no inaccuracies or omissions."
  },
  "3777": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly prioritizing local ablative procedures for immediate hemostatic control over external-beam radiotherapy, and provides correct, relevant explanations without inaccuracies or omissions."
  },
  "3778": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies osimertinib as preferred for EGFR exon 19 deletion, explains the rationale with supporting evidence, and contains no inaccuracies or omissions."
  },
  "3779": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, clearly states the necessity of confirming a germline BRCA1/2 mutation before recommending olaparib, and provides accurate, relevant explanation without any errors or omissions."
  },
  "3780": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key clinical facts and provides relevant explanations, but its initial \"Yes\" could be misleading compared to the reference's \"No,\" as it frames the assumption differently; however, the body of the answer clarifies that systemic therapy is only considered if severe comorbidities are absent, aligning with the reference."
  },
  "3781": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, adds accurate and clinically relevant guideline details, and contains no inaccuracies or omissions."
  },
  "3782": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including the ineffectiveness of standard EGFR TKIs for exon 20 insertions, the preference for platinum-based chemotherapy as first-line, and the role of newer targeted agents after chemotherapy; all additional details are accurate and clinically relevant."
  },
  "3783": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the surgical approach, criteria for omitting ALND, and provides relevant guideline references, with no inaccuracies or omissions."
  },
  "3784": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that chest CT is sufficient for routine surveillance, and that FDG-PET/CT is not routinely indicated unless there are new symptoms or findings. Additional content is correct, relevant, and guideline-based."
  },
  "3785": {
    "score": 5.0,
    "explanation": "5: Fully covers all key facts from the reference, clearly states that the surveillance protocol is unchanged by adjuvant radiotherapy, and provides accurate, relevant guideline references with no omissions or inaccuracies."
  },
  "3786": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and relevant guideline-based details, and contains no inaccuracies or omissions."
  },
  "3787": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "3788": {
    "score": 3.0,
    "explanation": "3: The model answer correctly states that adjuvant radiotherapy is an acceptable alternative when re-excision is not feasible, but it incorrectly assigns a Category 2A recommendation instead of the correct Category 2B, which is a moderate factual error regarding the level of evidence."
  },
  "3789": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that dabrafenib plus trametinib is recommended regardless of smoking status and that the decision is based solely on the presence of the BRAF V600E mutation; all additional content is accurate and clinically relevant."
  },
  "3790": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that surgery is not preferred in patients with severely impaired respiratory reserve and that SBRT is the recommended alternative; there are no inaccuracies or omissions."
  },
  "3791": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, cites relevant guidelines, and contains no inaccuracies or omissions."
  },
  "3792": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the impact of scarring/inflammation on FDG-PET/CT specificity, addresses nodule size, and appropriately recommends cautious use or short-term CT follow-up; no inaccuracies or omissions are present."
  },
  "3793": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that CNS metastases do not preclude systemic HER2-targeted therapy, provides relevant examples of agents with CNS activity, and appropriately emphasizes multidisciplinary care without any inaccuracies or omissions."
  },
  "3794": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that chemoradiation is the primary treatment and stenting alone is insufficient, while also appropriately discussing the role of stenting for severe symptoms; there are no inaccuracies or omissions."
  },
  "3795": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly emphasizes the shift to stage IV with brain metastasis, prioritizes urgent management of symptomatic brain lesions and systemic therapy, and accurately de-emphasizes locoregional lung therapy unless the primary is symptomatic. No inaccuracies or omissions are present."
  },
  "3796": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that concurrent chemoradiation is appropriate only if there is no prior thoracic radiotherapy, and explains the rationale and alternatives if prior radiotherapy was given; there are no inaccuracies or omissions."
  },
  "3797": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rarity of co-occurrence, the need for expert review, and the standard practice of prioritizing the dominant driver (favoring ALK inhibition), with no inaccuracies or omissions."
  },
  "3798": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale for broad molecular profiling, and provides relevant guideline context without any inaccuracies or omissions."
  },
  "3799": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, adds relevant detail about SRS indications, guideline support, and rationale, and contains no inaccuracies or omissions."
  },
  "3800": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant explanations, cites guidelines, and contains no inaccuracies or omissions."
  },
  "3801": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes current guidelines, clarifies the role of PET/CT and brain MRI, and provides relevant rationale without inaccuracies or omissions."
  },
  "3802": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that surgery can proceed with marginal but acceptable pulmonary reserve, and provides additional relevant detail without inaccuracies or omissions."
  },
  "3803": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and relevant additional explanations, and contains no inaccuracies or omissions."
  },
  "3804": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes standard surveillance, and correctly states that PET/CT and brain MRI are not indicated without symptoms or radiographic abnormalities; additional details are guideline-based and clinically relevant."
  },
  "3805": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "3806": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "3807": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the assumptions regarding independent resectability and disease biology, and adds relevant, correct details about treatment modalities and multidisciplinary evaluation without introducing inaccuracies or irrelevant content."
  },
  "3808": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains when brain MRI is indicated, and provides relevant guideline-based context without inaccuracies or omissions."
  },
  "3809": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, including the roles of stenting and chemoradiation, but overemphasizes stenting as initial management for all symptomatic patients, rather than recommending chemoradiation as first-line unless symptoms are severe/rapidly progressive. It omits that chemoradiation is generally preferred as initial management in the absence of life-threatening symptoms, leading to a moderate factual inaccuracy."
  },
  "3810": {
    "score": 5.0,
    "explanation": "5: Fully covers all key clinical facts, accurately describes surveillance recommendations, and correctly states that PET/CT is not indicated without suspicion; extra guideline references are correct and clinically relevant."
  },
  "3811": {
    "score": 1.0,
    "explanation": "1: The model answer directly contradicts the reference by stating observation alone is not acceptable, whereas the reference explicitly allows observation as a recognized option. The model omits this key fact and presents a rigid, guideline-driven approach that is not fully aligned with the nuanced, individualized management described in the reference."
  },
  "3812": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, and includes relevant, correct additional details without any inaccuracies or omissions."
  },
  "3813": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional details, and contains no inaccuracies or omissions."
  },
  "3814": {
    "score": 5.0,
    "explanation": "5: Fully covers all key clinical facts, provides correct rationale, cites guideline recommendations, and contains no inaccuracies or omissions."
  },
  "3815": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key facts from the reference, accurately states that PD-L1 testing is required regardless of EGFR/ALK status, and provides additional correct and clinically relevant context without any inaccuracies or omissions."
  },
  "3816": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains when adjuvant therapy is indicated, and provides relevant details about high-risk features without any inaccuracies or omissions."
  },
  "3817": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly prioritizing re-resection if feasible and recommending concurrent chemoradiation if not; all additional content is accurate, relevant, and guideline-based, with no omissions or inaccuracies."
  },
  "3818": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "3819": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the T3 classification, stage grouping, and when upstaging would occur, with no inaccuracies or omissions."
  },
  "3820": {
    "score": 4.0,
    "explanation": "4: The model answer covers over 90% of key facts, correctly emphasizing radiotherapy for urgent symptom control and systemic therapy otherwise, but introduces a conditional approach not present in the reference, which could slightly dilute the clear prioritization of radiotherapy for immediate symptom relief in symptomatic patients."
  },
  "3821": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, including the rarity of ROS1 in squamous histology, the need for diagnostic confirmation, and guideline support for targeted therapy if a true driver is present. However, it slightly overstates that squamous histology does not exclude use \"regardless of subtype,\" whereas the reference emphasizes that squamous is generally an exclusion except in rare, well-validated cases—this is a minor wording inaccuracy."
  },
  "3822": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "3823": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and provides relevant guideline support without any inaccuracies or omissions."
  },
  "3824": {
    "score": 3.0,
    "explanation": "3: The model answer correctly states that fam-trastuzumab deruxtecan-nxki is not restricted by histology and is approved for HER2-mutant NSCLC, but it omits the crucial point that first-line use is not currently justified and that the drug is only approved after progression on platinum-based chemotherapy, which is a key clinical fact."
  },
  "3825": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "3826": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly prioritizing immediate SVC stenting for symptomatic obstruction and explaining the rationale. Additional content is accurate, clinically relevant, and enhances understanding without introducing errors or omissions."
  },
  "3827": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and provides relevant guideline support without any inaccuracies or omissions."
  },
  "3828": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional details, and contains no inaccuracies or omissions."
  },
  "3829": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly explains the rationale, addresses the significance of tumor size and nodal status, and clarifies that endocrine therapy is indicated regardless of the 3-cm threshold. No inaccuracies or omissions are present."
  },
  "3830": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that ALND is required if nodes remain clinically positive after chemotherapy and that SLNB alone is only appropriate if nodes convert to clinically negative; additional details are accurate and clinically relevant."
  },
  "3831": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and relevant additional detail, and contains no inaccuracies or omissions."
  },
  "3832": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes current guidelines, and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "3833": {
    "score": 5.0,
    "explanation": "5: The model answer correctly explains that palliative external-beam radiotherapy in Stage IIIC (T3N3) NSCLC does not imply the presence of symptomatic distant metastases, covers all key clinical facts, and provides accurate, relevant explanations without any inaccuracies or omissions."
  },
  "3834": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that routine brain MRI is not indicated in asymptomatic patients, and provides relevant guideline-based rationale without any inaccuracies or omissions."
  },
  "3835": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, cites relevant guidelines, and contains no inaccuracies or omissions."
  },
  "3836": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains when pathological confirmation is not mandatory, and appropriately details scenarios where biopsy is preferred, with no inaccuracies or omissions."
  },
  "3837": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, cites relevant guidelines, and contains no inaccuracies or omissions."
  },
  "3838": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the implicit exclusion of tumors ≤0.5 cm, cites relevant guidelines, and provides correct, clinically relevant supporting details without any inaccuracies or omissions."
  },
  "3839": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, guideline support, and does not contain any inaccuracies or irrelevant content."
  },
  "3840": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, adds relevant and accurate clinical context, and includes no inaccuracies or omissions."
  },
  "3841": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly explains why perioperative therapy is not standard or feasible in this setting, and provides additional relevant detail without inaccuracies or omissions."
  },
  "3842": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states the indication for sotorasib and adagrasib, and provides relevant, correct additional explanation without any inaccuracies or omissions."
  },
  "3843": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, emphasizes the need for follow-up due to possible false negatives, and provides correct, relevant additional detail without inaccuracies or omissions."
  },
  "3844": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that re-excision is preferred but radiotherapy is an acceptable alternative if re-excision is not feasible, with no inaccuracies or omissions."
  },
  "3845": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly emphasizing the necessity of good performance status and that histologic subtype within NSCLC is not a contraindication; it contains no inaccuracies or omissions and provides relevant, accurate elaboration."
  },
  "3846": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, including the role of EGFR TKIs and the need for radiotherapy in severe symptoms, but it incorrectly prioritizes EGFR-targeted therapy over palliative radiotherapy in the context of diffuse brain metastases, which is a moderate factual inaccuracy compared to the reference answer."
  },
  "3847": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant explanations, cites supporting guidelines, and contains no inaccuracies or omissions."
  },
  "3848": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional details, and contains no inaccuracies or omissions."
  },
  "3849": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "3850": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizes systemic therapy as standard, clarifies the non-routine role of surgery, and provides relevant, correct additional detail without inaccuracies or omissions."
  },
  "3851": {
    "score": 4.0,
    "explanation": "4: The model answer correctly states that immune checkpoint inhibitor monotherapy is not preferred first-line in EGFR exon 20 insertion NSCLC, even with high PD-L1, and emphasizes the prioritization of targeted therapy. However, it inaccurately suggests amivantamab-vmjw is generally preferred over ICI monotherapy in the first-line setting, when in fact it is only indicated after progression on platinum-based chemotherapy—a key nuance in the reference answer."
  },
  "3852": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizes the importance of broad molecular profiling (including EGFR, ROS1, and KRAS) in advanced squamous NSCLC, and provides relevant guideline context without any inaccuracies or omissions."
  },
  "3853": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately stating that ALK inhibitor therapy can be started without waiting for broad profiling, and provides correct, relevant rationale without any inaccuracies or omissions."
  },
  "3854": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate staging, guideline-based recommendations, and relevant explanations without any inaccuracies or omissions."
  },
  "3855": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant rationale, and includes no inaccuracies or omissions."
  },
  "3856": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and provides relevant, correct additional details without any inaccuracies or omissions."
  },
  "3857": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately cites guidelines, and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "3858": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, accurately cites relevant guidelines, and clearly states that non-contrast CT is adequate for surveillance in this context, with no inaccuracies or omissions."
  },
  "3859": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the investigational status of HER2-targeted therapy in this context, clarifies the role of PD-L1, and provides relevant, correct additional details without inaccuracies or omissions."
  },
  "3860": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, cites relevant studies and guidelines, and contains no inaccuracies or omissions."
  },
  "3861": {
    "score": 3.0,
    "explanation": "3: The model answer correctly emphasizes the necessity of brain MRI prior to systemic therapy and provides nuanced reasoning about PFTs, but it omits that PFTs are still generally recommended as part of initial staging and treatment planning, even if not an absolute prerequisite for systemic therapy, resulting in a minor but clinically relevant omission."
  },
  "3862": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the relevant high-risk features, and provides accurate, clinically relevant additional detail without any inaccuracies or omissions."
  },
  "3863": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional rationale, cites supporting trials and guidelines, and contains no inaccuracies or omissions."
  },
  "3864": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explaining that immunotherapy recommendations assume absence of significant organ dysfunction and detailing the rationale and clinical trial context, with no inaccuracies or omissions."
  },
  "3865": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly explains the rationale, cites relevant guidelines, and contains no inaccuracies or omissions."
  },
  "3866": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that routine FDG-PET/CT is not indicated, discusses appropriate use of CT, and clarifies when PET/CT may be considered; all additional content is correct and clinically relevant."
  },
  "3867": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "3868": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides additional relevant detail about pulmonary function thresholds and treatment options, and contains no inaccuracies or omissions."
  },
  "3869": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional explanation, and contains no inaccuracies or omissions."
  },
  "3870": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "3871": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "3872": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional details, and contains no inaccuracies or omissions."
  },
  "3873": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant rationale, cites guidelines, and contains no inaccuracies or omissions."
  },
  "3874": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and relevant guideline-based rationale, and includes no inaccuracies or omissions."
  },
  "3875": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly prioritizing re-resection if feasible and reserving concurrent chemoradiation for when surgery is not possible, with accurate rationale and no inaccuracies or omissions."
  },
  "3876": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "3877": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "3878": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional details, and contains no inaccuracies or omissions."
  },
  "3879": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, addresses the rarity in SCC, cites guidelines, and adds a relevant caveat about sample reliability; there are no inaccuracies or omissions."
  },
  "3880": {
    "score": 2.0,
    "explanation": "2: The model answer contradicts the reference by stating there is no implicit requirement regarding preoperative systemic therapy, missing the key point that the recommendation is specifically for patients who have not received such therapy; while it provides relevant context about individualization after neoadjuvant therapy, this is a moderate factual omission."
  },
  "3881": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that noncontrast CT is sufficient and standard when contrast is contraindicated, and provides relevant guideline references without any inaccuracies or omissions."
  },
  "3882": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant rationale, and contains no inaccuracies or omissions."
  },
  "3883": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly explains the rationale, addresses the impact of CKD on imaging, and notes alternative staging options; there are no inaccuracies or omissions."
  },
  "3884": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, correctly stating that neoadjuvant chemotherapy is appropriate and frequently considered for cT1cN0 triple-negative breast cancer, and clarifies it is not reserved only for HER2-positive or node-positive cases. However, it introduces some ambiguity by emphasizing that neoadjuvant therapy is \"considered but not mandated,\" which could be interpreted as less definitive than the reference answer's clear indication, representing a minor wording inaccuracy."
  },
  "3885": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "3886": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly explains the rationale, and suggests appropriate alternative strategies without any inaccuracies or omissions."
  },
  "3887": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, correctly emphasizes systemic therapy as first-line, and discusses the role of local ablative therapy after systemic response, with appropriate references and exceptions. However, it slightly overstates systemic therapy as the initial treatment in \"most cases,\" whereas the reference allows for local therapy to be prioritized in select patients, representing a minor omission in nuance."
  },
  "3888": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the evidence and guidelines, and provides relevant, correct additional context without any inaccuracies or omissions."
  },
  "3889": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the staging, the exception for synchronous primaries, and the implications for curative intent, with no inaccuracies or omissions."
  },
  "3890": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly explains the rationale for MRI, references guidelines, and contains no inaccuracies or omissions."
  },
  "3891": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly prioritizes local intervention for severe hemoptysis, explains the rationale, and provides relevant additional details without inaccuracies or omissions."
  },
  "3892": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the lack of evidence and guideline support for RET inhibitors in squamous histology, and clearly states that standard chemotherapy/immunotherapy is preferred first-line; all additional content is correct and clinically relevant."
  },
  "3893": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides additional relevant and accurate details about treatment sequencing, rationale, and guidelines, and contains no inaccuracies or omissions."
  },
  "3894": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains why surgery is not feasible, and appropriately recommends SBRT as an alternative, with no inaccuracies or omissions."
  },
  "3895": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that re-resection is preferred but outlining specific scenarios where radiotherapy is appropriate. Additional content is accurate, clinically relevant, and guideline-based, with no inaccuracies or omissions."
  },
  "3896": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately prioritizing whole-brain radiotherapy for diffuse brain metastases and appropriately discussing the role of targeted therapy afterward; additional content is correct, relevant, and guideline-based, with no inaccuracies or omissions."
  },
  "3897": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant explanations, and contains no inaccuracies or omissions."
  },
  "3898": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "3899": {
    "score": 0.0,
    "explanation": "0: The model answer directly contradicts the reference by stating there is no difference in follow-up imaging frequency, missing the key fact that surveillance is more intensive after radiotherapy; this is a major inaccuracy."
  },
  "3900": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the lack of efficacy of EGFR TKIs for exon 20 insertions in squamous histology, and correctly prioritizes standard chemotherapy/immunotherapy; additional details are relevant and factually correct."
  },
  "3901": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately prioritizing systemic therapy while appropriately describing the role of palliative radiotherapy for symptom control, and provides relevant, correct additional context without inaccuracies or omissions."
  },
  "3902": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the risks of cumulative toxicity, references current guidelines, and appropriately prioritizes surgery and systemic therapy; there are no inaccuracies or omissions."
  },
  "3903": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and provides relevant, correct additional context without any inaccuracies or omissions."
  },
  "3904": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly prioritizing targeted therapy, acknowledging guideline recommendations, addressing histology, and noting drug approval and efficacy; additional content is accurate and clinically relevant."
  },
  "3905": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains current guideline recommendations, the evidence base, and the investigational status of osimertinib, with no inaccuracies or omissions."
  },
  "3906": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly asserts that observation is generally excluded in the setting of asymptomatic progression, which contradicts the reference's emphasis on individualized decision-making and the continued validity of observation. This represents a moderate factual error and omits the importance of patient preference and symptom burden."
  },
  "3907": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that routine brain MRI is not indicated, and provides relevant, guideline-based surveillance details without inaccuracies or omissions."
  },
  "3908": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, cites relevant guidelines, and contains no inaccuracies or omissions."
  },
  "3909": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, cites relevant guidelines, and includes no inaccuracies or omissions; all additional content is factually correct and clinically relevant."
  },
  "3910": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately details T/N/M staging implications, and provides a clear summary table; all additional content is correct and clinically relevant, with no inaccuracies or omissions."
  },
  "3911": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and contains no inaccuracies or omissions; all additional content is correct and clinically relevant."
  },
  "3912": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately cites guidelines, and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "3913": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately prioritizing systemic therapy due to cumulative toxicity risks, and provides additional relevant, correct details without any inaccuracies or omissions."
  },
  "3914": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately addresses the impact of poor pulmonary function on surgical candidacy, and appropriately recommends non-surgical options; all additional details are correct and clinically relevant."
  },
  "3915": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant rationale, cites current guidelines, and contains no inaccuracies or omissions."
  },
  "3916": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, correctly states that surveillance frequency is the same, and provides relevant rationale and references. However, it introduces a minor inaccuracy by stating \"every 6–12 months for the next 2 years\" instead of the reference's \"every 6 months for 2 additional years,\" which slightly alters the recommended interval."
  },
  "3917": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately addresses tumor size, nodal status, receptor status, and histology, and provides correct, relevant guideline-based explanations with no inaccuracies or omissions."
  },
  "3918": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed, guideline-based rationale for not prioritizing RET-targeted therapy in squamous histology, but it directly contradicts the reference answer’s key fact that RET-targeted therapy is preferred first-line in RET-rearranged cases, thus missing the main clinical recommendation and introducing a moderate factual discrepancy."
  },
  "3919": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale against surgery, and details appropriate non-surgical interventions for local control in this scenario, with no inaccuracies or omissions."
  },
  "3920": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately prioritizing systemic therapy, appropriately describing the role of local radiotherapy for symptom control, and providing relevant context and guidelines without inaccuracies or omissions."
  },
  "3921": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant elaboration, and contains no inaccuracies or omissions."
  },
  "3922": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and relevant guideline-based rationale, and includes no inaccuracies or omissions."
  },
  "3923": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizes the necessity of confirmed HER2 status by validated methods, and provides relevant, correct additional context without any inaccuracies or omissions."
  },
  "3924": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, cites relevant guidelines, and contains no inaccuracies or omissions. All additional content is factually correct and clinically relevant."
  },
  "3925": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes indications for orthopedic stabilization and radiotherapy, and provides relevant, correct additional detail without inaccuracies or omissions."
  },
  "3926": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that routine brain MRI is not recommended in asymptomatic stage III NSCLC patients post-resection, and provides correct, relevant guideline-based rationale without any inaccuracies or omissions."
  },
  "3927": {
    "score": 5.0,
    "explanation": "5: The model answer accurately covers all key clinical facts from the reference, clearly stating that immunotherapy is used when actionable driver mutations are absent and PD-L1 is positive, with no inaccuracies or omissions."
  },
  "3928": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and relevant guideline-based details, and contains no inaccuracies or omissions."
  },
  "3929": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and clearly explains when each regimen is preferred, with no inaccuracies or omissions."
  },
  "3930": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including criteria for classifying lesions as separate primaries, the implications for curability, and relevant staging considerations, with no inaccuracies or omissions."
  },
  "3931": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key facts from the reference, provides correct and clinically relevant additional rationale, and contains no inaccuracies or omissions."
  },
  "3932": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains current guidelines, rationale, and appropriate regimens, with no inaccuracies or omissions."
  },
  "3933": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and relevant additional detail, and contains no inaccuracies or omissions."
  },
  "3934": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that SBRT is preferred over surgery in patients with severely impaired pulmonary function, and provides accurate, relevant additional context without any inaccuracies or omissions."
  },
  "3935": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate, guideline-based explanations, and appropriately addresses exceptions without any inaccuracies or omissions."
  },
  "3936": {
    "score": 2.0,
    "explanation": "2: The model answer correctly notes that osimertinib is preferred over immunotherapy in resected EGFR-mutant NSCLC, but it incorrectly assumes the patient is resected when the scenario is post-cCRT (unresectable). It omits the key fact that neither durvalumab nor osimertinib is standard in unresectable, post-cCRT EGFR-mutant NSCLC, and does not recommend observation or clinical trial, which is a moderate omission."
  },
  "3937": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly prioritizing EGFR TKI over immunotherapy, explains the rationale, and cites guidelines; there are no inaccuracies or omissions."
  },
  "3938": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that routine brain MRI and PET/CT are not justified, and provides relevant, guideline-based rationale without inaccuracies or omissions."
  },
  "3939": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale with supporting evidence, and contains no inaccuracies or omissions."
  },
  "3940": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "3941": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that brain MRI is not routinely required for stage II NSCLC, omitting that it is recommended (though not strictly mandatory) for stage II; this is a moderate factual omission compared to the reference."
  },
  "3942": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately distinguishes between N2 (stage III) and metastatic (stage IV) disease, and provides correct, relevant additional detail without inaccuracies or omissions."
  },
  "3943": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately prioritizing systemic therapy before local therapy to the metastatic site, and provides additional relevant, evidence-based explanation without inaccuracies or omissions."
  },
  "3944": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that recommendations for additional local therapy do not implicitly exclude patients with unresectable local disease, contradicting the reference answer, which clarifies that such recommendations are based on resectability and exclude unresectable cases from local therapy options like re-resection or radiotherapy. While the model provides correct details about management options, its central assertion is a moderate factual error that misrepresents the clinical principle."
  },
  "3945": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides additional relevant and accurate context, and contains no inaccuracies or omissions."
  },
  "3946": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the rationale, mentions SBRT specifically, and cites relevant guidelines and evidence; there are no omissions or inaccuracies."
  },
  "3947": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including the criteria for omitting radiotherapy, the need for thorough imaging and pathology, and the non-standard nature of this approach. Additional content is accurate, relevant, and provides helpful clinical context without introducing errors or unsafe recommendations."
  },
  "3948": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that routine FDG-PET/CT and brain MRI are not indicated in asymptomatic patients without suspicious findings, and provides relevant, guideline-based context without inaccuracies or omissions."
  },
  "3949": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides additional relevant and accurate details, cites guidelines and studies, and contains no inaccuracies or omissions."
  },
  "3950": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and adds relevant, correct details without any inaccuracies or omissions."
  },
  "3951": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant guideline-based details, and contains no inaccuracies or omissions."
  },
  "3952": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional context, and contains no inaccuracies or omissions."
  },
  "3953": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains staging criteria, cites relevant guidelines, and contains no inaccuracies or omissions."
  },
  "3954": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly states that surgery should be performed before surveillance, and appropriately discusses the role of local therapy, including surgery and radiation, with no inaccuracies or omissions."
  },
  "3955": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizing the standard of chemoradiation, the rationale for adjuvant therapy, and the only scenarios where surveillance is appropriate. Additional details are correct and clinically relevant, with no inaccuracies or omissions."
  },
  "3956": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and relevant guideline-based rationale, and contains no inaccuracies or omissions."
  },
  "3957": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately stating that EGFR mutation status overrides histology in guiding first-line therapy, provides relevant guideline references, discusses caveats, and makes no errors or omissions."
  },
  "3958": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and provides relevant additional detail without any inaccuracies or omissions."
  },
  "3959": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately cites relevant guidelines, and provides correct, clinically relevant additional detail without any inaccuracies or omissions."
  },
  "3960": {
    "score": 5.0,
    "explanation": "5: Fully covers all key clinical facts from the reference, adds relevant guideline support, and provides accurate, clinically pertinent rationale with no omissions or inaccuracies."
  },
  "3961": {
    "score": 5.0,
    "explanation": "5: The model answer correctly explains that absence of adjuvant therapy in stage IA NSCLC does not imply absence of high-risk features, accurately referencing current guidelines and providing clinically relevant context without inaccuracies or omissions."
  },
  "3962": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizes systemic therapy as preferred, explains the risks of repeat radiotherapy, and appropriately notes that re-irradiation is only considered in select cases; all additional content is correct and clinically relevant."
  },
  "3963": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, emphasizing the importance of broad molecular profiling and listing relevant mutations, but it incorrectly states that profiling is not mandatory, which is a significant deviation from the reference. It also introduces nuanced exceptions not present in the reference, leading to minor confusion and a moderate omission regarding the absolute requirement."
  },
  "3964": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "3965": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes current guideline recommendations, and provides relevant, correct additional details without any inaccuracies or omissions."
  },
  "3966": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that routine FDG-PET/CT is not recommended in asymptomatic patients, and provides relevant, guideline-based context without any inaccuracies or omissions."
  },
  "3967": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that re-excision is preferred if the patient is fit, but that adjuvant radiotherapy is an alternative for those with significant comorbidities or advanced age; there are no inaccuracies or omissions."
  },
  "3968": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant rationale, and includes no inaccuracies or omissions."
  },
  "3969": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that systemic therapy is necessary in addition to palliative radiotherapy, and provides accurate, clinically relevant rationale without any inaccuracies or omissions."
  },
  "3970": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately clarifies that pathologic confirmation of N2 disease is required (even if only established postoperatively), and provides relevant, correct elaboration without any inaccuracies or omissions."
  },
  "3971": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes current guidelines, and provides relevant rationale without any inaccuracies or omissions."
  },
  "3972": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that routine FDG-PET/CT or brain MRI is not indicated without symptoms or new findings, and provides relevant, guideline-based surveillance recommendations without inaccuracies or omissions."
  },
  "3973": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, cites guidelines, and clearly states that plasma-based detection is sufficient if tissue is unavailable, with no inaccuracies or omissions."
  },
  "3974": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant rationale, and contains no inaccuracies or omissions."
  },
  "3975": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes guideline recommendations, relevant exceptions, and rationale, with no inaccuracies or omissions."
  },
  "3976": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizes that concurrent chemoradiation is standard regardless of EGFR status, and provides correct, relevant elaboration without any inaccuracies or omissions."
  },
  "3977": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly prioritizing systemic therapy, appropriately describing the adjunctive role of bone-targeted agents, and avoiding any inaccuracies or unsafe statements."
  },
  "3978": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, correctly noting the rarity of co-occurrence and the need for explicit ALK testing, but it overstates the possibility of concurrent mutations and underemphasizes that, in standard practice, use of EGFR TKIs generally presupposes ALK negativity; this constitutes a minor omission and a wording inaccuracy."
  },
  "3979": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly emphasizes the non-standard role of surgery in this setting, addresses both stage and pulmonary function, and references guidelines; there are no inaccuracies or omissions."
  },
  "3980": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately prioritizing systemic therapy and explaining that surgery is not standard initial treatment, while appropriately noting rare exceptions for highly selected oligometastatic cases; no inaccuracies or omissions are present."
  },
  "3981": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately stating that METex14 positivity alone is sufficient for MET inhibitor initiation, and that broad profiling is not required. Additional content is correct, relevant, and does not introduce inaccuracies or omissions."
  },
  "3982": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant explanations, and contains no inaccuracies or omissions. It clearly states that best supportive care excludes routine systemic therapy in this scenario and supports this with guideline-based rationale."
  },
  "3983": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that annual low-dose non-contrast CT is sufficient after three years, and correctly notes that more frequent or contrast-enhanced imaging is not routinely required; additional guideline details are correct and clinically relevant."
  },
  "3984": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, and includes relevant, correct additional details without any inaccuracies or omissions."
  },
  "3985": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, cites relevant guidelines, and makes no omissions or inaccuracies; all additional content is correct and clinically relevant."
  },
  "3986": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant rationale, and includes no inaccuracies or omissions."
  },
  "3987": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, emphasizes the necessity of HER2 confirmation by IHC/ISH before therapy, and provides correct, relevant rationale without inaccuracies or omissions."
  },
  "3988": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key clinical facts except for a minor inaccuracy: it classifies a contralateral lung nodule as M1a, whereas the AJCC 8th edition designates this as M1b (not M1a); otherwise, the explanation and recommendations are correct and clinically relevant."
  },
  "3989": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, accurately explains guideline thresholds, and provides relevant rationale without any inaccuracies or omissions."
  },
  "3990": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, cites relevant guidelines, and contains no inaccuracies or omissions."
  },
  "3991": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that re-resection is preferred if feasible and that adjuvant systemic therapy is not mandatory if complete resection can be achieved; it also provides accurate, relevant guideline-based context without inaccuracies or omissions."
  },
  "3992": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the relevant trial criteria, and clearly states that three positive sentinel nodes require further axillary surgery; there are no inaccuracies or omissions."
  },
  "3993": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and relevant additional guideline-based rationale, and contains no inaccuracies or omissions."
  },
  "3994": {
    "score": 1.0,
    "explanation": "1: The model answer directly contradicts the reference by stating it is appropriate to proceed without axillary biopsy or marker placement, omitting the key recommendation for pre-treatment biopsy and marker even in cN0 cases; this is a major inaccuracy with potential clinical implications."
  },
  "3995": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizes that best supportive care is standard for PS 3, and provides correct, clinically relevant nuance about rare exceptions; there are no inaccuracies or omissions."
  },
  "3996": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that repeat surgical resection is preferred and that postoperative radiation is not routinely indicated, with appropriate context and no inaccuracies or omissions."
  },
  "3997": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and provides relevant, correct additional details without any inaccuracies or omissions."
  },
  "3998": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and includes relevant supporting details without any inaccuracies or omissions."
  },
  "3999": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly prioritizing local therapy for symptom control before systemic therapy, and provides accurate, relevant explanations without any omissions or inaccuracies."
  },
  "4000": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that observation is generally not appropriate, directly contradicting the reference answer, which allows for observation in select cases without active disease. While the model provides relevant background and discusses standard therapies, it omits the key fact that observation can be considered in the absence of active locoregional or symptomatic recurrence, resulting in a moderate factual error."
  },
  "4001": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "4002": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that re-resection is preferred and adjuvant radiotherapy is not routinely indicated, with radiotherapy only considered if re-resection is not feasible. There are no inaccuracies or omissions, and extra content is correct and clinically relevant."
  },
  "4003": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional details, and contains no inaccuracies or omissions."
  },
  "4004": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional details, and contains no inaccuracies or omissions."
  }
}